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ABSTRACT 
Of the numerous l3-blockers clinically available to treat conditions such 
as angina pectoris, hypertension and heart failure, none possess 
antagonist activity specific to the 131-adrenoceptor. Those described as 
'cardioselective', such as nebivolol and bisoprolol, generally show less 
than 50-fold 131/132-selectivity, which can be lost at higher doses. Others, 
such as propranolol and sotalol are actually more 132-selective. Overall, 
a degree of concomitant 132-adrenoceptor blockade (risking 
compromised respiratory function and loss of peripheral vasodilatation) 
by current therapeutic agents precludes their use in patients with 
disorders such as asthma and peripheral vascular disease. 
This project aims to develop novel molecules with much improved 131/132-
selectivity over current 13-blocker therapy as well as improving 
knowledge of ligand-receptor interaction at the 131-adrenoceptor, 
through an analogue-based drug discovery approach. A highly 
selective or specific 131-adrenoceptor antagonist is likely to cause fewer 
side-effects and be suitable for use in previously contraindicated 
disease states. 
This thesis reports the design, synthesis and pharmacological data 
(provided by Dr. Jillian Baker) of a library of novel ligands for the 131-
adrenoceptor, based upon the lead compound LK 204-545. LK 204-
545 was selected based on reported high potency at the 131-
adrenoceptor as well as good 131/132-selectivity. 
Modification of various motifs on structures derived from LK 204-545 
allowed the generation of new structure-activity relationships and 
ultimately afforded the highly 131-adrenoceptor selective compound, 1-
(2-(3-(4-(2-(cyclopropylmethoxy)ethoxy)phenoxy)-2-hydroxypropyl 
amino)ethyl)-3-(4-hydroxyphenyl)urea hydroformate (12Sc). This 
compound acted as a highly-selective j31-adrenoceptor antagonist in a 
pilot in-vivo study in the regional hemodynamic rat model (carried out by 
Prof. Sheila Gardiner). 
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1. INTRODUCTION 
1.1 (3-adrenoceptors and the sympathetic nervous system 
The sympathetic, parasympathetic and enteric nervous systems 
collectively form the autonomic nervous system, which in general 
regulates smooth muscle activity, certain hormonal secretions, 
metabolic activities and the heart rate and force.2 
The well-known symptoms of the 'fight or flight' response are controlled 
by the sympathetic nervous system, through a series of receptors 
differentially distributed through tissues. It is the varying response of 
these 'adrenoceptors', to the hormone adrenaline (1) and 
neurotransmitter noradrenaline (2), that results in a range of 
physiological effects. 
OH H H O ~ N , ,
H O ~ ~
1 
Figure 1-1: Classical catecholamines 
OH 
H O ~ N H 2 2
H O ~ ~
2 3 
Endogenous sympathetic agonists: (R)-adrenaline (1) and (R)-noradrenaline (2) and synthetic ~ - a d r e n o c e p t o r r
selective agonist isoprenaline (3). Biosynthesis of 1 and 2 from the metabolism of tyrosine results in formation of the 
active (R)- enantiomer. 
The two adrenoceptor types: a and J3, can be further sub-divided. In 
general, activation of a1-adrenoceptors causes vasoconstriction, 
relaxation of the smooth muscle in the gut, and glycogen breakdown 
(glycogenolysis) in the liver; whereas a2-adrenoceptors can pre-
synaptically inhibit release of neurotransmitters, affect platelet 
aggregation and inhibit the release of insulin.2 
The J3-adrenoceptors can also be further classified into J31, J32 and J33 
receptors.2.3 The major concentration of the J31-adrenoceptor (J31AR) is 
in the heart. and activation causes an increase in the heart rate 
(chronotropy), and force (inotropy) of contraction. In the kidneys, J31AR 
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activation leads to the release of renin and subsequent increases in 
blood pressure through activation of the renin-angiotensin-aldosterone 
system. 
j32-adrenoceptors (j32ARs) are also present in the heart (in a lower 
number), but are more localised to the airways and peripheral 
vasculature. Activation causes opening of the airways and 
vasodilatation. In the liver, j32-adrenoceptor activation results in 
glycogenolysis, whereas in skeletal muscle, activation increases the 
speed of contraction.2 
j33-adrenoceptors (j33ARs) are predominantly found in adipose tissue 
and are involved in thermogenesis and lipolysis.2 
Although the endogenous catecholamines 1 and 2 activate all 
adrenoceptors, the synthetic catecholamine isoprenaline (3) displays a 
much more selective action. It is a selective and more potent agonist of 
the j3-adrenoceptor sub-type than 1 and 2?' 4-6 
1.2 i3-adrenoceptor structure 
Adrenoceptors are rhodopsin-like/family A GPCRs (G-protein coupled 
receptors), belonging to the superfamily of 'serpentine' or 'seven 
transmembrane' receptors, that share a common general structure.7 
- --Extracellular face 
Cytosollc fiKe 
- -
caOH 
Fllure 1·2: Schematic of rhodopsin-like/family A GPCR tarcet for small molecules 
Source: Adapted. originally from Jacoby et 0/. 20061 
El/E2/E3: extracellular loops; 11/12/13: intracellular loops; BLUE: cell membrane; ORANGE: ligand binding site. 
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The receptor structure consists of a single polypeptide chain,3 and is 
situated in the cell membrane with the N-terminus exposed to the 
extracellular environment and the C-terminus in the cytosol (Figure 
1-2). The seven hydrophobic transmembrane (TM) a-helix3, 7-9 regions 
are joined by intracellular and extracellular loops, and generally 
possess a disulfide bridge between cysteine residues on E1 and E2.7,9 
The transmembrane regions are not linearly positioned, and group to 
form the ligand binding domain, which is situated in this transmembrane 
bundle. A pseudo fourth intracellular loop is formed by anchoring of a 
palmitoylated cysteine residue to the cell membrane.3. 7-9 In the J32AR. 
this appears important for activation of adenylyl cyclase downstream in 
the signalling cascade (see section 1.2.3).3 
Sequencing and comparison of the three J3-adrenoceptor sequences 
reveals a number of similarities.3 The J31AR is a 477 amino-acid 
sequence, whereas the J32AR and J33ARs are 413 and 408 residues in 
length respectively.3. 10 The J31AR and J32AR share 48.9% sequence 
homology, in comparison, the J33AR has 50.7% homology with the 
J31AR and 45.5% homology with the J32AR.11 
Most of the information regarding residues in the sequence important 
for ligand binding, has arisen from studies involving site directed 
mutagenesis of the human f32AR. 11-13 Studies involving deletion of 
postulated transmembrane regions, and receptor chimeras, indicate 
that the ligand binding domain lies within the hydrophobic 
transmembrane regions where the seven a-helices group.13, 14 
Additionally, the hydrophilic extracellular N-terminal domain, 
intracellular C-terminal and inter-helix loops do not appear to be 
necessary for ligand binding.11.15 
Ligand-receptor interactions appear to differ for agonists compared to 
antagonists. 15 However an essential interaction shared by both types of 
ligand, is an ionic salt-bridge formed with the amino group of the J3-
amino alcohol motif common to all ligands. This key interaction is 
thought to take place with the acidic ASp113 on TM3 of the J32AR (see 
Figure 1_3).3,14,16 
3 
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The catecholamine motif present on 1, 2 and 3 appears to be 
responsible for agonist activity of these molecules. These phenolic 
groups are thought to interact via hydrogen-bonding with Ser204 and 
Ser2°7 on TM5 of the J32AR.3, 14, 17 Later studies found Ser2°3 to be of 
importance also.18 
Further interaction with the aromatic ring of catecholamine agonists is 
thought to take place with Phe289 and Phe290 on TM6. 19 It is postulated 
that interaction with Phe290 by the aromatic group on the ligand, may 
cause rotational movement of Phe290 and nearby residues, which may 
contribute to relative movement of TM3 and TM6, thus breaking ionic 
interactions stabilising the inactive state of the receptor. 20 This cascade 
of events may be important in GPCR activation and is described as a 
'rotamer toggle switch' .20 
4 
Ficure 1-3: Interactions of the aconlst noradrenaline with the P2AR (top) and P3AR (bottom) 
Adapted from: 132AR - Strosberg 199i, 133AR - Strosberg 199710 
Introduction 
el: extracellular N-terminal domain; e2-4 : extracellular loops; 11-3: intracellular loops; i4: intracellular C-terminal 
domain; tml-7: transmembrane regions. Although both agonists and antagonists share the essential interaction with 
Asp on tm3 at each receptor, antagonists rely on a variety of other interactions that are described below. 
Computer-based modelling of the J32AR (see below) indicates that 
Ser165 may form an important interaction with the J3-hydroxyl group of 
ethanolamine agonists, however mutagenesis studies show that Asn293 
5 
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is a key residue, forming a potential hydrogen bond with the hydroxyl 
group.21 Additionally Asn293 is involved with the stereoselective action 
of ligands (see section 1.5.3).21 
Other residues thought to be important in agonist activation of the G-
protein include; ASp79 on TM2, and Tyr316 on TM?3, 15, 16 Indeed 
mutations of ASp79 differentially reduced agonist binding and receptor 
activation, without affecting antagonist binding. 15, 16 The diverse effects 
of deletions on ASp79 and Asp 113 suggest separate, but overlapping 
sites for agonist and antagonist binding. 15, 16 
The key residues found in the f32AR are conserved in both the f31AR 
(ASp104, ASp138, S e ~ 2 8 , , S e ~ 2 9 , , S e ~ 3 2 2 and Phe341 )22 and f33AR (ASp83, 
Asp 117, S e ~ 0 8 , , S e ~ 0 9 , , S e ~ 1 2 , , Phe309 and Tyr336 , see Figure 1_3)10. 
However, recent site directed mutation studies of the f31AR indicate 
ASp104 and Phe341 are not so important in agonist binding.22 The 
existence of ligands with differing selectivity for each receptor 
demonstrates that, differing ligand-receptor interactions must also take 
place at each receptor to allow this sub-type selective binding, and in 
the case of agonists, activation. 
An additional residue important for binding the aryloxypropanolamine 
antagonist ligands, is Asn312 (TM? of f32AR). This seems to be 
important in forming a hydrogen bond with the ether oxygen atom of the 
general aryloxypropanolamine structure.23, 24 
Further mutagenesis studies of the rat f31AR indicate that different 
antagonists may occupy the receptor in different binding 
conformations?5, 26 Differences in binding conformations, may induce 
different conformational states at the level of the receptor, with the 
potential to activate diverse signalling cascades. Some evidence now 
exists to suggest that the f31AR and f33AR may support at least two 
binding sites or conformations.27, 28 
6 
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Figure 1-4: 4-(3-tertiarybutylamino-2-hydroxypropoxy)-benzimidazole-2-one (CGP 12177) 
CGP 12177 displays antagonist activity at lower concentrations, but agonist activity at higher concentrations at the 
131AR. 
An example of this is CGP 12177 (4) which binds to the ~ 1 A R R at low 
concentrations as an antagonist.27 At higher concentrations, 4 exhibits 
agonist activity, furthermore blockade of this activity is relatively difficult 
with classical ~ - b l o c k e r s . 2 7 . . 29. 30 
1.2.1 Adrenoceptor modelling and crystallography 
1.2.1.1 X-ray crystallography 
The ability to co-crystallise protein targets with corresponding agonist or 
antagonist ligands, allows x-ray diffraction experiments to be carried 
out, in order to identify the ligand binding site. The coordinates 
obtained can be translated into a three-dimensional image of the tertiary 
structure of the protein, revealing the site of ligand interaction, and 
allowing visualisation of likely binding sites. 
Ad re noceptors , belonging to the GPCR family, possess attributes that 
are undesirable in relation to the classical techniques employed in 
crystallising proteins. 
The transmembrane serpentine structure (see above) requires the cell 
membrane for support, and is generally unstable in detergent 
solutions31 . Consequently, not only is isolation and crystallisation of the 
pure protein difficult32, the purified product may not share the same 
folded structure as would be found on the membrane. 
Until recently, (see below) the only GPCR to be successfully 
crystallised, was bovine rhodopsin, with no ligand bound, i.e. in the 
inactive state.33 
7 
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1.2.1.2 Computational studies 
In the absence of a crystal structure of the desired receptor, 
computational techniques such as homology modelling and quantitative 
structure-activity relationships (QSAR) are available. 
Homology modelling for GPCRs has traditionally been based upon the 
crystal structure of bovine rhodopsin in its inactive state.34 The 
technique involves initial alignment of the amino acid sequence for the 
desired receptor, with that of bovine rhodopsin, based upon highly 
conserved residues amongst family A receptors. 34 Once aligned, the 
folding pattern of bovine rhodopsin can be used to predict that of the 
desired receptor. 34 
Although all family A GPCRs resemble rhodopsin in their general 
structure, the actual sequences are often vastly different. The ~ 1 A R , ,
J32AR and J33AR share only 16%, 15% and 18% sequence homology 
with bovine rhodopsin respectively (comparison of UniProtKB 
sequences for each human receptor with sequence for bovine 
rhodopsin using CLUSTALW2). 
Homology models generally include only the transmembrane areas of 
the receptor, with the assumption (see above) that this is where ligand 
binding occurs.34 In addition, use of the inactive state of rhodopsin 
limits modelling of activated receptor conformations.34 Overall, this 
means the modelling of J3-adrenoceptors based on bovine rhodopsin, is 
unlikely to provide an accurate prediction of detailed ligand-receptor 
interaction. 
Problems with receptor-based approaches, such as homology 
modelling, means ligand-based computational approaches can 
potentially offer valuable information about the nature of the target. 
Three dimensional QSAR methods, such as comparative molecular 
field analysis (CoMFA) require a training set of molecules that display a 
desired attribute (e.g. binding to or activation of a receptor), but have 
varying structures.35 CoMFA assumes a common binding site or 
orientation for all molecules in the training set, based upon a bioactive 
8 
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conformation.35 The bioactive conformation can be derived from a co-
crystal structure, or in the case of GPCRs, a ligand docked into a 
homology model. Based on this, a three-dimensional map of each 
molecule considering charge and steric distribution is generated, and 
measurements of theoretical interactions with various 'atomic probes' 
are taken across the molecule.35 The results of these interactions are 
correlated with pharmacological data (e.g. binding affinity). Once 
analysed, contour maps can be generated showing areas around 
molecules that favour/disfavour electronegative and electropositive 
substituents, as well as steric bulk.35 
1.2.1.3 Recent developments 
Towards the end of 2007, Rasmussen et af1 and then Cherezov et af6 
published crystal structures for the human ~ 2 A R R bound to carazolol (an 
inverse agonist) - the first successful GPCR crystal structures since 
that of bovine rhodopsin in 200033. 
ECL2 ECL2 
Fl,ure 1-5: Stereo view of the folded human p2AR·T4Iysozyme complex with carazolol bound" 
Source: Cherezov et al. 200736 
GREY: 1J2AR; GREEN : T4 lysozyme; BLUE: carazolol; YELLOW: lipid molecules bound to the receptor; ECl2 : 
extracellular loop 2. Transmembrane helices are numbered I-VII. an additional a-helix VIII runs parallel to the cell 
membrane. 
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Although modifications to the receptor were required to produce stable 
receptors and allow crystallisation, these modifications were shown not 
to affect ligand binding.31 , 36, 37 
The initial structure was stabilised with an antibody fragment bound to 
the third intracellular loop of the receptor.31 This structure gave only 
3.4A13.7A resolution, and much of the extracellular face was not 
visible. 31 A much higher 2.4A resolution structure was obtained by 
replacing intracellular loop 3 (deemed to be highly flexible and 
conferring conformational instability on the receptor), with T 4 lysozyme 
(a soluble protein that improves crystallisation properties) as shown in 
Figure 1_5.36, 38 Additionally, both modified receptors had residues 
removed from the intracellular C-terminus.31 , 36 
Both structures were found to be very similar to each other, with the T4 
lysozyme variant offering more detail on the extracellular face of the 
receptor also.39 In relation to the original bovine rhodopsin model, the 
general folding structure was conserved, however there were several 
distinct differences confirmed by both ~ 2 A R R structures.40 Firstly, the 
f32AR bears an unexpected additional a-helix in the second extracellular 
loop (Figure 1_5).40 This is stabilised by two disulfide bridges, leading 
to a maintained opening to the ligand binding site, thought to facilitate 
ligand diffusion.37, 40 In comparison, bovine rhodopsin bears a ~ - s h e e t , ,
that interacts with other extracellular loops and the N-terminus, 
effectively covering the binding site.4o 
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Ficure 1-6: licand bindinc pocket of the human P2AR-T41ysozyme complex co-crystallised with carazolol" 
Source: Rosenbaum etal, 2007.'" 
YELLOW: carazolol; RED: oxygen; BLUE: nitrogen. Stick structures are shown for all residues within 4A of carazolol. 
except for A2OO, N293, F289 and Y308. Structures in green are able to form polar contacts with carazolol (within 
3.S,\) . 
Based upon the structure of bovine rhodopsin, the inactive conformation 
of family A GPCRs was thought to feature an 'ionic lock', where Arg135 
(TM3) and Glu247 (TM6) form strong ionic and hydrogen bond 
interactions.4o It appears that activation of bovine rhodopsin involves 
breakage of the ionic lock.33 In the case of the human ~ 2 A R , , the 
equivalent residues; Arg 131 and Glu268 are 6.2A apart; too far to form the 
strong ionic interactions implied.4o Although such a difference may be 
due to the presence of the T 4 lysozyme, the original ~ 2 A R - a n t i b o d y y
complex displays an even larger distance of 10.S8A between the 
residues.4o It is possible that the binding of carazolol to the ~ 2 A R R may 
result in a receptor conformation with a broken ionic lock, but it still 
displays inverse agonist activity due to changes in downstream 
signalling pathways. It is difficult to imagine complex structures such as 
GPCRs, relying on disruption of a single interaction during receptor 
activation, and the disruption of differing interactions on binding of 
11 
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different ligands, may be the cause of the variety of activities displayed 
by a receptor. 
Flcure 1·7: Ribbon structure of the mutated turkey P1AR co-crystalllsed with cyanoplndolol ICYP)" 
Sou rce: Warne et 01, 2008." 
BLUE: "'· terminus; RED: [ ·terminus; EL2 : extracellular loop 2; CL1/2: cytoplasmic loops 1 and 2; PINK: sodium cat ion. 
Cyanopindolol is shown as a space·fi lling model. Disulfide bridges close to EL2 are shown in yellow. 
An examination of the ligand binding site of the j32AR in the presence of 
carazolol (Figure 1-6) confirms many key interacting residues as 
revealed by site-directed mutation studies (see above).38 As expected , 
Asp113 and Asn312 are able to form polar interactions with the amino and 
hydroxy groups of the oxypropanolamine backbone respectively.38 
Although Tyr316 does not interact with the ligand directly, mutational 
studies have identified it as important. Interestingly, S e ~ 0 3 3 was found to 
be important for agonist interaction with the receptor in mutational 
studies,18 and also forms a hydrogen bond with the heteroatom in the 
carazolol aromatic ring.38 
Phe290 , Va1117 and Phe 193 surround the aromatic group of carazolol 
forming a multitude of hydrophobic interactions.38 
The most recent GPCR crystal structure to be published, is that of a 
turkey j31AR bound to the high affinity antagonist cyanopindolol (CYP), 
12 
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by Warne ef af1 (Figure 1-7). This was chosen over the human J31AR 
due to better stability as a crystallisation target. Additional stability was 
achieved by removal of sequences from the N-terminus, C-terminus, 
and third intracellular 100p.41 Furthermore, mutations to the sequence, 
shifted the receptor to the inactive state, to which antagonists have 
theoretically higher affinity (see section 1.2.2.1 ).41 These 
modifications, allowed a structure with 2.7A resolution to be obtained.41 
H5 
Ficure 1-8: Ucand bindlnc pocket of the mutated turkey P1AR co-crystallised with CYP" 
Source: Warne et 0/, 2008.41 
YELLOW: CYP; RED: oxygen; BLUE: nitrogen; GREY: Stick structures for residues form ing non·polar contacts w ith CYP; 
AQUAMARINE: Stick structures for res idues forming non-polar contacts. 
The sequence homology between the human and turkey J31ARs is very 
high - around 82%, thus the obtained structure is still highly relevant to 
the human J31AR. 
Similarly to the J32AR, Arg 139 and Glu285 of the turkey J31AR (human 
J31AR residues Arg 156 and Glu319 respectively) do not form the ionic lock 
13 
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in this inactive receptor conformation, further questioning its importance 
beyond the interactions seen in the bovine rhodopsin structure.41 
In addition, the second extracellular loop of the J31AR bears a helix 
stabilised by two disulfide bridges, as in the J32AR. 
~ 2 2 T164 
H5 H4 
H3 
H7 
Figure 1-9: Overlay of Ilcand binding pockets for turkey PlAR (co-crystallised with CYP) and human P2AR-T4 
lysozyme complex (co-crystalllsed with carazolol)Cl 
Source: Warne et 0/,2008.41 
BLUE: nitrogen; RED: oxygen; YElLOW: ~ l A R R residues; GREY: ~ 2 A R R residues; CYP: CYP; CAR: carazolol. The ligand 
binding sites of the two receptors display very high sequence homology, however, w ithin 8A, differences occur at 
F325 and Vl72 of the ~ l A R R (equivalent residue of the ~ 2 A R R are Y308 and T164 respectively), Other residues shown 
are identical in nature, but appear rotated in their conformational orientation, ' 1 
Figure 1-8 shows the ligand binding pocket of the mutated turkey J31AR 
bound to CYP. The ligand binding pockets of both receptors share 
conserved key residues, and thus CYP interacts with the same 
corresponding residues in the 131AR as carazolol does in the 132AR.41 
Additionally, T h ~ o 3 3 of the turkey 131AR (human 131AR residue T h ~ 1 ) ) is 
able to hydrogen bond with the cyano group of Cyp.41 
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With regards to agonist interaction with the ligand binding pocket, 
modelling of adrenaline (1), with the inactive mutated turkey 131AR 
structure by Warne et at1 , suggests that when the essential interaction 
with Asp 121 (Asp 138 of the human 131AR) is present, the catechol moiety 
is too distant to form the postulated hydrogen bonds with S e ~ 1 1 , , S e ~ 1 2 2
and S e ~ 1 5 5 (Se,-228, S e ~ 2 9 9 and S e ~ 3 2 2 of the human 131AR), as suggested 
by mutagenesis studies (see above).41 If this interaction is indeed 
important, it is possible to imagine the receptor conformationally 
changing to form a tighter binding pocket, allowing polar contacts to be 
formed. 41 
The availability of crystal structures for both the 131AR and 132AR in 
inactive conformations, allows direct comparison of the ligand binding 
sites as shown in Figure 1-9. Both ligand binding sites and the 
orientation of ligands is very similar. The only residues to differ within 
sA of the ligand binding site are Phe325 and Val172 of the turkey 131AR 
(conserved on the human 131AR as Phe359 and Va1189) which correspond 
to Tyr308 and Thr164 of the 132AR respectively.41 These 132AR residues 
are more polar than their corresponding f31AR residues. In addition, 
Asn310 and S e ~ 1 1 1 of the turkey 131AR (Asn344 and S e ~ 2 8 8 of the human 
131 AR, and Asn293 and S e ~ 0 3 3 of the 132AR respectively) appear rotated 
in their conformation between the receptors.41 These small differences 
between the ligand binding sites may contribute to the differences in 
selectivity displayed by numerous ligands (see section 1.7.1). 
Although these recent advances in crystallising both the f31AR and 
f32AR bring a wealth of information regarding the structure of these 
adrenoceptors and other GPCRs in general, it is important to remember 
they represent a snapshot of a complex receptor with the propensity to 
adopt multiple conformations. The structures reinforce many of the 
mutational studies that have been carried out previously, and future 
structures with a variety of ligands as well as continued mutational 
work, may provide more detail on the complex sequence of events 
involved in activation and guanine nucleotide binding protein (G-protein) 
coupling. 
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1.2.2 Receptor activation 
1.2.2.1 Cubic ternary complex model 
The cubic ternary complex model (Figure 1-10) describes the different 
complexes that can exist when interaction between agonist, receptor 
and G-protein are considered. 
In this model, the receptor is able to exist in two states, either active 
(Ra) or inactive (Rj). Only Ra is able to activate the G-protein (G). The 
agonist (A) has affinity for both Rj and Ra, but affinity is higher for Ra (in 
the case of inverse agonists, affinity would be higher for Rj ).42 
Additionally, binding of A to Rj, to form ARj, promotes conversion to 
ARa (i.e. activation of the receptor). Finally, G can be activated when 
ARaG is formed (agonist binding and receptor activity), or when RaG is 
formed (representing constitutive activity).42 
Fieure 1-10: Cubic ternary complex model of GPCR activation 
Source: Adapted. originally from Kenakin 2002" 
A: agonist; G: G-protein; Ri : inactive form of receptor; R.: active form of receptor. 
A more complex extension to the model postulates different receptor 
active conformations, for which different ligands have varying affinity, 
and which may be able to signal via differing G-proteins and signalling 
cascades.43 
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1.2.2.2 G-protein activation cycle 
As a superfamily, serpentine receptors can be activated by a variety of 
stimuli, including photons (rhodopsin), ions (calcium receptors), odorant 
molecules (olfactory receptors), gustatory molecules 
(bitter/sweet/savoury receptors), peptides (endothelin receptors, CCK 
receptors). proteins (Iatrophil in receptor) and biogenic amines 
(adrenoceptors. histamine receptors)?-9 
t 
Flcure 1-11: G-proteln activation by GPCRs 
Source: Sven Jahnichen, 24.04.2006. 
I ~ ~ ~ ~ ~ ~ ~
~ ~ ~ ~ f f fggggg 
• 
1. The GPCR in the inactive conformation is bound to the heterotrimeric G-protein. The G·protein a-subunit in this 
inactive complex is bound to guanine diphosphate (GOP). 
2 and 3. The agonist binds to receptor, which undergoes a conformational change. 
4. The activated receptor causes the exchange of GOP for guanine triphosphate (GTP) on the G' protein a-subunit . 
5. Binding of GTP causes the G' protein a·subunit to dissociate from the l3y subunit 
6. The G' protein a·subunit possesses intrinsic GTPase activity causing hydrolysis of GTP to GOP. The GOP-bound a-
subunit can then re-associate w ith the rest of the G' protein and GPCR in the inactive state. 
In the case of the J3-adrenoceptors. activation is initiated by the 
endogenous catecholamines adrenaline (1) and noradrenaline (2) ,3 see 
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section 1.1. On binding of the ligand, the receptor undergoes a 
conformational change, causing activation of the bound G-protein 
(Figure 1_11).12 The inactive G-protein is bound to GOP and is 
comprised of a, (3 and V sub-units that are associated together. 12 The 
conformationally changed receptor results in displacement of GOP by 
GTP .11, 12 Consequently, the G-protein fragments into an a sub-unit 
and a (3v sub-unit. These are then able to activate other protein targets 
(see below). The activation cycle is terminated when the GTP bound to 
the a sub-unit is hydrolysed back to GOP. This GTPase activity is 
inherent within the a sub-unit as a self-control mechanism.44 The 
deactivated a sub-unit is then able to re-associate with a (3v sub-unit 
and receptor to reform the inactive GPCR complex. 
1.2.3 Signal transduction in p-adrenoceptors 
G-protein activation subsequent to agonist binding to the receptor (see 
section 1.2.2.2), is followed by a complex cascade of events which 
both transfer the signal and amplify it. 
All three (3-adrenoceptor sub-types are able to signal via the Gs 
(stimulatory) protein. A depiction of events downstream to Gs activation 
is shown in Figure 1-12, taking the (32AR as an example. 
On activation and dissociation of the G-protein, the as and (3v sub-units 
are capable of triggering separate signalling pathways. The as subunit 
causes activation of adenylyl cyclase, resulting in conversion of 
adenosine triphosphate (A TP) to cyclic adenosine monophosphate 
(cAMP).45 Signal amplification arises from multiple molecules of cAMP 
being produced by activation of each adenylyl cyclase, as well as in 
earlier steps of the cascade, where each as sub-unit can activate 
multiple adenylyl cyclases, and each activated receptor can in turn 
activate several G-proteins. 
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PKA 
Ficure 1-12: PZAR slCMllinC pathway" 
Source: Lynch and Ryall 2ooS4S 
AOP: adenosine diphosphate; Akt: protein kinase B; ATP: adenosine triphosphate; cAMP: cycl ic adenosine 
monophosphate; CNGs: cyclic nucleotide-gated ion channel; Epac: exchange protein activated directly by cAMP; GOP: 
guanine diphosphate; GTP: guanine triphosphate; POE: phosphodiesterase; PI3K: phosphoinosit ide-3-kinase; PKA: 
protein kinase A - comprising of two regulatory (Rlla and RIIP) and two catalytic subunits. 
A: The P2AR and adenylyl cyclase are t ransmembrane proteins. Prior to activation, the G-protein exists as the 
heterotrimer bound to GOP and is associated with the cell membrane.C5 
B: Binding of agonist (e.g. adrenaline) to the P2AR cause G-prote in activation and dissociation of the a and PY sub-
units (see section 1.2.2.2). The py sub-unit is able to activate the P13K/Akt pathway, whereas the a sub-unit (in the 
case of a G, protein) activates adenylyl cyclase. Adenylyl cyclase converts ATP to cAMP - the secondary messenger. 
cAMP is able to activate a number of targets such as CNGs, Epac and PKA. Signal control is achieved by activation of 
POEs by PKA that terminate the secondary messenger signal by hydrolysing cAMP." 
19 
Introduction 
The secondary messenger cAMP has several diverse signalling targets, 
including cyclic nucleotide-gated ion channels (CNGs), exchange 
protein activated directly by cAMP (Epac) and protein kinase A (PKA).45, 
46 CNGs are cation channels made up of multiple sub-units arranged to 
form a pore, and can be activated directly by cyclic nucleotides such as 
cAMP.45, 47 Modulation of the levels of cations such as Na+ and K+ 
allows control of cell excitability, whereas Ca2+ has secondary 
messenger role in other signalling pathways. Epac proteins (Epac 1 
and 2) modulate the activity of Rap1 and Rap2 which are members of 
the Ras-type monomeric GTPase protein family.45, 47 Essentia"y 
GTPase proteins are able to bind GTP and catalyse hydrolysis to GOP; 
in a similar manner to the heterotrimeric G-proteins, and act as 
signalling molecules in their own right.45, 48, 49 The GTPase activity of 
Ras-type proteins is facilitated by proteins such as GTPase activating 
proteins (GAPs), and guanine nucleotide exchange factors (GEFs).47 
GAPs cause acceleration of the hydrolysis reaction of Ras-type 
proteins, whereas GEFs are involved in the exchange of GOP for 
GTP.47 Epac proteins are GEFs specific to Rap1 and Rap2.45. 47 The 
Rap1 and Rap2 GTPases are subsequently able to interact with the 
mitogen-activated protein kinase (MAPK) signalling cascade 
downstream.45, 48, 49 
The main cAMP effector is PKA, a heterotetrameric protein comprising 
of two catalytic and two regulatory sub-units.45 Binding of cAMP to the 
regulatory sub-units induces a conformational change in the protein 
which unmasks the catalytic sub-units.45 Once exposed, PKA is able to 
phosphorylate a number of cytosolic and nuclear targets.45 Diffusion of 
the active catalytic PKA sub-units into the nucleus can result in 
phosphorylation of cAMP response element binding protein (CREB) and 
subsequent binding of phosphorylated CREB to cAMP response 
element (eRE) promoters on DNA, thus initiating gene transcription.45 
With regards to heart function, PKA phosphorylates L-type voltage-
dependant calcium channels, phospholamban and troponin I which are 
involved in the cardiac muscle contraction.5o 
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In addition, PKA can phosphorylate the J32AR, causing a switch in the 
signalling system from Gs to Gj • 11 , 49, 51-53 The OJ sub-unit of the Gj 
protein, in general has actions opposing those of the Os sub-unit; i.e. 
inhibition of certain adenylyl cyclases 11, a reduction in cAMP production 
and consequent dampening down of any cAMP-mediated signalling. 
Interestingly, during G-protein coupled receptor (GPCR) coupling to Gi, 
the J3v sub-unit appears to be able to activate the MAPK cascade. 11 , 49, 
52 
The J3v subunit may also have a role in activating the PI3KJAkt pathway 
which is involved in a variety of roles involving protein synthesis.45 The 
exact significance of this interaction is yet to be elucidated. 
The complex interplay between a variety of signalling systems means it 
is difficult to interpret the exact outcomes of J3-adrenoceptor activation. 
Although the immediate effects of receptor activation are evident (e.g. 
increases in heart ratelforce of contraction on stimulation of the J31AR 
via coupling of the cAMP signalling system to the cardiac contractile 
muscle machinery)5o, the longer term effects are less clear. 
It is known, for example that extensive exposure to agonists such as 3 
cause further phosphorylation (via J3-adrenergic receptor kinase (J3ARK) 
recruitment by J3v sub-units 11) of the J32AR (beyond the PKA-mediated 
desensitisation) allowing targeting by arrestins. 12, 54 The arrestins can 
bind to the G-protein binding domain preventing further G-protein 
activation, as well as facilitating internalisation of the receptor itself into 
clathrin-coated pits. 54 
The MAPK, PI3KJAkt, and theoretically other signalling cascades,11 
have the potential to affect almost all aspects of the cell cycle and cell 
activity. The actual outcome is likely to be a fine-tuned response reliant 
on cell type, length of receptor activation, agonist residency period as 
well as the nature of the agonist itself. Indeed extensions of the cubic 
ternary complex model (section 1.2.2.1), suggest that different agonists 
may induce different activated receptor conformations, that in turn have 
the potential to activate different signalling cascades, or activate 
signalling cascades to different degrees.43 
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1.3 History and development of 131-adrenoceptor antagonists 
The possibility that adrenoceptors might exist in two sub-types was first 
suggested by Raymond Ahlquist in 1948, when a tentative classification 
of a and ~ ~ adrenoceptors was made.4 Subsequently, in 1958, a young 
James Black began work with Imperial Chemical Industries PLC (ICI) 
with a clear objective in mind: 
" ... 1 wanted to find a {3-receptor antagonist. I expected this to reduce 
pulse rates at rest and during exercise and hoped that it would 
decrease the susceptibility of patients to angina pectoris." 55 
Remarkably, the notion that the ~ - a d r e n o c e p t o r s s could be further sub-
divided into ~ 1 A R R and ~ 2 A R s s did not surface until 196756 - some time 
after efforts to develop a ~ - a d r e n o c e p t o r r antagonist to treat cardiac 
diseases had already been initiated. 
1.3.1 First generation P-blockers 
The initial breakthrough in developing a ~ - a d r e n o c e p t o r r antagonist 
came in 1959, from the Lilly research laboratories with 
dichloroisoprenaline (DCI) (5).57 An analogue of isoprenaline (3), DCI 
had poor efficacy and retained partial agonist activity.55, 57-59 
OH H C I ~ N y y
CIA) 
5 
Figure 1-13: First generation compounds 
6 
Dichloroisoproterenol (5), pronethalol (6) and propranolol (7). 
7 
The naphthyl analogue of DCI was investigated as a replacement for 
the dichlorophenyl group, and became later known as pronethalol (6).55, 
58 Although the undesirable intrinsic sympathomimetic activity or partial 
agonist effects were considerably lower. 6 was found to produce thymic 
tumors in rats.58 Further studies aimed at eliminating any potential 
carcinogenicity, led to insertion of a methoxy linker before the 
ethanolamine mOiety.so Lack of availability of 2-naphthol at the time 
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prompted the use of 1-naphthol instead, subsequently in 1964, 
propranolol (7) - the first clinically relevant J3-blocker was reported.2, 58, 
61 When the 1-naphthol analogue was eventually synthesised it was 
found to be a poorer antagonist than 7. 
Propranolol was reported to be around 10-fold more active in blocking 
the actions of isoprenaline compared to pronethalol, had fewer side 
effects, and did not show any signs of carcinogenicity.61 
The versatility of propranolol is evident from its continual use in a 
variety of disorders in the current clinical setting, including; 
hypertension, portal hypertension, phaeochromocytoma, angina, 
arrhythmias, thyrotoxicosis, anxiety, and migraine prophylaxis.62 
With the observations published by Lands in 196756 , indicating the 
existence of at least two different types of J3-adrenoceptor came the 
realisation that propranolol was actually a non-discriminatory 
antagonist. The unsuitability of propranolol for patients suffering from 
chronic obstructive airways disorders had previously been identified.63 
Consequently, attention shifted to the development of cardiac-selective 
antagonists, which were less likely to induce bronchospasm. 
Earlier compounds such as 6 and 7 were also found to possess an 
undesirable 'membrane stabilising activity' or local anaesthetic 
activity.64 By affecting the conduction of nerve impulses, these drugs 
were found to have a direct depressant activitY64' 65 on the heart 
unrelated to their J3-adrenoceptor antagonist ability. This activity 
appeared to be related to lipophilicity65, thus subsequent approaches 
were also aimed at reducing Iipophilicity.59 
1.3.2 Second generation f3-blockers 
Practolol (8) was developed in 1968, and became the first compound 
available displaying selectivity towards the J31AR.66 It differs from 
propranolol by replacement of the napthyl group with an acetanilide 
structure; the acetamide group being positioned para- to the 
oxypropanolamine. This para-substitution was found to be important in 
conferring selectivity (see section 1.5.1.3).67 Although less potent than 
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propranolol as a J31 AR antagonist,64, 67 practolol was considered 
clinically superior, due to its improved selectivity profile and lack of 
membrane stabilising activity (MSA)64, 66. Unfortunately, practolol was 
found to cause oculomucocutaneous syndrome resulting in mucosal 
ulceration, conjunctivitis, drying of the eyes, and in some cases loss of 
vision.68 These unacceptable side-effects resulted in the withdrawal of 
practolol several years later. 
H 
' y N ~ ~
o ~ O ~ N ~ ~
OH H 
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Figure 1-14: Pioneering second generation compounds 
Practolol (8) and atenolol (9). 
Manipulation of the acetamide structure of 8 eventually led to the 
discovery of atenolol (9) in 1973, as a compound offering good activity 
as a J31AR antagonist, cardioselectivity and without intrinsic 
sympathomimetic activity (ISA) or MSA69. Selectivity was maintained 
by reversal of the amide configuration in practolol, however it was the 
insertion of a methylene linker that was found to remove the ISA.59 
C ( ~ N ~ ~
OH H 
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Figure 1-15: Second generation compounds with reponed cardloselectlvlty discovered during the 1970's 
Acebutolol1O (10), bevantolol" (11), pamatolol72 (12), metoprolol" (13) and tolamolol 14 (14). 
24 
Introduction 
During the 1970's, numerous examples of r31AR antagonists with 
differing selectivity and activity profiles were synthesised. Those 
reported to be cardioselective59 are shown in Figure 1-15. 
Many of these older compounds, although relatively more 
cardioselective than their precursors, are still associated with a large 
number of adverse effects (circulatory problems, male impotence, 
hypoglycaemia) 58,62 mediated by blockade of the r32AR. 
1.3.3 Third generation IJ-blockers 
In addition to further improving selectivity, the third generation of 
compounds resulted from a need to tackle the problem of metabolism 
with compounds such as acebutolol (10) and metoprolol (13).59 These 
drugs require twice or three times daily doses to maintain levels in the 
plasma,62 leading to potentially irregular therapy and patient compliance 
issues. 
I O ~ O ~ ~ I 
~ O ~ N ~ ~
OH H 
15 16 
17 
Figure 1-16: Third generiltlon compounds with improved philrmilcoklnetlc profiles 
Betaxolol (15), bisoprolol (16) and celiprolol (17). 
The problems surrounding metabolism were addressed by increasing 
the bulk of the substituent para to the oxypropanolamine group.59 
Consequently, betaxolol75 (15), bisoprolol (16) and celiprolol76 (17) 
became clinically available during the 1980's. 59 
Both bisoprolol and celiprolol are used in a once-daily dosing regimen.62 
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1.3.4 Nebivolol 
Nebivolol (18a + 18b as a racemic mixture) is the latest addition to the 
range of clinically available J3-blockers. It differs from previous 
compounds in both structure and activity. In animal studies (guinea pig 
atrial and lung assay), nebivolol displays 300-fold77 J31/J32-selectivity and 
is marketed as a highly selective J3-blocker. In human ventricular 
membrane assays, the selectivity was found only to be around 40-
fold.78.79 However, in isolated whole cell preparations expressing single 
human receptor sub-types, selectivity was found to be only around 14-
fold (see Table 1_1)80. 
Binding affinity, log Ko (M) Selectivity 
131- 132- 131 132 adrenoceptor adrenoceptor 
18a+18b Nebivolol -9.04 ± 0.03 -7.89 ± 0.03 14.1 
16 Bisoprolol -7.83 ± 0.04 -6.70 ± 0.05 13.5 
15 Betaxolol -8.21 ± 0.07 -7.38 ± 0.06 6.8 
9 Atenolol -6.66 ± 0.05 -5.99 ± 0.14 4.7 
10 Acebutolol -6.46 ± 0.03 -6.08 ± 0.07 2.4 
13 Metoprolol -7.26 ± 0.07 -6.89 ± 0.09 2.3 
19 labetolol -7.63 ± 0.05 -8.03 ± 0.07 2.5 
27 Carvedilol -8.75 ± 0.09 -9.40 ± 0.08 4.5 
t--
7 Propranolol -8.16 ± 0.08 -9.08 ± 0.06 8.3 
Sotalol r---20 -5.77 ± 0.11 -6.85 ± 0.09 12.0 
r---
26 Timolol -8.27 ± 0.08 -9.68 ± 0.02 25.7 
Table 1-1: Binding affinities and selectivity for human j!-adrenoceptors of neblvolol (18a+b) and other j!-blockers In 
clinical uselO•11 
Ko for a given compound is the concentration which displaces 50% of specifically bound radioligand - 'H-CGP12177. 
Selectivity refers to the relative ratios of affinity for the P1AR and the p2AR. I.e. nebivolol is 14.1-fold more selective 
for the P1AR over the P2AR. whereas timolol is 25.7-fold more selective for the P2AR over theplAR. 
Nebivolol also exhibits a vasodilatory activity which appears to be 
mediated by nitric oXide,79 though the clinical relevance of this is yet to 
be established.62 Additionally, the racemic preparation of nebivolol 
appears to have beneficial effects on left ventricular function. 79 
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18a 18b 
Figure 1-17: Neblvolol- marketed as the racemate 
(S,R,R,R)-nebivolol (l8a) and (R,S,S,S)-nebivolol (l8b) 
As with previous compounds, the oxypropanolamine motif is retained, 
however nebivolol has two of these in an almost-symmetrical 
arrangement around the nitrogen atom. Of the possible ten 
stereoisomers, 18a is the most active.77, 82 Intriguingly, the spacial 
configuration at both of the hydroxyl-bearing carbons in 18a is opposite 
to that found in the active stereoisomers of other J3-blockers (section 
1.5.3).82 Indeed the enantiomer 18b, has around 175-fold lower affinity 
for the J31AR.82 Interestingly, nebivolol is marketed in the racemic form 
and although 18a is the more active J3-blocker83, 18b appears to be 
responsible for the vasodilatory84 effects.82 It is only the racemic form 
that appears to display beneficial activity for the left ventricle, indicating 
that 18a and 18b may have a synergistic effect.79 
The unexpected J3-blocking activity of 18a with respect to other 
compounds (i.e. activity lies with the R-configuration at the carbinol 
group, as opposed to the S-configuration), may be explained by an 
alternative binding conformation of 18a at the receptor. The chromane-
based structure of 18a confers a relatively rigid oxypropanolamine 
group in comparison to other compounds. This rigidity may mean the 
molecule is held in a conformation that also allows favourable 
interaction with the receptor.82 
1.3.5 Non-cardioselective P-blockers 
The mainstream focus on developing more cardioselective J3-blockers 
has also produced a multitude of non-cardioselective molecules59 
(Figure 1-18). Some of these compounds are available clinically 
despite being essentially non-selective between the J31AR and J32ARs, 
often, their in-vitro profile indicates selectivity towards the J32AR.81 
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Figure 1-18: ~ - B l o c k e r s s with greater selectivity towards the I32AR 
Labetolol (19), sotalol (20), alprenolol (21), bupranolol (22), nadolol (23), carazolol (24), pindolol (25) and timolol 
(26).80.81 
It is important to remember that compounds exhibiting low selectivity 
towards either receptor in in-vitro assays, may be clinically non-
selective compounds, in terms of the pharmacological effect they exert. 
Often, these compounds have extremely high affinity for the f3-
adrenoceptors, and have proven to be useful drugs where 
cardioselectivity is not important, as a much lower dose is required for 
f3-blocking activity. 
1.4 Therapeutic indications for P1-adrenoceptor antagonists 
Although initially intended to treat angina pectoris, 55 there are numerous 
conditions for which f3-blockers are now indicated. 
Angina pectoris describes the chest pain experienced due to insufficient 
blood supply to the heart. This is usually brought about by progressive 
occlusion of the vessels supplying blood to the heart. With stable 
angina, this pain is usually precipitated by exertion, whereby the 
demand for oxygen by the heart cannot be met by the reduced supply.62 
As the disease progresses, the occlusive atherosclerotic plaques can 
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rupture, resulting in clots and pain even at rest (unstable angina) with 
high risk of myocardial infarction.62 ~ - B l o c k e r s s control the heart rate 
and force of contraction and so reduce the oxygen requirement of the 
heart, thus providing control of angina symptoms.62, 85 
Although the exact mechanisms are unclear85, ~ - b l o c k e r s s are useful in 
hypertension.62 They are often used additionally, or second-line to 
diuretic agents, or other antihypertensive agents such as ACE-
inhibitors. 
~ - B l o c k e r s s have been shown to reduce the risk of recurrent infarct and 
improve mortality,85, 86 and their use is advised in the secondary 
prevention of myocardial infarction.62,87 
Arrhythmias are a complex group of conditions of varying aetiology, but 
generally result in irregular beating of the heart, quite often due to 
abnormalities in electrical conduction. The anti-arrhythmic effect (Class 
II) of ~ - b l o c k e r s s as a class of compounds, is due to their ability to 
dampen the sympathetic nervous system, in addition to controlling the 
rate and force of heart contraction62, 88. In particular, sotalol (20) has 
additional 'Class III' anti-arrhythmic properties, based on its ability to 
block potassium ion channels, allowing it to be effective in the treatment 
of more specific types of arrhythmia.88 
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Figure 1-19: p-Blockers used In heart failure 
Carvedilol (27), bucindolol (28) and xamoterol (29), Xamoterol was withdrawn 2000·', 
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In heart failure, the cardiac muscle has reduced ability to pump blood 
around the body. As the disease progresses, structural changes in the 
heart muscle and enlargement, lead to a further increase in oxygen 
requirement and reduced functional efficiency. The initial contra-
indication of j3-blockers in treating heart failure, was based upon the 
logical assumption that further depression of an already failing heart 
would be detrimental. 85 However in more recent years, certain 
compounds, such as carvedilol (27), bisoprolol (16) and metoprolol (13) 
have been shown to reduce mortality.8s It is of interest to note that 
these compounds are devoid of ISA. Compounds such as bucindolol 
(28) and nebivolol (18a + 18b), with known ISA, do not appear to cause 
a significant reduction in mortality.8s Indeed xamoterol (29) was 
developed as a partial agonist with significant agonist activity90 but was 
actually found to increase mortality. Consequently, xamoterol was 
withdrawn from the market. 
j3-Blockers are also used to treat the glaucoma, the symptoms of 
anxiety, as well as prophylactically in migraine sufferers. The diverse 
spectrum of indications for j3-blocker usage, and the fact that the 
mechanism of action in many diseases is yet to be elucidated, is likely 
to be due to the differing activity profile of each individual agent. Apart 
from differences in receptor selectivity, ISA, MSA and lipophilicity, there 
may be other effects exerted by these compounds. As mentioned 
above, sotalol (20) has the ability to block potassium channels. 
Compounds such as nebivolol (18a + 18b), labetolol (19), celiprolol (17) 
and carvedilol (27) are able to cause arteriolar vasodilatation62 though 
the long-term clinical implications of this are not clear. 
An understanding of the structural foundations of these different 
activities, may allow design of compounds tailored to a particular 
disease state, and potentially minimise side-effects through unwanted 
activity. Indeed, the underlying mechanisms in these disease states 
may also become more apparent. 
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1.5 Known structure-activity relationships (SAR) for 131-
adrenoceptor antagonists 
Often, a comprehensive idea of SAR cannot be formed due to lack of a 
complete set of molecules for comparison, or multiple changes being 
made to a compound. In addition, studies were published from various 
institutions utilising different, often incomparable, methods of 
pharmacological analysis, and through a time period when 
pharmacological techniques were also developing rapidly. 
Much of the known SAR for ~ 1 A R R antagonists has arisen from an 
intense programme of research into the area by lei from the late 1960's 
to the 1980's. 59 
Taking the aryloxypropanolamine as a core motif, various modifications 
can be made to the molecule, resulting in improved affinity for the ~ 1 A R R
and better cardioselectivity. A summary of observations reported in the 
literature is provided below (Figure 1-20) 
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Figure 1-20: Structure activity relationships map of the core aryloxypropanolamine structure 
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1.5.1 The core aromatic ring 
Numerous investigations into the type of substituent, and substitution 
pattern, of the aromatic group of the core aryloxypropanolamine have 
been carried out. Although interpretation of the results is often 
complicated, some general trends can be visualised. 
1.5.1.1 ortho-substitution 
Substitution ortho- to the oxypropanolamine backbone appears to 
increase the potency of compounds, however without increasing the 
degree of selectivity between the J31AR and J32AR, i.e. improving 
binding at both receptors.91-96 
The increase in potency appears to correlate with increasing lipophilicity 
of the substituent, with alkyl and halogen groups conferring higher 
potencies within a given series.93, 94 
A discrete series of compounds bearing an N-substituted oxyacetamide 
group in the ortho- position displayed particularly raised potencies.95 
The potencies remained consistently high, despite changes to other 
parts of the molecule, suggesting the oxyacetamide moiety promotes 
favourable receptor interactions.95 
The general observation of an ortho-substituent improving potency, may 
be sensitive to changes in other parts of the molecule. Changing the N-
alkyl group from either iso-propyl or tert-butyl, to a more extensive 
phenoxyalkyl or alkyloxyalkyl group, causes a reversal of this trend.97 
With these more flexible molecules, ortho-substitution of the 
aryloxypropanolamine ring results in reduced potency.97 This may be 
indicative of an ability of more flexible molecules to adopt a different 
orientation, or conformation in the receptor, relative to the less flexible 
molecules, resulting in slightly different SAR. 
1.5.1.2 meta-substitution 
Substituents in the meta- position to the oxypropanolamine backbone 
have been reported to improve potency in a manner similar to those 
with comparable ortho- substituents (i.e. without increasing 
33 
Introduction 
selectivity).91, 92 However, in comparison to the ortho-substituents, the 
increase in potency is not as marked.91 , 92 
1.5.1.3 para-substitution 
Early investigations into J3-blocker structure did not benefit from the 
knowledge of multiple J3-adrenoceptor targets. Because of this, 
substitution para- to the oxypropanolamine backbone was not 
considered of particular interest, due to reported reduction in antagonist 
potency.92 After Lands's paper on the existence of at least two different 
types of J3-adrenoceptor in 1967,56 and the development of differential 
pharmacological techniques, substitution at the para- position was 
investigated with renewed interest. 
In general, para-substitution resulted in reduced antagonist potency, but 
was found to confer cardioselectivity; i.e. selectivity for the J31AR over 
the J32AR.67, 73, 74, 91, 98-102 
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Figure 1-21: Amldic-based para-5ubstituents 
R2 is either H or an alkyl group; R, is generally iso·propyl, tert.butyl or an aralkyl group.67, 9', 94, 96 
Initial focus on the para-acylamino group (Figure 1-21) led to the 
discovery of 8 (see section 1.3.2). Further investigation into isosteric 
groups has shown para-urea groups are also tolerated, and offer 
improved cardioselectivity over the acylamino moeity.94 Insertion of a 
methylene group between the ring and carbamoyl precursors, led to the 
discovery of 9 and was found to improve cardioselectivity.93, 96 
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However, when the same technique was investigated with the 
corresponding para-urea and acylamino substituents (Figure 1-21), a 
notable decrease in potency was observed. 93 
Although initial increases in length of the para-substituent caused a 
reduction in potency, 93,103 further extension of the substituent causes a 
return of potency, with retention of cardioselectivity.102. 104-106 This 
indicates the ~ 1 A R R is able to accommodate a more extensive para-
substituent than the J32AR.103 
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Figure 1-22: Compounds with high selectivity for the P1AR bearing extensive substltuents para- to the 
oxypropanolamine backbone·I-100.106, 107 
RO 31-1118/flusoxolol (30); Compound from Roche Products Ltd (31); cicioprolol (32); Compounds from Merck Sharp 
& Dohme Research Laboratories (33, 34). 
Investigation into bulkier or more extensive para-substituents has led to 
two major types of compound being developed; those containing alkyl 
or aromatic groups, attached to the aryloxypropanolamine by means of 
an ether-based Iinkage,98, 99, 106 and those linked more directly to 
heterocyclic aromatics 100.107 (Figure 1-22). 
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Although the nature of the para-substituent varies considerably in 30-
34, and in other examples,106 including 8, 9, 12, 13 and 15, the 
presence of a heteroatom spaced at 2-4 atoms from the 
aryloxypropanolamine motif is common. The presence of a heteroatom 
such as oxygen or nitrogen may be important in forming an interaction 
conferring selectivity towards the ~ ~1 AR. 
During investigations into the nature of the para-substituent, insight was 
gained into the property of ISA displayed by many molecules. It 
appears this may be linked to the presence of a heteroatom, such as 
oxygen or nitrogen attached to the para-position of the ring.98 Such a 
heteroatom may be able to emUlate the ligand-receptor interaction 
possible with catecholamine agonists 1, 2 and 3, and known partial 
agonists such as 29.98 Further evidence supporting this lies in the 
activity of two particular analogues of 30. These compounds had the 
same structure as 30, but were fluorinated in either the ortho- or meta-
position relative to the oxypropanolamine backbone.98 The ortho-
compound retained ISA, whereas the meta-compound was devoid of 
ISA. It would appear that the powerful electron-withdrawing effect of 
the fluorine atom in closer proximity to the para-substituent, is able to 
reduce the ability of the nearby oxygen atom to interact with the 
receptor and produce agonist activity.98 
This role of the heteroatom in the para-position is further substantiated 
when a methylene spacer is inserted, thus removing it from direct 
attachment to the ring. Such modifications result in molecules with 
much reduced or no ISA (33 and 34).99.107 
1.5.1.4 Replacement of the aromatic group 
The ability of the ~ 1 A R R to accommodate change to the type of aromatic 
group present in the core arylethanolamine or aryloxypropanolamine 
motif, is evident from the range of available ~ - b l o c k e r s . . The aromatic 
group can be varied from phenyl (as in betaxolol 15, bisoprolol 16 and 
celiprolol 17) to naphthyl (propranolol 7), carbazolyl (carvedilol 27), 
indolyl (pindolol 25) and thiodiazolyl108 (timolol 26) to name but a few. 
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Figure 1-23: Analogues of propranolol bearing heterocyclic ring systems In exchange for the naphthalene group 
Exchange of the naphthalene ring of 6 and 7, with a variety of 
heterocyclic and non-heterocyclic ring systems, resulted in compounds 
with similar potency to the parent compounds.67, 109-111 In the case of 
propranolol analogues, those where the oxypropanolamine was 
adjoined in the a-position were more potent (Figure 1_23).110 
Attempts to incorporate larger aromatic or bulkier groups (anthracene, 
phenanthrenes, N-benzylindole), were reported to cause reduced 
potency.112 Although anthracene and xanthene are of a similar size, the 
aromatic nature of anthracene confers coplanar geometry to the carbon 
atoms in the ring. In comparison, xanthene does not have a planar 
structure, whereas the parent naphthalene does. This indicates, that 
larger planar structures such as tricyclic aromatics may not be tolerated 
well at the ~ 1 A R , , where as the kinked structure of xanthenes and the 
smaller naphthalene are. Additionally, the presence of a heteroatom 
seems important as both 24 and 27 (bearing a carbazole nucleus), are 
high affinity ligands for the ~ 1 A R 8 0 , , 8\ however the naphthalene 
structure of 7 bears no such heteroatom. 
Overall it appears a combination of factors is important regarding 
interaction with the receptor, including size and shape of the group, as 
well as heteroatom presence. These comparisons rely on the 
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assumption that a common binding orientation is shared between these 
molecules, which may not be the case. Without detailed computational 
work into the nature of the active site using x-ray crystal structures or 
accurate homology models, a more conclusive interpretation of the data 
is not possible. 
1.5.2 Oxymethylene unit 
Arylethanolamines such as 5 and 6, were essentially derived from the 
natural catecholamine structures of 1 and 2. Attempts to remove the 
carcinogenic activity of 6 led to the discovery of the 
aryloxypropanolamine class of molecules and ultimately 7.60 The 
aryloxypropanolamines as a class, redefined the core structure of f31AR 
antagonists, and are the basis for most of the clinically successful 
molecules developed since 7. 
In comparison to the arylethanolamines, the aryloxypropanolamines 
bear an oxymethylene linker unit between the aromatic and hydroxyl 
groups (Figure 1-24). 
Chain extension studies involving the arylethanolamine, where extra 
methylene units were inserted adjacent to the aromatic ring to generate 
arylpropanolamine, arylbutanolamine, arylpentanolamine and aryl 
hexanolamine analogues have also been conducted. 113 The most 
potent antagonists were the arylbutanolamines (isosteric to the 
aryloxypropanolamines).113 Furthermore, conversion of the 
arylbutanolamine to the corresponding aryloxypropanolamine (by 
replacing the methylene adjacent to the aromatic ring with an oxygen 
atom) resulted in even more potent antagonists. 113,114 
The oxymethylene group seems optimal as a linker. Insertion of a 
further methylene unit to form the oxybutanolamine analogue of 7 
caused a total loss of activity.60 
1.5.3 The asymmetric carbon· 
Inherent to the general alkanolamine structure is a chiral centre at the 
carbinol. Resolution of the Rand S enantiomers of a variety of 
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arylethanolamine-based and aryloxypropanolamine-based ~ 1 A R R
antagonists, and their subsequent testing has been carried out in 
several studies74, 98,115,116. Results show in each case that only one of 
the stereoisomers holds the majority of the antagonist activity at the 
~ 1 A R . .
R-arylethanolamine S-aryloxypropanolamine 
Figure 1-24: General structure of active enantiomer of arylethanolamines and aryloxypropanolamines. 
As is evident from the general structures (Figure 1-24) of the two 
classes of ~ 1 A R R antagonist, both share the same spatial orientation at 
the chiral centre. The difference in nomenclature arises from the group 
assignment used in the standard Cahn-Ingold-Prelog rules for absolute 
configuration of chiral compounds.117, 118 
In comparison to the R-arylethanolamines and S-
aryloxypropanolamines, their respective enantiomeric counterparts 
need to be applied in much higher concentrations to see the same 
affects as ~ 1 A R R antagonists.74, 98, 115, 116, 119 In the case of propranolol 
(7), the S-enantiomer is approximately 100-fold more active than the R-
enantiomer,116, 120 In other aryloxypropanolamines, the S-enantiomer 
has been reported as 33 to 530 times more active than the R-
enantiomer, though different studies were carried out in different animal 
models.12o 
The naturally occurring catecholamine agonists 1 and 2 are also 
arylethanolamine-based, and share the same R-configuration at the 
chiral centre.82 It therefore appears that the interaction with the ~ 1 A R R is 
stereoselective. 
The exception to the above trend is (S,R,R,R)-nebivolol (18a) as 
discussed in section 1.3.4. In this case the activity resides in the R-
aryloxypropanolamine. An explanation for the apparent anomaly may 
lie in the rigid structure of 18a, as the aryloxypropanolamine motif is 
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anchored into a chromane-based structure. The unusual pharmacology 
of nebivolol is further exemplified by studies demonstrating that 
vasodilatory effects are mediated by the (R,S,S,S)-enantiomer 18b.84 
Interestingly, the majority of ~ - b l o c k e r s s are clinically administered as the 
racemic mixture. The potential for the 'inactive' enantiomer to exert 
other pharmacological effects, as with 18b, suggests a need to 
investigate these molecules independently to ascertain the 
appropriateness of administering a racemate. 
1.5.4 The hydroxyl group 
The importance of the free hydroxy group as a core component of the 
~ 1 A R R antagonist structure is evident from attempts to functionalise this 
moiety. 
Replacement of the hydroxyl group of pronethalol (6) with isothiourea, 
thiol, amine, methylamine. and methoxy groups resulted in much 
reduced antagonist potency.114 A similar reduction in potency was 
reported with the corresponding analogues of propranolol (7).114 
Conversion of the alcohol to an acetate ester or oxazolidine (with the 
amine group) also reduced the antagonist potency of these 
molecules.92,114 
Overall, the presence of the free hydroxyl appears essential for receptor 
interaction. This is likely to be due to a hydrogen bonding interaction in 
the receptor.21 
1.5.5 Branching of the propanolamine 
In general, the unbranched propanolamine backbone is the best-
tolerated, and branching results in reduced antagonist ability .121,122 
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Figure 1-25: Examples of branching to the propanolamlne backbone 
35: General structure of aryl-substituted oxypropanolamines with methylation a to the nitrogen atom; 36: tertiary 
alcohol analogue of propranolol; 37 and 38: analogues of propranolol methylated adjacent to the naphthyloxy group; 
39: chromane-based aryloxypropanolamine; 40: benzodioxane-based aryloxypropanolamine. 
Investigations involving aryloxypropanolamine analogues bearing a 
methyl group in the a-position to the nitrogen atom were carried out 
(general structure 35), with variation of the aromatic R-substituent and 
the N-alkyl group.122 All analogues showed a reduction in antagonist 
potency relative to corresponding compounds lacking the a-methyl 
group; indeed many of the compounds were inactive.122 Previous 
studies had shown that where R1 is tert-butyl (Figure 1-25), potency is 
greater than the corresponding iso-propyl compounds (see section 
1.5.6.2).94,96 However, insertion of the a-methyl group causes a total 
loss of activity with the N-tert-butyl compounds, indicating that 
excessive steric bulk in this region is not tolerated.122 
Analogues of 7 bearing various methylations along the propanolamine 
backbone have also been synthesised (36, 37 and 38).121 Methylation 
of the carbon adjacent to the naphthyloxy group is better tolerated, 
though 37 and 38 remain poorer antagonists relative to 7.121 
A series of chromane (39) and benzodioxane (40) analogues showed 
that branching of the propanolamine backbone at the carbon adjacent 
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to the aryloxy group is tolerated. 123 In fact, in the case of benzodioxane 
40, antagonist potency was five to ten-fold that of 7. 109, 123 Chromane 
39 had similar activity to 7. Overall, the benzodioxane compounds were 
five to ten-fold more potent than their corresponding chromane 
analogues.123 
The raised potency of 40 relative to 7 could be due to several reasons. 
Firstly, ring-locking of the oxypropanolamine structure generates a more 
rigid structure, potentially holding the molecules in a favourable 
conformation in the receptor. Secondly, the benzodioxane-based 
oxypropanolamine emulates the structure of the general ortho-
substituted aryloxypropanolamine, which is known to improve potency 
(see section 1.5.1.1). 
Interestingly, the individual diastereoisomers were not isolated and 
individually tested in the chomanyl/benzodioxanyl study.123 In light of 
the unusual activity of nebivolol (18a), and its chromane-based 
structure, it seems prudent to re-evaluate the chromanyl and 
benzodioxanyl class of compounds using a more refined 
stereochemical approach. 
1.5.6 Alkylation of the amine 
1.5.6.1 Secondary amines 
The amine group is thought to form an essential salt-bridge interaction 
with an acidic aspartate residue in the receptor. 16 The sensitivity of this 
interaction to modification of the amine is evident in numerous studies 
carried out, involving alkylation of the nitrogen to the tertiary amine.6o, 92, 
108,109,124 The tertiary amine analogues were found to have much lower 
ability to act as ~ - b l o c k e r s s (measured as % inhibition of tachycardia in 
animal studies) than their secondary amine counterparts.60, 92,108,109,124 
Doses required to elicit even low activity were often much higher, and in 
some cases the compounds were inactive.6o, 92, 108, 109, 124 
In addition the few examples of primary amine compounds synthesised 
also show poorer antagonist potency than secondary amine 
equivalents.60, 109, 124 
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The presence of a secondary amine appears to allow optimal 
interaction with the receptor. It may be the case that the more sterically 
hindered tertiary amines are less able to form this required interaction 
than their secondary amine analogues. 
1.5.6.2 N-iso-propyl and N-terl-butyl derivatives 
The N-iso-propyl group was initially found to confer selectivity towards 
J3-receptors over a-receptors. In fact, it was the differential activity 
profile of 1 and 3 in different organs and vascular beds that prompted 
Ahlquist to suggest the existence of the two different classes of 
adrenoceptor. 4 
The majority of early compounds developed, and many that are 
currently clinically available bear either an N-iso-propyl or N-tert-butyl 
alkyl substituent. In comparison to a variety of N-alkyl groups, those 
that were branched with three or four carbons were found to offer better 
antagonist potency in general.60, 67, 92,101,108,110,123,124 
Generally the N-tert-butylated compounds display higher potency than 
the corresponding N-iso-propylated compounds.94,96 However the N-
iso-propyl group may confer a higher degree of J31! J32-selectivity.93 
1.5.6.3 Extensive N-alkylations 
The N-iso-propyl and N-tert-butyl groups were used extensively in the 
lei research programme up until the early 1970s. Further investigations 
into the nature of the N-alkyl substituent revealed that an N-alkyl chain 
terminating in an aromatic ring often increased potency compared to the 
corresponding N-iso-propyl or N-tert-butyl derivatives,124 though the 
extent of the increase may be assay-dependent102. 
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Figure 1-26: N-substituents terminating In an aromatic ring conferring Improved cardioselectlvlty/potency 
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The N-( 4-carbamoyl)phenoxyethyI74 group and N-(3,4-
dimethoxy)phenethyl91, 100 groups were found to confer improved 
potency and 131/132-selectivity (Figure 1_26),97 
The ether based linker in compounds with the general structure in 
Figure 1-27 seems important as a determinant of cardioselectivity.97, 125 
Replacement of the oxygen atom with a variety of different groups 
offers a range of potencies and selectivities between receptors. 125, 126 
Where X is a sulphur atom compounds have reduced potency relative 
to the parent ethers, however sulfoxide-based compounds were similar 
in activity to the parent oxygen-containing compounds. 125 In 
comparison the sulfone-based analogues had very poor potency.125 
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Figure 1-27: Variations in the group adjacent to the aromatic ring of N-aralkyl substituted aryloxypropanolamlnes 
Rand Rl are either H or a variety of non-aromatic substituents (e.g. alkyl, halogen or heteroatom in nature). 
In general, groups of the amido type (urea, amide, acetamide, 
oxyacetamide and sulfonamide) appear to improve potency and 
selectivity (Figure 1_27).126,127 Potency appears to be lower where the 
amide is linked directly to the aromatic ring, as benzamide-based 
compounds were reported to be less potent than the phenylacetamides, 
and phenoxyacetamides. 126 
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Although the urea moiety was found to proffer relatively higher 
cardioselectivity than other amide-related isosteres, it was also found to 
be less potent.126 The sulfonamide group appears to be tolerated, 
though trends are less easy to discern.126 
In addition to their findings regarding amidic isosteres, Large and 
Smith 126 found the presence of an aromatic group attached to X is not 
absolutely necessary, and can be replaced with alkyl groups to give 
compounds with good potency and cardioselectivity.126 Where an 
aromatic group was present, studies involving substituent R1 were not 
extensive enough to draw strong conclusions. 
The ethylene linker was found to be of optimal size in acting as a 
spacer between X and the nitrogen atom of the aryloxypropanolamine 
group. Additionally, branching at the a-carbon to the nitrogen with 
methyl or dimethyl groups (to give iso-propylene or terl-butylene linkers) 
was also found to improve potency.124.126 
1.6 Problems with current P-blocker therapy 
Although there are many clinically available ~ - b l o c k e r s , , there is as yet 
no ~ 1 A R R specific antagonist available.2. 58 Many, such as 8, 9, 10, 13, 
15, 16, 18a+b and 29 are described cardioselective, but generally show 
less than 50-fold ~ 1 / ~ 2 - s e l e c t i v i t y ; 8 0 . . 81 with others such as 4, 7, 19, 20, 
26 and 27 being more selective for the ~ 2 A R R (see Table 1_1).81 For 
example, atenolol (9) is an established clinically available drug, 
regarded as being cardioselective. In-vitro testing on human receptors 
shows it to have similar affinity for both the J31AR and J32AR, being only 
around 5-fold ~ 1 - s e l e c t i v e 8 1 . .
The relatively low cardioselectivity of currently available drugs, is 
thought to be lost at higher doses that are routinely used in patients 128. 
This means there are unwanted effects arising from the concomitant 
blockage of J32ARs, such as bronchospasm (leading to compromised 
respiratory function), loss of peripheral vasodilatation (leading to cold 
extremities) as well as metabolic disturbances. Consequently, all 
current ~ - b l o c k e r r therapy, even that described as cardioselective, is 
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contra-indicated in patients with asthma and peripheral vascular 
disease.52 
Figures from the British Heart Foundation suggest that around 5.9% of 
the UK population (7.4% of men and 4.5% of women) suffer from 
coronary heart disease (including angina, heart failure and those that 
have suffered a myocardial infarction).129 These are patients that are 
likely to require ~ - b l o c k e r r therapy, but statistics do not take account 
those suffering from hypertension or any of the other conditions for 
which ~ - b l o c k e r r therapy is indicated. 
Overall, this means that patients that require regular ~ - b l o c k e r r therapy 
may also experience adverse effects, due to concomitant J32AR 
blockade. In addition, patients suffering from both cardiovascular and 
respiratory diseases are unable to benefit from the potentially life-
prolonging action of ~ - b l o c k e r s . .
1.7 Research aims 
1.7.1 Selection of a lead molecule 
Due to the afore-mentioned difficulties in designing ligands for GPCR 
targets (see section 1.2.1); an analogue-based approach was adopted. 
This involved selection of an appropriate lead compound; namely an 
antagonist with a combination of high affinity for the J31AR and low 
affinity for the J32AR (i.e. good selectivity). 
An evaluation of the literature reveals further drug development 
attempts that have yielded compounds with reportedly good 
cardioselectivity. Compounds such as 41-44, are the products of 
research programs focussing on the development of the para-
substituent, and N-alkyl substituent of the core aryloxypropanolamine 
structure (Figure 1-28). 
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43 
Figure 1-28: Compounds with high cardioselectivity 
lei 89406 (41); eGP 20712A (42); 01405 (43); LK 204-545 (44). 
The available data for binding affinities at the ~ 1 A R R and ~ 2 A R R and 
selectivity for the ~ 1 A R R is displayed in Table 1-2. Binding data are 
based on displacement of a radioligand from human receptors 
transfected into Chinese hamster ovary cells. 105, 130, 131 In the case of 
41 and 42, 3H-CGP 12177130 was used as the radioligand, whereas 
Louis et al use 1251_CYP105, 131. 
Binding affinity, log KD (M) PJfh 
Pl-adrenoceptor P2-adrenoceptor selectivity 
41 ICl89406 -8.91 ± 0.09 -7.07 ± 0.06 69 
42 CGP 20712A -8.81 ± 0.03 -6.11 ± 0.05 501 
43 01405 7.92 ± 0.01 (pK j)* ** ** 
44 LK 204-545 8.52 ± 0.12 (pKj )* 5.27 ± 0.08 (pK j)* 1778* 
Table 1-2: Binding affinities and selectivity for human ~ - a d r e n o c e p t o r s s of 41-44 
Values for lei 89406 and eGP 20712A from Baker 2005;11 • values reported previously in the literature by Louis et 
a/'OS. lJJ; •• no binding data to determine selectivity. 
Due to lack of a ~ 2 A R R binding affinity value for 43 in the literature, an 
accurate evaluation of its ~ 1 / ~ 2 - s e l e c t i v i t y y is not possible. However, 
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based upon functional in-vitro experiments on rodent atrial and tracheal 
preparations, values for potency (131AR pA2 = 8.15 ± 0.22, 132AR pA2 < 
4.5) are published to give 131/132-selectivity > 4400.132 In comparison, 
using the same pharmacological methods, the 131/132-selectivity of 44 is 
quoted as 6300,132 whereas for 42 it is 13183105. Based on this data, 
the selectivity of 43 at the human receptor is likely to be high, but still 
lower than 44. 
The in-vitro rodent model indicates compounds have a much higher 
selectivity than found at human receptors. This disparity raises the 
question of relevance and viability of previous studies that used other 
animals. However it appears that although the human and rodent 13-
receptors show differences in magnitude of binding affinity, the general 
trends are the same. 105. 131 
With the exception of 41, the remaining compounds in Figure 1-28 all 
conform to the general structural requirements outlined to confer 
cardioselectivity and potency for the 131AR (see section 1.5). These 
include para-substitution of the aryloxypropanolamine motif, with a 
heteroatom positioned two to four atoms from the ring, and alkylation of 
the amino group with a two carbon linker terminating in an aromatic 
ring. 
In comparison to the other compounds, the combination of the ureido 
group, and a para-substituent to the oxypropanolamine backbone 
bearing an ethylene glycol based linker on 44, seems to provide the 
best balance of high 131/132-selectivity and good potency. 
Further evidence for the importance of the ethylene glycol moiety is 
demonstrated when the classical N-isopropyl-propanolamine is retained 
(i.e. no extended aromatic N-alkyl group), and only the para-alkyl group 
is modified. With these compounds, the ether or diethylene glycol 
linkage to a bulky cyclic or aromatic structure, conSistently resulted in 
augmented 131/132 selectivity in the rodent model when compared to 
various other groups.106 
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Based on available data, and comparison to other molecules published 
in the literature, 44 was selected as a suitable lead compound. 
1.7.2 Aims 
As discussed above (see section 1.6), the low ~ 1 / / 3 2 - s e l e c t i v i t y y of 
clinically available /3-blockers means their use in several disease states 
is contraindicated. In addition, they possess a number of adverse 
effects which are mediated by concomitant blockade of the ~ 2 A R . .
This project aims to generate molecules with a much improved /31//32-
selectivity, using 44 (with reported high potency and selectivity) as a 
lead compound. 
Additionally. the problems associated with designing ligands for GPCR 
targets (see section 1.2.1), means there is much to be learnt regarding 
interactions at the active site of the ~ 1 A R . . As such, a systematic 
approach to drug design will undoubtedly improve understanding of the 
nature of the ligand-receptor interaction at the ~ 1 A R . .
The following chapters report the approach adopted in modifying 
various motifs on the structure of 44, the synthetic route adopted, 
pharmacological data (provided by Dr Jillian G Baker) and a description 
of new trends and SAR. 
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OF LK 204-545 
The reported high ~ 1 A R R affinity and ~ 1 / ~ 2 - s e l e c t i v i t y y of LK 204-545 (44), 
rationalised its selection as a lead compound. 131 Due to limited 
available data on the synthesis and analysis of 44 in the literature, it 
was prudent to synthesise the described molecule, and establish an 
independent activity profile of this compound. Not only did this define 
the benchmark pharmacological profile of the lead compound using our 
own pharmacological techniques, but also allowed evaluation of the 
general synthetic route encountered with this type of molecule. 
2.1 Synthetic route employed 
The synthesis of LK 204-545 is not described in the literature, however 
the structure of the final compound and pharmacological activity are.131 , 
133 A synthetic route to the related compound,1-(2-cyan0-4-(2-
cyclopropylmethoxyethoxy)phenoxy)-3-(2-(3-phenylureido)ethylamino)-
2-propanol, is broadly described as an example of the class in patent 
literature 133, 134, however this involves introduction of the cyano group 
using cuprous cyanide. Rather than engaging in a potentially 
hazardous cyanide addition, alternative synthetic pathways were 
investigated. Since 2,5-dihydroxybenzonitrile was not commercially 
available, suitable functional group interconversion was considered. 
The ability to easily convert an aryl aldehyde to its corresponding 
nitrile,135 allowed 2,5-dihydroxybenzaldehyde (45) to be selected as an 
appropriate starting material (Scheme 2-1). 
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Scheme 2-1: Synthesis of LK 204-545144). 
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Reagents and conditions: la) triethylamine (TEA), pivaloyl chloride, N,N·dimethylformamide (DMF), 0 ·C -7 rt, 72%; 
(b) i. NaH, DMF; ii. p-methoxybenzyl bromide, O·C -7 rt, 33%; (c) 37% NH3Ioo}, iodine, tetrahydrofuran (THF), 98%; 
(d) sodium tert-butoxide, methanol (MeOH), 34%; (e) allyloxyethanol, diisopropyl azodicarboxylate (DIAD), PPh3, 
dichloromethane (OeM), 100%; (f) diethyl zinc, diiodomethane, toluene 0 ·e -7 rt, 29% 51 and 25% 52; (g) eerie 
ammonium nitrate, water, acetonitrile (MeCN); (h) TEA, rac-epichlorohydrin, 80 ·e, 100%; (i) 4-
(benzyloxy)phenylisocyanate, DeM, 94%; UI i. concentrated Hel; ii. 2M NaOH loo), neutralisation, 73%; (k) propan-2-o1, 
reflux, 2%. 
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Literature procedure for the selective mono-protection of the 5-hydroxy 
group of 45, using pivaloyl chloride to generate pivaloate ester 46, was 
followed. 136 The regioselective formation of the pivaloate ester, is 
possible by attack of the less encumbered 5-hydroxy group on the 
sterically hindered carbonyl group of pivaloyl chloride. 
The remaining hydroxy group then required orthogonal protection to the 
pivaloate ester, and the para-methoxybenzyl (PMB) group was selected 
for this purpose. The relatively low yield of 47 obtained, may be a 
reflection of the poorly nucleophilic hydroxy group ortho to the 
aldehyde. 
The ability to cleave a PMB ether under oxidative conditions, using 
agents such as ceric ammonium nitrate (CAN)137 was anticipated, since 
this allowed selective removal of the group in the presence of the nitrile 
group later on. When the equivalent synthesis was attempted using the 
benzyl ether in place of PMB, hydrogenolysis of the benzyl group 
concomitantly reduced the nitrile to the corresponding primary amine 
(confirmed by MS and TLC analysis). 
Once the orthogonally protected pivaloate ester 47 was obtained, 
conversion from the benzaldehyde to the corresponding benzonitrile 48 
was achieved cleanly in near quantitative yield. This reaction is 
believed to proceed via oxidation of the intermediate imine. 135, 138 
After deprotection of the pivaloate ester, the corresponding phenol 49 
underwent Mitsunobu coupling with 2-(allyloxy)ethanol to afford 50. 
Cyclopropanation of 50 using Simmons-Smith chemistry 139 gave a 
mixture of products. The desired PMB-protected product 51 was 
isolated and subjected to CAN-mediated oxidative PMB group 
cleavage. Unfortunately, this did not yield the desired phenol 52, 
possibly due to instability of the molecule to CAN, or oxidative 
dealkylation of the aralkyl ether14o. Re-examination of products from 
the previous Simmons-Smith cyclopropanation revealed that these 
conditions had serendipitously caused partial deprotection of the PMB 
group. Consequently, phenol 52 was recovered, albeit as a side-
product and in low yield. 
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Alkylation of phenol 52 was conducted using TEA as a hindered base, 
and refluxing in rac-epichlorohydrin to obtain epoxide 53. This was 
used without further purification. 
Reaction of ethylenediamine (54) with 4-(benzyloxy)phenylisocyanate 
delivered the benzyl-protected compound 55. Poor solubility of 55 in 
most solvents meant standard Pd(O) catalytic hydrogenolysis 
progressed very slowly. Consequently, benzyl deprotection was 
achieved cleanly in concentrated (conc) HCI to give aminophenol 56 
after neutralisation. 
LK 204-545 (44) was obtained by refluxing epoxide 53 and amine 56 in 
propan-2-ol. 
2.2 Pharmacology data 
Radioligand binding studies were carried out by Dr. Jillian Baker 
(Institute of Cell Signalling, Queens Medical Centre, Nottingham) on 
Chinese hamster ovary (CHO-K1) cells stably expressing either human 
131 or 132-adrenoceptors.27, 81, 141 Binding affinities were determined by 
competitive displacement of 3H-CGP 12177. 
Binding affinity, log KD (M) PJP2 
Pl-adrenoceptor pz-adrenoceptor selectivity 
I Literature data 8.52 ± 0.12 (pK;)* 5.27 ± 0.08 (pK;)* 1778* 
I Experimental data -8.09 ± 0.04** -5.20 ± 0.03** 776** 
Table 2-1: Human 13, and jJ,-adrenoceptor binding affinities and receptor selectivity of LK 204-545 (44). 
"n ~ ~ 8 for all assays. 'values reported previously in the literature by Louis et aim. The pK, value is comparable to 
the log Ko with inversion of sign. 
The Ko is the dissociation constant for the ligand and gives a measure 
of receptor affinity. This corresponds to the concentration of applied 
ligand which displaces 50% of specifically bound radioligand. High 
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affinity ligands will displace the radioligand at lower concentrations, 
giving larger, negative log Ko values. 
Table 2-1 shows the binding profile of 44 at the ~ 1 A R R and ~ 2 A R . .
Although a very high affinity ligand for the ~ 1 A R , , with excellent 
selectivity, the ~ 1 A R R quoted in the literature is somewhat higher. 131 
This is likely to be due to experimental differences. In-house 
radioligand binding assays conducted by Dr. Jillian Baker use 3H-CGP 
12177 as the radioligand, whereas Louis et al use 1251_CYP131. 
According to the cubic ternary complex model of receptor-ligand 
interaction (see Section 1.2.2.1), different ligands are able to stabilise 
different conformations of the receptor. Thus, if 3H-CGP 12177 and 1251_ 
CYP are stabilising different receptor conformations, the ligand applied 
in the assay (in this case 44), may possess different affinity for each 
stabilised conformation. Overall, the different assays might give 
different binding affinities for the same ligand. 
The differing results obtained, highlight the value in the re-evaluation of 
LK 204-545 using in-house pharmacology. With this data, a more 
accurate, experimentally relevant comparison with further analogues 
can be made. 
The more hydrophilic nature of 3H-CGP 12177 compared to 1251_CYP, 
means it is more suitable as a radioligand in binding assays with 
respect to much reduced non-specific binding.142 Additionally, 3H-CGP 
12177 is considered a much safer radioligand than 1251_CYP, and is also 
more practical to use with regards to the extra safety precautions 
required when using 1251_CYP. 
2.3 Modifications to the core LK 204-545 (44) structure as a 
lead compound 
Synthesis of 44 was achieved in poor yield over multiple steps. The 
need for orthogonal protecting groups extended the synthesis. With the 
need to generate many analogues in a parallel synthetic manner, the 
complications afforded by the cyano group were deemed unreasonable. 
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Removal of the cyano group provided a more facile synthetic route with 
fewer steps and less prevalent use of protecting groups. Additionally, 
ortho substitution of the aryloxypropanolamine structure is known not to 
be essential for binding to the 131AR, though may modulate it92, 126, 143. 
Finally, the synthesis of these types of molecules would fall into 
previously unexploited chemical space. 
Previous studies involving para-substituted N-
isopropylphenoxypropanolamines 106 compared several motifs for 131AR 
and 132AR affinity. Of these para-substituents, the 2-
(cyclopentyloxy)ethoxy- group was found to have comparatively higher 
affinity for the 131AR compared to the 2-{cyclopropylmethoxy)ethoxy 
group present in LK 204-545. Synthesis of this group was also reported 
as a one step reaction with reasonably high yield. 144 
Overall, our new target lead pharmacophore was 1-(2-(3-(4-(2-
{cyclopentyloxy)ethoxy)phenoxy)-2-hyd roxypropylami no )ethyl)-3-( 4-
hydroxyphenyl)urea (57); illustrated in Figure 2-1. 
2.4 Areas for investigation on lead compound 
The new lead pharmacophore was designed to be amenable to a more 
parallel synthetic approach. Modifications to several key motifs on the 
core pharmacophore were planned in order to build up clear structure 
activity relationships. 
As previously described (see Section 1.5), the core 
aryloxypropanolamine structure is essential for binding to the 131AR. 
However, modifications to other areas of this particular pharmacophore 
have not been systematically investigated. 
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hydroxypropylamlno)ethyl)-3-(4-hydroxyphenyl)urea (57). 
The modifications described in Figure 2-1 will be detailed in the 
following chapters. These include modifying the nature and position of 
substituents on the aromatic ring adjacent to the urea (Chapter 3), 
investigation of urea isosteres or replacement groups (Chapter 4), 
modification of the ethylene glycol linker terminus and varying the 
substituents on the central ring (Chapter 5). 
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THE UREA 
Although similar compounds to 57 exist in the literature131 , 133, 134, an 
investigation into substitution of the aromatic ring adjacent to the urea, 
had not previously been carried out in a logical or systematic fashion. 
3.1 Principles behind synthetic strategy 
Taking 57 (derived from LK 204-545, Chapter 2) as an initial target 
compound, it was envisaged that a series of analogues with differing 
substituents on the aromatic ring adjacent to the urea, could be 
synthesised with relative ease. 
The classical route to aryloxypropanolamines involves aminolysis of the 
corresponding glycidyl aryl ether59 in either neutral or basic conditions, 
to effect opening of the epoxide via the least hindered carbon.145 On 
this basis, the strategy employed required separate syntheses of the 
epoxide and amine fragments, before a final convergent epoxide 
opening step. 
3.2 Phenyl mono-substituted compounds 
In order to evaluate the positional, steric and electronic effects of ring 
substituents, it was necessary to compare a range of ortho-, meta- and 
para- derivatives. Accordingly, the methyl, methoxy, fluoro, chloro, 
bromo, trifluoromethyl and hydroxy analogues were all synthesised 
alongside the unsubstituted phenyl urea. 
3.2.1 Synthesis of the epoxide fragment 
Generation of epoxide 62 was relatively straightforward, and high 
yielding, via four steps from commercially available starting materials 
(Scheme 3-1). 
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Scheme 3-1: Synthesis of Z-((4-(Z-(cyclopentyloxy)ethoxy)phenoxy)methyl)oxlrane (6Z). 
Reagents and condition: (a) NaBH., ZrCI., THF 0 - 5 'C, 81%. (b) PPh • .4-(benzyloxy)phenol, di-tert-butyl 
azodicarboxylate (DBAD), DCM, 75%; (c) H2, 10% Pd/C, ethanol (EtOH), 100%; (d) I. NaH, DMF, O'C ~ ~ rt; ii. roc-
epichlorohydrin, 84%. 
Reductive cleavage of cyclopentanone ethylene ketal 58 to 2-
(cyclopentyloxy)ethanol 59 was achieved via literature procedures. 144 
The alcohol 59, was then coupled directly to 4-benzyloxyphenol using 
Mitsunobu chemistry.146 DBAD was selected as the azodicarboxylate 
for reported acid lability and subsequent ease of removal on workup.147-
149 The benzyl (Bn) protected phenol 60 was subjected to standard 
hydrogenolysis conditions over Pd(O) to yield phenol 61. Finally, formal 
deprotonation of 61 with NaH, followed by treatment with excess rac-
epichlorohydrin, gave the desired 2-((4-(2-
(cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane 62. 132 
3.2.2 Synthesis of the amine fragments 
The majority of 1-(2-aminoethyl)-3-phenylureas were obtained from the 
corresponding substituted phenylisocyanates. Initially, direct reaction of 
o-methylphenylisocyanate with ethylenediamine was attempted 
(Scheme 3-2). This method required drop-wise addition of a solution of 
the reactive isocyanate to ethylenediamine at O°C. Although the 
phenylurea 63 was obtained in moderate yield, formation of the bis-urea 
was also observed, requiring further purification. In comparison, the 
use of 4-benzyloxyphenylisocyanate (see chapter 2, Scheme 2-1) in a 
similar manner was much more selective, and the desired product 55 
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was produced almost quantitatively. The lack of bis-urea formation in 
the latter example may be explained by steric hindrance from the benzyl 
group, and the associated difficulty of 55 in attacking a second molecule 
of 4-benzyloxyphenylisocyanate. 
(a) 
65a = H 65b = m-CH3 65e = p-CH3 
65d = o-OCH3 6Se = m-OCH3 65f= p-OCH3 
6Sg = o-F 65h = m-F 651 = p-F 
65j = o-CI 65k = m-CI 651 =p-CI 
65m = o-Br 65n = m-Br 650 = p-Br 
65p = O-CF3 65q = m-CF3 65r = p-CF3 
H 2 N ~ ~ I ( ~ ~ ~
oU 
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66a=H 66b= m-CH3 66e = p-CH3 
66d = o-OCH3 66e = m-OCH3 66f= p-OCH3 
66g = o-F 66h = m-F 661 = p-F 
66j = o-CI 66k= m-CI 661 =p-CI 
66m = o-Br 66n = m-Br 660 = p-Br 
66p = o-CF3 66q = m-CF3 66r = p-CF3 
Scheme 3-2: Synthesis of phenyl mono-substituted 1-(2-aminoethyl)-3-(phenyl)ureas derived from 
ethylenediamine (63, 66a-r). 
Reagents and conditions: (a)o-tolyl phenylisocyanate, OeM, 0 ·e 7 rt, 64%; (b) di-tert-butyl dicarboKylate (80C20 ), 
oeM, 87%; (c) phenyl-substituted phenylisocyanate, OeM, o·e 7 rt, 46-95%; (d)MeOH/conc Hel, 80-100%. 
Due to the problems encountered in the synthesis of 63, the mono-Boc 
protection of ethylenediamine (54)150 was employed to offer improved 
selectivity when reacting with the phenylisocyanates. As anticipated, 
stoichiometric addition of a range of substituted phenyl isocyanates to 
64, followed by addition of hexanes to the reaction mixture caused 
precipitation of the Boc-protected substituted phenylureas 65a-r 
(Scheme 3-2), which required no further purification. Finally Boc 
deprotection was achieved cleanly in a mixture of methanol and conc 
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Hel to give the hydrochloride salts of the mono-substituted 1-(2-
aminoethyl)-3-phenylureas 66a-r. 
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Scheme 3-3: Alternative synthesis of 1-(2-amlnoethyl)-3-(4-hydroxyphenyl)urea (56). 
Reagents and conditions: (a) SSr!, OeM, -78·C ~ ~ rt, 100%. 
It was envisaged that 65f could be used to give a cheaper and more 
efficient route to 56. Indeed treatment of 65f with BBr3151 , produced 56 
in quantitative yield in a single step (Scheme 3-3). 
Lack of the appropriate isocyanate starting materials, necessitated an 
alternative strategy for synthesis of the ortho- and meta-hydroxy 
substituted derivatives. In these examples, it was thought that the 
readily available 2- and 3-aminophenols could be used to attack the 
appropriate aliphatic isocyanate to give the desired urea compounds. 
With this in mind, synthesis was possible using J3-alanine (67), as a 
starting material (Scheme 3-4). 
(8) 
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Scheme 3-4: Synthesis of ortho- and meta-hydroxy substituted 1-(Z-amlnoethyl)-3-(hydroxyphenyl)urea 
hydrochlorides (7Da-b). 
Reagents and conditions: (a) phthalic anhydride, 150 ·C, 94%; (b) i. diphenylphosphoryl azide (OPPA), TEA, toluene; ii. 
Reflux; iii. 2-aminophenol or 3-aminophenol, 75-76%; (c) i. hydrazine monohydrate, EtOH, reflux; ii. acidic workup 
51-60%. 
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The phthalimide protecting group was selected to eliminate the 
nucleophilic nature of the nitrogen atom, thus preventing potential side 
reactions during isocyanate formation. As has previously been 
demonstrated with groups such as Boc, the mono-acylated amine still 
has a propensity to attack the isocyanate during Curtius 
rearrangement. 152 Overall, this leads to the undesirable formation of 
the cyclic Boc-protected urea side-product, and necessitates use of bis-
protected amine (as is present with phthalimide).152 
Protection of 67 was achieved with ease through a literature procedure 
to give 68. 153 Using DPPA in basic conditions, 68 was converted to the 
corresponding acyl azide before careful reflux to facilitate Curtius 
rearrangement to the isocyanate (not isolated).154 Once evolution of 
nitrogen had ceased, either 2- or 3-aminophenol was added to produce 
the corresponding hydroxyphenylureas 69a-b. The desired amines 
70a-b, were obtained as their hydrochloride salts, by standard 
hydrazinolysis of the phthalimide group followed by acidic workup 
(Scheme 3-4). 
3.2.3 Epoxide opening of 2-«4-(2-
(cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane (62) 
Opening of epoxide 62 was effected by refluxing with the appropriate 
amine in propan_2_01. 143, 155, 156 Where the amines were present as 
hydrochloride salts, a slight excess of NaOH was added (Scheme 3-5). 
Yields were typically poor, due to attack on the epoxide by the initial 
aryloxypropanolamine product. This is not generally a problem in the 
synthesis of most ~ - b l o c k e r s s due to isopropylamine or tert-butylamine 
being used to open the epoxide. 59 These low boiling amines are used 
as the reaction solvent, and are present in such a vast excess, that 
excessive alkylations are suppressed. 
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71a=H 
71 b = o-CH3 71 C = m-CH3 71 d = p-CH3 
71e = o-OCH3 71f = m-OCH3 719 = p-OCH3 
71h = o-F 711 = m-F 71j = p-F 
71k = o-CI 711 = m-CI 71m = p-CI 
71n = o-Br 
71q = o-CF3 
71t = o-OH 
710 = m-Br 
71r = m-CF3 
71u = m-OH 
71p = p-Br 
715 = p-CF3 
57 = p-OH 
Scheme 3-S: Synthesis of phenyl-substituted 1-(2-(3-(4-(2-(cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamlno)ethyl)-3-(phenyl)ureas (71a-u. 57). 
Reagents and conditions: (a) 56/63. propan-2-ol. reflux, 29-31%; (b) 66a-r, 7Qa-b, NaOH. H20. propan-2-ol, reflux, 7-
29%. 
3.2.3.1 Confirmation of epoxide aminolysis by hydroxyphenyl 
urea compounds 
Although relatively less nucleophilic than the primary amine, the 
phenolic groups present in 56 and 70a-b have the potential to compete 
with the amino moiety on the molecules during epoxide opening. 
Taking 57 as a case study, 1H_13C heteronuclear single quantum 
correlation (HSaC) and 1H_13C heteronuclear multiple bond correlation 
(HMBC) experiments were carried out to confirm that aminolysis of the 
epoxide had actually taken place (Figure 3-1, Figure 3-2). 
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FI,ure 3· 1: Full'H.uC HSQC/HMBC nuclear ma,netlc resonance spectroscopy (NMR) experiment overlay of 57 In 
deuterilted dimethyl sulfoxide (OMSO-d,). 
HSQC data is shown in red, HMBC data is overla id in green. The relevant 'H proton and U c carbon experiments are 
displayed on the x- and y-axes respectively. Phenol and urea proton peaks have been highlighted. The yellow section 
is magnif ied in Figure 3-2. 
The presence of the low-field phenolic proton at 8.91 ppm (Figure 3-1) 
and the chemical shift of the diastereotopic 'e' protons (2.56 - 2.71 
ppm, Figure 3-2) indicate that these protons are adjacent to a nitrogen 
atom (rather than an oxygen atom), thus aminolysis has occurred. In 
addition, if the coupling path of the 'E' protons (3.12 - 3.16 ppm, Figure 
3-2) is followed, there is clear coupling back through the secondary 
amine to the 'B' proton. 
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Figure 3-2: IH_lle HSQC/HMBe NMR experiment overlay of 57 in DMSO-d. - magnification of aliphatic region. 
Spectral assignment car ri ed out using IH_IH correlation spectroscopy (COSY) and 'HY C HSQC experiments. HSQC 
data is shown in red, HMBC data is overla id in green. The relevant ' H proton and BC carbon experiments are 
displayed on the x- and y-axes respectively. Overla id spectra clearly display a coupling route f rom methylene E to 
methine B; demonstrating aminolysis of the epoxide 62. The key coupling between 'D' protons and the 'C' carbon is 
highlighted. 
3.2.3.2 Confirmation of core aryloxypropanolamine structure 
It is widely accepted that nucleophilic opening of epoxides under neutral 
or basic conditions proceeds via the least hindered carbon to give the 
secondary alcohol. 145. 157-159 This configuration of the 
aryloxypropanolamines was present in all compounds synthesised. 
Evidence for regioselective opening can be taken from 1H_13C HSaC 
NMR experiment of 57 (Figure 3-2). The 'e' protons at 2.56 - 2.71 
ppm display a chemical shift too low to be adjacent to an oxygen atom 
64 
Substitution of the aromatic ring adjacent to the urea 
(as would be the case with the alternative epoxide opening). The 13C 
chemical shift for the "e' carbon (52.20 ppm) also supports this. 
In addition, it would be expected that both "e" and '0' signals for 1H and 
13e experiments would have similar chemical shifts, as both methylene 
groups flank the secondary amine. This is indeed the case as shown in 
Figure 3-2. 
3.2.4 Pharmacology results 
The binding affinity of 71a-u and 57 at both the J31AR and J32AR is 
compared below in Table 3-1 and Figure 3-3. All compounds have 
fairly poor affinity for the J32AR, and relatively higher affinity for the 
J31AR, thus displaying a degree of selectivity; however there are clear 
trends evident relating to the substitution pattern of R1. 
The J32AR binding affinities display no discernible trends with Ko values 
in the low millimolar to high nanomolar range, with the m-F (71 i, log Ko 
= -6.54 ± 0.02 M) and o-eH3 (71 b, log Ko = -6.27 ± 0.02 M) displaying 
the highest affinities. 
In comparison, binding at the J31AR displays clear trends (Figure 3-3).lf 
the unsubstituted derivative (71 a) is taken as a benchmark, it is evident 
that the o-substituted analogues have J31AR affinity that is generally 
around an order of magnitude lower than 71a. The exception is the o-F 
compound 71 h which displays comparable affinity to 71 a. The 
unusually high Ko value for the o-F analogue may be because binding 
at the J31AR is sterically sensitive towards ortho substituents. The 
similarity in atomic radius (van der Waals) between a hydrogen (1.2A) 
and fluorine atom (1.35A) 160 may mean that the o-F substituent exerts a 
similar steric presence to hydrogen. Consequently, larger groups are 
less well tolerated at the o-position. There also appears to be 
contributing electronic factors, as the steric argument does not hold 
when comparing the o-CH3 (71b) and o-CF3 (71q) analogues. 
The m- and p-substituted analogues display much higher J31AR affinity 
than corresponding o-substituted analogues, with m-substitution 
generally affording the highest affinity of all. Overall, the p-OH (57), m-
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F (71i), m-CI (711) and m-CH3 (71c) derivatives display the highest 
affinity at J31AR. Other analogues display either slightly reduced J31AR 
affinity or, as in the case of p-CI, m-OH and m-Br compounds, had 
comparable affinity to when there was no substitution (71a). 
Rl 
Binding affinity, log KD (M) f3Jf32 
f31-adrenoceptor f32-adrenoceptor selectivity 
71a H -7.90 ± 0.05 -5.52 ± 0.03 240 
71b O-CH3 -7.33 ± 0.03 -6.27 ± 0.02 11 
71c m-CH3 -8.04 ± 0.04 -6.06 ± 0.03 96 
71d p-CH 3 -7.76 ± 0.04 -5.80± 0.03 91 
71e O-OCH3 -7.02 ± 0.04 -5.93 ± 0.02 12 
71f m-OCH3 -7.76 ± 0.03 -6.05 ± 0.03 51 
71g P-OCH3 -7.80 ± 0.04 -5.86 ± 0.04 87 
71h o-F -7.82 ± 0.03 -s.94± 0.04 76 
711 m-F -8.17 ± 0.03 -6.s4± 0.02 43 
71j p-F -7.70 ± 0.04 -5.92 ± 0.09 60 
71k o-CI -7.11 ± 0.03 -5.54 ± 0.03 37 
711 m-CI -8.14 ± 0.04 -5.59 ± 0.05 355 
71m p-CI -7.95 ± 0.05 -5.91 ± 0.06 110 
71n o-Br -7.11 ± 0.01 -6.10 ± 0.03 10 
710 m-Br -7.92 ± 0.05 -5.99 ± 0.04 85 
71p p-Br -7.77 ± 0.04 -5.86 ± 0.04 81 
71q O-CF3 -6.94 ± 0.01 -5.84 ± 0.02 13 
71r m-CF3 -7.77 ± 0.06 -5.86 ± 0.06 81 
71s P-CF3 -7.70 ± 0.04 -5.76 ± 0.04 87 
71t o-OH -6.99 ± 0.08 -5.96 ± 0.05 11 
71u m-OH -7.89 ± 0.06 -5.85 ± 0.06 110 
57 p-OH -8.16 ± 0.08 -5.45 ± 0.10 513 
Table 3-1: Human ~ , , and /i.-adrenoceptor binding affinities and receptor selectivity of phenyl-substituted 1-(Z-(3-
(4-(Z-(cyclopentyloxy)ethoxy)phenoxy)-Z-hydroxypropylamlno)ethyl)-3-(phenyl)ureas (71a-u. 57). 
n ~ ~ 5 for all assays. 
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The p-OH (57) analogue is of particular interest, as it has much higher 
affinity than other p-substituents and the corresponding m-OH 
compound. This is possibly due to hydrogen bond-donor activity of this 
group with the ~ 1 A R , , as other substituents at this position would be 
unable to form this kind of interaction. 
With the exception of the m-F (71i) compound, high ~ 1 A R R affinity 
translates into relatively high ~ 1 / ~ 2 2 selectivity. This is due to the 
comparably low affinity these compounds have for the ~ 2 A R . . The m-F 
compound is unique, as although it has the highest ~ 1 A R R affinity, it also 
has reasonable ~ 2 A R R affinity, resulting in only 43-fold receptor 
selectivity towards ~ 1 A R . . This indicates that the m-F group, or its effect 
on the phenylurea, may cause preferential interactions in the ~ 2 A R . .
The best ~ 1 / ~ 2 - s e l e c t i v i t i e s s are conferred by the p-OH (513 fold) and m-
el (355 fold) derivatives, with the unsubstituted compound having 240 
fold selectivity. 
3.3 PhenyI3,4-di-substituted compounds 
The pharmacological data for the phenyl mono-substituted compounds 
71a-u and 57 displayed a clear trend as discussed above. Based on 
these findings and considering the two analogues with highest ~ 1 A R R
affinity - 57 (p-OH, log Ko = -8.16 ± 0.08 M) and 71i (m-F, log Ko = -
8.17 ± 0.03 M), it was deemed prudent to investigate the binding affinity 
of the 3-f1uoro-4-hydroxy di-substituted analogue. The presence of both 
these motifs on the molecule could potentially confer an even higher 
~ 1 A R R affinity than each in isolation. In order to compare the combined 
effects of f1uoro- and hydroxy- functionalities, three further analogues 
were considered to be of interest. Accordingly, syntheses of 3,4-
difluoro-, 3,4-dihydroxy- and 3-f1uoro-4-hydroxy- phenylurea derivatives 
were attempted. 
As before, the amine fragments were constructed separately before 
using each in the aminolysis of epoxide 62. 
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3.3.1 Synthesis of the amine fragments 
The commercial availability of 3,4-difluorophenyl isocyanate allowed 
facile synthesis of 1-(2-aminoethyl)-3-(3,4-difluorophenyl)urea 73 as the 
hydrochloride salt, by reaction with Boc-protected diamine 64 and 
subsequent acid-mediated Boc removal (Scheme 3-6). 
(a) 
@ H H 
(b) H N ~ N N ............ N1):F __ .3 II I 
~ I I 0 ..& F 
64 73 
Scheme 3-6: Synthesis of 1-(2-amlnoethyl)-3-(3,4-dlfluorophenyl)urea hydrochloride (73). 
Reagents and conditions: (a) 3,4-difluorophenylisocyanate, DCM, 75%; (b) MeOH/conc Hel, 100%. 
1-(2-aminoethyl)-3-(3-fluoro-4-hydroxyphenyl)urea hydrochloride 77 
was constructed in a similar manner to 70a-b via intermediate Curtius 
rearrangement of acid 68 to the corresponding isocyanate. Aniline 75 
was readily obtained by reduction of 2-fluoro-4-nitrophenol (74) by 
catalytic hydrogenation over Pd(O) (Scheme 3-7). 
(a) (b) 
76 
77 
Scheme 3-7: Synthesis of 1-(2-amlnoethyl)-3-(3-fluoro-4-hydroxyphenyl)urea hydrochloride (77). 
Reagents and conditions: (a) H2, 10% Pd/e, MeOH, 90%; (b) i. 68, DPPA, TEA, toluene; ii. Reflux; iii. 75, 55%; (c) 
hydrazine monohydrate, EtOH, reflux, 84% 
The method employed in Scheme 3-7 to synthesise 77 could not be 
used in the case of the 4-fluoro-3-hydroxy- analogue, due to lack of 
commercial availability of 2-fluoro-5-nitrophenol. 
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With regards to the 3,4-dihydroxy analogue, attempted synthesis by 
initial reduction of 4-nitrocatechol was unsuccessful. Although 
reduction to 4-aminocatechol does occur, the product undergoes 
spontaneous air oxidation to 2-hydroxy-4-iminoquinone. 161 
Consequently, synthesis of the remaining amines B4a-b was attempted 
from the corresponding substituted benzoic acids 7Ba-b. Presence of 
nucleophilic phenol moieties in 7Ba-b necessitated protection prior to 
Curtius rearrangement of the acid group (Scheme 3-B). Protection of 
the phenol resulted in concomitant formation of the benzyl esters 79a-b, 
requiring saponification to liberate the free acids BOa-b. 
o o 
H O ~ O H H (a) 
~ R R
B n o ~ o B n n (b) 
~ R R
o 
H O ~ o B n nI ~ ~
R: 7Sa = F 
7Sb=OH 
R: 79a=F 
79b= OBn 
(d) • C b Z ' N ~ N H 2 2
H 
82 
(f) 
R 
R: SOa = F 
80b= OBn 
R: 81a = F 
81b = OBn 
R: 84a = F V R: 83a = F 
84b= OH .. ------------7"\.-----.--.-.--- 83b = OBn 
Scheme 3-8: Synthesis of phenyl dl-substltuted 1-(2-amlnoethyl)-3-(phenyl)urea hydrochlorides (S4a-b) derived 
from di-substituted benzoic acids (7Sa-b). 
Reagents and conditions: la) i. NaH, DMF, O'C -7 rt; ii. benzyl bromide (BnBr), 100%; (b) UOH, H,O/THF/MeOH, 85-
86%; Ie) DPPA, TEA, toluene; ii. Reflux; (d) benzyl chloroform ate, DCM, O'C, 36%; Ie) Stir, rt; 15-61%; (f) cone HCI, 
10% Pd/C, EtOH, 100%. 
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The benzyl ether protected benzoic acid derivatives 80a-b then 
underwent Curtius rearrangement to the corresponding 
phenylisocyanates 81a-b (not isolated), before reaction with protected 
diamine 82. In this instance, ethylenediamine (54) was mono-protected 
using the carboxybenzyl (Cbz) group, in a manner analogous to mono 
terl-butyloxycarbonyl (Boc) protection (Scheme 3-2). This strategy 
allowed global deprotection of benzyl and Cbz groups by catalytic 
hydrogenation over Pd(O) in the presence of acid. Although successful 
for the synthesis of 84a, the hydrogenation conditions employed did not 
produce 84b. The red solid obtained from this reaction was analysed 
by 1H NMR and high performance liquid chromatography (HPLC). The 
1 H spectra showed a series of broad peaks uncharacteristic of 
analogues of 84b, and relative peak integrations did not correlate with 
the desired structure. HPLC analysis showed multiple peaks, both 
broad and sharp with low retention times. It would appear that the 
attempted deprotection of 83b resulted in degradation of the molecule, 
possibly caused by presence of the catechol-type system. 
3.3.2 Opening of the epoxide 
Q o ~ o ~ ~
~ o - - - . . . . . - o o
62 V 
I 
(a) 
(b) , 
I 
I 
, 
I 
85a: R2 = F R3 =OH : 85b: R2 = F R3=F 
t--------X--------- 8Se: R2 = OH R3 = F 
Scheme 3-9: Synthesis of phenyl di-substituted 1-(2-(3-(4-(2-(cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(phenyl)ureas ( 8 S a ~ ) . .
Reagents and conditions: (a) 77, TEA, EtOH, microwave (MW) 80W, 140 ·C, 250psi, 13%; (b) 73, TEA, propan-2-ol, 
reflux, 28%. 
Due to the long reaction times required in previous epoxide openings 
(compounds 71a-u, 57); the conditions for the reaction were varied. In 
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the case of 85a, the epoxide 62 was opened using 77 in ethanol under 
microwave conditions (Scheme 3-9). This method has been reported 
to give complete aminolysis of epoxides in 4 minutes, requiring only 1.5 
equivalents of amine relative to the epoxide. 159 
The reaction did not appear to be complete in 4 mins by TLC analysis, 
so longer reaction times were required. In the cited study, most of the 
amines used were sterically encumbered, secondary amines and 
hydrophobic in nature. In comparison, the urea and primary amine 
moieties present in 77, make it more polar and poorly soluble in the 
majority of available solvents. The primary amine group allows further 
alkylations to occur once the secondary propanolamine is initially 
generated. 
The remaining two amines 73 and 84a were used to open epoxide 62, 
by reflux in propan-2-01 (Scheme 3-9). In these reactions TEA was 
used to neutralise the hydrochloride salts instead of NaOH. It was 
anticipated this would eliminate potential attack on the epoxides by 
nucleophilic hydroxide anions. 
The reaction for target compound 85c failed. Attempted purification of 
the crude material by preparative HPLC allowed isolation of the major 
peak. Although MS analysis of this collected peak displayed the correct 
mass, 1H NMR analysis indicated the desired product had not formed. 
The aromatic peaks on the spectrum were found to integrate to areas 
around twelve times that of the rest of the molecule. 
3.3.3 Pharmacology results 
The binding affinity of successfully synthesised 3,4-disubstituted 
analogues (85a-b), is compared to the relevant mono-substituted in 
Table 3-2. 
In terms of ~ 1 A R R affinity, both 3,4-disubstituted compounds 85a and 
85b have higher affinity than the p-F analogue (71j), thus both 
substitution patterns can be accommodated at the receptor. However, 
the ~ 1 A R R affinities are lower than the corresponding m-F and p-OH 
compounds, indicating that there is no additive effect, or improvement in 
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affinity with both groups present. Indeed the slightly lower ~ 1 A R R
affinities for 85a and 85b, suggest that favourable interaction of m-F or 
poOH substituents alone is reduced by the presence of a neighbouring 
fluorine atom. 
R2 R3 
Binding affinity, log Ko (M) J3dJ32 
J31-adrenoceptor J32-adrenoceptor selectivity 
71a H H -7.90 ± 0.05 -5.52 ± 0.03 240 
71i F H -8.17 ± 0.03 -6.54 ± 0.02 43 
71j H F -7.70 ± 0.04 -5.92 ± 0.09 60 
57 H OH -8.16 ± 0.08 -5.45 ± 0.10 513 
85a F OH -8.07 ± 0.09 -5.59 ± 0.03 302 
85b F F -8.02 ± 0.03 -5.88 ± 0.03 138 
Table 3-2: Human 131 and 13,-adrenoceptor binding affinities and receptor selectivity of phenyl dl-substltuted 1-(2-
(3-(4-(2-(cyclopentyloxy)ethoxy)phenoxy)-2-hydroxypropylamlno)ethyl)-3-(phenyl)ureas (8Sa-b). 
n = 7 for all assays. 
Overall, the 3-fluoro-4-hydroxy- compound (85a) has lower selectivity 
than the poOH compound, due to a concomitant slight rise in ~ 2 A R R
affinity. Interestingly, the 3,4-difluoro compound (85b) displays better 
selectivity than either m-F or p-F analogue. This is due to a reduction in 
~ 2 A R R affinity relative to the m-F compound, as well as an increase in 
~ 1 A R R affinity relative to the p-F compound - i.e. adoption of different 
desirable properties of both molecules. 
The difficulties thus far encountered synthesising the 3,4-dihydroxy and 
4-f1uoro-3-hydroxy- compounds, means it is difficult to draw further 
conclusion regarding 3,4-disubstitution effects. 
3.4 Structure-activity relationships of phenyl-substituted 1-
(2-(3-(4-(2-(cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(phenyl)ureas 
Substitution studies of the phenyl ring adjacent to the urea moiety in 
71a, allow several structure-activity relationships to be inferred. 
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The unsubstituted ring displays nanomolar range affinity for the f31AR 
(log Ko = -7.90 ± 0.05 M). The presence of an o-substituent relative to 
the urea reduces f31AR affinity greatly. This occurs in a seemingly 
sterically-sensitive fashion, as is evident in the relatively high f31AR 
affinity of the o-F analogue. In addition there are likely to be steric and 
electronic effects on the urea proton adjacent to the ring, due to the 
proximity of the o-substituent. This may account for the differences in 
binding between the o-CH3 and O-CF3 compounds, as they have 
opposing electronic effects, but similar atomic radii. 
Substituents at the para position give f31AR affinity that is comparable 
or slightly lower than 71 a. The exception to this rule is 57, containing p-
OH substitution and much higher f31AR affinity. This suggests a 
potential hydrogen bond donor interaction with the receptor, as other 
substituents do not display this activity. 
In comparison, meta substituents generally improve f31AR affinity 
relative to 71a (only m-CF3 and m-OCH3 cause a slight reduction). 
It is important to consider that the effects of these substituents will not 
be localised to their immediate receptor environment. Indeed, the 
electronic effects on the aromatic ring, and transmitted effects through 
to the adjacent urea, may alter interactions at the receptor level that are 
not immediately apparent, and difficult to predict without knowledge of 
the exact nature of the interactions at these sites. 
In terms of the f32AR affinity, there does not appear to be a discernible 
trend with position or electronic nature of the substituent. All 
analogues, with the exception of m-F gave relatively poor affinity at 
f32AR. 
Overall, the best f31/f32-selectivity is achieved with the m-CI and p-OH 
analogues. 
Disubstitution with the highest affinity substituents (i.e. 3-f1uoro-4-
hydroxy-) does not improve affinity at the f31AR and actually causes a 
slight reduction in affinity and consequently selectivity. 
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4. MODIFICATION OF THE UREA 
MOIETY 
The concept of isosterism, and later bioisosterism, originated with 
observations by Irving Langmuir in 1919 on atoms and molecules with a 
similar arrangement of valence electrons having similar 
physicochemical properties. 162 More recent definitions of classical 
bioisosteres relate size, shape, and electron distribution of the group 
with activity. 160, 163 
The urea moiety may be of importance in imparting high J31AR affinity, 
and subsequent high J31/J32 selectivity. The polar nature of the group, 
and heteroatom configuration, allows it to function as both a hydrogen 
bond donator and acceptor. On this basis, isosteric groups with the 
potential to form similar interactions were considered to be of interest. 
These would allow evaluation of the sensitivity of the pharmacophore to 
changes to this group. 
Q o ~ o u u
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Figure 4-1: Intended target compounds containing replacement functionality of the urea group. 
Of particular interest were the thiourea, carbamate, amide, sulfonamide, 
and ester moieties. In addition, an analogue containing a simple ether 
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linkage was included in this group. Although it is a non-classical 
bioisostere,16o this linker is found in carvedilol and CGP 20712A, which 
both display high 131AR affinity.81 With the exception of the thiourea 
(which can be considered a direct replacement of the urea) and ether, 
the remaining groups can be installed in two orientations (Figure 4-1). 
Accordingly, synthesis of both variants was attempted. 
4.1 Principles of synthetic strategy 
In a similar fashion to the synthesis of the phenyl-substituted analogues 
described in Chapter 3, the final aryloxypropanolamine compounds 
were obtained by aminolysis of 2-«4-(2-
(cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane (62) by a series of 
amine fragments. The synthesis of 62, is detailed in Chapter 3. 
To allow comparison of replacement groups directly, the unsubstituted 
phenyl ring was deemed the best option as a terminal group, even 
though p-OH substitution of this ring offers the best 131AR affinity and 
131/132 selectivity (chapter 3). In addition, this strategy avoided the 
complication of protecting a phenolic functionality on the ring and its 
subsequent deprotection. Finally, unsubstituted starting materials were 
found to be more widely available and economically more viable. 
4.2 Synthesis of the amine fragments 
The synthesis of the amine fragments can be broken down into three 
major groups defined by the corresponding starting material. The final 
amine fragments were derived from ethylenediamine (Scheme 4-1), 
GABA (v-amino butyric acid) (Scheme 4-2) or ethanolamine (Scheme 
4-3). 
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Scheme 4-1: Ethylenediamine derived amine fragments 87, 89, 91 and 93. 
Reagents and conditions: (a) phenyl chloroformate, TEA, OCM, 87%; (b) 4M HCI/dioxane 86·100%; (c) phenylacetyl 
chloride, TEA, DCM 0 'C 7 rt, 84%; (d) trifluoroacetic acid (TFA)/OCM 1:1, 100%; (e) phenylisothiocyanate, OCM, 
84%; (f) Phenylmethanesulfonyl chloride, TEA, OCM O·C 7 rt, 78%. 
Amines derived from ethylenediamine (Scheme 4-1) were synthesised 
with ease, in high yields. Boc-protected diamine 64 (see Chapter 3), 
was reacted with phenyl chloroformate, phenylacetyl chloride or 
phenylmethanesulfonyl chloride in the presence of TEA to generate 
Boc-protected carbamate (86), amide (88), and sulfonamide (92) 
respectively. Reactions with the carbonyl chloride reagents proceeded 
rapidly, whereas phenylmethanesulfonyl chloride required overnight 
reaction as expected. 
Protected thiourea (90), was produced in an identical fashion to urea 
(65a), utilising phenylisothiocyanate. 
Amines 87, 89, 91, and 93, were obtained in the acid salt form after 
acid-mediated removal of the Boc group. 
Use of GABA (94) (Scheme 4-2) allowed facile conversion of the acid 
terminus to the desired amide or ester. Initial Boc protection of the 
amine terminus was carried out in water, with THF as a co-solvent, in 
the presence of NaHC03 to neutralise the carboxylic acid. Boc-
protected GABA (95) underwent carboxylate activation with N,N'-
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dicyclohexylcarbodiimide (DCC), before addition of nucleophile. In the 
case of aniline, coupling was achieved directly to give amide 96. The 
less nucleophilic phenol required a catalytic amount of 4-
dimethylaminopyridine (DMAP) as an auxiliary nucleophile to accelerate 
formation of ester 98. 
(8). B O C ' N ~ O H H
/ H 95 0 ~ ( d ) )
/,(b) ~ ~
H 
B O C ' N ~ N ~ ~
H 0 V 
96 
Scheme 4-2: GABA derived amine fragments 97 and 99. 
B O C ' N ~ O ~ ~
H 0 V 
98 
~ H ~ ~ O ~ ~
o V 
99 
Reagents and conditions: (a) BoczO, NaHC03, water/THF 4:1, 86%; (b) DCC, aniline, DCM, 86%; (c) TFA/DCM 1:1, 
100%; (d) DCC, DMAP, phenol, DCM, 69%; (e) 4M HCI/dioxane, 98%. 
Amines 97 and 99 were obtained by acid-mediated Boc cleavage. 
Finally, ethanolamine (100) was used to generate amines 103 and 106. 
Once again protection of the amine was necessary, prior to further 
functionalisation. Phthaloyl protection was achieved in the absence of 
solvent according to literature procedures 153. The phthaloyl-protected 
ethanolamine (101), was reacted with phenylisocyanate directly to give 
carbamate 102 in poor yield. The poor nucleophilicity of the primary 
alcohol is likely to be the cause of this, and the reaction may proceed 
more rapidly if the alcohol is initially deprotonated. 
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100 
P h t h N ~ O H H B O C ' N ~ O H H
H 
101 104 I (b) I (.) 
H 
P h t h N ~ O y N D D
o I ~ ~ B O C ' N ~ O r o oHOi ~ ~
102 105 I (e) I (n 
H ~ I H 3 ~ ~ O y N D D ~ I H 3 ~ ~ O r o o
o I ~ ~ 0 1 .0 
103 106 
Scheme 4-3: Ethanolamine derived amine fragments 103 and 106. 
Reagents and conditions: (a) phthalic anhydride, 150 ·C, 83%; (bl phenylisocyanate, OCM, 12%; (el i. hydrazlne 
monohydrate, EtOH, reflux; ii. acidic workup, 74%; (dl 80C20, water/THF 3:1, 99%; leI phenyl acetyl chloride, TEA, 
OCM, o·C ~ ~ rt, 94%; (f) 4M HCI/dioxane, 91%. 
Hydrazinolysis of the phthaloyl group and subsequent acidic workup 
afforded the desired amine (103) as the hydrochloride salt. Boc-
protection of ethanolamine was achieved in much higher yield than the 
corresponding phthaloyl protection and was carried out according to 
literature procedures 164. Subsequent formation of ester 105 was rapidly 
achieved using phenyl acetyl chloride in basic conditions. Acidic Boc 
cleavage afforded the amine 106 as the hydrochloride salt. 
4.2.1 Attempted 
sulfonamide 
synthesis of N-phenyl-3-aminopropyl 
Synthesis of N-phenyl-3-aminopropyl sulfonamide was attempted via 
several routes. Initially, 3-aminopropane sulfonic acid (107), was 
phthaloyl protected. Protection was initially attempted by heating in the 
absence of solvent with phthalic anhydride (as for protection of 
ethanolamine, see above); however only starting material was 
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recovered from this reaction. Consequently, reflux in pyridine was 
employed to give the protected sulfonic acid as the pyridinium salt. 
eO (b) or (c) H 
- I or (d) N 
(a), P h t h N 6 ~ b O O ( t ) ~ ~ ~ u--X-.-- P h t h N 6 / ~ b b1) 
107 108 109 
Scheme 4-4: Attempted synthesis of N-Phenyl-3-aminopropyl sulphonamide (109). 
Reagents and conditions: (a) phthalic anhydride, pyridine, reflux, 91%; (b) i. thionyl chloride, reflux; ii. TEA, aniline, 
OeM; (c) i. triphenylphosphine oxide, triflic anhydride, OeM; II. TEA, aniline, o'e ~ ~ rt; (d) i. trichloroacetonitrile, 
PPh" OeM, reflux; ii. TEA, aniline. 
Various attempts were made to activate the sulfonate group on 108 to 
allow sulfonamide bond formation (Scheme 4-4). Firstly reflux of 108 in 
thionyl chloride was anticipated to generate the sulfonyl chloride. After 
removal of excess thionyl chloride, the crystalline pyridinium salt had 
become a yellow waxy solid. This was not isolated, but immediately 
reacted with aniline in the presence of TEA. Unfortunately TLC analysis 
failed to show any change after overnight reaction, which would be 
expected had the sulfonyl chloride formed. It is likely that conversion 
from the sulfonate to the sulfonyl chloride did not proceed by this 
method. 
Activation of sulfonate salts using triphenylphosphine oxide/triflic 
anhydride prior to exposure of amine has been shown to give 
sulfonamides in high yields.165• 166 When attempted, this method did not 
give the desired sulfonamide; as confirmed by 1 H NMR and MS 
analysis. 
Finally, activation was attempted using trichloroacetonitrile and 
triphenylphosphine. 167 Although formation of triphenylphosphine oxide 
was noted (indicating displacement of a sulfonate oxygen), formation of 
the sulfonamide was not evident by 1H NMR and MS analysis. 
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4.3 Opening of the epoxides 
Commercially available 2-phenoxyethylamine was used to open 
epoxide 62 to generate the desired ether derivative 110a (Scheme 4-5). 
As the free amine was available, no base was required, and ring 
opening was carried out in neutral conditions, by reflux in propan-2-01 
with an excess of the amine. Remaining analogues 110b-f, were 
obtained by opening epoxide 62 with amines 89, 91, 93, 97 and 103 in 
the presence of TEA as described previously in Chapter 3. 
Q o - - - - - - o ~ ~~ ~62 o ~ O O
(a) or (b) 
X: 
110a = 0 110d = O(C=O)NH 
110b = NH(C=S)NH 110e = CH2(C=0)NH 
110c = NH(S02)CH2 110f = NH(C=O)CH2 
Scheme 4-5: Synthesis of analogues of 1-12-13-14-12-lcyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamlno)ethyl)-3-lphenyl)urea modified at the urea moiety 110a-e. 
Reagents and conditions: la) 2-phenoxyethylamine, propan-2-01, reflux, 68%; (b) 89, 91, 93, 97 and 103, TEA, propan-
2-01, reflux, 16-45%. 
4.3.1 Problematic epoxide openings 
Attempted opening of epoxide 62 with 87, and 99 and 106 did not give 
the desired ester (111, 112a) and carbamate (112b) derivatives 
(Scheme 4-6). In the case of the phenyl acetate ester (111), analysis 
by HPLC indicated a single peak. When the 1H NMR spectrum was 
examined, the areas of the spectrum where the propanolamine 
backbone is normally visible, displayed a multitude of indistinguishable 
peaks. Although overall integration of these peaks was correct, some 
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of the individual peaks represented half the expected area. Initially, the 
observed spectrum was attributed to rotational isomerism brought about 
by the ester group. However raising the temperature of the 1 H NMR 
from 25°C to 50°C resulted in no change in the spectrum. If individual 
rotamers were indeed visible initially, then the raise in experimental 
temperature would have allowed free rotation about the C-O bond and 
aligned the individual rota mer signals. 
Attempts to synthesise phenolic ester 112a and carbamate 112b, 
resulted in intramolecular cyclisation reactions to the corresponding 
lactam 113a and oxazolidinone 113b (Scheme 4-6) . 
. 
. 
' ~ ~
~ ~
112a = CH2 
112b= NH 
Scheme 4-6: Attempted synthesis of ester and phenolic carbamate analolues 111 and 112a-b. 
Reagents and conditions: (a) 106, TEA, EtOH; (b) 87/99, TEA, EtOH, BOW, 140 ·C, 2S0psi, 6-7%. 
The ability of phenol to act as a leaving group, especially under the 
thermodynamic conditions employed for epoxide opening, promoted 
intramolecular attack of the secondary amine on the carbonyl group in 
these reactions. 
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The acidic nature of phenol means its conjugate base, the phenoxide 
anion portrays leaving group ability. As such, any future attempted 
syntheses are likely to require installation of the phenol as a terminal 
step. Such a reaction could be carried out after epoxide opening of 62 
with either GABA or 3-aminopropanoic acid. The GABA derivative 
could be carboxylate-activated and converted to the phenyl ester 112a. 
In order to generate the corresponding carbamate 112b, conversion of 
the 3-aminopropanoic acid derivative to the corresponding alkyl 
isocyanate, prior to reaction with phenol, may be a possible route. In 
both cases, the appropriate amine/alcohol protection strategy would 
have to be employed to prevent intramolecular cyclisation reactions. 
Previous investigations into the nature of the nitrogen atom on the 
aryloxypropanolamines, have shown tertiary nitrogen structures to have 
considerably lower affinity for the J31AR. As such, these side-products 
were found not to be useful. 124, 126, 168 Indeed, the secondary amine 
motif is required to form a salt-bridge interaction with an aspartate 
residue in the receptor (see Chapter 1).16,25,169,170 
4.4 Pharmacology results 
A comparison of parent urea compound 71 a pharmacology and that of 
the analogues is made in Table 4-1. 
With the exception of amide compound 110e, the remaining analogues 
display at least a 0.5 log unit increase in affinity for the ~ 2 A R R over the 
urea compound (71a). Affinity for the J31AR is generally reduced, 
although still reasonable with all Ko values remaining below 100 nM. 
The exception to this is phenyl acetamide 110f, which actually displays 
a higher affinity, with a ~ 1 A R R Ko value of around 4 nM. 
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Binding affinity, log Ko (M) 
13dlh X 131- 13z- selectivity 
adrenoceptor adrenoceptor 
71a NH(C=O)NH -7.90± 0.05 -5.52 ± 0.10 240 
110a 0 -7.46 ± 0.04 -6.04 ± 0.02 26 
110b NH(C=S)NH -7.09 ± 0.06 -6.16 ± 0.04 9 
110c NH(S02)CH2 -7.59 ± 0.03 -6.03 ± 0.04 36 
110d O(C=O)NH -7.53 ± 0.07 -6.33 ± 0.03 16 
110e CH2(C=O)NH -7.15 ± 0.03 -S.83± 0.02 21 
110f NH(C=O)CH2 -8.42 ± 0.03 -7.27 ± 0.02 14 
Table 4-1: Human 13, and 13,-adrenoceptor binding affinities and receptor selectivity of 1-(2-(3-(4-(2-
(cyclopentyloxy)ethoxy)phenoxy)-2-hydrQ)(ypropylamlno)ethyl)-3-(phenyl)urea analogues modified at the urea 
moiety (llOa-f). 
n ~ ~ 6 for all assays. 
Remarkably, replacement of the urea moiety with a simple ether linkage 
retains reasonable f31AR activity. In comparison to the other 
replacement groups, the ether 110a has no hydrogen bond donor 
activity, yet is still comparable to the rest of the analogues in terms of 
f31 AR activity and overall selectivity. 
The two amide analogues 110e-f, display quite striking differences in 
their activity profile. Broadly speaking, each amide can be thought to 
represent the individual nitrogen groups present on the urea compound, 
in isolation. Butanamide 110e retains low f32AR affinity, but also 
displays a reduction in f31AR affinity relative to urea 71a. Conversely, 
phenyl acetamide 110f has a higher f31AR affinity than 110e, but also 
exhibits a marked increase in affinity for the f32AR. It appears that N-H 
group adjacent to the ring is important in suppressing f32AR affinity, 
whereas the more distant N-H group (alkyl chain side of the urea) is 
important for high f31AR activity. In addition, the presence of the same 
N-H group promotes f32AR binding. The urea group incorporates both 
of these individual features, offering good f31AR affinity whilst 
suppressing f32AR affinity. 
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Carbamate 110d displays a slight reduction in ~ 1 A R R affinity compared 
to the urea, alongside a marked increase in ~ 2 A R R affinity. Although this 
illustrates the importance of the more distant (to the phenyl) N-H group 
in promoting ~ 1 A R R binding, the presence of the more electronegative 
oxygen atom does not appear particularly deleterious in comparison to 
butanamide 11 Oe (where the corresponding group is CH2). Additionally, 
the ether compound 110a contains an oxygen atom in the same relative 
position, and retains a similar level of ~ 1 A R R affinity. This indicates that 
an electronegative atom (possibly a hydrogen bond acceptor), at or 
near this position, is important for ~ 1 A R R activity. However the additional 
presence of hydrogen bond donor activity (as in N-H) appears to offer 
even greater interaction with the receptor. The marked rise in ~ 2 A R R
affinity of the carbamate, with respect to the urea, indicates that the 
presence of an electronegative atom is also important for interaction 
with this receptor. Again, replacement of the oxygen with CH2, as in 
amide 110e, shows further reduction in ~ 2 A R R affinity. 
The sulfonamide 110c, displays a similar profile to other analogues 
containing the distant N-H (such as 110f). It retains ~ 1 A R R affinity with a 
slight increase in ~ 2 A R R affinity. 
Finally, the thiourea 110b exhibits diminished affinity for ~ 1 A R R and a 
raised ~ 2 A R R affinity. It might be expected that the urea and thiourea 
would have similar properties, on account of the above observations 
regarding the two N-H groups. The difference observed may be 
attributable to the diverse nature of the urea and thiourea groups. 
There is a stark difference in the polarity across the C=O bond in urea 
and the C=S in thiourea (C and S have similar electronegativity, 
whereas 0 is much more electronegative).16o The urea group is able to 
function as both an efficient donor and acceptor of hydrogen-bonds 
(due to the basicity of the oxygen atom).171 In comparison, the larger 
size of the sulfur atom (van der Waals radii: 0 = 1.4A, S = 1.85A) and 
lower charge density means it is less basic and consequently less 
effective as a hydrogen-bond acceptor. 171 However, the thiourea is 
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more acidic, and thus a better hydrogen-bond donor than the urea 
group. 171 
Overall, the lower ~ 1 A R R affinity of the thiourea may be a consequence 
of reduced hydrogen-bond acceptor functionality. Indeed the higher 
~ 1 A R R affinity of the ether compound may further point towards the 
importance of a good hydrogen-bond acceptor in this area. 
Additionally, there may also be a steric effect to consider as larger 
groups, such as the thiourea and sulfonamide appear to have reduced 
~ 1 A R R affinity. 
Unfortunately, due to difficulties synthesising the phenolic carbamate 
112b, esters 111 and 112a and propyl sulfonamide derivatives, a full 
comparison is not possible, especially with regard to determining the full 
effects of the N-H group adjacent to the phenyl. 
Overall, the best selectivity was retained with the parent urea 
compound. 
4.5 Structure-activity relationships of 
( cyclopentyloxy)ethoxy)phenoxy)-2-
hyd roxypropylami no )ethyl)-3-(phenyl)u rea 
modified at the urea moiety 
1-(2-(3-(4-(2-
analogues 
Modification of the urea moiety has allowed several structure-activity 
relationships to be determined. 
The best ~ 1 / ~ 2 2 selectivity was retained by the parent urea compound 
71a. Of all the functional groups investigated as direct bioisosteres, or 
indirect replacements (i.e. ether), good affinity for ~ 1 A R , , and a varying 
degree of selectivity (9 - 36 fold) was maintained. As such, the urea 
group is not essential for receptor binding in either sub-types, but does 
seem to offer a role in differential selectivity between the receptors. 
The presence of an electronegative atom, at a distance of two carbon 
units from the propanolamine nitrogen, seems important for affinity at 
both receptors, although further studies would be required to determine 
the optimal length of the carbon linker. It appears this electronegative 
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atom may be important as a hydrogen bond acceptor. If the 
electronegative atom also has hydrogen bond donator capability (e.g. 
N-H), this appears to offer greater ~ 1 / ~ 2 2 selectivity by increasing affinity 
for the ~ ~1 AR. 
Initial observations indicate the N-H group adjacent to the ring may be 
important in reducing ~ 2 A R R binding. Full analyses cannot be conducted 
due to difficulties in synthesising the alternate carbamate and 
sulfonamide compounds, as well as the ester derivatives. 
Hydrogen bond acceptor functionality may be of importance as the 
thiourea shows lower affinity for the ~ 1 A R , , compared to the parent 
urea. 
As well as the electronic and hydrogen bond effects, the presence of 
larger groups at this position appears to be less well tolerated at the 
~ 1 A R . .
The urea group offers the best receptor selectivity, although the best 
~ 1 A R R affinity is imparted by phenyl acetamide 110f. 
Overall, the ability to modify the urea moiety without hugely deleterious 
effects on ~ 1 A R R affinity and maintaining some degree of ~ 1 1 1 ~ 1 1
selectivity indicates this part of the ligand is amenable to more 
extensive modification that could offer an enhanced selectivity profile. 
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GROUP AND ASSOCIATED 
LINKERS 
There are several studies in the literature that investigate substitution of 
the aryloxypropanolamine ring,74, 92, 95,102,126 as well as the nature of the 
substituent para- to the propanolamine91 , 98, 99, 103, 106, 107, 172 side chain 
(see Chapter 1).105 
Incorporating known SAR into the design, with the aims of improving 
selectivity for the 131 AR over the 132AR, and improving affinity for the 
131AR; the synthesis of a third series of analogues was initiated. Based 
upon previous findings (cf Chapters 3 and 4), analogues were 
synthesised incorporating the urea moiety, and either m-CI or p-OH 
substitution of the phenylurea. 
5.1 Modification of the terminus attached to the ethylene 
glycol linker 
Investigations into this region of similar molecules have been extensive, 
with a variety of motifs and alkyl chain length being compared 105, 106. 
Whilst retaining the p-OH substitution on the phenylurea (as in 57). 
modifications were made to the terminus of the ethylene glycol motif in 
the parent compound. The ethylene glycol unit itself has been shown to 
impart good affinity for the 131AR as well as good 131AR/I32AR selectivity 
in a variety of analogues, 105, 106 thus modifications were limited to the 
group attached to this linker. These analogues included the 4-
fluorophenethyl-, cyclopropylmethyl- and ethyl- derivatives, previously 
shown to have good 131AR affinity.105, 106 
5.1.1 Principles behind synthetic strategy 
Synthesis was adopted in a similar fashion to that described for 57 
(Chapter 3). Once again the epoxide and amine fragments were 
combined in a convergent step, under basic or neutral conditions to 
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generate the desired aryloxypropanolamine pharmacophore. Each 
fragment was synthesised in isolation with 1-(2-aminoethyl)-3-(4-
hydroxyphenyl)urea (56), being employed from previous synthesis. 
5.1.2 General synthesis 
Initially, synthesis of the 2-(alkyloxy)ethanol fragments was required, 
where there was lack of commercial availability. 2-(4-
f1uorophenethyloxy)ethanol (116) was constructed according to 
literature methods (Scheme 5_1).98 This involved condensation of 2-(4-
f1uorophenyl)ethanol (114) with chloroacetic acid after deprotonation of 
the alcohol with NaH. Reduction of the product, 2-(4-
f1uorophenethyloxy)acetic acid (115) to the alcohol 116, was achieved 
using LiAIH4. 
F ~ ~I ~ ~ OH (a) F ~ ~I ~ ~ o"Tr0H (b) F ~ ~I ~ ~ O ~ O H H
114 115 0 116 
V OH 
(c) V o ~ O U U (d) . V o ~ O H H
117 118 119 
Scheme 5-1: Synthesis of 2-(alkyloxy)ethanol fralments 1116 and 119). 
Reagents and conditions: la) i. NaH, DMF 60 ·C; ii. chloroacetic acetic acid, 60 ·C, 50%; (b) LiAIH., THF, 0 ·C, 67%; (c) 
NaH, THF; ii. 2-chloroethoxytetrahydro-2H-pyran, 21 % (d) pyridinium pora-toluenesulfonate (PPT5), EtOH, 55 ·C, 
79%. 
2-(cyclopropylmethoxy)ethanol (119) synthesis initially required 
condensation of cyclopropylmethanol (117) with 2-
chloroethoxytetrahydro-2H-pyran. The reaction proceeded, though in 
low yield, which is likely due to a combination of factors. Firstly, 117 
may not be stable to formal deprotonation by NaH due to allylic 
rearrangement. Secondly, the ether product 118 may be volatile such 
that loss through rotary evaporation may have been encountered. 
Deprotection of the THP-protected alcohol was carried out in acidic 
conditions using PPTS, according to literature procedures.173 
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The remainder of epoxide syntheses was carried out largely in the 
manner described for the cyclopentyl derivative 62 in Chapter 3. 
Initially, the 2-(alkyloxy)ethanols 116, 119, and 120 were condensed 
with 4-(benzyloxy)phenol using Mitsunobu chemistry (Scheme 5-2). 
Use of different azodicarboxylates was attempted, however diethyl 
azodicarboxylate (DEAD) and DIAD were found to offer the best results. 
Although DBAD is designed for easy removal on acidic workup 147. 148, 
the removal of the hydrazine product was found not to be problematic. 
116 R1 = p-FCeH4CH2CH2 
120 R1 = CH3CH2 
119 R1 = Cyclopropylmethyl 
121 R1 = Allyl 
(a) R1 .... 0 ~ O ~ ~~ o B n n
122a R1 = p-FCeH4CH2CH2 
122b Rl = CH3CH2 
C 122c R1 = Cyclopropylmethyl (b) 122d R1 = Allyl 
124a R1 = p-FCeH4CHzCHz 
124b R1 = CH3CH2 
124c R1 = Cyclopropylmethyl 
(e) R1 .... 0 ~ O ~ ~~ O H H
123a R1 = p-FCeH4CH2CH2 
123b R1 = CH3CH2 
123c R1 = Cyclopropylmethyl 
(d) or (e) 
Scheme 5-2: Synthesis of 1-(Z-(3-(4-(2-(alkyloxy)ethoxy)phenoxy)-Z-hydroxypropylamino)ethyl)-3-U4-
hydroxy)phenyl)urea analogues varied at the ethylene glycol linker terminus (125a-c). 
Reagents and conditions: (a)PPh., 3-(benzyloxy)phenol, DEAD or DBAD or DIAD, DCM, 35 - 85%; (b) diethyl zinc, 
diiodomethane, toluene, 0 ·C --+rt, 97%; (c) Hz, 10% Pd/C, EtOH, 68 - 100%; (d) i. 2M NaOH(oq); Ii. rae-
epichlorohydrin, 60 ·C, 62 - 84%; (e) i. NaH, DMF; Ii. rac-epichlorohydrin. 71- 84%; (f) 56, propan-2-ol, reflux, 21 -
43%. 
Benzyl deprotection of ethers 122a-c was achieved via catalytic 
hydrogenation using 10% Pd/C, as previously described to afford 
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phenols 123a-c. Finally, alkylation of phenols 123a-c was carried out in 
one of two conditions. In the case of 123c, aqueous NaOH was 
employed as a base143, followed by reflux in rac-epichlorohydrin. This 
approach was selected, as NaH was deemed too strong a base in the 
presence of the cyclopropyl group. The remaining phenols were 
deprotonated using NaH as the base, in DMF, before stirring in an 
excess of rac-epichlorohydrin at room temperature, based on literature 
precedent 132. 
The poor yields obtained in the initial synthetic steps for the 
cyclopropylmethoxy- analogue, prompted an alternative route to be 
investigated. A more direct route was envisaged by employing 
Simmons-Smith chemistry 139. Coupling of the readily-available 2-
(allyloxy)ethanol (121), with 4-(benzyloxy)phenol under Mitsunobu 
conditions, allowed formation of the ether 122d. Direct conversion of 
122d to 122c, in near-quantitative yield, was achieved using diethyl zinc 
and diiodomethane as Simmons-Smith reagents. 139 This route 
eliminates several problems of the initial synthesis. Firstly, the reaction 
can be monitored with ease by visualisation under UV light at 254 nm, 
due to the presence of the aryl groups. Consequently, this allows 
easier purification by column chromatography. Secondly the non-
volatile nature of the ether product 122d, eradicates any loss through 
evaporation during solvent removal. Finally, the late installation of the 
cyclopropyl group means there is no need to use cyclopropylmethanol 
(117), as an initial starting material - thus removing any loss through 
incompatibilities with NaH. Overall, ether 122c is obtained over 2 high-
yielding steps rather than three steps, two of which are low to moderate 
in yield. 
Aryloxypropanolamines 12Sa-c were obtained by overnight reflux of 
epoxides 124a-c, in propan-2-0I, with an excess of amine 56 present. 
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5.1.3 Pharmacology results 
5.1.3.1 Whole cell binding 
The 131AR and 132AR binding affinities, and subsequent selectivity of the 
newly synthesised analogues, are compared in Table 5-1. 
As can be seen, all four compounds are highly selective towards the 
131AR. The bulkier and more extensive 4-fluorophenethyl compound 
125a displayed the highest 131AR affinity of all , but also a ra ised affinity 
for the 132AR and consequently the lowest degree of relative receptor 
se lectiv ity. 
R 1 1 O ~ ° ' Q QI H H ~ ~ O ~ N ~ N I I N ~ ~
OHH 0 ~ O H H
Binding affinity, log Ko (M) PdP2 R1 131- Pr selectivity 
adrenoceptor adrenoceptor 
57 cyclopentyl -8.16 ± 0.08 -5.45 ± 0.10 513 
125a 4-fluorophenethyl -8.50 ± 0.07 -5.99 ± 0.04 326 
125b ethyl -7.08 ± 0.04 log ICso > -4 * HIGH 
12Sc cyclopropylmethyl -7.52 ± 0.03 log ICso > -4* HIGH 
Table 5-1: Human 131 and Ih-adrenoceptor binding affinities and receptor selectivity of 1-(2-(3-(4-(2-
(cyclopentyloxy)ethoxy)phenoxy)-2-hydroxypropylamino)ethyl)-3-((4-hydroxy)phenyl)urea analogues varied at the 
ethylene glycol linker terminus (125a-c). 
n <: 5 for all assays. • maximum concentration of compound applied within limits of experiment, with no binding 
act ivity detected. 
Although the smaller ethyl and cyclopropylmethyl R1 groups caused a 
lowering of the 131AR affinity relative to the parent cyclopentyl 
compound 57, they also displayed no detectable binding at the 132AR 
when concentrations of 100 IJM were applied. The concentration of 
compound that can be applied is limited by the amount of DMSO 
required to dissolve it, and therefore by the amount of DMSO that can 
be applied in the assay. In the case of 125b and 125c, a maximum 
concentration of 100 IJM of compound was tolerated . Even at this 
concentration, neither compound showed complete displacement of the 
radioligand . Consequently, although it is possible to report a log IC50 
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value of > -4 M for both 125b and 125c, an accurate value for Ko 
cannot be extrapolated. It is entirely possible that neither 125b nor 
125c bind to the J32AR, however it is not possible to determine this from 
the assay employed. It is evident that both 125b and 125c are highly 
selective towards the J31AR, with 125c being the more selective of the 
two compounds on account of its higher J31AR affinity. 
Overall, the larger groups such as cyclopentyl and 4-fluorophenethyl 
impart higher levels of binding for the J31AR, but also raise affinity for 
the J32AR. It may be that both receptors share similar bulk-preferring 
pockets at this part of the binding site for these ligands. 
The variability in binding across the two receptors with these simple 
modifications, highlights the need for more extensive modification to this 
part of the core structure. 
When the cyclopropylmethyl compound 125c is compared to LK 204-
545 (44) (see Chapter 1), it is evident that although the presence of the 
nitrile group increases affinity for the J31AR, the selectivity conferred by 
125c may be higher due to lack of J32AR binding within the limits of the 
assay. Bearing in mind the difficulty encountered in synthesising 44, 
the lower J31 AR affinity (but higher selectivity) offered by lack of the 
nitrile group on 125c seems acceptable. 
5.1.3.2 In-vivo activity of 1-(2-(3-(4-(2-
(cyclopropylmethoxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(4-hydroxyphenyl)urea 
(125c) 
The anticipated high J 3 1 / ~ 2 - s e l e c t i v i t y y of 1-(2-(3-(4-(2-
(cyclopropylmethoxy)ethoxy)phenoxy)-2-hydroxypropylamino)ethyl)-3-
(4-hydroxyphenyl)urea (125c), prompted an investigation into whether 
high selectivity would be maintained in vivo. 
A small study (n = 4) was carried out by Professor Sheila Gardiner 
(School of Biomedical Sciences, QMC, University of Nottingham), 
monitoring regional hemodynamics in the conscious rat, 174. 
175according to the following procedure. All drugs were administered by 
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intra-venous injection through the tail. After a baseline period of at least 
30 minutes, all animals were given atropine (1 mg/kg) as a bolus dose, 
with maintenance dosing of 1 mg/kg/h throughout the experiment to 
block vagal effects on reflex tachycardia. Starting 45 minutes after 
initial atropine administration, animals were given 3 minute infusions of 
either salbutamol (1.8 1J9/kg/min) or isoprenaline (360 ng/kg/min). After 
20 minutes, those animals that had been administered salbutamol were 
given isoprenaline, and those that had been administered isoprenaline 
were given salbutamol (doses as above). After a further 20 minutes, all 
animals were given a single bolus dose of 125c (10 mg/kg), and 30 
minutes thereafter, ~ - a g o n i s t t administration was repeated as above. 
Salbutamol 
Isoprenaline 
Isoprenaline 
!+ 
( ~ } } >[ 
Hindquarters vasodilatation 
1 Total peripheral resistance ) 
~ ~
1 Blood pressure 
~ ~ Atropine ! 
t Hel rtrate ) <X I ( Valal effects ) 
Flcure S· l: Pictorial representation of homeostatic response to peripheral vasodilatation elicited by 15,-
adrenoceptor activation In the In-villO rat model. 
As can be seen in Figure 5-1, administration of salbutamol, a selective 
~ 2 A R R agonist causes ~ 2 - m e d i a t e d d hindquarters vasodilatation. This in 
turn causes a fall in total peripheral resistance and subsequent drop in 
blood pressure evoking a reflex tachycardia response. The tachycardia 
is comprised of both sympathetic and vagal components. The effects of 
the vagal reflex can be removed by pre-treatment with the muscarinic 
94 
Variants of the aryloxy group and associated linkers 
antagonist, atropine. As such, any observed reflex tachycardia is 
sympathetic in this model, and mediated by the J31AR in the heart. 
When isoprenaline (a non-selective J31AR and J32AR agonist) is applied 
in the place of salbutamol, the same reflex tachycardia is observed 
downstream of J32AR activation. In addition, direct, non-reflex activation 
of the J31AR occurs, increasing tachycardia further. 
This model allows parameters such as tachycardia, hypotension and 
vascular conductance to be recorded from the freely moving animal. 
Heart rate response % Increase In Hypotension (mm Hg) hindquarters vascular (beats/min) 
conductance 
Before After Before After Before After 
Salbutamol +55 ± 14 +7 ±4 -11 ± 1 -11± 3 +106 ± 20 +98 ± 15 
Isoprenaline +74± 12 +11±4 -19 ± 3 -18 ± 2 +126 ±20 +129 ± 19 
Table 5-2: Effect on changes (relative to basal levels) in heart rate, hypotension and increase in hindquarters 
vascular conductance elicited by either salbutamol or isoprenaline, before and after administration of USc (10 
mg/kg) in the conscious, freely-moving rodent model (n = 4). 
Table 5-2 shows data on the cardiovascular parameters before and 
after exposure to 125c. The 'before' data were obtained in the absence 
of 125c, and displays the effects of administering either salbutamol or 
isoprenaline to the animals. Both salbutamol and isoprenaline cause 
increases in the heart rate response (Le. reflex tachycardia, J31AR 
mediated), hypotension (J32AR mediated reduction in blood pressure 
through vasodilatation), and an increase in vascular conductance 
(J32AR mediated). The tachycardia in the isoprenaline experiments is 
clearly higher - a reflection of direct J31AR mediated cardiac stimulation. 
The 'after' data was obtained by administering 125c before repeated 
agonist challenge by either isoprenaline or salbutamol. The J31AR-
mediated tachycardia elicited directly by isoprenaline, and indirectly by 
salbutamol, is considerably reduced by 125c in both cases to little over 
basal levels. Within the realms of experimental error, the J32AR related 
parameters are unaffected. Although quantitative values for receptor 
selectivity cannot be obtained, this preliminary study has demonstrated 
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the ability of 125c to block agonist responses at the J31AR in-vivo, 
without affecting J32AR related parameters measured in the 
hindquarters vascular bed. This demonstrates, in principle, the role of 
125c as a potentially potent and specific J31AR antagonist. 
5.1.3.3 Reporter gene assays 
An assessment of the functional profile of 125c was carried out in a 
high expression reporter gene assay by Dr. Jillian Baker. 
In cells expressing the human J31AR, ligands with agonist activity are 
able to activate the receptor and initiate the secondary messenger 
signalling system (G-protein activation of AC, and production of cAMP -
see Chapter 1). The downstream expression of the reporter gene 
(after phosphorylation of CREB by PKA and subsequent binding the 
eRE promoter) produces secreted placental alkaline phosphatase 
(SPAP), which is secreted by the cell and can then be quantified.27, 176 
Application of 125c to the assay cells was found to cause SPAP 
production, indicating 125c possesses agonist activity at the human 
J31AR. However, the physiological relevance of this activity is unclear 
for a number of reasons. Firstly, the assay comprises of cells with very 
high surface receptor expression which is not comparable to 
physiological levels. Secondly the effect of signal amplification inherent 
to the secondary messenger system means a very weak agonist 
stimulus can result in considerable levels of SPAP production 
downstream. 
An accurate evaluation of whether 125c is an efficacious agonist would 
require an assay measuring activation of AC, thus minimising Signal 
amplification. Additionally, physiological relevance could only be 
assessed in an assay employing phYSiological levels of surface receptor 
concentration. 
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5.2 Modification of the aryloxy group adjacent to the 
propanolamine 
To gain further insight into the effect on ~ 1 A R R and ~ 2 A R R affinity from 
modification of the central aryloxypropanol ring. synthesis of a series of 
analogues was initiated based upon known ligands with high affinity for 
~ 1 A R ; 8 1 1 propranolol (7). bupranolol (22) and ICI 89406 (41) (Table 5-3); 
as well as commercial availability of precursors. 
Bupranolol and propranolol are actually more selective towards the 
~ 2 A R R (Table 5-3). Despite this, their high affinity for the ~ 1 A R R makes 
them suitable candidates for investigation. 
The results from Chapter 3 indicate that additional selectivity for the 
r31AR is conferred by the presence of m-CI or p-OH substituents on the 
phenylurea ring. Combining these fragments with the 
aryloxypropanolamine motifs of the high ~ 1 A R R affinity compounds was 
postulated to give compounds with both high ~ 1 A R R affinity and high 
selectivity. 
Binding affinity, log Ko (M) 1311'132 Compound 131- 132- selectivity 
adrenoceptor adrenoceptor 
7 Propranolol -8.16 ± 0.08 -9.08±0.06 -8· 
22 Bupranolol -8.51 ±0.04 -9.85±0.05 -22· 
41 ICI89406 -8.91 ± 0.09 -7.07± 0.06 69 
Table 5-3: Human PI and pz-adrenoceptor binding affinities and receptor selectivity of propranolol, bupranolol and 
1(189406. 
Data taken from selectivity study carried out by Dr. Jillian Baker using the same assay techniques,,1 • These 
compounds are actually more selective towards the j32AR. 
In addition. the corresponding m-CI analogues of 125b and 125c were 
made. The phenyl derivative was also synthesised as there are no 
substituents on the ring of the aryloxypropanolamine component. The 
remaining p-OH analogues are yet to be synthesised. 
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5.2.1 Principles of synthetic strategy 
Once again, synthesis of the appropriate epoxide was required before 
opening with 1-(2-aminoethyl)-3-(3-chlorophenyl)urea (66k). Phenyl 
glycidyl ether (127c) was commercially available and epoxides 124b 
and 124c had been previously synthesised (see above). 
5.2.2 General synthesis 
Synthesis of aromatic glycidyl ether compounds 127a, 127b and 130 
was carried out in a similar fashion to previous phenol alkylation 
reactions, with rac-epichlorohydrin (see above and Chapter 3). In each 
case, NaH was used as the base to generate the sodium phenolate 
salt, before overnight reaction with excess rac-epichlorohydrin (Scheme 
5-3 and Scheme 5-4). 
126a R2 = CN R3 = H 
126b R2 = CI R3 = CH3 
(a) 
128a R2 = CN R3 = H 
128b R2 = CI R3 = CH3 
128c R2 = R3 = H 
127a R2 = CN R3 = H 
127b R2 = CI R3 = CH3 
127c R2 = R3 = H 
Scheme 5-3: Synthesis of 1-(2-(3-(aryloxy)-2-hydroxypropylamlno)ethyl)-3-((3-chloro)phenyl)urea analocues with 
modified substituents on the aryl croup adjacent to propanolamine I 128a-c) 
Reagents and conditions: (a) i. NaH, DMF; ii. rac-epichlorohydrin, 21 - 50%; (b) 66k, TEA, propan-2-ol, reflux, 11 -
14%. 
The alkylation of phenols 126a-b provided the desired compounds 
127a-b, though in much lower yield than the corresponding reaction 
involving 1-naphthol (129). 
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(a) (b) 
129 130 131 
Scheme 5-4: Synthesis of 1-(2-(2-hydroxy-3-(naphthalen-l-yloxy)propylamino)ethyl)-3-(3-chlorophenyl)urea (131). 
Reagents and conditions: (a) i. NaH, DMF; ii. rac-epichlorohydrin, 100%; (b) 66k, TEA, propan-2-01, reflux, 16%; 
Opening of epoxide compounds 127a-c, 130, and 124b-c was carried 
out under previously described conditions, by the amine 66k in propan-
2-01, using TEA to neutralise the hydrochloride salt (Scheme 5-3, 
Scheme 5-4 and Scheme 5-5). 
(a) 
124b R1 = CH3CH2 132a R1 = CH3CH2 
124c R1 = Cyclopropylmethyl 132b R1 = Cyclopropylmethyl 
Scheme S-5: Synthesis of 1-(2-(3-(4-(2-(alkyloxy)ethoxy)phenoxy)-2-hydroxypropylamlno)ethyl)-3-((3-
chloro)phenyl)urea analogues varied at the ethylene glycol linker terminus. 
Reagents and conditions: (a) 66k, TEA, propan-2-ol, reflux, 9 -11%. 
As before, all desired aryloxypropanolamine compounds were obtained 
in relatively low yield. 
5.2.3 Pharmacology results 
Pharmacology data for the m-CI analogues 128a-c, 131 and 132a-b is 
particularly interesting (Table 5-4). Firstly, if m-CI compounds 711, 132a 
and 132b are compared with the corresponding p-OH compounds 57, 
125b and 125c (Table 5-1), trends between different alkyloxy 
substituents are preserved. The cyclopentyloxy- compounds 57 and 
711 have higher j31AR affinity than their corresponding ethoxy- and 
cyclopropylmethoxy- counterparts. 
99 
Variants of the ary/oxy group and associated linkers 
Ethoxy- compound 132a displays a higher 131AR affinity than the 
corresponding compound containing the p-OH substituent (125b), 
which would not be expected . In fact, the binding profiles between m-CI 
compounds 132a and 132b is essentially identical, whereas in the case 
of the corresponding p-OH compounds, the cyclopropylmethoxy- motif 
offers a higher 131AR affinity. 
Binding affinity, log Ko (M) 
131/13z Rz R] R4 131- 132- selectivity 
adrenoceptor adrenoceptor 
711 H H 2-(cyclopentyloxy)ethoxy -8.14 ± 0.04 -5.59 ± 0.05 355 
128a (N H H -9.23 ± 0.05 -7.15 ± 0.06 120 
128b (I CH 3 H -8.88 ± 0.04 -7.62 ± 0.11 18 
128c H H H -8.52 ± 0.04 -7.00 ± 0.07 33 
131 naphthyl ring -8.39 ± 0.08 -7.52 ± 0.03 7 
132a 2-(ethoxy)ethoxy -7.50 ± 0.06 -5.20 ± 0.04 200 
132b 2-(cyclopropylmethoxy)ethoxy -7.53 ± 0.06 -5.24 ± 0.03 195 
Table 5-4: Human Ih and ~ r a d r e n o c e p t o r r binding affinities and receptor selectivity of 1-(2-(3-(4-(2-
(cyclopentyloxy)ethoxy)phenoxy)-2-hydroxypropylamino)ethyl)-3-((3-chloro)phenyl)urea analogues varied at the 
ethylene glycol linker terminus I aromatic ring adjacent to the propanolamine (128·c, 131, 132a-b). 
n ~ ~ 5 for all assays. 
The difference between the p-OH and m-CI substituents appears to 
arise from the change in affinity for the 132AR. The difference between 
the cyclopentyl compounds 57 and 711 is not so great. However with 
the ethoxy- and cyclopropylmethoxy- compounds, changing the 
substitution pattern of the phenylurea from p-OH to m-CI causes an 
increase in affinity for the 132AR, although binding is still poor. Overall, 
this means the pattern of p-OH compounds offering better 131/132 
selectivity than the corresponding m-CI remains. 
The remaining compounds from Table 5-4 posses no alkyl substituent 
at the R4 position. Remarkably, very minor changes to the nature of the 
aromatic component of the aryloxypropanolamine motif, confer quite 
large changes to the binding profiles of each compound to the two 
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receptors. Interestingly, all these aryl motifs (compounds 128a-c and 
131) have very high 131AR affinity as well high 132AR affinity. 
The presence of an o-CN group on 128a augments the affinity for the 
131AR to sub-nanomolar levels, whilst only marginally increasing affinity 
for the !32AR relative to the unsubstituted compound 128c. In 
comparison, compound 128b (where R2 = CI and R3 = CH3) exhibits a 
slightly raised 131AR affinity, but a more pronounced increase in 132AR 
affinity. It may be that these effects are due to the electronic nature of 
the aromatic ring, with binding to the !31AR being favoured by more 
electron deficient rings such as that on 128a. In comparison, the 
compounds with an alkyloxy-substituent at the R4 position display a 
much reduced affinity for the 132AR, as well as a reduction in 131AR 
affinity. The 1,4-dialkaryl ether system means the central aromatic ring 
is more electron proficient due to mesomeric donation by each of the 
oxygen atoms. 
In addition to apparent electronic effects, the effect due to the steric 
presence of the R4 group is apparent. Both the 2-
(cyclopropylmethoxy)ethoxy- and 2-(ethoxy)ethoxy- compounds have 
lower 131AR affinities, whereas the bulkier 2-(cyclopentyloxy)ethoxy-
compound has a higher 131AR affinity. So although R4 substituents 
appear to diminish affinity for the 131AR and 132AR considerably, the 
termination of this substituent in a bulkier group allows the !31AR affinity 
to be regained at the relative expense of !32AR affinity - i.e. selectivity 
improves. This indicates that although both receptors tolerate para-
substituents on the aromatic ring less well, relative to no substitution at 
this position, the !31AR appears to have a preference for bulkier groups 
attached to this substituent, but further away from the 
aryloxypropanolamine motif. 
The importance of the 1-(2-aminoethyl)-3-(3-chlorophenyl)urea group in 
imparting !31/!32-selectivity is further demonstrated by 128b and 131. 
The !32AR selective compounds propranolol and bupranolol (Table 5-3), 
have been converted to !31AR selective compounds by replacement of 
the N-alkyl group with this motif. 
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In order for the full steric and electronic effects of ring substituents to be 
compared, a much more comprehensive study is necessary to elucidate 
structure activity relationships. Quite evidently both the J31AR and 
J32AR are sensitive to minor changes at the aromatic region of the 
aryloxypropanolamine motif. 
In addition, the full ranges of corresponding analogues bearing the p-
OH substituent on the phenylurea ring are yet to be synthesised. 
Earlier results (Table 5-1) would indicate that these would confer much 
better selectivity over the m-CI analogues, through a reduction in affinity 
for the J32AR. 
5.3 Structure-activity relationships 
The modifications to the core pharmacophore introduced in this chapter 
are in some cases quite subtle, though produce quite drastic changes in 
the binding profiles of the relevant compounds. 
In terms of p-substituents on the aromatic ring of the 
aryloxypropanolamine motif, it is evident that these cause a reduction in 
affinity for both the J31AR and J32AR, relative to no substituent on the 
ring. The reduction in affinity is more drastic for the J32AR. The affinity 
reduction for the J31AR imparted by this modification can be reversed if 
the ethylene glycol linker is terminated with a more bulky cyclopentyl or 
extended 4-f1uorophenethyl group. This indicates the presence of a 
bulk-preferring pocket in the J31AR, some distance away from the core 
aryloxypropanolamine motif, which is not present in the J32AR. 
The electron withdrawing CN group placed ortho to the 
oxypropanolamine chain confers very high J31AR affinity without great 
increases in J32AR binding. However the overall effect when several 
substituents are present on this ring is more complicated. 
In the case of LK 204-545 (44), the combination of an o-CN and p-
alkyloxy group produces gains in terms of J31AR affinity but, also a 
potential loss in selectivity due to an associated rise in J32AR affinity, in 
comparison to 125c. 
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This complicated multi-substituent effect is again evident when a 2-
chloro-5-methyl- system is present as both f31AR and f32AR affinities 
increase considerably relative the unsubstituted compound. 
Simple aryl groups (not extensively substituted) are tolerated with high 
affinity at both receptors. The relative sensitivity of the receptors to 
modifications to the ring on the aryloxypropanolamine motif is apparent, 
as relatively minor changes bring about changes in selectivity. 
The ability of both receptors to tolerate a larger aromatic system is 
evident from the high affinity imparted by the naphthyl group on both 
receptors. 
The aryloxypropanolamine is known to be essential for binding at both 
receptors 170, and as would be expected, subtle change on or near to the 
motif produce distinct differences in the binding profile of subsequent 
ligands. In order to get a clearer picture of the effect of changes to this 
region of the core pharmacophore, a more extensive library of 
molecules needs to be synthesised. 
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6.1 General conclusions 
Using LK 204-545 (44) as an initial lead compound, an extensive library 
of aryloxypropanolamine analogues were synthesised, characterised 
and underwent in-vitro testing for binding at human 131 and 132 
adrenoceptors (carried out by Dr Jillian Baker). 
A novel and safer route for the synthesis of 44 was devised, though was 
found to be protracted and low yielding. This route could be improved 
by selection of a more appropriate protecting group to replace PMB. 
The affinity of 44 for the J31AR was found to be lower than the literature 
value 131, though this is likely to be due to differences in assays used. 
On the basis of synthetic ease, a new lead was selected omitting the 
nitrile motif of 44. The cyclopropylmethyl group was replaced with a 
cyclopentyl group with the aim of increasing J31AR affinity106 whilst 
retaining a facile synthetic route. 
Modification of various moieties on the new lead compound 57, allowed 
the generation of new SAR and ultimately afforded the highly P1AR 
selective compound 125c. This compound was selected for a pilot in-
vivo study in the regional hemodynamic rat model174, 175 and displayed 
essentially selective J31AR antagonist activity (carried out by Professor 
Sheila Gardiner). 
A summary of the SAR generated is given below. 
6.1.1 Substitution of the aromatic ring adjacent to the urea 
Substitution of the aromatic ring adjacent to the urea was investigated, 
including ortho-, meta-, and para- substitution with a variety of electron 
donating and withdrawing groups (trifluoromethyl, fluoro, chloro, bromo, 
methyl, hydroxy, and methoxy). The unsubstituted analogue 71a was 
also synthesised. 
104 
Conclusions and future work 
With the exception of the m-F derivative 71 i, all variants had poor J32AR 
affinity (KD = 537 nM - 3548 nM). Relative to the unsubstituted variant 
71a, all ortho-substituents were found to reduce J31AR affinity in a 
sterically sensitive fashion (o-F retained reasonable J31AR affinity). The 
meta-substituents generally increased J31AR affinity, whilst para-
substituents generally caused a small reduction in J31AR affinity, with 
the exception of the p-OH variant which displayed extremely high J31AR 
affinity (KD = 7 nM). 
Overall, the highest J31AR affinity was displayed by the m-F, m-CI and 
p-OH analogues, whilst best J31/J32 selectivity was afforded by p-OH, m-
CI and unsubstituted analogues. 
Attempts to combine substituents conferring the highest affinity (m-F 
and p-OH) to produce a 3,4-disubstituted compound resulted in lower 
J31AR affinity overall. 
6.1.2 Modification of the urea moiety 
Isosteres of the urea moiety were investigated, including thiourea, 
sulfonamide, amide, and carbamate. Additionally, the ether compound 
110a was synthesised. 
Overall, the parent urea compound 71 a retained the best J31/J32 
selectivity. Generally, replacement groups resulted in lower affinity for 
the J31AR and raised J32AR affinity. Although the urea is not essential 
for binding at the J31AR receptor (the ether compound 110a retains 
relatively high affinity), its ability to act as both hydrogen bond donor 
and acceptor seems key to selectivity. 
The two amide compounds 110e and 110f indicate that the two N-H 
groups present on the urea have very specific roles affecting receptor 
binding. The N-H group adjacent to the ring seems to be important in 
suppressing J32AR affinity, whereas the more distant N-H group (alkyl 
chain side of the urea) is important for high J31AR activity. Indeed 
phenylacetamide 11 Of displays higher J31 AR affinity than the parent 
urea compound. 
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The thiourea 110b displays lower ~ 1 A R R affinity than the parent urea 
compound 71 a, which may suggest the importance of a good hydrogen-
bond acceptor motif. 
Larger groups (sulfonamide, thiourea) appear to be less well tolerated 
than smaller groups in this area. 
A complete investigation of analogues was not possible due to 
difficulties synthesising the ester, phenolic carbamate, and N-phenyl 
sulfonamide compounds. 
6.1.3 Variants of the aryloxy group and associated linkers 
The aromatic ring of the aryloxypropanolamine is particularly sensitive 
to substituent changes. 
Simple aromatic derivatives bearing either phenyl or naphthyl rings 
possess high affinity at both receptor sub-types, and thus poor 
selectivity. The N-alkyl substituent is likely to be responsible for the 
degree of selectivity exhibited by compounds 128c and 131. 
Substitution para- to the oxypropanolamine group results in a reduction 
in affinity for both receptors, relative to the unsubstituted compound 
128c. However, the reduction in affinity is more pronounced for the 
~ 2 A R . . Termination of the ethylene glycol linker with a bulkier group 
allows affinity for the ~ 1 A R R to return. Thus cyclopentyl (57) and 4-
fluorophenethyl (125a) compounds were found to have higher ~ 1 A R R
affinities than the corresponding ethyl (125b) and cyclopropylmethyl 
(12Sc) variants. These groups have a small effect on raising the ~ 2 A R R
affinities; hence selectivity was lower in the bulkier compounds. 
The electronic nature of the aryloxy group may be key in determining 
the binding profile of these compounds. Installation of an electron 
withdrawing o-CN group alone proffers extremely high ~ 1 A R R affinity and 
good selectivity, whereas the 2-chloro-5-methyl analogue has raised 
affinity at both receptor subtypes. Overall, it is likely that a balance of 
steric and electronic factors is important in determining the best 
selectivity and affinity for the ~ ~1 AR. 
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The interplay between different ring modifications is best displayed 
when comparing LK 204-545 (44) with 125c. LK 204-545 has high 
J31AR affinity and selectivity. Although removal of the nitrile group 
causes a small reduction in J31AR affinity, there is also no detectable 
J32AR affinity within experimental limits for 125c, thus high selectivity is 
retained. 
Overall, a more extensive investigation into ring substituents is 
necessary as well as completion of synthesis of the corresponding 
analogues with p-OH substitution in place of the m-CI group. 
6.2 Future work 
Work carried out to date has provided several avenues for further 
investigation, these are detailed below. 
6.2.1 Computational studies 
6.2.1.1 QSAR 
The structural similarity of the analogues, yet diversity of binding 
profiles of the compounds synthesised to date warrants an in-depth 
QSAR study to be undertaken. Although QSAR algorithms such as 
CoMFA assume a single binding conformation in the receptor of all 
ligands included, such a study could generate a wealth of valuable 
information based upon fixed parameters and attributes of functional 
groups. 
The information generated, would be used to design and synthesise a 
new library of molecules. This kind of iterative process allows a more 
rational approach to drug design. 
6.2.1.2 Molecular modelling 
The recent publication of coordinates from crystal structures for the 
J31AR and J32AR may prove timely for this project. 31 , 36, 38, 41 In 
particular, the J31AR has been co-crystallised with the antagonist 
cyanopindolol.41 Taking the conformation of cyanopindolol as a general 
template for antagonist binding at the J31AR, the structures of 
107 
Conclusions and future work 
compounds synthesised in this project could be aligned and visualised. 
Similar modelling experiments on the ~ 2 A R , , and subsequent 
comparison, may reveal key favourable or unfavourable interactions 
responsible for the high selectivity of compounds such as 57 and 125a-
c. 
Identification of these key residues, or even residues near the binding 
site which could be accessed, would form the basis of structural 
modifications designed to access them. 
6.2.2 Further modification of the phenylurea 
The differences in ~ 1 A R R affinity displayed by the installation of simple 
substituents on the aromatic ring adjacent to the urea group, provide a 
basis for much more extensive modification. 
Firstly the aromatic ring could be substituted for non-aromatic rings, and 
alkyl groups of differing size, as well as investigating substituent effects. 
This would evaluate the ability of the receptor to accommodate bulkier 
and more flexible structures, in comparison to the planar aromatic 
groups. Previous studies have shown some alkyl-substituted ureas 
(such as ethyl- and n-butyl) to have better antagonist potency and 
cardioselectivity than their substituted phenylurea analogues.126 
Replacement of the phenyl ring with a variety of heterocycles may 
prove useful. Heteroatoms such as nitrogen in pyridine could 
potentially form polar interactions with acidic residues, whilst still 
maintaining TT-stacking interactions. Also, larger aromatic structures 
may be tolerated differentially between the J31AR and J32AR. 
6.2.3 Amine-urea linker study 
A more in-depth study into the nature of the carbon linker between the 
amino and urea motifs could be of use. It is known that extremely 
lengthy, flexible structures such as salmeterol (133) can be 
accommodated by the J32AR177, however similar studies with the J31AR 
do not appear to have been conducted. 
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OH ~ ~H O ~ ~ ~ O ~ ~~ ~ J J JHO 133 
Figure 6-1: Salmeterol- a long acting selective ~ ~ agonist 
The branching of this linker could also be investigated. Branching 
would offer the potential to tether on additional functional groups to this 
part of the molecule. Previously, branching on the amino-substituent 
has been shown to improve antagonist potency in molecules (the tert-
butyl substituent often imparts higher antagonist potency than 
corresponding iso-propyl derivatives94, 96, but can have lower 
cardioselectivitl3). 
6.2.4 Aryloxy group modification 
There is much scope for investigation of the aryloxy group. The nature 
of the aryl group itself had been shown to be relatively open to 
modification, with heteroatom containing aromatics (e.g. pindolol 25), 
five membered rings (e.g. timolol 26) and bi/tricyclic structures (e.g. 
propranolol 7 and carazolol24) being tolerated. 
Figure 6-2: Analogues of 12Sc bearing the aromatic core of propranolol (top) and carazolol (bottom) 
Replacement of the aromatic group, whilst retaining para-substitution 
could potentially result in compounds with higher affinity for the ~ 1 A R , ,
whilst retaining the high cardioselectivity. Figure 6-2 shows possible 
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analogues of 125c bearing the naphthyl and carbazolyl groups of 
propranolol (7) and carazolol (24) respectively. The parent compounds 
7 and 24 possess relatively high affinity at the J31AR, but poor 
selectivity . 
So far, the variety of para-substituents investigated in this project has 
been limited to 2-(ethoxy)ethoxy-, 2-(cyclopropylmethoxy)ethoxy, 2-
(cyclopentyloxy)ethoxy, and 2-(4-fluorophenethyloxy)ethoxy)- (see 
Chapter 5). There is much scope to alter this substituent, including a 
study into length of the linker between the aryloxy group and the 
terminal alkyl/aryl substituent, the effects of branching this linker and 
the nature of the terminal group. 
6.2.5 Removal of ISA 
Initial reporter gene-based assays of 125c indicate it is able to activate 
the J31AR. These assays were carried by Dr. Jillian G Baker (Institute of 
Cell Signalling, Queens Medical Centre, Nottingham) using established 
methodology27, 81, 141 based on CHO-K1 cells expressing human J31-
adrenoceptors and transfected with the SPAP reporter gene. 176 
The extent and physiological relevance of activation cannot be 
quantified without more extensive study using AC based assays in cells 
with physiological levels of surface receptor expression. The presence 
of ISA is unsurprising when the structure of 12Sc is considered with 
respect to existing SAR. The presence of the alkyloxy group para- to 
the oxypropanolamine motif would be expected to impart a degree of 
agonist activity on the molecule. Such activity may possibly be 
eliminated using previous techniques (see Chapter 1) of removal of the 
oxygen atom linker on the para-substituent, or reducing its basicity (e.g. 
by installation of an electron withdrawing group on the adjacent 
aromatic ring). 
It is possible to derive empirically that the agonist effects of 125c are 
likely to be quite low, based upon the in-vivo studies carried out. In 
these experiments, 125c was clearly acting as a selective antagonist of 
the J31AR. 
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6.2.6 Optimisation of synthetic route 
Although attempts to improve the synthetic route have been successful 
throughout this work, the extent to which it is amenable to parallel 
synthesis is limited. 
Improvement of the Mitsunobu reactions can be envisaged by use of 
resin-bound PPh3, allowing ease of removal of triphenylphosphine 
oxide. Reagents such as DBAD can be eliminated by acidic workup. 
Overall, this may eliminate the need for silica-based purification from 
these reactions. 
The lowest yielding reaction in the pathway is the terminal epoxide 
opening. An alternative route could be employed where the epoxide is 
opened with either N-benzyl-2-nitroethylamine or N-benzyl-2-
azidoethylamine present in stoichiometric quantities. Opening of the 
epoxide with a secondary amine should eliminate the expected side 
products, as well as the need to use a large excess of amine. 
Subsequent reduction of the nitro/azide group would then liberate a 
reactive primary amine, which could be further functionalised as the 
appropriate urea. The desired secondary amine could then be released 
after hydrogenolysis of the N-benzyl group. Such a route may improve 
the overall yield obtained. In addition, purification of the final compound 
is likely to be relatively straightforward as it would not require separation 
of mixtures of amines. 
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7 . EXPERIMENTAL 
7.1 General chemistry 
Chemicals and solvents were purchased from standard suppliers and 
used without further purification. Merck Kieselgel60, 230-400 mesh, for 
flash column chromatography (FCC) was supplied by Merck KgaA 
(Darmstadt, Germany) and de ute rated solvents were purchased from 
Goss International Limited (England) and Sigma-Aldrich Company Ltd 
(England). 
Unless otherwise stated, reactions were carried out at ambient 
temperature. Reactions were monitored by thin layer chromatography 
on commercially available precoated aluminium backed plates (Merck 
Kieselgel 60 F254). Visualisation was by examination under UV light 
(254 and 366 nm). General staining carried out with Ninhydrin (solution 
in ethanol), KMn04 or phosphomolybdic acid (PMA). All organic 
extracts after aqueous work-up procedures were dried over MgS04 or 
Na2S04 before gravity filtering and evaporation to dryness. Organic 
solvents were evaporated in vacuo at ~ ~ 40°C (water bath temperature). 
Purification using preparative layer chromatography (PLC) was carried 
out using Fluka silica gel 60 PF254 containing gypsum (200 mm x 200 
mm x 1 mm). Flash chromatography was performed using Merck 
Kieselgel 60 (0.040-0.063 mm). 
Melting points (Mp) were recorded on a Reichert 7905 apparatus or 
Perkin Elmer Pyris 1 differential scanning calorimeter and were 
uncorrected. Fourier transform - infrared (FT-IR) spectra were 
recorded as thin films or KBr discs in the range of 4000 - 500 cm-1 
using and Avatar 360 Nicolet FT-IR spectrophotometer. Optical rotation 
was measured on a Bellingham-Stanley ADP220 polarimeter. 
High resolution mass spectra (HRMS) - time of flight, electrospray 
(TOF ES +1-) were recorded on a Waters 2795 separation 
modulelmicromass LCT platform. 
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1H NMR spectra were recorded on a Bruker-AV 400 at 400.13 MHz. 
13C NMR spectra were recorded at 101.62 MHz. Chemical shifts ( ~ ) ) are 
recorded in parts per million (ppm) with reference to the chemical shift 
of the deuterated solvent/an internal tetramethylsilane (TMS) standard. 
Coupling constants (J) and carbon-fluorine coupling constants (JCF) are 
recorded in Hz and the significant multiplicities described by singlet (s), 
doublet (d), triplet (t), quadruplet (q), broad (br), multiplet (m), doublet of 
doublets (dd), doublet of triplets (dt). Spectra were assigned using 
appropriate COSY, distortionless enhanced polarisation transfer 
(DEPT), HSaC and HMBC sequences. Unless otherwise stated all 
spectra were recorded in CDCb. 
Analytical HPLC was performed using system 1 a/1 b and either system 
2 or system 3 to confirm purity. All retention times (Rt) are quoted in 
minutes. System 1: Phenomenex Onyx Monolithic reverse phase C18 
column (100 x 4.6 mm), a flow rate of 5.00 mUmin (system 1a) or 3.00 
mUmin (system 1b) and UV detection at 287 nm. Linear gradient 5% -
95% solvent B over 10 minutes. Solvent A: 0.1 % formic acid (FA) in 
water; solvent B: 0.1 % FA in MeCN. 
System 2: Vydac reverse phase C8 column (150 x 4.6 mm), a flow rate 
of 1.00 mUmin and UV detection at 287 nm. Linear gradient 5% - 95% 
solvent B over 24 minutes. Solvent A: 0.06% TFA in water; solvent B: 
0.06% TFA in MeCN. 
System 3: Waters symmetry reverse phase C18 column (75 x 4.6 mm), 
a flow rate of 1.00 mUmin and UV detection at 287 nm. Linear gradient 
5% - 95% solvent B over 20 minutes. Solvent A: 0.1 % FA in water; 
solvent B: 0.1% FA in MeOH. 
Preparative HPLC was performed using a Phenomenex Onyx 
Monolithic reverse phase C18 column (100 x 10 mm), a flow rate of 
14.10 mUmin and UV detection at 287 nm. Samples were run in 5% -
95% solvent B over 10 minutes. Solvent A: 0.1 % FA in water; solvent 
B: 0.1% FA in MeCN. 
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1-(2-(3-(2-Cyano-4-(2-(cyclopropylmethoxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(4-hydroxyphenyl)urea hydroformate 
(44) 
The experimental procedure for this compound is listed after the entry 
for 1-(2-aminoethyl)-3-(4-hydroxyphenyl)urea (56). 
3-Formyl-4-hydroxyphenyl pivalate (46) 
PivO -P' CHO 2,5-Dihydroxybenzaldehyde (45) (5.237 g, 37.92 
Yp mmol) was dissolved in dry DMF (40 mL) at 0 °c, ~ O H H
under a nitrogen atmosphere. TEA (4.200 g, 5.813 
mL, 41.71 mmol, 1.1 molar equivalents (eq» followed by dropwise 
addition of pivaloyl chloride (4.801, 4.599 mL, 39.81 mmol, 1.05 eq). 
The mixture was then stirred at room temperature for 4 hours. After 
quenching with MeOH, all solvent was removed in vacuo. The resulting 
slurry was dispersed in water (100 mL) and extracted with ethyl acetate 
(EtOAc) (3 x 50 mL). The combined organic layers were washed with 
brine (50 mL) before concentration. Purification via FCC (eluent 
EtOAc/hexanes 20:80) afforded 6.100 g of viscous yellow oil 
Yield: 72%. 
IR: 3411 (br, O-H, stretch (str», 2976 (alkyl C-H. str), 2937, 2874 
(aldehyde C-H, str), 1754 (ester C=O, str), 1690 (aldehyde C=O, str), 
1608,1586,1494 (aryl, str), 1398 (C(CH3h, str), 1293, 1188 (ester C-O, 
str), 1109 (C-OH, str). 
1H NMR: 6 9.98 (s, 1 H, CHO), 7.18 (d, J = 2.8 Hz, 1 H, aryl 2-H), 7.00 
(dd, J = 8.9/2.8 Hz, 1 H, aryl 6-H), 6.94 (d, J = 8.9 Hz, 1 H, aryl 5-H), 
6.60 (br s, 1 H, OH), 1.40 (s, 9H, (CH3h). 
13C NMR: 6 188.71 (CHO), 178.10 (ester C=O), 154.52 (aryl 4-C), 
145.54 (aryl 1-C), 128.53 (aryl 3-C), 124.25 (aryl 6-C), 122.89 (aryl 2-
C), 115.51 (aryI5-C), 39.35 (C(CH3», 27.10 «CH3)J). 
mlz: HRMS (TOF ES-) C12H1304 [M-Hr calcd 221.0819; found 
221.0818. 
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4-(4-Methoxybenzyloxy)-3-formylphenyl pivalate (47) 
PiV0'(XCHO NaH 60% suspension in mineral oil (495 mg, 
~ ~ I equivalent to 297 mg of NaH, 12.37 mmol, 1.1 eq) 
OPMB 
was suspended in dry DMF (10 mL) at 0 °C, under 
a nitrogen atmosphere. To this was added 3-formyl-4-hydroxyphenyl 
pivalate (46) (2.500 g, 11.25 mmol) in dry DMF (5 mL) and p-
methoxybenzyl bromide (2.488 g /1.783 mL, 12.37 mmol, 1.1 eq) in dry 
DMF (5 mL). After overnight stirring at room temperature and removal 
of DMF in vacuo, the resulting slurry was dispersed in water (30 mL) 
and extracted with diethyl ether (Et20) (4 x 25 mL). The combined 
organic fractions were washed with aqueous 2 M NaOH (20 mL) and 
brine (20 mL). After concentration the crude material was purified by 
FCC (eluent EtOAc/petroleum ether 40-60 (PE) 5:95 for 2 column 
volumes, 10:90 for 6 column volumes then 30:70) to give 1.267 g of 
white crystalline solid. 
Yield: 33%. 
Mp: 69 - 71°C. 
IR: 2972 (alkyl C-H, str) , 2941, 2867 (aldehyde C-H, str), 1749 (ester 
C=O, str) , 1684 (aldehyde C=O, str) , 1612, 1587, 1517 (aryl, str) , 1394 
(C(CH3h str) , 1268, 1255 (ester C-O, str), 1127, 1093 (C-O-C, str), 869 
(aryl C-H, bend, para-disubstituted ring). 
1H NMR: ~ ~ 10.46 (s, 1H, CHO), 7.51 (d, J = 3.2 Hz, 1H, aryI2-H), 7.34 
(d, J = 9.0 Hz, 2H, PMB C-H meta to methoxy group), 7.23 (dd, J = 
8.6/2.9 Hz, 1H, aryI6-H), 7.06 (d, J = 9.0 Hz, 1H, aryl 5-H), 6.92 (d, J = 
8.6 Hz, 2H, PMB C-H ortho to methoxy group), 5.10 (s, 2H, PMB CH2), 
3.81 (s, 3H, PMB CH3), 1.34 (s, 9H, (CH3h). 
13C NMR: ~ ~ 188.94 (CHO), 177.17 (ester C=O), 159.80 (PMB COCH3), 
158.74 (aryI4-C), 144.81 (aryI1-C), 129.23 (PMB C-H meta to methoxy 
group), 129.01 (PMB quaternary (4°) C para to methoxy group), 127.87 
(aryl 6-C), 125.69 (aryl 3-C), 120.79 (aryl 2-C), 114.26 (aryl 5-C), 
114.21 (PMB C-H ortho to methoxy group), 70.97 (PMB CH2), 53.34 
(PMB CH3), 39.09 (C(CH3h), 27.15 «CH3h). 
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m/z: HRMS (TOF ES+) C2oH2305 [MHt calcd 365.1359; found 
365.1341. 
4-(4-Methoxybenzyloxy)-3-cyanophenyl pivalate (48) 
PiV0YpCN 4-( 4-Methoxybenzyloxy)-3-formylphenyl pivalate 
~ O P M B B (47) (1.250 g, 3.65 mmol) was dissolved in THF (5 
mL) and aqueous 37% NH3 solution (20 mL) with 
stirring. To this was added iodine (1.019 g, 4.02 mmol, 1.1 eq) and the 
mixture stirred for 2 hours at room temperature. After quenching with 
excess aqueous 10% sodium thiosulphate solution, the entire mixture 
was extracted with DCM (4 x 25 mL) and concentrated to afford 1.210 g 
of brown crystalline solid requiring no further purification. 
Yield: 98%. 
Mp: 95 - 97°C. 
IR: 2970, 2936, 2877 (alkyl C-H, str), 2231 (CN, str) , 1749 (ester C=O, 
str), 1612, 1586, 1516 (aryl, str), 1392 (C(CH3h. str) , 1273, 1256 (ester 
C-O, str) , 1119, 1098 (C-O-C, str), 825 (aryl C-H, bend, para-
disubstituted ring). 
1H NMR: ~ ~ 7.36 (d, J = 8.5 Hz, 2H, PMB C-H meta to methoxy group), 
7.28 (d, J = 3.1 Hz, 1H, aryI2-H), 7.19 (dd, J = 9.2/2.6 Hz, 1H, aryl 6-
H), 6.98 (d, J = 9.2 Hz, 1H, aryl 5-H), 6.91 (d, J = 8.8 Hz, 2H, PMB C-H 
ortho to methoxy group), 5.13 (s, 2H, PMB CH2), 3.81 (s, 3H, PMB 
CH3), 1.34 (s, 9H, (CH3h). 
13C NMR: ~ ~ 177.04 (ester C=O), 159.81 (PMB COCH3), 158.15 (aryl 4-
C), 144.25 (aryl 1-C), 128.97 (PMB C-H meta to methoxy group), 
127.73 (aryl 6-C), 127.58 (PMB 4° C para to methoxy group), 126.59 
(aryl 2-C), 115.65 (eN), 114.31 (PMB C-H ortho to methoxy group), 
113.98 (aryl 5-C), 103.09 (aryl 3-C), 71.21 (PMB CH2), 55.46 (PMB 
CH3), 39.22 (C(CH3h), 27.18 «CH3h). 
mlz: HRMS (TOF ES+) C2oH21NNa04 [MNat calcd 362.1363; found 
362.1388. 
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2-(4-Methoxybenzyloxy)-5-hydroxybenzonitrile (49) 
4-(4-Methoxybenzyloxy)-3-cyanophenyl pivalate (48) 
H0Y"!{CN 
~ ~ (1.200 g, 3.54 mmol) and sodium terl-butoxide (850 
OPMB mg, 8.84 mmol, 2.5 eq) were dissolved in MeOH (30 
mL) and stirred for 2 hours. After removal of MeOH in vacuo, the crude 
product was dispersed in water (40 mL) and washed with OCM (1 x 30 
mL). This formed an inseparable emulsion and was passed through a 
celite filter (suction) to effect layer separation. The aqueous layer was 
then acidified to pH 4 with careful addition of conc HCI, before 
extraction with OCM (4 25 mL). Concentration of the combined organic 
extracts gave 311 mg of an orange solid, requiring no further 
purification. 
Yield: 34%. 
Mp: 165 - 167°C. 
IR: 3299 (br, O-H, str) , 3055 (aryl C-H, str), 2930, 2835 (alkyl C-H, str) , 
2243 (CN, str) , 1614, 1587, 1499 (aryl, str) , 822 (aryl C-H, bend, para-
disubstituted ring). 
1H NMR: 57.36 (d, J = 8.5 Hz, 2H, PMB C-H meta to methoxy group), 
7.03 (d, J = 2.9 Hz, 1 H, aryl 6-H), 6.98 (dd, J = 8.6/2.9 Hz, 1 H, aryl 4-
H), 6.91 (d, J = 8.6 Hz, 2H, PMB C-H ortho to methoxy group), 6.88 (d, 
J = 9.2 Hz, 1 H, aryl 3-H), 5.21 (br, s, OH), 5.07 (s, 2H, PMB CH2), 3.81 
(s, 3H, PMB CH3). 
13C NMR: 5 159.71 (PMB COCH3), 154.97 (aryl 2-C), 149.59 (aryl 5-C), 
129.03 (PMB C-H meta to methoxy group), 128.10 (PMB 4° C para to 
methoxy group), 121.79 (aryl 4-C), 119.78 (aryl 6-C), 116.31 (CN), 
115.18 (aryl 3-C), 114.23 (PMB C-H ortho to methoxy group), 103.09 
(aryI1-C), 71.47 (PMB CH2), 55.45 (PMB CH3). 
m/z: HRMS (TOF ES-) C1sH12N03 [M-Hr catcd 254.0823; found 
254.0839. 
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5-(2-(Allyloxy)ethoxy)-2-(4-methoxybenzyloxy)benzonitriIe (50) 
2-Allyloxyethanol (174 mg, 182 IJL, 
HA 
Ar a eN 1.70 mmol, 1.5 eq), HB ~ ~ o ~ ~ '(XI triphenylphosphine (449 mg, 1.70 
He ~ ~ aPMS 
mmol, 1.5 eq), and 2-(4-
methoxybenzyloxy)-5-hydroxybenzonitrile (49) (290 mg, 1.14 mmol) 
were dissolved in DCM (10 mL). DIAD (346 mg, 337 IJL, 1.70 mmol, 
1.5 eq) was added dropwise to the reaction mixture and allowed to stir 
overnight. The reaction mixture was then transferred to a separating 
funnel and washed with aqueous 2 M NaOH (1 x 10 mL), and brine (1 x 
10 mL). After concentration of the organic layer, purification was 
achieved via FCC (eluent EtOAc/PE 10:90 for 3 column volumes then 
30:70) to give the desired product as clear colourless oil in quantitative 
yield. 
Yield: 100%. 
IR: 3019 (alkene C-H, str), 2936 (alkyl C-H, str), 2231 (CN, str), 1499 
(aryl, str), 1107 (C-O-C, str), 930 (alkene C-H, deformation). 
1H NMR: ~ ~ 7.35 (d, J = 8.7 Hz, 2H, PMB C-H meta to methoxy group), 
7.08 (s, 1 H, aryl 6-H), 7.07 (dd, J = 8.6/3.1 Hz, 1 H, aryl 4-H), 6.92 (d, J 
= 9.4 Hz, 1 H, aryl 3-H), 6.90 (d, J = 8.6 Hz, 2H, PMB C-H ortho to 
methoxy group), 5.82 - 5.98 (m, 1H, He), 5.30 (ddt, J = 17.3/1.5/1.5 Hz, 
1 H, HA), 5.21 (ddt, J = 10.1/1.5/1.5 Hz, 1 H, He), 5.08 (s, 2H, PMB CH2), 
4.05 - 4.09 (m, 4H, CH2=CHCH2, CH20Ar), 3.81 (s, 3H, PMB CH3), 
3.76 (t, J = 4.8 Hz, 2H, CH2CH20Ar). 
13C NMR: ~ ~ 159.70 (PMB COCH3), 155.06 (aryI2-C), 152.78 (aryl 5-C), 
134.51 (C-Hc), 129.00 (PMB C-H meta to methoxy group), 128.09 
(PMB 4° C para to methoxy group), 121.69 (aryI4-C), 118.68 (aryl 6-C), 
117.64 (CH2=CH), 116.45 (CN), 115.01 (aryl 3-C), 114.21 (PMB C-H 
ortho to methoxy group), 103.97 (aryl 1-C), 72.53 (CH2=CHCH2), 71.39 
(PMB CH2), 68.55, 68.46 (OCH2CH20), 55.42 (PMB CH3). 
m/z: HRMS (TOF ES+) C2oH22N04 [MHt calcd 340.1543; found 
340.1508. 
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methoxybenzyloxy)benzon itrile (51) 
Experimental 
~ O ~ O U C N N 5-(2-(Allyloxy)ethoxy)-2-(4-methoxy 
V ~ ~ I benzyloxy)benzonitrile (50) (408 mg, 
OPMB 
1.20 mmol) was dissolved in dry toluene 
(5 mL) under a nitrogen atmosphere and cooled to 0 °c with stirring. 
Oiethyl zinc (2.40 mL as 1 M/hexanes, 2.40 mmol, 2 eq) was added, 
followed by dropwise addition of diiodomethane (644 mg / 194 IJL, 2.40 
mmol, 2 eq). After stirring for 15 minutes, the vessel was allowed to 
reach room temperature, and then stirred overnight. The reaction was 
quenched with aqueous saturated ammonium chloride solution (20 mL), 
before extraction with OCM (3 x 20 mL). After removal of solvent in 
vacuo, the residue was purified by FCC (eluent MeOH/OCM 1:199). 
The title compound was the first of two bands to be eluted from the 
column as 121 mg of dark yellow oil. 
Yield: 29%. 
IR: 3050 (cyclopropyl (CPr) C-H, str) , 2935, 2872 (alkyl C-H, str), 2228 
(CN), 1614, 1586, 1500 (aryl, str), 1109 (C-O-C, str), 824 (aryl C-H, 
bend, para-disubstituted ring). 
1H NMR: 07.33 (d, J = 8.7 Hz, 2H, PMB C-H meta to methoxy group), 
7.06 (s, 1H, aryI6-H), 7.05 (dd, J = 7.4/3.2 Hz, 1H, aryI4-H), 6.90 (d, J 
= 9.4 Hz, 1 H, aryl 3-H), 6.87 (d, J = 8.6 Hz, 2H, PMB C-H ortho to 
methoxy group), 5.04 (s, 2H, PMB CH2), 4.04 (t, J = 4.6 Hz, 2H, 
CH20Ar), 3.77 (s, 3H, PMB CH3), 3.76 (t, J = 4.8 Hz, 2H, CH2CH20Ar), 
3.34 (d, J = 6.9 Hz, 2H, cPrCH20), 1.00 - 1.12 (m, 1 H, cPr CH), 0.47 -
0.58 (m, 2H, cPr CH2)*, 0.15 - 0.26 (CPr CH2)*. *Refers to cis-protons of 
cPr ring. 
13C NMR: 0 159.52 (PMB COCH3), 154.84 (aryl 2-C), 152.64 (aryl 5-C), 
128.87 (PMB C-H meta to methoxy group), 127.95 (PMB 4° C para to 
methoxy group), 121.52 (aryl 4-C), 118.52 (aryl 6-C), 116.37 (CN), 
114.80 (aryl 3-C), 114.03 (PMB C-H ortho to methoxy group), 102.67 
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(aryl 1-C), 76.24 (CPrCH20), 71.16 (PMB CH2), 68.69, 68.40 
(OCH2CH20), 55.27 (PMB CH3), 10.51 (CPr CH), 3.07 (CPr CH2). 
m/z: HRMS (TOF ES+) C21H24N04 [MHt calcd 354.1700; found 
354.1698. 
5-(2-(Cyclopropylmethoxy)ethoxy)-2-hydroxybenzonitrile (52) 
~ O ~ O ~ C N N The title compound was found to be the 
V ~ ~ second band eluted from the flash column 
OH. . dUring synthesIs of 5-(2-
(cyclopropylmethoxy)ethoxy)-2 -( 4-methoxybenzyloxy)benzonitrile (51 ) 
as 71 mg of clear, colourless oil. 
Yield: 25%. 
IR: 3280 (broad, O-H, str) , 3083 (CPr C-H, str), 3006 (aryl C-H, str), 
2934, 2876 (alkyl C-H, str) , 2228 (CN, str) , 1510 (aryl, str), 1370 (O-H, 
bend), 1093 (C-O-C, str). 
1H NMR: 67.66 (br s, 1 H, OH), 6.94 (dd, J = 9.3/3.1 Hz, 1 H, aryl 4-H), 
6.87 (d, J = 3.0 Hz, 1 H, aryl 6-H), 6.86 (d, J = 9.1 Hz, 1 H, aryl 3-H), 
4.04 (t, J = 4.6 Hz, 2H, CH20Ar), 3.81 (t, J = 4.8 Hz, 2H, CH2CH20Ar), 
3.40 (d, J = 6.9 Hz, 2H, cPrCH20), 1.02 - 1.14 (m, 1 H, cPr CH), 0.46 -
0.59 (m, 2H, cPr CH2)*, 0.15 - 0.27 (CPr CH2)*. *Refers to cis-protons of 
cPr ring. 
13C NMR: 6 153.75 (aryl 2-C), 151.96 (aryl 5-C), 122.76 (aryl 4-C), 
117.89 (aryl 6-C), 116.75 (aryl 3-C), 116.63 (CN), 99.45 (aryl 1-C), 
76.52 (CPrCH20), 68.87, 68.19 (OCH2CH20), 10.44 (CPr CH), 3.26 (CPr 
CH2). 
m/z: HRMS (TOF ES-) C13H14N03 [M-Hr calcd 232.0979; found 
232.0981. 
2-«Oxiran-2-yl)methoxy)-5-(2-
(cyclopropylmethoxy)ethoxy)benzonitrile (53) 
~ O ~ O ~ C N N 5-(2-(Cyclopropylmethoxy)ethoxy)-2-
V ~ ~ ~ I I hydroxybenzonitrile (52) (70 mg, 0.30 
o 'v0 
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mmol) and TEA (33 mg, 46 IJL, 0.33 mmol, 1.1 eq) were dissolved in 
rac-epichlorohydrin ( 5 mL) and heated under reflux at 80°C for 2 
hours. Excess rac-epichlorohydrin was removed in vacuo before 
dissolving the crude residue in EtOAc (30 mL). After washing with 
aqueous 1 M HCI (10 mL), aqueous 1 M NaOH (10 mL) and brine (10 
mL), the organic layer was concentrated to afford the desired epoxide in 
quantitative yield as clear colourless oil. 
Yield: 100%. 
IR: 2962, 2919 (alkyl C-H, str), 2227 (CN, str), 1501 (aryl, str) , 1261, 
800 (epoxide C-O, str) , 1096 (C-O-C, str). 
1H NMR: t5 7.09 (dd, J = 9.0/3.1 Hz, 1 H, aryl 4-H), 7.06 (d, J = 2.8 Hz, 
1 H, aryl 6-H), 6.92 (d, J = 9.0 Hz, 1 H, aryl 3-H), 4.30 (dd, J = 11.3/2.8 
Hz, 1 H, ArOCH2) 4.06 (t, J = 4.6 Hz, 2H, CH20Ar), 4.01 (dd, J = 
11.3/5.4 Hz, 1 H, ArOCH2), 3.77 (t, J = 4.6 Hz, 2H, CH2CH20Ar), 3.34 
(d, J = 7.2 Hz, 2H, cPrCHzO), 3.31 - 3.38 (m, 1 H, epoxide CH), 2.89 
(dd, J = 4.7/4.7 Hz, 1H, epoxide CH2), 2.79 (dd, J = 4.9/2.7 Hz, 1H, 
epoxide CH2), 1.00 - 1.13 (m, 1H, cPr CH), 0.46 - 0.59 (m, 2H, cPr 
CH2)*, 0.15 - 0.27 (CPr CH2)*. *Refers to cis-protons of cPr ring. 
13C NMR: t5 154.70 (aryl 2-C), 153.00 (aryl 5-C), 121.67 (aryl 4-C), 
118.65 (aryl 6-C), 116.16 (CN), 114.52 (aryl 3-C), 102.55 (aryl 1-C), 
76.29 (CPrCH20), 70.16 (ArOCH2), 68.72, 68.52 (OCH2CH20), 50.03 
(epoxide CH), 45.54 (epoxide CH2), 10.53 (CPr CH), 3.08 (CPr CH2). 
m/z: HRMS (TOF ES+) C1sH20N04 [MHt calcd 290.1387; found 
290.1411. 
1-(2-Aminoethyl)-3-(4-(benzyloxy)phenyl)urea (55) 
H H A solution of 4-(benzyloxy) 
~ N N N'Q H2N I( I "=:: phenyl isocyanate (3.739g 16.61 mmol) in 
o 0-
OBn anhydrous OCM (30 mL) was dripped into 
a flask containing vigorously stirred 1,2-ethanediamine (54) (6 mL, 
89.80 mmol, 5.4 eq) under nitrogen. Instant precipitation of a white 
solid was noted and the reaction was allowed to stir for a further 3 
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hours. After removal of all volatiles, the crude solid was washed with 
Et20, before drying to give 4.472 g of white solid. 
Yield: 94%. 
Mp: 147 - 149°C. 
IR: 3300 (primary (1°) amine N-H, str), 2932, 2864 (alkyl C-H, str), 1642 
(urea C=O, str) , 1604 (1° amine N-H, bend), 1111 (C-O, str), 830 (aryl 
C-H, bend, para-disubstituted ring), 741, 697 (aryl C-H, bend, phenyl 
ring). 
1H NMR (DMSO-d6): ~ ~ 8.48 (s, 1H, NHAr), 7.31 - 7.44 (m, 5H, aromatic 
benzyl CH), 7.28, 6.88 (d, J = 9.0 Hz, 2 X 2H, para-disubstituted ring), 
6.24 (t, J = 5.2 Hz, 1 H, NHCONHAr), 5.02 (s, 2H, PhCH20), 4.27 (br s, 
2H, NH2), 3.10 - 3.17 (m, 2H, CH2NH), 2.67 (t, J = 6 Hz, CH2NH2). 
13C NMR (DMSO-cl6): ~ ~ 155.72 (C=O), 152.88, 137.37, 133.97 (4° C), 
128.37, 127.71, 127.63 (benzyl CH), 119.29, 114.87 (aryl CH), 69.37 
(benzyl CH2), 40.87 (CH2NH2), 40.38 (CHNH). 
mlz: HRMS (TOF ES+) C16H20N302 [MHt calcd 286.1550; found 
286.1547. 
1-(2-Aminoethyl)-3-(4-hydroxyphenyl)urea (56) 
H H Method A 
~ N V N ' Q Q
H2N 8 I 1-(2-Aminoethyl)-3-(4-(benzyloxy)phenyl) 
.0 OH 
urea (55) (113 mg, 0.40 mmol) was stirred 
overnight in a solution of concentrated HCI (10 mL). All solvent was 
removed in vacuo and the residue redissolved in water (10 mL) before 
neutralisation with 0.5 M aqueous NaOH. After removal of water in 
vacuo, the residue was dissolved in the minimum amount of MeOH and 
filtered (gravity) before purification by PLC (eluent 37% aq 
NHJlMeOH/DCM 2:25:73). This gave 56 mg of brown semi-solid. 
Yield: 73%. 
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MethodS 
tert-Butyl 2-(3-(4-methoxyphenyl)ureido)ethylcarbamate (65t) (3.00 g, 
9.70 mmol was dissolved in OCM (20 mL) under a nitrogen atmosphere 
and cooled to -78 °C. BBr3 (1.0 M in OCM, 50 mL, 50 mmol, 5.15 eq) 
was added before stirring at room temperature for 2 hours. The 
reaction mixture was quenched by addition of MeOH over an ice bath 
before removal of all volatiles in vacuo. The crude solid was purified 
over a silica plug (initial eluent OCM, followed by 37% aq 
NHJlMeOH/OCM 2:25:73) to give the desired brown semi-solid in 
quantitative yield. 
Yield: 100%. 
IR: 3339 (1 0 amine N-H, str), 3118 (br, O-H, str), 1643 (urea C=O, str), 
1615 (10 amine N-H, bend), 1570 (aryl, str), 836 (aryl C-H, bend, para-
disubstituted ring). 
1H NMR (MeOD-d4): 5 7.17 (d, J = 8.7 Hz, 2H, aryl 3-H and 5-H), 6.73 
(d, J = 8.7 Hz, 2H, aryl 2-H and 6-H), 3.45 (t, J = 5.6 Hz, 2H, 
CH2NH(C=O)NH), 3.05 (t, J = 6.0 Hz, 2H, CH2NH2). 
13C NMR (MeOD-d4): 5 159.38 (4 0 aryl 4-C), 154.70 (C=O), 132.02 (4 0 
aryl 1-C), 123.61, 116.32 (aryl CH), 41.73 (CH2NH2), 38.79 
(CH2NH(C=O)NH). 
mlz: HRMS (TOF ES+) C9H14N302 [MHt calcd 196.1081; found 
196.1081. 
1-(2-(3-(2-Cyano-4-(2-( cyclopropylmethoxy )ethoxy)p hen oxy )-2-
hydroxypropylamino)ethyl)-3-(4-hydroxyphenyl)urea hydroformate 
(44) 
2 -( (Oxiran-2 -yl)methoxy)-5-(2 -( cyclopropylmethoxy)ethoxy)benzon itrile 
(53) (52 mg, 0.18 mmol) and 1-(2-aminoethyl)-3-(4-hydroxyphenyl)urea 
(56) (70 mg, 0.36 mmol, 2 eq) were dissolved in propan-2-ol (5 mL) and 
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heated under reflux at 90°C overnight. After removal of all volatiles in 
vacuo, the crude product was purified by PLC (eluent 37% aq 
NHyMeOH/DCM 1: 1 0:89) and preparative HPLC to give 2 mg of 
hygroscopic white solid. 
Yield: 2%. 
1H NMR (DMSO-d6): 6 8.39 (br s, 1H, OH), 8.19 (s, 1H, 
NH(C=O)NHAr), 7.31 (d, J = 3.0 Hz, 1 H, cyanophenyl ring 3-H), 7.23 
(dd, J = 9.4/3.0 Hz, 1 H, cyanophenyl ring 5-H), 7.18 (d, J = 9.1 Hz, 1 H, 
cyanophenyl ring 6-H), 7.13 (d, J = 8.7 Hz, 2H, hydroxyphenyl ring 2-H 
and 6-H), 6.61 (d, J = 8.7 Hz, 2H, hydroxyphenyl ring 3-H and 5-H), 
6.02 (t, J = 5.1 Hz, 1H, NH(C=O)NHAr), 3.97 - 4.10 (m, 4H, CH20Ar, 
ArOCH2), 3.84 - 3.93 (m, 1H, CH(OH», 3.68 (t, J = 4.7 Hz, 2H, 
CH2CH20Ar), 3.28 (d, J = 6.7 Hz, 2H, cPrCH20), 3.13 (dt, J = 5.7/5.4 
Hz, 2H, NHCH2CH2), 2.56 - 2.77 (m, 4H, CH(OH)CH2NH, NHCH2CH2), 
0.93 - 1.07 (m, 1 H, cPr CH), 0.40 - 0.52 (m, 2H, cPr CH2)*, 0.13 - 0.20 
(CPr CH2)*. *Refers to cis-protons of cPr ring. 
13C NMR (MeOD-d4): 6 159.66 (hydroxyphenyl ring 4-C), 156.18 (C=O), 
154.78 (cyanophenyl ring 1-C), 154.53 (cyanophenyl ring 4-C), 132.07 
(hydroxyphenyl ring 1-C), 123.59 (hydroxyphenyl ring 2-C and 6-C), 
123.07 (cyanophenyl ring 5-C), 119.49 (cyanophenyl ring 3-C), 117.35 
(CN), 116.36 (hydroxyphenyl ring 3-C and 5-C), 115.63 (cyanophenyl 
ring 6-C), 103.11 (cyanophenyl ring 2-C), 77.09 (CPrCH20), 72.81 
(ArOCH2), 70.01 (CH2CH20Ar), 69.61 (CH20Ar). 67.55 (CH(OH», 
51.97. 50.79 (CH(OH)CH2NH, NHCH2CH2), 38.85 (NHCH2CH2). 11.36 
(CPr CH). 3.44 (CPr CH2)' 
m/z: HRMS (TOF ES+) C2sH33N40s [MHt calcd 485.2395; found 
485.2408. 
HPLC Rt : 3.40 (System 1 b), 9.32 (System 3). 
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1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(4-hydroxyphenyl)urea (57) 
The experimental procedure for this compound is listed after the entry 
for 1-(2-(3-( 4-(2-( cyclopentyloxy)ethoxy)phenoxy)-2-hydroxypropyl 
amino)ethyl)-3-(3-hydroxyphenyl)urea (71 u). 
2-(Cyclopentyloxy)ethanol (59) 
h Zirconium chloride (10.021 g, 43 mmol, 1.1 eq) was 
~ O ~ O H H dissolved in dry THF (100 mL) under a nitrogen 
atmosphere. To this was added sodium borohydride (6.507 g, 172 
mmol, 4.4 eq) in portions at room temperature with stirring, resulting in 
hydrogen gas evolution and formation of a cream suspension. A 
solution of cyclopentanone ethylene ketal (58) (5.000 g, 4.85 mL, 39 
mmol) in dry THF (50 mL) was added slowly whilst maintaining the 
vessel temperature between 0 - 5 °c. After stirring at room 
temperature for 4 hours, the mixture was quenched with cautious 
addition of aqueous 2 M HCI over an ice bath. All organic solvent was 
removed in vacuo and the remaining aqueous slurry extracted with 
EtOAc (3 x 50 mL). The combined organic layers were washed with 
brine (1 x 30 mL) before concentration to a crude oil. This was purified 
by FCC (eluent EtOAc/hexanes 50:50) to give 4.114 g of clear 
colourless oil. 
Yield: 81%. 
IR: 2943, 2865 (alkyl C-H, str) , 1109 (C-O-C, str) 
1H NMR: ~ ~ 3.84 - 3.89 (m, 1 H, CH), 3.60 - 3.63 (m, CH20H), 3.41 (t, J 
= 4.9 Hz, 2H, cPeOCH2), 2.84 (t, J= 5.6 Hz, 1H, OH), 1.51-1.72 (m, 
6H, cyclopentyl (CPe) CH2), 1.38 - 1.50 (m, 2H, cPe CH2). 
13C NMR: ~ ~ 81.80 (CH), 69.94 (CPeOCH2), 61.80 (CH20H), 32.17 (2-C 
and 5-C cPe ring), 23.46 (3-C and 4-C cPe ring). 
m/z: HRMS (TOF ES-) CSH1S0 4 [M+HC02r calcd 175.0976; found 
175.0995. 
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1-(2-(Cyclopentyloxy)ethoxy)-4-(benzyloxy)benzene (60) 
~ ~ 2-(Cyclopentyloxy)ethanol (59) (3.751 g, 
~ o ~ 0 1 0 0 28.81 mmol), triphenylphosphine (9.448 g, 
~ O B n n 36.02 mmol, 1.25 eq), and 4-
(benzyloxy)phenol (5.769 g, 28.81 mmol, 1 eq) were dissolved in DCM 
(70 mL). DBAD (8.294 g, 36.02 mmol, 1.25 eq) in OCM (20 mL) was 
added dropwise to the reaction mixture and allowed to stir overnight. 
After removal of approximately half of the solvent from the reaction 
mixture, the resulting slurry was diluted with hexanes (100 mL) and 
washed with aqueous 1 M HCI (2 x 50 mL), aqueous 1 M NaOH (2 x 50 
mL), water (2 x 50 mL) and brine (1 x 50 mL). The organic layer was 
concentrated and redissolved in DCM (30 mL). On addition of hexanes 
a precipitate of triphenylphosphine oxide began to form. The flask was 
left in the freezer for 1 hour before filtration of the precipitate and 
washing with hexanes and Et20. After concentration of the filtrate, 
purification was achieved via FCC (eluent Et20/hexanes 10:90) to give 
6.75 g of clear colourless oil. 
Yield: 75%. 
IR: 2870, 2954 (alkyl C-H, str) , 1507 (aryl, str) , 1109 (C-O-C, str) , 824 
(aryl C-H, bend, para-disubstituted ring), 738, 696 (aryl C-H bend, 
phenyl ring). 
1H NMR: (5 7.34 - 7.48 (m, 5H, aromatic benzyl CH), 6.91, 6.96 (d, J = 
9.2 Hz, 2 x 2H, aryl-dioxy ring), 5.04 (s, 2H, PhCH20), 4.09 (t, J = 4.9 
Hz, 2H, CH20ArOBn), 4.02 - 4.06 (m, 1 H, cPe CH), 3.76 (t, J = 5.3 Hz, 
2H, CH2CH20ArOBn), 1.73 - 1.84 (m, 6H, cPe CH2), 1.56 - 1.63 (m, 
2H, cPe CH2). 
13C NMR: (5 153.02,153.26 (4° C, aryl-dioxy ring), 137.29 (4° benzyl C), 
127.44, 127.83, 128.50 (benzyl CH), 115.62, 115.68 (CH aryl-dioxy 
ring), 81.89 (CPe CH), 70.55 (benzyl CH2), 68.16 (CH20ArOBn), 67.28 
(CH2CH20ArOBn), 32.27 (2-C and 5-C cPe ring), 23.55 (3-C and 4-C 
cPe ring). 
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m/z: HRMS (TOF ES+) C2oH2503 [MHt calcd 313.1798; found 
313.1766. 
4-(2-(Cyclopentyloxy)ethoxy)phenol (S1) 
II 1-(2-(Cyclopentyloxy)ethoxy)-4-(benzyloxy) 
~ o ~ O ~ ~ benzene (SO) (6.326 g, 20.25 mmol) was 
V OH dissolved in EtOH (120 mL) before 
hydrogenating over 10% Pd/C (633 mg) at room temperature and 
atmospheric pressure overnight. After addition of powdered charcoal 
and filtration over celite, no workup was required and the desired 
compound isolated in quantitative yield as clear oil. 
Yield: 100%. 
IR: 3381 (br, O-H, str) , 2960, 2871 (alkyl C-H, str) , 1510 (aryl, str), 1104 
(C-O-C, str) , 827 (aryl C-H, bend, para-disubstituted ring). 
1H NMR: 67.60 (br s, 1H, OH), 6.69, 6.73 (d, J = 9.2 Hz, 2 x 2H, para-
disubstituted phenol), 3.96 - 3.99 (m, 3H, CH, CH20Ar), 3.70 (t, J = 5.0 
Hz, 2H, cPeOCH2), 1.62 - 1.78 (m, 6H, cPe CH2), 1.45 - 1.53 (m, 2H, 
cPe CH2). 
13C NMR: 6 150.05, 152.01 (4° C), 115.53, 115.88 (CH phenolic ring), 
82.05 (CPe CH), 67.82 (CH20Ar), 67.11 (CH2CH20Ar), 32.87 (2-C and 
5-C cPe ring), 23.20 (3-C and 4-C cPe ring). 
mlz: HRMS (TOF ES-) C13H1703 [M-Hr calcd 221.1183; found 
221.1191. 
2-((4-(2-(Cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane (S2) 
Q NaH 60% suspension in mineral oil 
o ~ ~ ~ (863 mg, equivalent to 518 mg of 
.0 O ~ O O NaH, 21.58 mmol, 1.1 eq) was 
suspended in dry DMF (20 mL) with 
stirring under a nitrogen atmosphere. After 5 minutes 4-(2-
(cyclopentyloxy)ethoxy)phenol (S1) (4.360 g, 19.61 mmol) in dry DMF 
(20 mL) was added dropwise with the vessel cooled over an ice bath. 
This was then allowed to stir at room temperature for 20 minutes before 
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addition of rac-epichlorohydrin (15.34 mL, 196.10 mmol, 10 eq). The 
mixture was stirred for 7 hours then quenched cautiously with MeOH. 
After removal of all volatiles, the crude residue was partitioned between 
water (30 mL) and Et20 (30 mL) and the aqueous layer washed again 
with EhO (3 x 30 mL). The combined organic extracts were 
concentrated before purification over a silica plug (initial wash with 
hexanes, followed by EtOH/OCM 5:95) to give 4.558 g of clear yellow 
oil. 
Yield: 84%. 
IR: 3052 (epoxide C-H, str, weak), 2961, 2870 (alkyl C-H. str). 1508 
(aryl, str) , 1110 (C-O-C, str) , 828 (aryl C-H, bend, para-disubstituted 
ring). 
1H NMR: (5 6.80 (s, 4H, aryl C-H), 4.11 (dd, J = 11.1/3.1 Hz, 1 H, 
ArOCH2CH), 3.99 (t, J = 4.9 Hz, 2H, CH20Ar) , 3.92 - 3.96 (m, 1 H, cPe 
CH), 3.82 (dd, J = 11.1/5.7, 1H, ArOCH2CH), 3.67 (t, J = 5.3 Hz, 2H, 
cPeOCH2), 3.25 - 3.29 (m, 1 H, epoxide CH), 2.82 (d, J = 4.9/4.9 Hz, 
1 H, epoxide CH2). 2.67 (dd. J = 5.0/2.7 Hz, 1 H, epoxide CH2) , 1.58 -
1.77 (m, 6H, cPe CH2), 1.41 -1.56 (m, 2H, cPe CH2). 
13C NMR: (5 152.65, 153.36 (4° C), 115.46, 115.53 (aryl CH), 69.35 
(ArOCH2CH), 68.08 (CH20Ar), 67.18 (CH2CH20Ar), 50.13 (epoxide 
CH), 44.49 (epoxide CH2), 32.17 (2-C and 5-C cPe ring), 23.45 (3-C and 
4-C cPe ring). 
m/z: HRMS (TOF ES+) C16H22Na04 [MNat calcd 301.1410; found 
301.1414. 
1-(2-Aminoethyl)-3-(2-methylphenyl)urea (63) H Hu) 1,2-Ethanediamine (54) (11.3 g, 12.5 mL, 188 
~ N N N 
H2N I( I ~ ~ mmol, 50 eq) was diluted with dry OCM (15 mL) 
o -& 
under a nitrogen atmosphere and cooled to 0 
°C. To this, a solution of o-tolylphenyl isocyanate (500 mg, 466 IJL, 
3.76 mmol) in dry OCM (7.5 mL) was added dropwise. After 30 minutes 
of stirring at room temperature, all solvent was removed and the crude 
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slurry purified by FCC (eluent 37% aq NHJlMeOH/OCM 2:30:68) to give 
466 mg of beige solid. 
Yield: 64%. 
Mp: 179 - 181°C. 
IR: 3325 (br, 1° amine N-H, str) , 2926, 2864 (alkyl C-H, str), 1634 (urea 
C=O, str), 1587 (aryl, str), 753 (aryl C-H, bend, orlho-disubstituted ring). 
1H NMR (DMSO-d6): 67.81 (d, J = 8.1 Hz, 1 H, aryl6-H), 7.70 (br s, 1 H, 
NH(C=O)NHAr), 7.05 - 7.11 (m, 2H, aromatic C-H), 6.85 (dd, J = 
8.1/8.1 Hz, 1 H, aromatic C-H), 6.64 (t, J = 5.4 Hz, 1 H, NH(C=O)NHAr), 
3.07 (dt, J = 6.0/6.0 Hz, 2H, CH2NH), 2.61 (t, J = 6.2 Hz, 2H, CH2NH2), 
2.17 (s, 3H, CH3). 
13C NMR (DMSO-d6): ~ ~ 155.52 (C=O), 138.35, 126.56 (4° C), 130.02, 
126.02, 121.68, 120.35 (Aryl C-H), 42.43 (CH2NH), 41.81 (CH2NH2), 
17.95 (CH3). 
m/z: HRMS (TOF ES+) C10H16N30 [MHt calcd 194.1288; found 
194.1308. 
telt-Butyl 2-aminoethylcarbamate (64) 
BOc .... N ~ N H 2 2 1,2-Ethanediamine (54) (50 mL, 927 mmol, 8.75 eq) 
H was diluted in OCM (200mL) with vigorous stirring. Oi-
terl-butyl dicarbonate (23.2 g, 106 mmol) was dissolved in OCM (1.3 L) 
and then added dropwise to the solution of 1,2-ethanediamine over 24 
hours. After removal of all volatiles, the remaining residue was 
partitioned between water (250 mL) and OCM (250 mL). The aqueous 
layer was washed again with OeM (250 mL) before combining the 
organic solvents and concentrating. The residue was dissolved in 
aqueous 0.5 M KHS04 (250 mL) and washed with OCM (2 x 100 mL). 
The aqueous layer was then basified with aqueous 2 M NaOH before 
final extraction with OCM (4 x 100 mL). The combined organic extracts 
were dried and concentrated to give 12.989 of viscous translucent oil. 
Yield: 87%. 
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IR: 3354 (1° amine N-H, str) , 2977, 2933 (alkyl C-H, str), 1694 
(carbamate C=O, str), 1524 (carbamate - amide 11* N-H bend), 1392, 
1366 (C(CH3h, str), 1252, 1174 (C-O, str). *nomenclature derived from 
hydrogen-bonded and non-hydrogen bonded bands shown with amides. 
1H NMR: ~ ~ 5.16 (br s, 1H, CONH), 3.06 - 3.10 (m, 2H, CH2NH), 2.71 
(t, J = 6 Hz, CH2NH2), 1.36 (s, 9H, C(CH3)J), 1.24 (br s, 2H, NH2). 
13e NMR: ~ ~ 156.26 (C=O), 79.25 (C(CH3)J), 42.85, 41.70 (CH2), 28.42 
(C(CH3h)· 
mlz: HRMS (TOF ES+) C7H17N202 [MHt calcd 161.1285; found 
161.1300. 
General procedure for synthesis of phenyl substituted tert-butyl 2-
(3-phenylureido)ethylcarbamates 
H H tert-ButyI 2-aminoethylcarbamate (64) (1 
B O C , ~ ~ N I ( N ~ ~ X eq) was dissolved in dry DCM (10 mL) and 
o V cooled to 0 °c with stirring under a 
nitrogen atmosphere. To this was added dropwise, a solution of the 
desired substituted phenyl isocyanate (500 mg) in dry DCM (5 mL). The 
mixture was stirred overnight at room temperature, before addition of 
hexanes until precipitation occurred. The solid mass was collected by 
filtration (vacuum) and washed with hexanes before drying in vacuo. 
tert-Butyl 2-(3-phenylureido)ethylcarbamate (65a) 
H H Yield: 46%. 
B O C ' N ~ N I ( N ~ ~
H 0 V Mp: 153-155 °c. 
IR: 3323 (br, carbamate N-H, str) , 2980, 2936 (alkyl C-H, str), 1682 
(carbamate C=O, str) , 1646 (urea C=O, str), 1547 (aryl, str), 755, 694 
(aryl C-H bend phenyl ring). 
1H NMR (DMSO-d&): ~ ~ 8.53 (s, 1 H, NH(C=O)NHPh), 7.37 (d, J = 7.7 
Hz, 2H, 2-H and 6-H phenyl ring), 7.20 (dd, J = 7.5n.5 Hz, 2H, 3-H and 
5-H phenyl ring), 6.86 - 6.89 (m, 2H, 4-H phenyl ring, NH(C=O)NHPh), 
6.16 (t, J = 5.5 Hz, 1 H, O(C=O)NH), 3.11 (dt, J = 6.1/6.1 Hz, 2H, 
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CH2NH(C=O)NH), 2.99 (dt, J = 5.8/5.8 Hz, 2H, CH2NH(C=O)O), 1.38 
(s, 9H, C(CH3)J). 
13C NMR (DMSO-d6): is 155.73, 155.29 (C=O), 140.54 (4 0 C), 128.63 
(phenyl 3-C and 5-C), 120.98 (phenyl 4-C), 117.63 (phenyl 2-C and 6-
C), 77.64 (Boc 4 0 C), 40.46, 39.01 (CH2), 28.26 (CH3). 
mlz: HRMS (TOF ES+) C14H22N303 [MHt calcd 280.1656; found 
280.1668. 
tert-Butyl 2-(3-m-tolylureido )ethylcarbamate (65b) 
H H Yield: 59%. 
~ ~ I( I ~ ~ Mp: 135-137 °c. Boc, ~ N N NU 
o h 
IR: 3354 (br, carbamate N-H, str) , 2978, 2940 (alkyl C-H, str), 1687 
(carbamate C=O, str) , 1658 (urea C=O, str), 1530 (aryl, str) , 786 (aryl 
C-H bend meta-disubstituted aromatic ring). 
1H NMR (DMSO-ds): is 8.43 (s, 1 H, NH(C=O)NHAr), 7.21 (s, 1 H, aryl 2-
H), 7.15 (d, J = 8.4 Hz, 1H, aryI6-H), 7.08 (dd, J = 7.6n.6 Hz, 1H, aryl 
5-H), 6.86 (t, J = 5.2 Hz, 1 H, NH(C=O)NHAr), 6.69 (d, J = 7.3 Hz, 1 H, 
aryl 4-H), 6.12 (t, J = 5.5 Hz, 1 H, O(C=O)NH), 3.11 (dt, J = 6.4/6.4 Hz, 
2H, CH2NH(C=O)NH), 2.99 (dt, J = 5.8/5.8 Hz, 2H, CH2NH(C=O)O), 
2.23 (s, 3H, CH3), 1.37 (s, 9H, C(CH3)J). 
13C NMR (DMSO-ds): is 155.71, 155.26 (C=O), 140.43, 137.69 (4 0 C), 
128.46 (aryl 5-C), 121.74 (aryI4-C), 118.18 (aryI2-C), 114.84 (aryl 6-
C), 77.63 (Boc 4 0 C), 40.46, 39.02 (CH2), 28.25 (Boc CH3), 21.25 (CH3). 
mlz: HRMS (TOF ES+) C1sH24N303 [MHt calcd 294.1812; found 
294.1838. 
tert-Butyl 2-(3-p-tolylureido)ethylcarbamate (6Se) 
H H Yield: 86%. 
B o c ' N ~ N I ( N ~ ~
H 0 ~ ~ Mp: 145-147 °c. 
IR: 3345 (br, carbamate N-H, str) , 2982, 2928 (alkyl C-H, str), 1680 
(carbamate C=O, str) , 1655 (urea C=O, str), 1520 (aryl, str) , 823 (aryl 
C-H bend para-disubstituted aromatic ring). 
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1H NMR (DMSO-d6): 58.39 (s, 1H, NH(C=O)NHAr), 7.25 (d, J = 8.4 Hz, 
2H, aryl 2-H and 6-H) 7.01 (d, J = 8.3 Hz, 2H, aryl 3-H and 5-H), 6.85 (t, 
J = 5.1 Hz, 1 H, NH(C=O)NHAr), 6.09 (t, J = 5.5 Hz, 1 H, O(C=O)NH), 
3.10 (dt, J = 6.0/6.0 Hz, 2H, CH2NH(C=O)NH), 2.98 (dt, J = 5.8/5.8 Hz, 
2H, CH2NH(C=O)O), 2.20 (s, 3H, CH3), 1.37 (s, 9H, C(CH3h). 
13C NMR (DMSO-d6): 5 155.72, 155.35 (C=O), 137.96, 129.68 (4 0 C), 
117.76, 129.03 (aryl CH), 77.63 (Boc 4 0 C), 40.50, 39.00 (CH2), 28.26 
(Boc CH3), 20.31 (CH3). 
m/z: HRMS (TOF ES+) C1SH24N303 [MHt calcd 294.1812; found 
294.1839. 
tert-Butyl 2-(3-(2-methoxyphenyl)ureido)ethylcarbamate (65d) 
H Ht)"O Yield: 76%. 
oc N N 
B ' ~ ~ ~ I( I ":::: Mp: 155 -157 °C. 
o A 
IR: 3328 (br, carbamate N-H, str) , 2978, 
2927 (alkyl C-H, str), 1689 (carbamate C=O, str), 1650 (urea C=O, str) , 
1540 (aryl, str), 751 (aryl C-H bend orlho-disubstituted aromatic ring). 
1H NMR (DMSO-d&): 5 8.06 (dd, J = 7.5/2.0 HZ,1 H, aryl 6-H), 7.91 (s, 
1 H, NH(C=O)NHAr), 6.90 - 6.96 (m, 2H, aromatic C-H, 
NH(C=O)NHAr), 6.80 - 6.88 (m, 3H, aromatic C-H, O(C=O}NH), 3.82 
(s, 3H, OCH3), 3.10 (dt, J = 6.4/6.4 Hz, 2H, CH2NH(C=O)NH), 2.98 (dt, 
J = 5.9/5.9 Hz, 2H, CH2NH(C=O)O), 1.37 (s, 9H, C(CH3h). 
13C NMR (DMSO-d6): 5 155.66, 155.24 (C=O), 147.27, 129.46 (40 C), 
120.93, 120.45, 110.54 (aromatic C-H), 117.94 (aryI6-C), 77.63 (Boc 4 0 
C), 55.64 (CH3), 40.48, 38.70 (CH2), 28.26 (Boc CH3). 
m/z: HRMS (TOF ES+) C1sH24N304 [MHt calcd 310.1761; found 
310.1763. 
132 
Experimental 
tert-Butyl 2-(3-(3-methoxyphenyl)ureido)ethylcarbamate (65e) 
H H Yield: 93%. 
~ ~ II IMp: 159-161 °c. Soc.... ~ N ' y " N O O O ........ 
o ~ ~
IR: 3326 (br, carbamate N-H, str) , 2978, 2926 (alkyl C-H, str), 2837 (0-
CH3, str, weak), 1678 (carbamate C=O, str), 1647 (urea C=O, str), 1513 
(aryl, str), 787 (aryl C-H bend meta-disubstituted aromatic ring). 
1H NMR (DMSO-ds): 6 8.53 (s, 1 H, NH(C=O)NHAr), 7.13 (dd, J = 
2.2/2.2 Hz, 1H, aryI2-H), 7.10 (dd, J = 8.1/8.1 Hz, 1H, aryI5-H), 6.83-
6.87 (m, 2H, aryl 6-H, NH(C=O)NHAr), 6.46 (dd, J = 8.1/2.0 Hz, 1 H, aryl 
4-H), 6.14 (t, J = 5.6 Hz, 1 H, O(C=O)NH), 3.70 (s, 3H, OCH3), 3.11 (dt, 
J = 6.4/6.4 Hz, 2H, CH2NH(C=O)NH), 2.99 (dt, J = 5.8/5.8 Hz, 2H, 
CH2NH(C=O)O), 1.37 (s, 9H, C(CH3h). 
13C NMR (DMSO-ds): 6 159.63, 141.76 (4 0 C), 155.72, 155.19 (C=O), 
129.35 (aryl 5-C), 110.00 (aryl 6-C), 106.42 (aryl 4-C), 103.41 (aryl 2-
C), 77.65 (Boc 4 0 C), 54.83 (CH3), 40.42, 38.99 (CH2), 28.26 (Boc CH3). 
m/z: HRMS (TOF ES+) C1sH24N304 [MHt calcd 310.1761; found 
310.1744. 
tert-Butyl 2-(3-(4-methoxyphenyl)ureido)ethylcarbamate (65f) 
Yield: 72%. 
H H Mp: 102 -104 °c. 
BOC .... N ~ N ' y " N O O
H II I 
o ~ ~ 0/ IR: 3350 (br, carbamate N-H, 5tr) , 2971, 
2939 (alkyl C-H, 5tr), 2836 (O-CH3, 5tr, weak), 1684 (carbamate C=O, 
5tr) , 1643 (urea C=O, 5tr) , 1511 (aryl, 5tr), 829 (aryl C-H bend para-
di5ub5tituted aromatic ring). 
1H NMR (DMSO-d6): 6 8.31 (5, 1 H, NH(C=O)NHAr), 7.27 (d, J = 9.0 Hz, 
2H, aryl 2-H and 6-H), 6.85 (t, J = 4.6 Hz, 1 H, NH(C=O)NHAr), 6.80 (d, 
J = 9.0 Hz, 2H, aryl 3-H and 5-H), 6.04 (t, J = 5.6 Hz, 1 H, O(C=O)NH) 
3.68 (5, 3H, OCH3) , 3.10 (dt, J = 6.4/6.4 Hz, 2H, CH2NH(C=O)NH), 2.98 
(dt, J = 5.8/5.8 Hz, 2H, CH2NH(C=O)O), 1.37 (5, 9H, C(CH3h). 
133 
Experimental 
13C NMR (DMSO-d6): ~ ~ 155.72, 155.51 (C=O), 153.90, 133.65 (4° C), 
119.42 (aryl 2-C and 6-C), 113.85 (aryl 3-C and 5-C), 77.63 (Boc 4° C), 
55.12 (CH3), 40.54, 38.81 (CH2), 28.26 (Boc CH3). 
m/z: HRMS (TOF ES+) C15H24N304 [MHt calcd 310.1761; found 
310.1769. 
tert-Butyl 2-(3-(2-fluorophenyl)ureido)ethylcarbamate (65g) 
H H F Yield: 83%. 
Boc .... ~ N N ND ~ ~ n I '-':: Mp: 181 -183°C. 
o ~ ~
IR: 3368, 3331 (carbamate/urea N-H, str), 2981, 2935 (alkyl C-H, str) , 
1673 (carbamate C=O, str) , 1661 (urea C=O, str) , 1551 (aryl, str) , 1256 
(C-F, str) , 752 (aryl C-H bend ortho-disubstituted aromatic ring). 
1H NMR (DMSO-d6): ~ ~ 8.32 (s, 1 H, NH(C=O)NHAr), 8.11 (dd, J = 7.2 
Hz, 1H, aryl 5-H), 7.16 (ddd, J = 11.8/8.2/1.4 Hz, 1H, aryl 3-H), 7.06 
(dd, J = 7.9f7.9 Hz, 1H, aryl 4-H), 6.85 - 6.93 (m, 2H, NH(C=O)NHAr, 
aryl 6-H), 6.66 (t, J = 5.5 Hz, 1 H, O(C=O)NH), 3.12 (dt, J = 6.3/6.3 Hz, 
2H, CH2NH(C=O)NH), 2.99 (dt, J = 5.8/5.8 Hz, 2H, CH2NH(C=O)O), 
1.37 (s, 9H, C(CH3)J). 
13C NMR (DMSO-d6): ~ ~ 155.71, 154.96 (C=O), 151.59 (JCF = 240.6 Hz, 
CF), 128.33 (JCF = 10.3 Hz, aryl 1-C), 124.35 (JCF = 3.3 Hz, aryl 4-C), 
121.48 (JCF = 7.3 Hz, aryl 6-C), 120.16 (aryl 5-C), 114.77 (JCF = 19.0 
Hz, aryl 3-C), 77.65 (Boc 4° C), 40.35, 38.77 (CH2), 28.25 (Boc CH3). 
m/z: HRMS (TOF ES+) C14H21FN30 3 [MHt calcd 298.1561; found 
298.1550. 
tert-Butyl 2-(3-(3-fluorophenyl)ureido)ethylcarbamate (65h) 
H H Yield: 53%. 
BOc .... N ~ N n N l ( Y F F
H 0 V Mp: 114-116°C. 
IR: 3353 (carbamate N-H, str) , 2982, 2944 (alkyl C-H, str), 1679 
(carbamate C=O, str) , 1654 (urea C=O, str) , 1515 (aryl, str), 1277 (C-F, 
str), 773 (aryl C-H bend meta-disubstituted aromatic ring). 
134 
Experimental 
1H NMR (DMSO-d6): l) 8.78 (s, 1 H, NH(C=O)NHAr), 7.45 (ddd, J = 
12.3/2.2/2.2 Hz, 1H, aryl 2-H), 7.22 (ddd, J = 8.2/8.2/8.2 Hz, 1H, aryl 5-
H), 7.01 (dd, J = 8.2/1.1 Hz, 1 H, aryl 6-H), 6.86 (t, J = 5.3 Hz, 1 H, 
NH(C=O)NHAr), 6.68 (dd, J = 8.7/2.5 Hz, 1 H, aryl 4-H), 6.22 (t, J = 5.5 
Hz, 1H, O(C=O)NH), 3.12 (dt, J = 6.4/6.44 Hz, 2H, CH2NH(C=O)NH), 
3.00 (dt, J = 5.8/5.8 Hz, 2H, CH2NH(C=O)O), 1.37 (s, 9H, C(CH3h). 
13C NMR (DMSO-d6): 0 162.43 (JCF = 240.0 Hz, CF), 155.73, 155.05 
(C=O), 142.46 (JCF = 11.5 Hz, aryl 1-C), 130.10 (JCF = 9.8 Hz, aryl 5-C), 
113.27 (aryI6-C), 107.23 (JCF = 21.3 Hz, aryI4-C), 104.24 (JCF = 26.5 
Hz, aryI2-C), 77.65 (Boc 4° C), 40.31,39.04 (CH2), 28.25 (Boc CH3). 
m/z: HRMS (TOF ES+) C14H21FN303 [MHt calcd 298.1561; found 
298.1569. 
tert-Butyl 2-(3-(4-fluorophenyl)ureido)ethylcarbamate (6Si) 
H H Yield: 85%. 
B o c " ' N ~ N y N ~ ~
H 0 ~ F F Mp: 152 -154°C. 
IR: 3340 (carbamate N-H, str) , 2979, 2940 (alkyl C-H, str), 1686 
(carbamate C=O, 5tr) , 1639 (urea C=O, 5tr) , 1509 (aryl, str), 1286 (C-F, 
str) , 834 (aryl C-H bend para-disubstituted aromatic ring). 
1H NMR (DMSO-d6): 0 8.56 (5, 1 H, NH(C=O)NHAr), 7.38 (dd, J = 
7.0/5.0 Hz, 2H, aryl 2-H and 6-H), 7.04 (dd, J = 8.9/8.9 Hz, 2H, aryl 3-H 
and 5-H), 6.86 (t, J = 5.3 Hz, 1 H, NH(C=O)NHAr), 6.13 (t, J = 5.5 Hz, 
1 H, O(C=O)NH), 3.11 (dt, J = 6.4/6.44 Hz, 2H, CH2NH(C=O)NH), 2.99 
(dt, J = 5.8/5.8 Hz, 2H, CH2NH(C=O)O), 1.37 (5, 9H, C(CH3h). 
13C NMR (DMSO-d6): l) 156.86 (JCF = 237.0 Hz, CF), 155.73, 155.33 
(C=O), 136.91 (aryl 1-C), 119.22 (JCF = 7.5 Hz, aryl 2-C and 6-C), 
115.08 (JCF = 22.0 Hz, aryl 3-C and 5-C), 77.64 (Boc 4° C), 40.43, 
38.86 (CH2), 28.26 (Boc CH3). 
m/z: HRMS (TOF ES+) C14H21 FN303 [MHt calcd 298.1561; found 
298.1550. 
135 
Experimental 
tert-Butyl 2-(3-(2-chlorophenyl)ureido)ethylcarbamate (65j) 
H H CI Yield: 52%. 
Boc, ~ N N ND ~ ~ I( I ~ ~ Mp: 167 - 169°C. 
o ,,0 
IR: 3332 (carbamate N-H, str), 2972, 2933 
(alkyl C-H, str) , 1673 (carbamate C=O, str), 1665 (urea C=O, str), 1528 
(aryl, str) , 751 (aryl C-H bend ortho-disubstituted aromatic ring), 656 (C-
CI, bend). 
1H NMR (DMSO-d6): l) 8.14 (d, J = 8.2 Hz, 1H, aryl 6-H), 8.03 (s, 1H, 
NH(C=O)NHAr), 7.38 (dd, J = 8.0/1.4 Hz, 1H, aryl 3-H), 7.23 (ddd, J = 
7.8n.8/1.4 Hz, 1 H, aryl C-H), 7.07 (t, J = 5.3 Hz, 1 H, NH(C=O)NHAr), 
6.94 (dd, J = 7.8/1.5 Hz, 1 H, aryl C-H), 6.87 (t, J = 5.2 Hz, 1 H, 
O(C=O)NH), 3.13 (dt, J = 6.3/6.3 Hz, 2H, CH2NH(C=O)NH), 3.00 (dt, J 
= 5.8/5.8 Hz, 2H, CH2NH(C=O)O), 1.38 (s, 9H, C(CH3)J). 
13C NMR (DMSO-d6): l) 155.68,154.85 (C=O), 136.73, 121.10 (4° C), 
129.05 (aryl 3-C), 127.42, 122.38 (aryl C-H), 120.73 (aryl 6-C), 77.64 
(Soc 4° C), 40.28, 38.96 (CH2), 28.24 (Soc CH3). 
mlz: HRMS (TOF ES+) C14H21CIN303 [MHt calcd 314.1266; found 
314.1274. 
tert-Butyl 2-(3-(3-chlorophenyl)ureido)ethylcarbamate (65k) 
H H Yield: 60%. 
~ ~ I( I ~ ~ Mp:117-119°C. Boc, ~ N N NOCI 
o ,,0 
IR: 3341 (carbamate N-H, str), 2979, 2942 (alkyl C-H, str), 1685 
(carbamate C=O, str) , 1642 (urea C=O, str) , 1528 (aryl, str), 780 (aryl 
C-H bend meta-disubstituted aromatic ring), 639 (C-CI, bend). 
1H NMR (DMSO-d6): l) 8.76 (s, 1 H, NH(C=O)NHAr), 7.66 (s, 1 H, aryl 2-
H), 7.21 (dd, J = 7.9n.9 Hz, 1H, aryl 5-H), 7.17 (d, J = 8.2 Hz, 1H, aryl 
C-H), 6.92 (d, J = 7.7 Hz, 1H, aryl C-H), 6.87 (t, J = 5.1 Hz, 1H, 
NH(C=O)NHAr), 6.23 (t, J = 5.3 Hz, 1 H, O(C=O)NH), 3.11 (dt, J = 
6.1/6.1 Hz, 2H, CH2NH(C=O)NH), 3.00 (dt, J = 5.8/5.8 Hz, 2H, 
CH2NH(C=O)O), 1.37 (s, 9H, C(CH3h). 
136 
Experimental 
13C NMR (DMSO-ds): 6 155.73, 155.01 (C=O), 142.09, 133.07 (4 0 C), 
130.22 (aryl 5-C), 120.57 (aryl C-H), 116.96 (aryl 2-C), 115.97 (aryl C-
H), 77.65 (Boc 4 0 C), 40.28,38.92 (CH2), 28.25 (Boc CH3). 
m/z: HRMS (TOF ES+) C14H21CIN30 3 [MHt calcd 314.1266; found 
314.1276. 
tert-Butyl 2-(3-(4-chlorophenyl)ureido)ethylcarbamate (651) 
H H Yield: 82%. 
Boc .... ~ N ~ N U U~ ~ 8 I Mp: 165 - 167 DC. 
~ ~ CI 
IR: 3339 (carbamate N-H, str) , 2979, 
2941 (alkyl C-H, str), 1685 (carbamate C=O, str), 1641 (urea C=O, str) , 
1528 (aryl, str), 829 (aryl C-H bend para-disubstituted aromatic ring), 
644 (C-CI, bend). 
1H NMR (DMSO-ds): 68.70 (s, 1H, NH(C=O)NHAr), 7.41 (d, J = 8.9 Hz, 
2H, aryl C-H), 7.25 (d, J = 8.9 Hz, 2H, aryl C-H), 6.86 (t, J = 5.3 Hz, 1H, 
NH(C=O)NHAr), 6.20 (t, J = 5.5 Hz, 1 H, O(C=O)NH), 3.11 (dt, J = 
6.4/6.4 Hz, 2H, CH2NH(C=O)NH), 2.99 (dt, J = 5.8/5.8 Hz, 2H, 
CH2NH(C=O)O), 1.37 (s, 9H, C(CH3)J). 
13C NMR (DMSO-d6): 5 155.73, 155.12 (C=O), 139.56, 124.42 (4 0 C), 
128.45, 119.09 (aryl C-H), 77.65 (Boc 40 C), 40.35, 38.78 (CH2), 28.25 
(Boc CH3). 
m/z: HRMS (TOF ES+) C14H21CIN303 [MHt calcd 314.1266; found 
314.1261. 
tert-Butyl 2-(3-(2-bromophenyl)ureido)ethylcarbamate (65m) 
B o c ' N ~ ~ Y ~ v t t : : : d ; : : ~ 3 8 8 .C. 
H 0 V 
IR: 3345, 3312 (carbamate/urea N-H, str), 
2976, 2926 (alkyl C-H, str) , 1686 (carbamate C=O, str), 1657 (urea 
C=O, str) , 1539 (aryl, str), 745 (aryl C-H bend ortho-disubstituted 
aromatic ring), 663 (C-Br, bend). 
137 
Experimental 
1H NMR (DMSO-d6): 6 8.06 (d, J = 8.2 Hz, 1 H, aryl 6-H), 7.85 (s, 1 H, 
NH(C=O)NHAr), 7.54 (dd, J = 8.0/1.4 Hz, 1 H, aryl 3-H), 7.27 (ddd, J = 
7.8n.8/1.4 Hz, 1H, aryl C-H), 7.14 (t, J = 5.4 Hz, 1H, NH(C=O)NHAr), 
6.85 - 6.90 (m, 2H, aryl C-H, O(C=O)NH), 3.12 (dt, J = 6.4/6.4 Hz, 2H, 
CH2NH(C=O)NH), 3.01 (dt, J = 5.8/5.8 Hz, 2H, CH2NH(C=O)O), 1.38 
(s, 9H, C(CH3h). 
13C NMR (DMSO-d&): 6 155.67,154.87 (C=O), 137.83, 112.15 (4° C), 
132.33 (aryl 3-C), 127.91, 123.13 (aryl C-H), 121.53 (aryl 6-C), 77.63 
(Boc 4° C), 40.29, 39.00 (CH2), 28.24 (Boc CH3). 
m/z: HRMS (TOF ES+) C14H21BrN303 [MHt calcd 358.0761; found 
358.0760. 
tett-Butyl 2-(3-(3-bromophenyl)ureido)ethylcarbamate (6Sn) 
H H Yield: 85%. 
Boc, ~ N ' ) 1 " ' N ~ B r r~ ~ 8 V Mp: 122 - 124°C. 
IR: 3338 (carbamate N-H, str) , 2979, 2940 (alkyl C-H, str), 1685 
(carbamate C=O, str) , 1645 (urea C=O, str), 1539 (aryl, str), 778 (aryl 
C-H bend meta-disubstituted aromatic ring), 682 (C-Br, bend). 
1H NMR (DMSO-d6): 6 8.76 (s, 1H, NH(C=O)NHAr), 7.81 (dd, J = 
1.8/1.8 Hz, 1 H, aryl 2-H), 7.21 (ddd, J = 8.5/1.4/1.4 Hz, 1 H, aryl C-H), 
7.16 (dd, J = 7.817.8 Hz, 1 H, aryl 5-H), 7.05 (ddd, J = 7.7/1.2/1.2 Hz, 
1 H, aryl C-H), 6.86 (t, J = 5.3 Hz, 1 H, NH(C=O)NHAr), 6.24 (t, J = 5.5 
Hz, 1 H, O(C=O)NH), 3.11 (dt, J = 6.3/6.3 Hz, 2H, CH2NH(C=O)NH), 
3.00 (dt, J = 5.8/5.8 Hz, 2H, CH2NH(C=O)O), 1.37 (s, 9H, C(CH3h). 
13C NMR (DMSO-d6): 6 155.73, 155.00 (C=O), 142.25, 121.66 (4° C), 
130.55 (aryl 5-C), 123.47 (aryl C-H), 119.83 (aryl 2-C), 116.36 (aryl C-
H), 77.65 (Boc 4° C), 40.28, 38.89 (CH2), 28.25 (Boc CH3). 
m/z: HRMS (TOF ES+) C14H21BrN303 [MHt calcd 358.0761; found 
358.0750. 
138 
Experimental 
tert-Butyl 2 - ( 3 - ( 4 - b r o m o p h e n y l ) u r e i d ~ ) e t h y l c a r b a m a t e e (650) 
H H Yield: 86%. 
~ ~ I( I '>:::: Mp: 192 - 194°C. Boc ..... ~ N N NO 
o h Br 
IR: 3337 (carbamate N-H, str) , 2978, 
2938 (alkyl C-H, str), 1686 (carbamate C=O, str) , 1643 (urea C=O, str) , 
1528 (aryl, str) , 826 (aryl C-H bend para-disubstituted aromatic ring), 
641 (C-Br, bend). 
1H NMR (DMSO-d6): (5 8.70 (s, 1H, NH(C=O)NHAr), 7.37 (s, 4H, aryl C-
H), 6.86 (t, J = 5.3 Hz, 1 H, NH(C=O)NHAr), 6.20 (t, J = 5.5 Hz, 1 H, 
O(C=O)NH), 3.11 (dt, J = 6.3/6.3 Hz, 2H, CH2NH(C=O)NH), 2.99 (dt, J 
= 5.8/5.8 Hz, 2H, CH2NH(C=O)O), 1.37 (s, 9H, C(CH3h). 
13C NMR (DMSO-d6): (5 155.71,155.06 (C=O), 139.96, 112.23 (4° C), 
131.32,119.51 (aryl C-H), 77.63 (Soc 4° C), 40.33,38.85 (CH2), 28.24 
(Soc CH3). 
mlz: HRMS (TOF ES+) C14H21SrN303 [MHt calcd 358.0761; found 
358.0767. 
tert-ButyI 
(65p) 
2-(3-(2-(trifluoromethyl)phenyl)ureido)ethylcarbamate 
H H CF3 Yield: 95%. 
BOC ..... N ~ N v N D DII IMp: 149 - 151°C. 
H 0 h 
IR: 3331 (carbamate N-H, str), 2979, 2931 
(alkyl C-H, str) , 1688 (carbamate C=O, str), 1654 (urea C=O, str), 1541 
(aryl, str) , 1322 (C-F, str), 766 (aryl C-H bend orlho-disubstituted 
aromatic ring). 
1H NMR (DMSO-d6): (5 7.96 (d, J = 8.2 Hz, 1 H, aryl C-H), 7.80 (s, 1 H, 
NH(C=O)NHAr), 7.60 (d, J = 7.9 Hz, 1 H, aryl C-H), 7.56 (dd, J = 8.1/8.1 
Hz, 1H, aryl C-H), 7.17 (dd, J = 7.4n.4 Hz, 1H, aryl C-H), 7.03 - 7.10 
(m, 1 H, NH(C=O)NHAr), 6.82 - 6.90 (m, 1 H, O(C=O)NH), 3.08 - 3.18 
(m, 2H, CH2NH(C=O)NH), 2.95 - 3.06 (m, 2H, CH2NH(C=O)O), 1.38 (s, 
9H, C(CH3h)· 
139 
Experimental 
13C NMR (DMSO-d6): 6 155.70, 155.07 (C=O), 137.36 (4° C), 132.74, 
124.64, 122.59 (aryl C-H), 125.77 (JCF = 5.3 Hz, aryl C-H), 124.10 (JCF 
= 273.0 Hz, CF3), 77.65 (Boc 4° C), 40.27, 38.90 (CH2), 28.24 (Boc 
CH3). 
mlz: HRMS (TOF ES+) C1SH21 F3N303 [MHf calcd 348.1530; found 
348.1529. 
tert-ButyI 
(65q) 
2-(3-(3-(trifluoromethyl)phenyl)ureido)ethylcarbamate 
Yield: 90%. H H 
B O C " ' N ~ N ' t f ' N V C F 3 3
II I Mp: 102 - 103°C. 
H 0 // 
IR: 3338 (carbamate N-H, str) , 2980, 
2937 (alkyl C-H, str), 1686 (carbamate C=O, str) , 1654 (urea C=O, str), 
1569 (aryl, str) , 1339 (C-F, str) , 795 (aryl C-H bend meta-disubstituted 
aromatic ring), 700 (C-F, bend). 
1H NMR (DMSO-d6): 6 8.93 (s, 1H, NH(C=O)NHAr), 7.97 (s, 1H, aryl 2-
H), 7.49 (d, J = 8.3 Hz, 1H, aryI6-H), 7.43 (dd, J = 7.6n.6 Hz, 1H, aryl 
5-H), 7.21 (d, J = 7.4 Hz, 1 H, aryl 4-H), 6.87 (t, J = 5.1 Hz, 1 H, 
NH(C=O)NHAr), 6.28 (t, J = 5.2 Hz, 1 H, O(C=O)NH), 3.13 (dt, J = 
6.3/6.3 Hz, 2H, CH2NH(C=O)NH), 3.01 (dt, J = 5.8/5.8 Hz, 2H, 
CH2NH(C=O)O), 1.37 (s, 9H, C(CH3)J). 
13C NMR (DMSO-ds): 6 155.75, 155.12 (C=O), 141.40, (4° C), 129.73 
(aryl 5-C), 129.41 (JCF = 30.9 Hz, aryl 3-C), 124.31 (JCF = 272.3 Hz, 
CF3), 121.11 (aryl 6-C), 117.19 (JCF = 4.2 Hz, aryI4-C), 113.52 (JCF = 
4.1 Hz, aryl 2-C), 77.66 (Boc 4° C), 40.27, 38.94 (CH2), 28.25 (Boc 
CH3). 
m/z: HRMS (TOF ES+) C1sH21F3N303 [MHr calcd 348.1530; found 
348.1540. 
140 
Experimental 
tert-Butyl 
(65r) 
2-(3-(4-(trifluoromethyl)phenyl)ureido)ethylcarbamate 
IR: 3391. 3336 (urea/carbamate N-H. 
str), 2981, 2935 (alkyl C-H, str), 1699 (carbamate C=O, str). 1666 (urea 
C=O, str), 1553 (aryl, str), 1329 (C-F, str). 838 (aryl C-H bend para-
disubstituted aromatic ring), 657 (C-F, bend). 
1H NMR (DMSO-d6): (58.99 (s, 1 H, NH(C=O)NHAr), 7.59 (d, J = 9.1 Hz, 
2H, aryl C-H), 7.55 (d, J = 9.1 Hz. 2H, aryl C-H), 6.88 (t, J = 5.3 Hz, 1 H. 
NH(C=O)NHAr), 6.31 (t, J = 5.5 Hz, 1 H, O(C=O)NH), 3.13 (dt, J = 
6.3/6.3 Hz. 2H, CH2NH(C=O)NH), 3.01 (dt, J = 5.8/5.8 Hz, 2H, 
CH2NH(C=O)O), 1.37 (s, 9H, C(CH3h). 
13C NMR (DMSO-d6): (5 155.74, 154.91 (C=O), 144.26, 121.07 (4° C), 
125.96 (JCF = 3.7 Hz, aryl 3-C and 5-C), 122.04 (JCF = 226.7 Hz, CF3), 
117.19 (aryl 2-C and 6-C), 77.66 (Boc 4° C), 40.24, 38.89 (CH2), 28.24 
(Boc CH3). 
m/z: HRMS (TOF ES+) C15H21F3N303 [MHt calcd 348.1530; found 
348.1516. 
General procedure for synthesis of phenyl substituted 1-(2-
aminoethyl)-3-(phenyl)urea hydrochlorides 
H H The desired phenyl substituted Boc-protected 
H3N I( I ~ x x phenylurea (compounds 65a-65r) was < ± ) ~ N N N'O 
~ ~ 0 // dissolved in MeOH (6 mL) with the aid of 
sonication and heat if necessary. This was then added to vigorously 
stirred concentrated aqueous HCI (5 mL) and stirred for 3 hours. All 
solvents were removed in vacuo and the resulting hydrochloride salts of 
the desired compounds were freeze-dried. 
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1-(2-Aminoethyl)-3-phenylurea hydrochloride (66a) 
Yield: 92%. 
e H H 
CI - H 3 ~ ~ N n N ~ ~ Mp: 186 - 188 DC. 
o ~ ~
IR: 3329, 3234 (urea N-H, str), 2958 
(NH3+, str), 2761, 2681 (alkyl C-H, str) , 1660 (urea C=O, str), 1597, 
1499 (NH3+, bend), 1563 (aryl, str) , 764, 693 (aryl C-H bend phenyl 
ring). 
1H NMR (DMSO-ds): ~ ~ 8.93 (s, 1H, NH(C=O)NHPh), 7.89 (br s, 3H, 
NH3+), 7.41 (d, J = 7.6 Hz, 2H, 2-H and 6-H phenyl ring), 7.22 (dd, J = 
7.5fi.5 Hz, 2H, 3-H and 5-H phenyl ring), 6.90 (dd, J = 7.3fi.3 Hz, 1H, 
4-H phenyl ring), 6.34 (t, J = 5.7 Hz, NH(C=O)NHPh), 3.30 - 3.34 (m, 
2H, CH2NH(C=O)NH), 2.83 - 2.93 (m, 2H, CH2NH3+). 
13C NMR (DMSO-ds): ~ ~ 155.76 (C=O), 140.33 (4 0 C), 128.64 (phenyl 3-
C and 5-C), 121.23 (phenyI4-C), 117.80 (phenyl 2-C and 6-C), 39.12, 
37.17 (CH2). 
mlz: HRMS (TOF ES+) C9H14N30 [MHt calcd 180.1131; found 
180.1140. 
1-(2-Aminoethyl)-3-(3-methylphenyl)urea hydrochloride (66b) 
H H Yield: 100%. 
CI < t l ~ N v N y y y
e H3N 8 V Mp: 185 - 187 DC. 
IR: 3323 (urea N-H, str) , 3009 (NH3+, str), 2753 (alkyl C-H, str) , 1677 
(urea C=O, str), 1612, 1489 (NH3+, bend), 1567 (aryl, str), 775 (aryl C-H 
bend meta-disubstituted aromatic ring). 
1H NMR (DMSO-ds): ~ ~ 9.01 (s, 1 H, NH(C=O)NHAr), 8.02 (br s, 3H, 
NH3+), 7.18 - 7.25 (m, 2H, aryl2-H, aryl C-H), 7.09 (dd, J = 7.7fi.7 Hz, 
1 H, aryl 5-H), 6.67 - 6.75 (m, 2H, aryl C-H, NH(C=O)NHAr), 3.31 (dt, J 
= 6.2/6.2 Hz, 2H, CH2NH(C=O)NH), 2.87 (t, J = 6.2 Hz, CH2NH3 +), 2.23 
(s, 3H, CH3). 
142 
Experimental 
1lC NMR (DMSO-d6): ~ ~ 155.82 (C=O), 140.33, 137.67 (4° C), 128.46 
(aryl 5-C), 121.90, 118.25, 114.94 (aryl C-H), 39.04 (CH2NH3+), 37.14 
(CH2NH(C=O)NH), 21.26 (CH3) 
m/z: HRMS (TOF ES+) C1oH16N30 [MHt calcd 194.1288; found 
194.1289. 
1-(2-Aminoethyl)-3-(4-methylphenyl)urea hydrochloride (66c) 
H H Yield: 96%. 
® ~ N N N ~ ~~ ~ H3N r ~ ~ Mp: 214 - 216°C (literature (lit). 213 
0C) 143. 
IR: 3312 (urea N-H, str), 3005 (NH3 +, str), 1670 (urea C=O, str), 1603, 
1512 (NH3+, bend), 1558 (aryl, str), 810 (aryl C-H bend para-
disubstituted aromatic ring). 
1H NMR (DMSO-d6): ~ ~ 8.95 (s, 1H, NH(C=O)NHAr), 8.01 (br s, 3H, 
NH3+), 7.29 (d, J = 8.4 Hz, 2H, aryl 2-H and 6-H), 7.02 (d, J = 8.4 Hz, 
2H, aryl 3-H and 5-H), 6.63 (t, J = 5.8 Hz, 1 H, NH(C=O)NHAr), 3.31 (dt, 
J = 6.2/6.2 Hz, 2H, CH2NH(C=O)NH), 2.86 (t, J = 6.2 Hz, 2H, CH2NH3+), 
2.20 (s, 3H, CH3). 
13C NMR (DMSO-ds): 6 155.85 (C=O), 137.82, 129.84 (4° C), 129.01 
(aryl 3-C and 5-C), 117.84 (aryl 2-C and 6-C), 39.07 (CH2NH3+), 37.13 
(CH2NH(C=O)NH), 20.32 (CH3). 
m/z: HRMS (TOF ES+) C10H16N30 [MHr calcd 194.1288; found 
194.1283. 
1-(2-Aminoethyl)-3-(2-methoxyphenyl)urea hydrochloride (66d) 
H HD'O Yield: 85%. 
e ® N N 
CI H 3 N ~ ~ I( I ~ ~ Mp: 156 - 158°C. 
o ~ ~
IR: 3373, 3282 (urea N-H, str) , 2998 (NH3+, 
str), 1647 (urea C=O, str) , 1576, 1499 (NH3+, bend), 1533 (aryl, str), 
755 (aryl C-H bend orlho-disubstituted aromatic ring). 
1H NMR (DMSO-d6): ~ ~ 8.05 (dd, J = 7.8/1.8 Hz, 1H, aryl 6-H), 8.03 (s, 
1H, NH(C=O)NHAr), 8.00 (br s, 3H, NH3+), 7.19 - 7.26 (m, 1H, 
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NH(C=O)NHAr), 6.96 (dd, J = 7.9/1.6 Hz, 1 H, aryl 3-H), 6.88 (ddd, J = 
7.417.4/1.8 Hz, 1 H, aryl C-H), 6.84 (ddd, J = 7.817.8/1.7 Hz, 1 H, aryl C-
H), 3.82 (s, 3H, CH3), 3.31 (dt, J = 6.1/6.1 Hz, 2H, CH2NH(C=O)NH), 
2.87 (tq, J = 5.8/5.8 Hz, CH2NH3 +). 
13C NMR (DMSO-d6): 6 156.06 (C=O), 147.90, 129.61 (4° C), 121.75, 
120.89 (aryl C-H), 118.62 (aryl 6-H), 111.10 (aryl 3-H), 56.13 (CH3), 
39.63 (CH2NH3+), 37.50 (CH2NH(C=O)NH). 
m/z: HRMS (TOF ES+) C1oH16N302 [MHt calcd 210.1237; found 
210.1234. 
1-(2-Aminoethyl)-3-(3-methoxyphenyl)urea hydrochloride (66e) 
H H Yield: 99%. 
CI e H ~ ~ N I ( N ~ O , ,
3 0 V Mp: 183-188°C. 
IR: 3389, 3301 (urea N-H, str), 2883 (NH3+, str), 1658 (urea C=O, str), 
1576, 1497 (NH3+, bend), 1522 (aryl, str), 785 (aryl C-H bend meta-
disubstituted aromatic ring). 
1H NMR (DMSO-d6): 6 9.03 (s, 1 H, NH(C=O)NHAr), 7.95 (br s, 3H, 
NH3+), 7.16 (dd, J = 2.2/2.2 Hz, 1H, aryI2-H), 7.11 (dd, J = 8.1/8.1 Hz, 
1H, aryI5-H), 6.89 (dd, J = 8.1/1.7 Hz, 1H, aryI6-H), 6.61(t, J = 5.7 Hz, 
1 H, NH(C=O)NHAr), 6.48 (dd, J = 8.1/2.4 Hz, 1 H, aryI4-H), 3.69 (s, 3H, 
CH3), 3.32 (dt, J = 6.2/6.2 Hz, 2H, CH2NH(C=O)NH), 2.87 (tq, J = 
5.9/5.9 Hz, CH2NH3 +). 
13C NMR (DMSO-d6): 6 159.60, 141.60 (4° C), 155.69 (C=O), 129.36 
(aryl 5-C), 110.15 (aryI6-C), 106.53 (aryI4-C), 103.60 (aryl 2-C), 54.86 
(CH3), 39.06 (CH2NH3+), 37.13 (CH2NH(C=O)NH). 
m/z: HRMS (TOF ES+) C1oH16N302 [MHt calcd 210.1237; found 
210.1216. 
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1-(2-Aminoethyl)-3-(4-methoxyphenyl)urea hydrochloride (66t) 
H H Yield: 88%. 
e <±> N N 
CI H 3 N ~ ~ I( ~ ~
o ~ o / / Mp: 180-182 °C. 
IR: 3335 (urea N-H, str), 3007 (NH3 +, str), 1629 (urea C=O, str), 1508 
(NH3+, bend), 1570 (aryl, str) , 827 (aryl C-H bend para-disubstituted 
aromatic ring). 
1H NMR (DMSO-d6): 6 8.75 (s, 1H, NH(C=O)NHAr), 7.93 (br s, 3H, 
NH3+), 7.30 (d, J = 9.1 Hz, 2H, aryl 2-H and 6-H), 6.81 (d, J = 9.1 Hz, 
2H, aryl 3-H and 5-H), 6.47 (t, J = 5.8 Hz, 1 H, NH(C=O)NHAr), 3.69 (s, 
3H, CH3), 3.33 (dt, J = 6.1/6.1 Hz, 2H, CH2NH(C=O)NH), 2.86 (tq, J = 
5.8/5.8 Hz, CH2NH3 +). 
13C NMR (DMSO-d6): 6 156.44, 154.49, 133.88 (4° C), 120.05 (aryl 2-C 
and 6-C), 114.30 (aryl 3-C and 5-C), 55.59 (CH3), 39.90 (CH2NH3+), 
37.67 (CH2NH(C=O)NH). 
mlz: HRMS (TOF ES+) C1oH1SN302 [MHt calcd 210.1237; found 
210.1237. 
1-(2-Aminoethyl)-3-(2-fluorophenyl)urea hydrochloride (66g) 
<±> N N 
H HDF Yield: 97%. 
~ ~ H 3 N ~ ~ I( I '-'::: Mp: 208 - 210°C. 
o .0 
IR: 3320 (urea N-H, str) , 3011 (NH3+, str), 
2755 (alkyl C-H, str), 1678 (urea C=O, str), 1605, 1490 (NH3 +, bend), 
1561 (aryl, str), 1258 (C-F, str) , 745 (aryl C-H bend ortho-disubstituted 
aromatic ring). 
1H NMR (DMSO-d6): 6 8.57 (d, J = 2.1 Hz, 1H, NH(C=O)NHAr), 8.05 -
8.10 (m, 4H, aryl C-H, NH3+), 7.11 - 7.21 (m, 2H, aryl 3-H, 
NH(C=O)NHAr), 7.08 (dd, J = 7.8n.8 Hz, 1H, aryl C-H), 6.90 - 6.96 
(m, 1 H, aryl C-H), 3.34 (dt, J = 6.0/6.0 Hz, 2H, CH2NH(C=O)NH), 2.88 
(t, J = 6.2 Hz, 2H, CH2NH3+). 
1lC NMR (DMSO-d&): 6 155.44 (C=O), 151.85 (JCF = 241.2 Hz, C-F), 
128.65 (JCF = 10.3 Hz, aryI1-C), 124.34 (JCF = 3.6 Hz, aryl C-H), 121.93 
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(JCF = 7.4 Hz, aryl C-H), 120.64 (aryl C-H), 114.90 (JCF = 19.1 Hz, aryl 
3-C), 38.82 (CH2NH3+), 37.11 (CH2NH(C=O)NH). 
m/z: HRMS (TOF ES+) C9H13FN30 [MHt ealed 198.1037; found 
198.1034. 
1-(2-Aminoethyl)-3-(3-fluorophenyl)urea hydrochloride (66h) 
H H Yield: 91 %. 
~ ~ H3N Y I ~ ~ Mp: 184-186 °C. ® ~ N N N'CrF 
o .,& 
IR: 3310 (urea N-H, str) , 3005 (NH3+, str) , 2686 (alkyl C-H, str) , 1678 
(urea C=O, str) , 1610, 1494 (NH3+, bend), 1558 (aryl, str), 1271 (C-F, 
str), 785 (aryl C-H bend meta-disubstituted aromatic ring), 682 (C-F, 
bend). 
1H NMR (DMSO-ds): ~ ~ 9.42 (s, 1 H, NH(C=O)NHAr), 8.00 (br s, 3H, 
NH3+), 7.46 (ddd, J = 12.3/2.2/2.2 Hz, 1H, aryl 2-H), 7.23 (ddd, J = 
8.2/8.217.0 Hz, 1 H, aryl 5-H), 7.06 (dd, J = 8.2/1.8 Hz, 1 H, aryl 6-H), 
6.76 (t, J = 5.8 Hz, 1H, NH(C=O)NHAr), 6.69 (ddd, J = 8.7/8.7/2.5 Hz, 
1 H, aryl 4-H), 3.33 (dt, J = 6.2/6.2 Hz, 2H, CH2NH(C=O)NH), 2.87 (tq, J 
= 5.4/5.4 Hz, 2H, CH2NH3 +). 
13C NMR (DMSO-ds): ~ ~ 162.40 (JCF = 240.1 Hz, C-F), 155.58 (C=O), 
142.37 (JCF = 11.6 Hz, aryl 1-C), 130.13 (JCF = 9.7 Hz, aryl 5-C), 113.38 
(JCF = 2.2 Hz, aryl 6-C), 107.39 (JCF = 21.2 Hz, aryl 4-C), 104.31 (JCF = 
26.5 Hz, aryI2-C), 39.19 (CH2NH3+), 37.09 (CH2NH(C=O)NH). 
m/z: HRMS (TOF ES+) C9H13FN30 [MHt ealed 198.1037; found 
198.1027. 
1-(2-Aminoethyl)-3-(4-fluorophenyl)urea hydrochloride (66i) 
H H Yield: 100%. 
<gJ H3N Y I ~ ~ Mp: 203 - 205°C. ® ~ N N N'O 
o .,& F 
IR: 3336 (urea N-H, str), 3012 (NH3+, str), 
1647 (urea C=O, str) , 1615, 1509 (NH3+, bend), 1565 (aryl, str) , 1225 
(C-F, str), 827 (aryl C-H bend para-disubstituted aromatic ring), 756 (C-
F, bend). 
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1H NMR (OMSO-d6): 5 9.17 (s, 1H, NH(C=O)NHAr), 8.02 (br s, 3H, 
NH3+), 7.42 (dd, J = 9.2/5.0 Hz, 2H, aryl 2-H and 6-H), 7.05 (dd, J = 
8.9/8.9 Hz, 2H, aryl 3-H and 5-H), 6.62 - 6.73 (m, 1 H, NH(C=O)NHAr), 
3.27 - 3.38 (m, 2H, CH2NH(C=O)NH), 2.86 (tq, J = 5.7/5.7 Hz, 2H, 
CH2NH3+). 
13C NMR (OMSO-ds): 5 156.93 (JCF = 237.2 Hz, C-F), 155.83 (C=O), 
136.81 (JCF = 2.3 Hz, 1-C), 119.31 (JCF = 7.5 Hz, aryl 2-C and 6-C), 
115.09 (JCF = 22.0 Hz, aryl 3-C and 5-C), 39.07 (CH2NH3 +), 37.15 
(CH2NH(C=O)NH). 
m/z: HRMS (TOF ES+) C9H13FN30 [MHt calcd 198.1037; found 
198.1021. 
1-(2-Aminoethyl)-3-(2-chlorophenyl)urea hydrochloride (66j) 
H H CI Yield: 80%. 
e ® N ND CI H 3 N ~ ~ n I ~ ~ Mp: 205 - 207 °C. 
o 0 
IR: 3327 (urea N-H, str), 2978 (NH3+, str), 
2748 (alkyl C-H, str), 1675 (urea C=O, str), 1589, 1528 (NH3+, bend), 
1567 (aryl, str), 748 (aryl C-H bend orlho-disubstituted aromatic ring), 
627 (C-CI, bend). 
1H NMR (OMSO-d6): ~ ~ 8.44 (br s, 1 H, NH(C=O)NHAr), 8.12 (dd, J = 
8.3/1.5 Hz, 1H, aryl C-H), 8.07 (br s, 3H, NH3+), 7.52 (t, J = 5.6 Hz, 1H, 
NH(C=O)NHAr), 7.40 (dd, J = 8.0/1.5 Hz, 1 H, aryl C-H), 7.24 (dd, J = 
7.8/1.4 Hz, 1H, aryl C-H), 6.96 (dd, J = 7.8/1.5 Hz, 1H, aryl C-H), 3.31 -
3.39 (m, 2H, CH2NH(C=O)NH), 2.89 (br s, 2H, CH2NH3+). 
13C NMR (OMSO-ds): 5 155.78 (C=O), 136.97, 121.98 (4 0 C), 129.58, 
127.87, 123.19, 121.51 (aryl C-H), 38.93 (CH2NH3+), 37.54 
(CH2NH(C=O)NH). 
m/z: HRMS (TOF ES+) CgH13CIN30 [MHt calcd 214.0742; found 
214.0724. 
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1-(2-Aminoethyl)-3-(3-chlorophenyl)urea hydrochloride (66k) 
H H Yield: 92%. 
e ( ± ) ~ N N N ~ C I I
CI H3N l C Mp: 193-195 °C. 
IR: 3319 (urea N-H, str), 3009 (NH3+, str) , 1681 (urea C=O, str) , 1598, 
1506 (NH3+, bend), 1558 (aryl, str) , 774 (aryl C-H bend meta-
disubstituted aromatic ring), 680 (C-CI, bend). 
1H NMR (DMSO-ds): ~ ~ 9.25 (s, 1H, NH(C=O)NHAr), 7.86 (br s, 3H, 
NH3+), 7.66 - 7.70 (m, 1H, aryI2-H), 7.20 - 7.27 (m, 2H, aryl C-H), 6.94 
(ddd, J = 6.7/2.2/2.2 Hz, 1H, aryl C-H), 6.62 (t, J = 5.8 Hz, 1H, 
NH(C=O)NHAr), 3.32 (dt, J = 6.2/6.2 Hz, 2H, CH2NH(C=O)NH), 2.88 
(tq, J = 5.8/5.8 Hz, 2H, CH2NH3+). 
13C NMR (DMSO-ds): ~ ~ 155.53 (C=O), 141.95, 133.06 (4 0 C), 130.27, 
120.79, 116.10 (aryl C-H), 117.11 (aryl 2-C), 39.70 (CH2NH3+), 37.16 
( CH2NH(C=O)NH). 
m/z: HRMS (TOF ES+) CgH13CIN30 [MHr ealed 214.0742; found 
214.0737. 
1-(2-Aminoethyl)-3-(4-chlorophenyl)urea hydrochloride (661) 
e H H Yield: 94%. - (±) N N 
CI H 3 N ~ ~ I( ~ ~ ~
o 0 Mp: 223 - 225 °C. 
CI 
IR: 3380, 3307 (urea N-H, str) , 2879 (NH3+, str) , 1647 (urea C=O, str) , 
1593, 1491 (NH3+, bend), 1518 (aryl, str) , 836 (aryl C-H bend para-
disubstituted aromatic ring), 647 (C-CI, bend). 
1H NMR (DMSO-ds): ~ ~ 9.25 (s, 1 H, NH(C=O)NHAr), 7.95 (br s, 3H, 
NH3+), 7.45, 7.27 (d, J = 8.9 Hz, 2 x 2H, aryl C-H), 6.67 (t, J = 5.8 Hz, 
1 H, NH(C=O)NHAr), 3.32 (dt, J = 6.2/6.2 Hz, 2H, CH2NH(C=O)NH), 
2.87 (tq, J = 5.7/5.7 Hz, 2H, CH2NH3+). 
13C NMR (DMSO-ds): ~ ~ 155.61 (C=O), 139.43, 124.59 (4 0 C), 128.47, 
119.19 (aryl C-H), 39.24 (CH2NH3+), 37.13 (CH2NH(C=O)NH). 
m/z: HRMS (TOF ES+) CgH13CIN30 [MHt calcd 214.0742; found 
214.0732. 
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1-(2-Aminoethyl)-l-(2-bromophenyl)urea hydrochloride (66m) 
~ ~ H 3 ~ ~ ~ I ( ~ ~ ~ : : : d ; : : ~ 1 9 7 7 ·C. 
oU 
IR: 3329 (urea N-H, str), 3014 (NH3+, str), 
2743 (alkyl C-H, str), 1676 (urea C=O, str), 1582, 1527 (NH3+, bend), 
1558 (aryl, str), 749 (aryl C-H bend orlho-disubstituted aromatic ring), 
668 (C-Br, bend). 
1H NMR (DMSO-d6): 8.09 (br s, 3H, NH3+), 7.99 - 8.06 (m, 2H, 
NH(C=O)NHAr, aryl C-H), 7.54 - 7.60 (m, 2H, NH(C=O)NHAr, aryl C-
H), 7.28 (dd, J = 7.8/1.4 Hz, 1 H, aryl C-H), 6.91 (dd, J = 8.0/1.6 Hz, 1 H, 
aryl C-H), 3.29 - 3.38 (m, 2H, CH2NH(C=O)NH), 2.89 (tq, J = 5.6/5.6 
Hz, 2H, CH2NH3 +). 
13C NMR (DMSO-ds): 0 155.34 (C=O), 137.63, 112.60 (4° C), 132.41, 
127.94, 123.50, 121.87 (aryl C-H), 38.79 (CH2NH3+), 37.12 
( CH2NH(C=O)NH). 
m/z: HRMS (TOF ES+) C9H13BrN30 [MHt calcd 258.0237; found 
258.0211. 
1-(2-Aminoethyl)-l-(l-bromophenyl)urea hydrochloride (66n) 
H H Yield: 98%. 
CI ( f ) ~ N N NyyBr 
e H3
N 8 V Mp: 196-198 °C. 
IR: 3324 (urea N-H, str) , 3009 (NH3+, str) , 1680 (urea C=O, str), 1589, 
1495 (NH3+, bend), 1556 (aryl, str) , 772 (aryl C-H bend meta-
disubstituted aromatic ring), 680 (C-Br, bend). 
1H NMR (DMSO-ds): 0 9.41 (5, 1H, NH(C=O)NHAr), 7.98 (br 5, 3H, 
NH3 +), 7.82 (dd, J = 1.9/1.9 Hz, 1 H, aryl 2-H), 7.28 (ddd, J = 8.2/1.9/0.9 
Hz, 1H, aryl C-H), 7.17 (dd, J = 8.0/8.0 Hz, 1H, aryl 5-H), 7.06 (ddd, J = 
7.9/1.9/1.0 Hz, 1H, aryl C-H), 6.76 (t, J = 5.8 Hz, 1H, NH(C=O)NHAr), 
3.32 (dt, J = 6.3/6.3 Hz, 2H, CH2NH(C=O)NH), 2.87 (t, J = 5.8 Hz, 2H, 
CH2NH3+). 
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13C NMR (DMSO-d6): 6 155.52 (C=O), 142.14, 121.59 (4° C), 130.27 
(aryl 5-C), 123.58, 116.39 (aryl C-H), 119.85 (aryl 2-C), 39.19 
(CH2NH3+), 37.10 (CH2NH(C=O)NH). 
mlz: HRMS (TOF ES+) C9H13BrN30 [MHt calcd 258.0237; found 
258.0213. 
1-(2-Aminoethyl)-3-(4-bromophenyl)urea hydrochloride (660) 
e H H Yield: 99%. 
CI H 3 N ~ N I ( N ' O O
e 0 I ~ ~ Mp: 229 - 231°C (lit. 234 °C)143. 
Br 
IR: 3292 (urea N-H, str) , 3010 (NH3 +, str) , 1675 (urea C=O, str), 1590, 
1487 (NH3+, bend), 1553 (aryl, str), 820 (aryl C-H bend para-
disubstituted aromatic ring), 621 (C-Br, bend). 
1H NMR (DMSO-d6): 6 9.30 (s, 1H, NH(C=O)NHAr), 7.98 (br s, 3H, 
NH3+), 7.37 - 7.43 (m, 4H, aryl C-H), 6.71 (t, J = 5.8 Hz, 1H, 
NH(C=O)NHAr), 3.32 (dt, J = 6.3/6.3 Hz, 2H, CH2NH(C=O)NH), 2.87 (t, 
J = 5.6 Hz, 2H, CH2NH3+). 
13C NMR (DMSO-d&): 6 155.59 (C=O), 139.88, 112.42 (4° C), 131.35, 
119.61 (aryl C-H), 39.21 (CH2NH3+), 37.12 (CH2NH(C=O)NH). 
m/z: HRMS (TOF ES+) C9H13BrN30 [MHt calcd 258.0237; found 
258.0211. 
1-(2-Aminoethyl)-3-(2-trifluoromethylphenyl)urea 
(66p) 
H H CF3 Yield: 97%. 
CI H ~ ~ N v N ' 6 6e 3 II I Mp:153-155°C. 
o .0 
hydrochloride 
IR: 3317 (urea N-H, str) , 2998 (NH3+, str) , 1636 (urea C=O, str), 1573 
(aryl, str), 1322 (C-F, str), 763 (aryl C-H bend orlho-disubstituted 
aromatic ring). 
1H NMR (DMSO-d6): 8.09 (br s, 3H, NH3+), 8.01 (s, 1H, 
NH(C=O)NHAr), 7.94 (d, J = 8.3 Hz, 1H, aryl 6-H), 7.62 (d, J = 7.9 Hz, 
1 H, aryl 3-H), 7.58 (dd, J = 8.1/8.1 Hz, 1 H, aryl C-H), 7.46 (t, J = 5.5 Hz, 
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1 H, NH(C=O)NHAr), 7.21 (dd, J = 7.617.6 Hz, 1 H, aryl C-H), 3.32 - 3.39 
(m, 2H, CH2NH(C=O)NH), 2.89 (t, J = 6.3 Hz, 2H, CH2NH3+). 
1lC NMR (DMSO-ds): ~ ~ 155.63 (C=O), 137.09 (aryl 1-C), 132.78, 
123.07 (aryl C-H), 125.85 (JCF = 5.3 Hz, aryl 3-C), 125.16 (aryl 6-C), 
124.03 (JCF = 273.0 Hz, aryl CF3), 119.32 (JCF = 29.0 Hz, aryl 2-C), 
38.81 (CH2NH3+), 37.22 (CH2NH(C=O)NH). 
m/z: HRMS (TOF ES+) C1oH13F3N30 [MHr calcd 248.1005; found 
248.0988. 
1-(2-Aminoethyl)-3-(3-trifluoromethylphenyl)urea 
(66q) 
H H Yield: 94%. 
e H3N II I CI E f ) ~ N ' t 1 " ' N V C F 3 3o ~ ~ Mp: 175 - 177°C. 
hydrochloride 
IR: 3302 (urea N-H, str) , 3000 (NH3+, str) , 1682 (urea C=O, str) , 1604 
(NH3+, bend), 1575 (aryl, str) , 1342 (C-F, str), 799 (aryl C-H bend meta-
disubstituted aromatic ring), 700 (C-F, bend). 
1H NMR (DMSO-d6): 9.59 (s, 1H, NH(C=O)NHAr), 7.92 - 8.04 (m, 4H, 
aryl 2-H, NH3+), 7.55 (d, J = 8.5 Hz, 1H, aryI6-H), 7.45 (dd, J = 7.817.8 
Hz, 1H, aryl 5-H), 7.22 (d, J = 7.6 Hz, 1H, aryI4-H), 6.80 (t, J = 5.7 Hz, 
1 H, NH(C=O)NHAr), 3.30 - 3.40 (m, 2H, CH2NH(C=O)NH), 2.89 (t, J = 
6.1 Hz, 2H, CH2NH3+). 
13C NMR (DMSO-d6): ~ ~ 156.10 (C=O), 141.77 (aryI1-C), 130.19 (aryl 5-
C), 129.83 (JCF = 31.3 Hz, aryl 3-C), 124.75 (JCF = 272.4, aryl 3-C), 
121.61 (aryI6-C), 117.76 (JCF = 3.9 Hz, aryI4-C), 114.03 (JCF = 4.0 Hz, 
aryI2-C), 39.22 (CH2NH3+), 37.59 (CH2NH(C=O)NH) 
m/z: HRMS (TOF ES+) C1OH13F3N30 [MHt calcd 248.1005; found 
248.1019. 
151 
1-(2-Aminoethyl)-l-(4-trifluoromethylphenyl)urea 
(66r) 
Yield: 96%. 
H H 
e 3 II I 
Experimental 
hyd roch loride 
CI H ~ ~ N ' w " " N O O Mp: 203 - 206°C. 
o ~ ~ CF3 IR: 3311 (urea N-H, str), 3007 (NH3+, 
str), 1681 (urea C=O, str) , 1607 (NH3+, bend), 1573 (aryl, str), 1330 (C-
F, str), 839 (aryl C-H bend para-disubstituted aromatic ring). 
1H NMR (DMSO-d&): 6 9.66 (s, 1 H, NH(C=O)NHAr), 8.02 (br s, 3H, 
NH3+), 7.62 (d, J = 8.7 Hz, 2H, aryl 2-H and 6-H), 7.57 (d, J = 8.9 Hz, 
2H, aryl 3-H and 5-H), 6.87 (t, J = 5.8 Hz, 1 H, NH(C=O)NHAr), 3.35 (dt, 
J = 6.1/6.1 Hz, 2H, CH2NH(C=O)NH), 2.89 (t, J = 6.2 Hz, 2H, CH2NH3 +). 
1lC NMR (DMSO-d&): 6 155.46 (C=O), 144.19 (aryI1-C), 125.96 (JCF = 
3.7 Hz, aryl 3-C and 5-C), 124.67 (JCF = 270.7 Hz, CF3), 121.03 (JCF = 
32.0 Hz, aryI4-C), 117.26 (aryl 2-C and 6-C), 38.84 (CH2NH3+), 37.11 
( CH2NH(C=O)NH). 
m/z: HRMS (TOF ES+) C10H13F3N30 [MHt calcd 248.1005; found 
248.1026. 
3-Phthalimidopropanoic acid (68) 
o Phthalic anhydride (14.8 g, 0.1 mol) and ~ - a l a n i n e e (67) 
P h t h N ~ O H H (8.9 g, 0.1 mol, 1 eq) were heated at 150°C with 
stirring under a condenser for 2 hours. After cooling to room 
temperature, the crude solid was dispersed in water (150 mL) and 
collected by filtration (suction) before drying to give 20.7 g of white 
crystalline solid requiring no further purification. 
Yield: 94 %. 
Mp: 151 - 153°C 
IR: 3210 (br, O-H, str) , 1770 (phth C=O, str) , 1701 (br, C=O, str), 1610 
(aryl, str), 1377 (O-H, bend), 729 (aryl C-H, bend, orlho-disubstituted 
ring). 
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1H NMR (DMSO-d6): l) 12.39 (s, 1H, COOH), 7.81-7.89 (m, 4H, aryl C-
H), 3.79 (t, J = 7.3 Hz, 2H, phth-NCH2), 2.60 (t, J = 7.4 Hz, 2H, 
CH2COOH). 
13C NMR (DMSO-d6): l) 172.14 (acid C=O), 167.63 (phth C=O), 134.42, 
131.65,123.05 (phth CH, 4 CC), 33.60 (phth-NCH2) 32.37 (CH2COOH). 
mlz: HRMS (TOF ES+) C11H10N04 [MHt calcd 220.0604; found 
220.0615. 
1-(2-Hydroxyphenyl)-3-(2-phthalimidoethyl)urea (69a) 
H H OH A solution of 3-phthalimidopropanoic acid (68) 
P h t h N ~ N I ( N ~ ~ (2.000 g, 9.12 mmol), DPPA (1.966 mL, 9.12 
o V mmol, 1 eq) and TEA (2.543 ml, 2 eq, 18.25 
mmol) in dry toluene (60 mL) was stirred at room temperature, under a 
nitrogen atmosphere. After disappearance of starting materials by TLC 
(approximately 1 hour), the mixture was refluxed to promote conversion 
to the isocyanate. After evolution of nitrogen gas had ceased, the 
reaction mixture was split into half (by volume). 2-aminophenol (747 
mg, 1.5 eq, 6.84 mmol) was added to one half of the isocyanate 
solution and stirred under reflux for 16 hours. On cooling to room 
temperature a yellow precipitate formed, which was collected by 
filtration (suction) and washed with EtOAc. On drying, 867 mg of pale 
yellow solid was obtained requiring no further purification. 
Yield: 75 %. 
Mp: 219 - 220 cC. 
IR: 3368 (O-H, str), 3342 (urea N-H, str) , 1770, 1709 (phth C=O, str), 
1674 (urea C=O, str) , 1575 (aryl, str) , 740, 712 (aryl C-H, bend, ortho-
disubstituted ring). 
1H NMR (DMSO-d6): l) 9.76 (s, 1H, OH), 7.81 - 7.90 (m, 4H, phth CH), 
7.77 (dd, J = 7.8/1.5 Hz, 1 H, hydroxyphenyl 6-H), 7.76 (s, 1 H, 
NH(C=O)NHAr ), 6.95 (t, J = 6.2, 1 H, NH(C=O)NHAr), 6.62 - 6.78 (m, 
3H, hydroxyphenyl 3-H, 4-H, 5-H), 3.66 (t, J = 5.3Hz, 2H, phth-NCH2), 
3.35 (dt, J = 6.0/5.8 Hz, 2H. C H ~ N H ) . .
153 
Experimental 
13C NMR (DMSO-d6): l) 167.98 (phth C=O), 155.49 (urea C=O), 145.34 
(hydroxyphenyl 2-C), 134.33 (phth C-H), 131.77 (phth 4° C), 128.34 
(hydroxyphenyl 1-C), 123.02, (phth C-H), 121.24, 119.05, 114.58 
(hydroxyphenyl 3-C, 4-C, 5-C), 118.45 (hydroxyphenyl 6-C) , 38.24 
(phth-NCH2), 37.27 (CH2-NH). 
mlz: HRMS (TOF ES+) C17H16N304 [MHt calcd 326.1135; found 
326.1165. 
1-(3-Hydroxyphenyl)-3-(2-phthalimidoethyl)urea (69b) 
H H Isocyanate solution was prepared as 
PhthN I( r' I described for 1-(2-hydroxyphenyl)-3-(2-~ N N N'V0H 
o ~ ~ phthalimidoethyl) urea (69a). To the 
remaining half portion was added 3-aminophenol (747 mg, 1.5 eq, 6.84 
mmol) and stirred under reflux for 16 hours. 
After cooling and removal of solvent, the crude residue was dispersed 
in EtOAc (50 mL) and washed with aqueous 2M HCI (2 x 30 mL). 
Concentration of the organic layer gave 1.134 g of pale yellow solid. 
Yield: 76 %. 
Mp: 225 - 228°C. 
IR: 3393 (O-H, str), 3343 (urea N-H, str) , 1769, (phth C=O, str) , 1694 
(urea C=O, str) , 1563 (aryl, str) , 727 (aryl C-H, bend, ortho-disubstituted 
ring). 
1H NMR (DMSO-d6): l) 9.15 (br s, 1H, OH), 8.31 (s, 1H, 
NH(C=O)NHAr), 7.81 - 7.88 (m, 4H, phth CH), 6.91 - 6.95 (m, 2H, aryl 
2-H, 5-H), 6.63 (dd, J = 8.0/1.0 1H, aryl 6-H), 6.26 (dd, J = 7.6/1.7 Hz, 
1 H, aryl 4-H), 6.20 (t, J = 5.8 Hz, 1 H, NH(C=O)NHAr), 3.68 (t, J = 5.7 
Hz, 2H, phth-NCH2), 3.34 (dt, J = 5.7/5.7 Hz, 2H, CH2-NH). 
13C NMR (DMSO-d6): l) 167.97 (phth C=O), 157.58 (hydroxyphenyl 3-
C), 155.14 (urea C=O), 141.44 (hydroxyphenyI1-C), 134.27 (phth C-H), 
131.76 (phth 4° C), 129.11 (hydroxyphenyl 5-C), 122.96 (phth C-H), 
108.58 (hydroxyphenyl 6-C), 108.21 (hydroxyphenyl 4-C), 104.91 
(hydroxyphenyl 3-C), 38.13 (phth-NCH2), 37.51 (CH2-NH). 
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m/z: HRMS (TOF ES+) C17H1sN304 [MHt calcd 326.1135; found 
326.1169. 
1-(2-Aminoethyl)-3-(2-hydroxyphenyl)urea hydrochloride (70a) 
H H OH A solution of 1-(2-hydroxyphenyl)-3-(2-
~ ~ H 3 ~ ~ N I ( N ~ ~ phthalimidoethyl)urea (69a) (700mg, 2.13 
o V mmol) and hydrazine monohydrate (232 1-11, 
4.5 mmol, 2.1 eq) in EtOH (20 mL) was stirred under reflux for 2 hours. 
After cooling to room temperature, solvent was removed in vacuo. The 
crude residue was dispersed in EtOAc (30 mL) and washed with 
aqueous 2M HCI (2 x 30 mL). The combined aqueous layers were 
concentrated in vacuo to give 296 mg of yellow solid requiring no further 
purification. 
Yield: 60 %. 
Mp: 160 - 165°C. 
IR: 3346 (O-H, str) , 3267 (urea N-H, str), 3137, 3023 (br, NH3+, str) , 
1645 (urea C=O, str), 1568 (aryl, str) , 751 (aryl C-H, bend, ortho-
disubstituted ring) 
1H NMR (DMSO-ds): ~ ~ 9.92 (br s, 1 H, OH), 8.11 (s,1 H, NH(C=O)NHAr), 
7.82 (dd, J = 7.9/1.7 Hz, 1 H, aryl 6-H), 7.27 (t, J = 5.6 Hz, 1 H, 
NH(C=O)NHAr), 6.84 (dd, J = 7.7/1.5 Hz, 1 H, aryl 3-H), 6.74 (ddd J = 
7.4n.4/1.7 Hz, 1H, aryl4-H or 5-H), 6.67 (ddd, J = 7.8n.8/1.5 Hz, 1H, 
aryl 4-H or 5-H), 3.31 (dt, J = 6.2/5.9 Hz, 2H, CH2NH), 2.86 (t, J = 6.3 
Hz, 2H, CH2NH3 +). 
13C NMR (DMSO-d6): ~ ~ 156.05 (C=O), 145.86 (aryI2-C), 128.12 (aryl 1-
C), 121.64 (aryl 4-C), 118.96 (aryl 6-C), 118.87 (aryl 5-C), 114.92 (aryl 
3-C), 39.15 (CH2NH3+), 37.14 (CH2NH). 
m/z: HRMS (TOF ES+) C9H14N302 [MHt calcd 196.1081; found 
196.1071. 
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1-(2-Aminoethyl)-3-(2-hydroxyphenyl)urea hydrochloride (70b) 
e lL\ H H 0 Phthalimide deprotection of 1-(3-
- ~ ~ N ' V ' N U U H 
CI H3N II I hydroxyphenyl)-3-(2-phthalimidoethyl) 
o ~ ~
urea (69b) (700 mg, 2.13 mmol) was 
carried out as described for 1-(2-hydroxyphenyl)-3-(2-
phthalimidoethyl)urea (69a) to give 252 mg of yellow solid requiring no 
further purification. 
Yield: 51 %. 
Mp: 106 - 109°C. 
IR: 3406 (br, O-H, str) , 3104 (br, NH3+, str), 2899, 2595 (alkyl C-H, str), 
1682 (urea C=O, str) , 1557 (aryl, str) , 763 (aryl C-H, bend, meta-
disubstituted ring). 
1H NMR (DMSO-d6): ~ ~ 8.94 (s, 1 H, NH(C=O)NHAr), 8.05 (br s, 3H, 
NH3+), 6.96 - 6.98, (m, 2H, aryl 2H, 5-H), 6.78 (m, 1H, aryI6-H), 6.30 
(dd, J = 8.0/2.3/0.7 Hz, 1H aryl 4-H), 3.31 (t, J = 6.4 Hz, 2H, CH2 
NH3+), 2.83 (dt, J = 6.0/6.0 Hz, 1H, CH2NH). 
13C NMR (DMSO-d6): ~ ~ 157.71 (aryI3-C), 155.78 (C=O), 141.47 (aryl 1-
C), 129.18 (aryl 5-C), 108.54 (aryl 6-C), 108.41 (aryl 4-C), 104.89 (aryl 
2-C), 39.18 (CH2NH3+), 37.14 (CH2NH). 
mlz: HRMS (TOF ES+) C9H14N302 [MHt calcd 196.1081; found 
196.1065. 
General procedure for synthesis of substituted 1-(2-(3-(4-(2-
(cyclopentyloxy)ethoxy)phenoxy)-2-hydroxypropylamino )ethyl)-3-
(aryl)ureas 
Substituted 1-(2-aminoethyl)-3-(aryl)urea (1 eq, compounds 56, 63, or 
66a-r) and 2-«4-(2-( cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane (62) 
(50 mg, 0.18 mmol) were suspended in propan-2-ol (3 mL). In the case 
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where 1-(2-aminoethyl)-3-(aryl)ureas were hydrochloride salts, NaOH 
(1.1 eq as 10M aqueous solution) was also added. The mixture was 
heated under reflux overnight, after which all solvent was removed in 
vacuo. The crude residue was purified via PLC (eluent 37% aq 
NHJlMeOH/DCM 2:10:88). Analogues with substitution meta to the 
urea group were purified using a weaker eluent (NH)!MeOH/DCM 
2:5:93). The final aryloxypropanolamines were freeze-dried to give 
white solids. Where further purification was necessary by preparative 
HPLC, the final compounds were isolated as the hydroformate salt. 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-phenylurea (71 a) 
Yield: 22%. 
Mp: 109 - 115°C. 
IR: 3310 (br, O-H, str) , 2930, 2868 (alkyl C-H, str) , 1634 (urea C=O, 
str), 1509, 1567 (aryl, str) , 1110 (C-O-C, str) , 764, 693 (aryl C-H, bend. 
phenyl ring). 
1H NMR (DMSO-d6): ~ ~ 8.61 (s, 1 H, NH(C=O)NHAr), 7.38 (dd, J = 
8.7/1.1 Hz, 2H, 2-H and 6-H phenyl ring), 7.20 (dd, J = 7.4n.4 Hz, 2H. 
3-H and 5-H phenyl ring), 6.81 - 6.89 (m, 5H. 4-H phenyl ring, aryl-
dioxy ring), 6.22 (t. J = 5.4 Hz, 1 H, NH(C=O)NHAr), 5.07 (br s. 1 H, NH) 
3.79 - 3.97 (m, 6H, CH20Ar, cPe CH, CH(OH), ArOCH2) , 3.61 (t, J = 
4.8 Hz, 2H, cPeOCH2), 3.19 (dt. J = 5.8/5.8 Hz, 2H, NHCH2CH2), 2.75 
(dd. J = 12.0/4.0 Hz. 1H. CH(OH)CH2NH). 2.68 (t, J = 6.0 Hz, 2H. 
N H C H ~ H 2 ) , , 2.63 (dd. J = 12.2/6.8 Hz, 1H, CH(OH)CH2NH), 1.52 -
1.74 (m. 6H. cPe CH2). 1.40 -1.52 (m. 2H. cPe CH2)' 
13C NMR (DMSO-d6): ~ ~ 155.37 (C=O). 152.70. 152.53. 140.59 (aryl 4° 
C). 128.64 (phenyl 3-C and 5-C), 120.2943 (phenyl 4-C), 117.57 
(phenyl 2-C and 6-C). 115.34 (CH aryl-dioxy ring). 80.85 (CPe CH), 
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71.14 (ArOCH2), 67.79 (CH(OH)), 67.71 (CH20Ar), 66.73 (CPeOCH2), 
51.98 (CH(OH)CH2NH), 49.14 (NHCH2CH2), 38.78 (NHCH2CH2), 31.80 
(2-C and 5-C cPe ring), 23.14 (3-C and 4-C cPe ring). 
m/z: HRMS (TOF ES+) C25H36N305 [MHt calcd 458.2649; found 
458.2611. 
HPLC Rt : 3.62 (System 1 b), 12.67 (System 3). 
1-(2-(3-( 4-(2-( Cyclopentyloxy)ethoxy)phenoxy)-2-
hyd roxypropylamino)ethyl)-3-(2-methylphenyl)lurea (71 b) 
Yield: 31%. 
Mp: 114-115°C. 
IR: 3329 (br, O-H, str), 2928, 2871 (alkyl C-H, str), 1636 (urea C=O, 
str), 1509, 1567 (aryl, str) , 1109 (C-O-C, str) , 827 (aryl C-H, bend, para-
disubstituted ring), 764 (aryl C-H, bend, ortho -disubstituted ring). 
1H NMR (DMSO-d6): () 7.80 (d, J = 7.6 Hz, 1H, aryl 6-H), 7.70 (s, 1H, 
NH(C=O)NHAr), 7.05 - 7.11 (m, 2H, C-H tolyl ring), 6.80 - 6.87 (m, 5H, 
C-H aryl-dioxy ring, C-H tolyl ring), 6.60 (t, J= 5.4 Hz, 1 H, 
NH(C=O)NHAr), 4.95 (br s, 1H, NH), 3.77 - 4.01 (m, 6H, CH20Ar, cPe 
CH, CH(OH), ArOCH2), 3.61 (t, J = 4.9 Hz, 2H, cPeOCH2), 3.17 (dt, J = 
5.9/5.9 Hz, 2H,), 2.70 (dd, J = 11.8/4.2 Hz, 1 H, CH(OH)CH2NH), 2.64 
(t. J = 6.0 Hz, 3H, NHCH2CH2), 2.59 (dd, J = 11.7/6.3 Hz, 
CH(OH)CH2NH), 2.17 (s, 3H, CH3), 1.52 - 1.76 (m, 6H, cPe CH2) , 1.40 
- 1.52 (m, 2H, cPe CH2). 
13C NMR (DMSO-d6): () 155.48 (C=O), 152.75, 152.49, 138.31 (aryl 4° 
C), 130.03, 126.02, 121.72 (aryl C-H), 120.42 (aryl 6-C), 115.32 (CH 
aryl-dioxy ring), 80.85 (CPe CH), 71.25 (ArOCH2), 68.17 (CH(OH)), 
67.70 (CH20Ar), 66.73 (CPeOCH2), 52.34 (CH(OH)CH2NH), 49.39 
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(NHCH2CH2), 39.10 (NHCH2CH2), 31.80 (2-C and 5-C cPe ring), 23.14 
(3-C and 4-C cPe ring), 17.97 (CH3). 
m/z: HRMS (TOF ES+) C26H3SN305 [MHt calcd 472.2806; found 
472.2764. 
HPLC Rt : 4.07 (System 1b), 7.60 (System 3). 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hyd roxypropylamino )ethyl)-3-(3-methylphenyl)urea (71 c) 
Yield: 9%. 
Mp: 112 -114 DC. 
IR: 3408 (urea N-H, str) , 3316 (br, O-H, str) , 2930, 2870 (alkyl C-H, str), 
1633 (urea C=O, str) , 1509, 1569 (aryl, str), 1111 (C-O-C, str) , 819 (aryl 
C-H, bend, para-disubstituted ring), 760 (aryl C-H, bend, meta-
disubstituted ring). 
1H NMR (DMSO-d6): ~ ~ 8.51 (s, 1H, NH(C=O)NHAr), 7.21 (s, 1H, aryl 2-
H), 7.10 (d, J = 8.4 Hz, 1 H, aryl 6-H), 7.08 (dd, J = 7.6n.6 Hz, 1 H, aryl 
5-H), 6.85, 6.83 (d, J = 9.2 Hz, 2 x 2H, C-H aryl-dioxy ring), 6.46 (d, J = 
7.4 Hz, 1 H aryl 4-H), 6.20 (t, J = 5.4 Hz, 1 H, NH(C=O)NHAr), 5.09 (br s, 
1 H, NH), 3.78 - 4.00 (m, 6H, CH20Ar, cPe CH, CH(OH), ArOCH2), 3.61 
(t, J = 4.9 Hz, 2H, cPeOCH2), 3.19 (dt, J = 5.9/5.9 Hz, 2H, NHCH2CH2), 
2.77 (dd, J = 11.8/3.6 Hz, 1 H, CH(OH)CH2NH), 2.61 - 2.73 (m, 3H, 
CH(OH)CH2NH, NHCH2CH2), 2.23 (s, 3H, CH3), 1.52 - 1.75 (m, 6H, 
cPe CH2), 1.41 -1.52 (m, 2H, cPe CH2). 
13C NMR (DMSO-d6): ~ ~ 155.38 (C=O), 152.66, 152.53, 140.47, 121.72 
(aryl 4D C), 137.70 (aryl 4-C), 128.48 (aryl 5-C), 118.12 (aryl 2-C), 
115.32 (CH aryl-dioxy ring), 114.80 (aryl 6-C), 80.84 (CPe CH), 71.08 
(ArOCH2), 69.77 (CH(OH», 67.69 (CH20Ar), 66.72 (CPeOCH2), 51.82 
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(CH(OH)CH2NH), 49.05 (NHCH2CH2), 38.56 (NHCH2CH2), 31.79 (2-C 
and 5-C cPe ring), 23.13 (3-C and 4-C cPe ring),21.26 (CH3). 
m/z: HRMS (TOF ES+) C2sH3SN30S [MHt calcd 472.2806; found 
472.2825. 
HPLC Rt : 4.25 (System 1 b), 8.28 (System 3). 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(4-methylphenyl)urea (71d) 
Yield: 19%. 
Mp: 142 - 144°C. 
IR: 3319 (br, O-H, str) , 2926, 2868 (alkyl C-H, str), 1634 (urea C=O, 
str) , 1509, 1566 (aryl, str), 1110 (C-O-C, str) , 821 (aryl C-H, bend, para-
disubstituted ring). 
1H NMR (DMSO-d6): ~ ~ 8.46 (s, 1 H, NH(C=O)NHAr), 7.26 (d, J = 8.4 Hz, 
2H, aryl 2-H and 6-H), 7.01 (d, J = 8.3 Hz, 2H, aryl 3-H and 5-H), 6.82, 
6.85 (d, J = 9.2 Hz, 2 x 2H, C-H aryl-dioxy ring), 6.14 (t, J = 5.5 Hz, 1 H, 
NH(C=O)NHAr), 5.04 (br s, 1 H, NH), 3.79 - 3.97 (m, 6H, CH20Ar, cPe 
CH, CH(OH), ArOCH2) , 3.61 (t, J = 4.9 Hz, 2H, cPeOCH2), 3.18 (dt, J = 
5.8/5.8 Hz, 2H, NHCH2CH2), 2.74 (dd, J = 11.9/3.6 Hz, 1 H, 
CH(OH)CH2NH), 2.59 - 2.70 (m, 3H, CH(OH)CH2NH, NHCH2CH2), 
2.21 (s, 3H, CH3), 1.52 - 1.76 (m, 6H, cPe CH2) , 1.41 - 1.52 (m, 2H, 
cPe CH2). 
13C NMR (DMSO-d6): ~ ~ 155.42 (C=O), 152.78, 152.51, 138.02,129.61 
(aryl 4° C), 129.02 (2-C and 6-C tolyl ring), 117.67 (3-C and 5-C tolyl 
ring), 115.31 (CH aryl-dioxy ring), 80.84 (CPe CH), 71.12 (ArOCH2), 
67.81 (CH(OH», 67.68 (CH20Ar), 66.71 (CPeOCH2), 51.98 
(CH(OH)CH2NH), 49.16 (NHCH2CH2), 38.48 (NHCH2CH2), 31.79 (2-C 
and 5-C cPe ring), 23.13 (3-C and 4-C cPe ring), 20.30 (CH3). 
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m/z: HRMS (TOF ES+) C2sH3SN30S [MHt calcd 472.2806; found 
472.2834. 
HPLC Rt : 4.18 (System 1 b), 13.52 (System 3). 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(2-methoxyphenyl)urea (71e) 
Yield: 27%. 
Mp: 78 - 83°C. 
IR: 3332 (br. O-H, str), 2929. 2864 (alkyl C-H, str) , 1651 (urea C=O, 
str), 1508, 1549 (aryl, str), 1109 (C-O-C, str), 823 (aryl C-H, bend, para-
disubstituted ring), 748 (aryl C-H, bend, ortho -disubstituted ring). 
1H NMR (DMSO-d6): 0 8.07 (dd, J = 7.6/2.0 Hz, 1H, aryl 6-H), 7.97 (s, 
1 H, NH(C=O)NHAr), 6.92 - 6.99 (m, 2H, C-H methoxyphenyl ring, 
NH(C=O)NHAr), 6.79 - 6.89 (m, 6H, C-H aryl-dioxy ring, C-H 
methoxyphenyl ring), 5.07 (br s, 1H, NH), 3.76 - 4.00 (m, 6H, CH20Ar, 
cPe CH, CH(OH). ArOCH2) , 3.82 (s, 3H, CH3), 3.61 (t, J = 4.8 Hz. 2H. 
cPeOCH2), 3.18 (dt, J = 5.9/5.9 Hz, 2H, NHCH2CH2), 2.74 (dd, J = 
11.9/3.9 Hz, 1 H, CH(OH)CH2NH), 2.59 - 2.70 (m, 3H, CH(OH)CH2NH, 
NHCH2CH2), 1.52 - 1.75 (m, 6H, cPe CH2) , 1.40 - 1.51 (m, 2H, cPe 
CH2). 
1lC NMR (DMSO-d6): 0 155.32 (C=O), 152.70, 152.52, 147.30, 129.51 
(aryl 4° C), 120.90, 120.45, 110.54 (aryl C-H), 117.98 (aryI6-C), 115.32 
(CH aryl-dioxy ring), 80.85 (CPe CH), 71.14 (ArOCH2), 67.80 (CH(OH», 
67.69 (CH20Ar), 66.73 (CPeOCH2), 55.63 (CH3), 52.03 
(CH(OH)CH2NH), 49.23 (NHCH2CH2), 38.93 (NHCH2CH2), 31.80 (2-C 
and 5-C cPe ring), 23.14 (3-C and 4-C cPe ring). 
m/z: HRMS (TOF ES+) C2sH3SN30S [MHt calcd 488.2755; found 
488.2777. 
161 
Experimental 
HPLC Rt : 3.77 (System 1b), 12.87 (System 3). 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(3-methoxyphenyl)urea (71f) 
Yield: 16%. 
Mp: 103 - 110°C. 
IR: 3316 (br, O-H. str). 2928, 2869 (alkyl C-H. str) , 1630 (urea C=O. 
str), 1509, 1570 (aryl. str) , 1110 (C-O-C, str) , 824 (aryl C-H, bend, para-
disubstituted ring), 765 (aryl C-H, bend, meta-disubstituted ring). 
1H NMR (DMSO-ds): Z) 8.63 (s, 1 H, NH(C=O)NHAr), 7.14 (dd, J = 
2.2/2.2 Hz. 1H. aryl 2-H). 7.10 (dd, J = 8.1/8.1 Hz, 1H, aryl 5-H). 6.79-
6.89 (m, 5H, C-H aryl-dioxy ring, aryl 6-H), 6.46 (ddd, J = 8.2/2.4/0.6 
Hz, 1 H aryl 4-H), 6.22 (t, J = 5.4 Hz, 1 H, NH(C=O)NHAr), 5.05 (br s, 
1 H, NH), 3.79 - 3.97 (m, 6H, CH20Ar, cPe CH, CH(OH), ArOCH2), 3.69 
(s, 3H, CH3), 3.61 (t, J = 4.8 Hz, 2H, cPeOCH2), 3.18 (dt, J = 5.9/5.9 Hz, 
2H. NHCH2CH2), 2.73 (dd, J = 11.9/3.9 Hz, 1H, CH(OH)CH2NH), 2.50-
2.70 (m, 3H, CH(OH)CH2NH, NHCH2CH2), 1.52 - 1.74 (m, 6H, cPe 
CH2). 1.41 - 1.52 (m, 2H, cPe CH2). 
13C NMR (DMSO-ds): Z) 155.28 (C=O), 159.64, 152.71, 152.52. 141.84 
(aryl 4° C), 129.36 (aryl 5-C), 115.34 (CH aryl-dioxy ring), 109.94 (aryl 
6-C), 106.33 (aryl 4-C), 103.35 (aryl 2-C), 80.85 (CPe CH), 71.16 
(ArOCH2), 67.87 (CH(OH», 67.70 (CH20Ar), 66.73 (CPeOCH2), 54.82 
(CH3), 52.02 (CH(OH)CH2NH), 49.13 (NHCH2CH2), 38.77 (NHCH2CH2), 
31.80 (2-C and 5-C cPe ring), 23.14 (3-C and 4-C cPe ring). 
mlz: HRMS (TOF ES+) C26H38N30 6 [MHt calcd 488.2755; found 
488.2786. 
HPLC Rt : 3.40 (System 1b), 12.42 (System 3). 
162 
Experimental 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino )ethyl)-3-(4-methoxyphenyl)urea (71 g) 
Yield: 7%. 
Mp: 121 - 125°C. 
IR: 3327 (br, O-H, str), 2927, 2867 (alkyl C-H, str), 1635 (urea C=O, 
str), 1509, 1565 (aryl, str), 1110 (C-O-C, str) , 828 (aryl C-H, bend, para-
disubstituted ring). 
1H NMR (DMSO-d&): ~ ~ 8.37 (s, 1H, NH(C=O)NHAr), 7.10 (d, J = 9.0 Hz, 
2H, aryl 2-H and 6-H), 6.82 - 6.87 (m, 4H, C-H aryl-dioxy ring), 6.80 (d, 
J = 9.0 Hz, 2H, aryl 3-H and 5-H), 6.07 (t, J = 5.5 Hz, 1 H, 
NH(C=O)NHAr), 5.00 (br s, 1 H, NH), 3.75 - 4.00 (m, 6H, CH20Ar, cPe 
CH, CH(OH), ArOCH2) , 3.68 (s, 3H, CH3), 3.61 (t, J = 4.7 Hz, 2H, 
cPeOCH2), 3.15 (dt, J = 5.8/5.8 Hz, 2H, NHCH2CH2), 2.55 - 2.76 (m, 
4H, CH(OH)CH2NH, NHCH2CH2), 1.52 - 1.74 (m, 6H, cPe CH2) , 1.41 -
1.52 (m, 2H, cPe CH2). 
13C NMR (DMSO-d6): ~ ~ 155.55 (C=O), 153.82, 152.73, 152.49, 133.75 
(aryl 4° C), 119.28 (2-C and 6-C methoxyphenyl ring), 115.32 (CH aryl-
dioxy ring), 113.86 (3-C and 5-C methoxyphenyl ring), 80.85 (CPe CH), 
71.20 (ArOCH2), 68.03 (CH(OH», 67.69 (CH20Ar), 66.73 (CPeOCH2), 
55.12 (CH3), 52.17 (CH(OH)CH2NH), 49.33 (NHCH2CH2), 38.27 
(NHCH2CH2). 31.80 (2-C and 5-C cPe ring), 23.14 (3-C and 4-C cPe 
ring). 
mlz: HRMS (TOF ES+) C2sH3SN30S [MHt calcd 488.2755; found 
488.2717. 
HPLC Rt : 3.37 (System 1b), 12.02 (System 3). 
163 
Experimental 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(2-fluorophenyl)urea (71 h) 
Yield: 11%. 
Mp: 115 -117°C. 
IR: 3322 (br, O-H, str), 2929, 2871 (alkyl C-H, str), 1640 (urea C=O, 
str) , 1509, 1568 (aryl, str) , 1241 (C-F, str) , 1110 (C-O-C, str), 827 (aryl 
C-H, bend, para-disubstituted ring), 764 (aryl C-H, bend, ortho -
disubstituted ring), 744 (C-F, bend). 
1H NMR (DMSO-da): ~ ~ 8.38 (s, 1H, NH(C=O)NHAr), 8.12 (dd, J = 
8.3/1.5 Hz, 1H, aryI6-H), 7.16 (ddd, J = 11.8/8.2/1.4 Hz, 1H, aryl 3-H), 
7.06 (dd, J = 8.2/8.2 Hz, 1 H, aryl 5-H), 6.87 - 6.94 (m, 1H, aryl 4-H), 
6.85, 6.82 (d, J = 9.3 Hz, 2 x 2H, C-H aryl-dioxy ring), 6.70 (t, J = 5.4 
Hz, 1 H, NH(C=O)NHAr) 4.99 (br s, 1 H, NH), 3.77 - 4.01 (m, 6H, 
CH20Ar, cPe CH, CH(OH), ArOCH2), 3.61 (t, J = 4.8 Hz, 2H, cPeOCH2), 
3.18 (dt, J= 6.0/6.0 Hz, 2H, NHCH2CH2), 2.71 (dd, J= 11.8/3.9 Hz, 1H, 
CH(OH)CH2NH), 2.56 - 2.67 (m, 3H, CH(OH)CH2NH, NHCH2CH2), 
1.51 -1.75 (m, 6H, cPe CH2), 1.41-1.51 (m, 2H, cPe CH2). 
13C NMR (DMSO-ds): ~ ~ 155.16 (C=O), 152.75, 152.50, 136.85 (aryl 4° 
C), 125.40 (aryl 6-C), 124.35 (aryl 5-C), 121.43 (aryl 4-C), 114.67 (aryl 
3-C), 115.31 (CH aryl-dioxy ring), 80.84 (CPe CH), 71.22 (ArOCH2), 
68.06 (CH(OH», 67.69 (CH20Ar), 66.72 (CPeOCH2), 51.18 
(CH(OH)CH2NH), 48.89 (NHCH2CH2), 38.99 (NHCH2CH2), 31.79 (2-C 
and 5-C cPe ring), 23.13 (3-C and 4-C cPe ring). 
m/z: HRMS (TOF ES+) C2sH3SFN30S [MHt calcd 476.2555; found 
476.2596. 
HPLC Rt : 4.05 (System 1b), 12.35 (System 3). 
164 
Experimental 
1-(2-(3-( 4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(3-fluorophenyl)urea (71 i) 
Yield: 27%. 
Mp: 108 - 110 °C. 
IR: 3317 (br, O-H, str) , 2926, 2869 (alkyl C-H, str), 1636 (urea C=O, 
str) , 1509, 1569 (aryl, str) , 1118 (C-O-C, str) , 1238 (C-F, str) , 827 (aryl 
C-H, bend, para-disubstituted ring), 765 (C-F, bend). 
1H NMR (DMSO-d6): ts 8.86 (s, 1H, NH(C=O)NHAr), 7.45 (ddd, J = 
12.3/2.2/2.2 Hz, 1H, aryl 2-H), 7.22 (ddt, J = 8.2/8.2.2/8.2 Hz, 1H, aryl 
5-H), 7.00 (ddd, J = 8.2/1.2 Hz, 1 H, aryl 6-H), 6.79 - 6.89 (m, 4H, C-H 
aryl-dioxy ring), 6.68 (ddd, J = 8.2/8.2/2.1 Hz, 1 H, aryl 4-H), 6.28 (t, J = 
5.4 Hz, 1 H, NH(C=O)NHAr), 5.04 (br s, 1 H, NH), 3.77 - 4.01 (m, 6H, 
CH20Ar, cPe CH, CH(OH), ArOCH2), 3.61 (t, J = 4.8 Hz, 2H, cPeOCH2), 
3.18 (dt, J = 5.8/5.8 Hz, 2H, NHCH2CH2), 2.57 - 2.79 (m, 4H, 
CH(OH)CH2NH, NHCH2CH2), 1.52 -1.75 (m, 6H, cPe CH2), 1.40 -1.52 
(m, 2H, cPe CH2). 
13C NMR (DMSO-d6): ts 162.44 (JCF = 240.8 Hz, C-F), 155.11 (C=O), 
152.72, 152.51 (aryl 40 C), 142.53 (JCF = 11.8 Hz, aryl 1-C), 130.11 (JCF 
= 10.9 Hz, aryI5-C), 115.33 (CH aryl-dioxy ring), 113.22 (JCF = 2.7 Hz, 
aryI6-C), 107.16 (JCF = 20.5 Hz, aryl 4-C), 104.16 (JCF = 26.2 Hz, aryl 
2-C), 80.85 (CPe CH), 71.17 (ArOCH2), 67.93 (CH(OH», 67.70 
(CH20Ar), 66.73 (CPeOCH2), 52.05 (CH(OH)CH2NH), 49.06 
(NHCH2CH2), 38.66 (NHCH2CH2), 31.80 (2-C and 5-C cPe ring), 23.14 
(3-C and 4-C cPe ring). 
mlz: HRMS (TOF ES+) C25H35FN305 [MHt calcd 476.2555; found 
476.2514. 
HPLC Rt : 4.02 (System 1 b), 13.32 (System 3). 
165 
Experimental 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(4-fluorophenyl)urea (71j) 
Q o ~ 0 ' O OI H H ~ ~ O ~ N ~ N I ( N ~ ~
OH H 0 ~ F F
Yield: 19%. 
Mp: 130 - 133 °C. 
IR: 3318 (br, O-H, str) , 2927, 2868 (alkyl C-H, str) , 1630 (urea C=O, 
str) , 1509, 1572 (aryl, str) , 1111 (C-O-C, str) , 1232 (C-F, str) , 827 (aryl 
C-H, bend, para-disubstituted ring), 764 (C-F, bend). 
1H NMR (DMSO-d6): 6 8.69 (5, 1H, NH(C=O)NHAr), 7.39 (dd, J = 
9.1/5.0 Hz, 2H, 2-H and 6-H fluorophenyl ring), 7.04 (dd, J = 8.9/8.9 Hz, 
2H, 3-H and 5-H fluorophenyl ring), 6.80 - 6.88 (m, 4H, aryl-dioxy ring), 
6.23 (t, J = 5.4 Hz, 1 H, NH(C=O)NHAr), 5.13 (br s, 1 H, NH), 3.78 - 4.00 
(m, 6H, CH20Ar, cPe CH, CH(OH), ArOCH2) , 3.61 (t, J = 4.8 Hz, 2H, 
cPeOCH2), 3.15 - 3.24 (m, 2H, NHCH2CH2), 2.78 (dd, J = 11.9/3.7 Hz, 
1 H, CH(OH)CH2NH), 2.61 - 2.74 (m, 3H, CH(OH)CH2NH, NHCH2CH2), 
1.52 -1.75 (m, 6H, cPe CH2), 1.40 -1.52 (m, 2H, cPe CH2). 
13C NMR (DMSO-d6): i5 155.45 (C=O), 152.66, 152.55 (aryl 40 C), 
136.94 (JcF = 1.8 Hz, 1-C), 119.15 (JCF = 8.0 Hz, 2-C and 6-C 
fluorophenyl ring), 115.33 (CH aryl-dioxy ring), 115.08 (JCF = 21.6 Hz, 3-
C and 5-C fluorophenyl ring), 80.85 (CPe CH), 71.07 (ArOCH2), 67.70 
(CH20Ar), 67.49 (CH(OH», 66.73 (CPeOCH2), 51.80 (CH(OH)CH2NH), 
49.02 (NHCH2CH2), 38.43 (NHCH2CH2), 31.80 (2-C and 5-C cPe ring), 
23.14 (3-C and 4-C cPe ring). 
m/z: HRMS (TOF ES+) C25H35FN305 [MHr calcd 476.2555; found 
476.2529. 
HPLC Rt : 4.12 (System 1b), 13.20 (System 3). 
166 
Experimental 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(2-chlorophenyl)urea (71 k) 
Yield: 9%. 
Mp: 99 - 103°C. 
IR: 3317 (br, O-H, str), 2929, 2868 (alkyl C-H, str) , 1638 (urea C=O, 
str) , 1508, 1559 (aryl, str), 1112 (C-O-C, str), 820 (aryl C-H, bend, para-
disubstituted ring), 750 (aryl C-H, bend, ortho -disubstituted ring), 730 
(G-GI, bend). 
1H NMR (DMSO-ds): ~ ~ 8.14 (dd, J = 8.3/1.3 Hz, 1H, aryl 6-H), 8.09 (s, 
1H, NH(G=O)NHAr), 7.38 (dd, J = 8.0/1.4 Hz, 1H, aryl 3-H), 7.22 (ddd, J 
= 7.8n.8/1.4 Hz, 1 H, aryl 5-H), 7.07 (t, J = 5.2 Hz, 1 H, NH(G=O)NHAr), 
6.93 (ddd, J = 7.8n.8/1.5 Hz, 1 H, aryl 4-H), 6.79 - 6.86 (m, 4H, C-H 
aryl-dioxy ring), 4.98 (br s, 1 H, NH), 3.73 - 4.01 (m, 6H, GH20Ar, cPe 
CH, CH(OH), ArOCH2), 3.61 (t, J = 4.8 Hz, 2H, cPeOCH2), 3.18 (dt, J = 
5.8/5.8 Hz, 2H, NHCH2CH2), 2.57 - 2.72 (m, 4H, GH(OH)CH2NH, 
NHCH2CH2), 1.51 - 1.74 (m, 6H, cPe CH2) , 1.41 - 1.51 (m, 2H, cPe 
CH2). 
13C NMR (DMSO-ds): ~ ~ 154.89 (C=O), 152.76, 152.50, 136.83 (aryl 4° 
G), 129.07 (aryl 3-C), 127.42 (aryl 5-C), 122.34 (aryl 4-C), 120.81 (aryl 
6-C), 115.33 (CH aryl-dioxy ring), 80.86 (CPe CH), 71.24 (ArOCH2), 
68.15 (CH(OH», 67.71 (CH20Ar), 66.73 (CPeOCH2), 52.30 
(CH(OH)CH2NH), 49.22 (NHCH2CH2), 39.19 (NHCH2CH2), 31.81 (2-C 
and 5-C cPe ring), 23.15 (3-C and 4-C cPe ring). 
m/z: HRMS (TOF ES+) C25H35CIN305 [MHt calcd 492.2260; found 
492.2254. 
HPLC Rt : 3.50 (System 1b), 13.09 (System 3). 
167 
Experimental 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino )ethyl)-3-(3-chlorophenyl)urea (711) 
Q o ~ o u uI H H ~ ~ O ~ N ~ N I ( N ~ C I I
OH H 0 V 
Yield: 17%. 
Mp: 102 - 109°C. 
IR: 3316 (br, O-H, str), 2930, 2869 (alkyl C-H, str) , 1639 (urea C=O, 
str) , 1509, 1570 (aryl, str), 1119 (C-O-C, str) , 819 (aryl C-H, bend, para-
disubstituted ring), 765 (C-CI, bend). 
1H NMR (OMSO-d&): ~ ~ 8.85 (s, 1 H, NH(C=O)NHAr), 7.67 (dd, J = 
2.0/2.0 Hz, 1 H, aryl 2-H), 7.22 (dd, J = 8.1/8.1 Hz, 1 H, aryl 5-H), 7.16 
(ddd, J = 8.2/1.8/1.2 Hz, 1H, aryl 6-H), 6.92 (ddd, J = 7.7/2.1/1.2 Hz, 
1 H, aryl 4-H), 6.85 (d, J = 9.3 Hz, 2H, C-H aryl-dioxy ring), 6.82 (d, J = 
9.3 Hz, 2H, C-H aryl-dioxy ring), 6.29 (t, J = 5.4 Hz, 1 H, 
NH(C=O)NHAr), 5.03 (br s, 1H, NH), 3.77 - 4.00 (m, 6H, CH20Ar, cPe 
CH, CH(OH), ArOCH2), 3.61 (t, J = 4.8 Hz, 2H, cPeOCH2), 3.18 (dt, J = 
5.9/5.9 Hz, 2H, NHCH2CH2), 2.57 - 2.77 (m, 4H, CH(OH)CH2NH, 
NHCH2CH2), 1.51 - 1.74 (m, 6H, cPe CH2), 1.40 - 1.51 (m, 2H, cPe 
CH2). 
1lC NMR (DMSO-ds): ~ ~ 155.08 (C=O), 152.71, 152.51, 146.03, 133.10 
(aryl 4° C), 130.24 (aryl 5-C), 120.51 (aryl 4-C), 116.87 (aryl 2-C), 
115.90 (aryl 6-C), 115.32 (CH aryl-dioxy ring), 80.85 (CPe CH), 71.17 
(ArOCH2)' 67.92 (CH(OH», 67.70 (CH20Ar), 66.72 (CPeOCH2), 52.05 
(CH(OH)CH2NH), 49.04 (NHCH2CH2), 38.90 (NHCH2CH2), 31.80 (2-C 
and 5-C cPe ring), 23.14 (3-C and 4-C cPe ring). 
m/z: HRMS (TOF ES+) C2sH3sCIN30s [MHt calcd 492.2260; found 
492.2250. 
HPLC Rt : 3.88 (System 1 b), 13.87 (System 3). 
168 
Experimental 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino )ethyl)-3-(4-chlorophenyl)urea (71 m) 
Yield: 18%. 
Mp: 133 - 140 DC. 
IR: 3321 (br, O-H, str), 2926, 2867 (alkyl C-H, str), 1633 (urea C=O, 
str), 1510, 1565 (aryl, str) , 1110 (C-O-C, str), 827 (aryl C-H, bend, para-
disubstituted ring), 764 (C-CI, bend). 
1H NMR (DMSO-d&): ~ ~ 8.76 (s, 1 H, NH(C=O)NHAr), 7.41, 7.25 (d, J = 
8.9 Hz, 2 x 2H, C-H of chlorophenyl ring), 6.81 - 6.86 (m, 4H, C-H aryl-
dioxy ring), 7.23 (t, J = 5.4 Hz, 1H, NH(C=O)NHAr), 5.00 (br s, 1H, NH), 
3.76 - 3.99 (m, 6H, CH20Ar, cPe CH, CH(OH), ArOCH2), 3.61 (t, J = 
4.8 Hz, 2H, cPeOCH2), 3.17 (dt, J= 5.8/5.8 Hz, 2H, NHCH2CH2), 2.57-
2.72 (m, 4H, CH(OH)CH2NH, NHCH2CH2), 1.52 - 1.74 (m, 6H, cPe 
CH2), 1.40 - 1.51 (m, 2H, cPe CH2). 
13C NMR (DMSO-d&): ~ ~ 155.15 (C=O), 152.72, 152.50, 139.62, 124.32 
(aryl 4 0 C), 128.45, 118.99 (CH chlorophenyl ring), 115.31 (CH aryl-
dioxy ring), 80.84 (CPe CH), 71.19 (ArOCH2), 68.01 (CH(OH», 67.69 
(CH20Ar), 66.72 (CPeOCH2), 52.12 (CH(OH)CH2NH), 49.14 
(NHCH2CH2), 38.95 (NHCH2CH2), 31.79 (2-C and 5-C cPe ring), 23.13 
(3-C and 4-C cPe ring). 
m/z: HRMS (TOF ES+) C2SH3SCIN30S [MHt calcd 492.2260; found 
492.2284. 
HPLC Rt : 3.80 (System 1b), 13.73 (System 3). 
169 
Experimental 
1-(2-(l-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-l-(2-bromophenyl)urea hydroformate 
(71n) 
Yield: 9%. 
Mp: semi-solid. 
IR: 3360 (br, O-H, str), 2950, 2870 (alkyl C-H, str) , 1678 (urea C=O, 
str), 1508, 1581 (aryl, str) , 1130 (C-O-C, str) , 826 (aryl C-H, bend, para-
disubstituted ring), 753 (aryl C-H, bend, ortho -disubstituted ring), 722 
(C-Br, bend). 
1H NMR (DMSO-d6): 5 8.04 (dd, J = 8.3/1.5 Hz, 1H, aryl 6-H), 7.98 (s, 
1H, NH(C=O)NHAr), 7.56 (dd, J = 8.0/1.4 Hz, 1H, aryl 3-H), 7.22 -7.32 
(m, 2H, aryl 5-H, NH(C=O)NHAr), 6.79 - 6.94 (m, 5H, aryl 4-H, aryl-
dioxy ring), 3.76 - 4.15 (m, 6H, CH20Ar, cPe CH, CH(OH), ArOCH2), 
3.61 (t, J = 4.8 Hz, 2H, cPeOCH2), 3.18 - 3.56 (m, 10H, H20, 
NHCH2CH2), 2.55 - 3.13 (m, 4H, CH(OH)CH2NH, NHCH2CH2), 1.52-
1.75 (m, 6H, cPe CH2), 1.40 - 1.52 (m, 2H, cPe CH2). 
13C NMR (DMSO-d6): 5 155.30 (C=O), 152.70, 152.42, 137.62 112.54 
(aryl 4° C), 132.62 (aryl 3-C), 127.95 (aryl 5-C), 123.49 (aryl 4-C), 
121.89 (aryl 6-C), 115.39, 115.35 (CH aryl-dioxy ring), 80.85 (CPe CH), 
70.63 (ArOCH2), 67.71 (CH20Ar), 66.71 (CPeOCH2), 65.09 (CH(OH», 
50.58 (CH(OH)CH2NH), 48.21 (NHCH2CH2), 37.21 (NHCH2CH2), 31.79 
(2-C and 5-C cPe ring), 23.13 (3-C and 4-C cPe ring). 
m/z: HRMS (TOF ES+) C2sH3SBrN30S [MHt calcd 536.1755; found 
536.1800. 
HPLC Rt : 4.09 (System 1b), 13.34 (System 3). 
170 
Experimental 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(3-bromophenyl)urea (710) 
Yield: 12%. 
Mp: 120 - 122°C. 
IR: 3323 (br, O-H, str) , 2926, 2868 (alkyl C-H, str), 1630 (urea C=O, 
str) , 1509, 1565 (aryl, str), 1111 (C-O-C, str), 825 (aryl C-H, bend, para-
disubstituted ring), 683 (C-Br, bend). 
1H NMR (DMSO-d6): ~ ~ 8.83 (s, 1H, NH(C=O)NHAr), 7.81 (dd, J = 
1.9/1.9 Hz, 1H, aryl 2-H), 7.21 (ddd, J = 8.2/1.7/1.7 Hz, 1H, aryl 6-H), 
7.16 (dd, J = 7.7n.7 Hz, 1 H, aryl 5-H), 7.05 (ddd, J = 7.7/1.2/1.2 Hz, 
1 H, aryl 4-H), 6.85 (d, J = 9.3 Hz, 2H, C-H aryl-dioxy ring), 6.82 (d, J = 
9.3 Hz, 2H, C-H aryl-dioxy ring), 6.29 (t, J = 5.3 Hz, 1 H, 
NH(C=O)NHAr), 5.02 (br s, 1H, NH), 3.76 - 4.00 (m, 6H, CH20Ar, cPe 
CH, CH(OH), ArOCH2)I 3.61 (t, J = 4.8 Hz, 2H, cPeOCH2), 3.13 - 3.21 
(m, 2H, NHCH2CH2), 2.71 (dd, J = 11.7/3.7 Hz, 1 H, CH(OH)CH2NH), 
2.67 (dd, J = 6.1/6.1 Hz, 2H, NHCH2CH2), 2.60 (dd, J 11.9/6.7 Hz, 1 H, 
CH(OH)CH2NH), 1.52 - 1.75 (m, 6H, cPe CH2), 1.40 - 1.52 (m, 2H, cPe 
CH2). 
13C NMR (DMSO-ds): ~ ~ 155.05 (C=O), 152.72, 152.49, 142.33, 121.69 
(aryl 4° C), 130.57 (aryl 5-C), 123.41 (aryl 4-C), 121.69 (aryl 2-C), 
116.29 (aryl 6-C), 115.33 (CH aryl-dioxy ring), 80.85 (CPe CH), 71.89 
(ArOCH2), 67.97 (CH(OH», 67.70 (CH20Ar), 66.73 (CPeOCH2), 52.08 
(CH(OH)CH2NH), 49.06 (NHCH2CH2), 38.70 (NHCH2CH2), 31.81 (2-C 
and 5-C cPe ring), 23.14 (3-C and 4-C cPe ring). 
m/z: HRMS (TOF ES+) C2sH3SBrN30S [MHt calcd 536.1755; found 
536.1735. 
HPLC Rt : 4.47 (System 1 b), 14.42 (System 3). 
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1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(4-bromophenyl)urea (71 p) 
Q o ~ o u uI H H 
.lj O ~ N ~ N I ( N ~ ~
OH H 0 ~ B r r
Yield: 23%. 
Mp: 148 - 150°C. 
IR: 3326 (br, O-H, str), 2926, 2869 (alkyl C-H, str), 1633 (urea C=O, 
str), 1509, 1560 (aryl, str), 1110 (C-O-C, str), 822 (aryl C-H, bend, para-
disubstituted ring). 
1H NMR (DMSO-ds): ~ ~ 8.77 (s, 1H, NH(C=O)NHAr), 7.37 (s, 4H, C-H of 
bromophenyl ring), 6.84 (d, J = 9.3 Hz, 2H, C-H aryl-dioxy ring), 6.82 (d, 
J = 9.2 Hz, 2H, C-H aryl-dioxy ring), 6.25 (t, J = 5.4 Hz, 1 H, 
NH(C=O)NHAr), 5.03 (br s, 1H, NH), 3.78 - 3.97 (m, 6H, CH20Ar, cPe 
CH, CH(OH), ArOCH2), 3.61 (t, J = 4.8 Hz, 2H, cPeOCH2), 3.17 (dt, J = 
5.8/5.8 Hz, 2H, NHCH2CH2), 2.71 (dd, J = 11.8/3.9 Hz, 1 H, 
CH(OH)CH2NH), 2.57 - 2.68 (m, 3H, CH(OH)CH2NH, NHCH2CH2), 
1.51 - 1.74 (m, 6H, cPe CH2), 1.40 - 1.51 (m, 2H, cPe CH2). 
1lC NMR (DMSO-d6): ~ ~ 155.12 (C=O), 152.69, 152.49, 140.04,112.14 
(aryl 4° C), 131.34, 119.43 (CH bromophenyl ring), 115.30 (CH aryl-
dioxy ring), 80.84 (CPe CH), 71.15 (ArOCH2), 67.92 (CH(OH», 67.68 
(CH20Ar), 66.72 (CPeOCH2), 52.05 (CH(OH)CH2NH), 49.08 
(NHCH2CH2), 38.85 (NHCH2CH2), 31.79 (2-C and 5-C cPe ring), 23.13 
(3-C and 4-C cPe ring). 
m/z: HRMS (TOF ES+) C2sH3SBrN30s [MHt calcd 536.1755; found 
536.1773. 
HPLC Rt : 4.47 (System 1b), 14.45 (System 3). 
172 
Experimental 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylami no )ethyl)-3-(2-(trifl uoromethyl)phenyl)u rea (71 q) 
Yield: 12%. 
Mp: 128 - 130°C. 
IR: 3330 (br, O-H, str), 2923, 2866 (alkyl C-H, str) , 1645 (urea C=O, 
str), 1510, 1571 (aryl, str), 1121 (C-O-C, str) , 1323 (C-F, str), 820 (aryl 
C-H, bend, para-disubstituted ring), 768 (aryl C-H, bend, ortho-
disubstituted ring). 
1H NMR (DMSO-d6): ~ ~ 7.95 (d, J = 8.4 Hz, 1 H, aryl 6-H), 7.86 (s, 1 H, 
NH(C=O)NHAr), 7.60 (d, J = 7.9 Hz, 1H, aryl 3-H), 7.55 (dd, J = 7.9n.9 
Hz, 1H, aryI5-H), 7.17 (dd, J = 7.6n.6 Hz, 1H, aryI4-H), 7.08 (t, J = 5.2 
Hz, 1H, NH(C=O)NHAr), 6.84 (s, 4H, aryl-dioxy ring), 5.04 (br s, 1H, 
NH), 3.77 - 4.02 (m, 6H, CH20Ar, cPe CH, CH(OH), ArOCH2), 3.61 (t, J 
= 4.9 Hz, 2H, cPeOCH2) , 3.21 (dt, J = 5.8/5.8 Hz, 2H, NHCH2CH2), 2.62 
- 2.77 (m, 4H, CH(OH)CH2NH, NHCH2CH2), 1.52 - 1.75 (m, 6H, cPe 
CH2) , 1.42 - 1.52 (m, 2H, cPe CH2). 
13C NMR (DMSO-d6): ~ ~ 155.12 (C=O), 152.69, 152.52, 137.36 (aryl 4° 
C), 132.72 (aryl 5-C), 126.82 (JCF = 274.6 Hz, CF3), 125.79 (aryl 3-C), 
124.77 (aryl 6-C), 122.59 (aryl 4-C), 115.32 (CH aryl-dioxy ring), 80.84 
(CPe CH), 71.13 (ArOCH2), 67.80 (CH(OH», 67.69 (CH20Ar), 66.71 
(CPeOCH2), 52.03 (CH(OH)CH2NH), 49.03 (NHCH2CH2), 39.02 
(NHCH2CH2), 31.78 (2-C and 5-C cPe ring), 23.13 (3-C and 4-C cPe 
ring). 
mlz: HRMS (TOF ES+) C2sH35F3N305 [MHr calcd 526.2523; found 
526.2538. 
HPLC Rt : 4.27 (System 1b), 13.55 (System 3). 
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1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(3-(trifluoromethyl)phenyl)urea (71 r) 
Yield: 7%. 
Mp: 96 - 98°C. 
IR: 3331 (br, O-H, str) , 2927, 2869 (alkyl C-H, str) , 1633 (urea C=O, 
str), 1509, 1566 (aryl, str) , 1125 (C-O-C, str) , 1344 (C-F, str) , 821 (aryl 
C-H, bend, para-disubstituted ring), 764 (aryl C-H, bend, meta-
disubstituted ring), 702 (C-F, bend). 
1H NMR (DMSO-d6): 6 9.03 (5, 1H, NH(C=O)NHAr), 7.97 (5, 1H, aryl 2-
H), 7.50 (d, J = 8.5 Hz, 1H, aryl 6-H), 7.44 (dd, J = 7.717.7 Hz, 1H, aryl 
5-H), 7.21 (d, J = 7.5, 1H, aryl 4-H), 6.85 (d, J = 9.2 Hz, 2H, C-H aryl-
dioxy ring), 6.82 (d, J = 9.3 Hz, 2H, C-H aryl-dioxy ring), 6.36 (t, J = 5.3 
Hz, 1H, NH(C=O)NHAr), 5.13 (br 5, 1H, NH), 3.81 - 3.97 (m, 6H, 
CH20Ar, cPe CH, CH(OH), ArOCH2), 3.61 (t, J = 4.9 Hz, 2H, cPeOCH2), 
3.22 (dt, J = 5.7/5.7 Hz, 2H, NHCH2CH2), 2.63 - 2.83 (m, 4H, 
CH(OH)CH2NH, NHCH2CH2), 1.51 -1.74 (m, 6H, cPe CH2), 1.41 -1.51 
(m, 2H, cPe CH2). 
13C NMR (DMSO-d6): 6 155.22 (C=O), 152.65, 152.55, 141.43, (aryl 40 
C), 129.74 (aryl 5-C), 124.31 (JCF = 270.6 Hz, CF3), 121.06 (aryl 6-C), 
117.12 (aryI4-C), 115.32 (CH aryl-dioxy ring), 113.44 (aryI2-C), 80.85 
(CPe CH), 71.05 (ArOCH2), 67.70 (CH20Ar), 67.51 (CH(OH», 66.72 
(CPeOCH2), 51.74 (CH(OH)CH2NH), 48.83 (NHCH2CH2), 38.60 
(NHCH2CH2), 31.80 (2-C and 5-C cPe ring), 23.14 (3-C and 4-C cPe 
ring). 
m/z: HRMS (TOF ES+) C2sH3SF3N30S [MHt calcd 526.2523; found 
526.2474. 
HPLC Rt : 4.64 (System 1b), 14.77 (System 3). 
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1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hyd roxypropylami no )ethyl)-3-( 4-(trifluoromethyl )phenyl)u rea (71 s) 
Yield: 26%. 
Mp: 134 -136°C. 
IR: 3293 (br, O-H, str) , 2932, 2871 (alkyl C-H, str) , 1694 (urea C=O, 
str), 1509, 1568 (aryl, str) , 1122 (C-O-C, str) , 1328 (C-F, str) , 821, 841 
(aryl C-H, bend, para-disubstituted ring), 703 (C-F, bend). 
1H NMR (DMSO-d6): ~ ~ 9.08 (s, 1 H, NH(C=O)NHAr), 7.59 (d, J = 9.0 Hz, 
2H, 2-H and 6-H of trifluoromethylphenyl ring), 7.55 (d, J = 9.1 Hz, 2H, 
3-H and 5-H of trifluoromethylphenyl ring), 6.85 (d, J = 9.2 Hz, 2H, C-H 
aryl-dioxy ring), 6.82 (d, J = 9.3 Hz, 2H, C-H aryl-dioxy ring), 6.38 (t, J = 
5.4 Hz, 1H, NH(C=O)NHAr), 5.03 (br s, 1H, NH), 3.77 - 4.01 (m, 6H, 
CH20Ar, cPe CH, CH(OH), ArOCH2), 3.61 (t, J = 4.9 Hz, 2H, cPeOCH2), 
3.21 (dt, J = 5.8/5.8 Hz, 2H, NHCH2CH2), 2.74 (dd, J = 11.8/3.8 Hz, 1 H, 
CH(OH)CH2NH), 2.69 (t, J = 5.9 Hz, 2H, NHCH2CH2), 2.63 (dd, J = 
12.0/6.6 Hz, 1H, CH(OH)CH2NH), 1.52 -1.75 (m, 6H, cPe CH2), 1.38-
1.52 (m, 2H, cPe CH2). 
13C NMR (DMSO-ds): ~ ~ 154.97 (C=O), 152.69, 152.51, 144.32, (aryl 4° 
C), 125.93 (JCF = 3.4 Hz, 3-C and 5-C of trifluoromethylphenyl ring), 
124.68 (JCF = 269.6 Hz, CF3), 120.82 (JCF = 34.7 Hz, 4-C of 
trifluoromethylphenyl ring), 117.11 (2-C and 6-C of trifluoromethylphenyl 
ring), 115.31 (CH aryl-dioxy ring), 80.84 (CPe CH), 71.13 (ArOCH2), 
67.83 (CH(OH», 67.68 (CH20Ar), 66.71 (CPeOCH2), 51.96 
(CH(OH)CH2NH), 48.94 (NHCH2CH2), 38.64 (NHCH2CH2), 31.78 (2-C 
and 5-C cPe ring), 23.12 (3-C and 4-C cPe ring). 
mlz: HRMS (TOF ES+) C26H35F3N305 [MHt calcd 526.2523; found 
526.2480. 
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HPLC Rt : 4.67 (System 1b), 14.90 (System 3). 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino )ethyl)-3-(2-hydroxyphenyl)urea (71 t) 
To 2-«4-(2-(cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane (62) (51 
mg, 0.18 mmol) was added TEA (75 IJI, 0.53 mmol, 3 eq), 1-(2-
aminoethyl)-3-(2-hydroxyphenyl)urea hydrochloride (70a) (83 mg, 0.36 
mmol, 2 eq) and propan-2-01 (5 mL). The mixture was stirred under 
reflux for 16 hours. After removal of all volatiles in vacuo, the crude 
residue was purified by PLC (eluent 37% aq NH:lMeOH/DCM 2:5:93) to 
give 18 mg of beige semi-solid. 
Yield: 21 %. 
IR: 3319 (br, O-H, str) , 2920, 2900 (alkyl, C-H, str), 1653 (urea C=O, 
str) , 1558, 1506 (aryl, str) , 1109 (C-O-C, str) , 823 (aryl, C-H, bend, 
para-disubstituted ring), 750 (aryl, C-H, bend, ortho-disubstituted ring). 
1H NMR (DMSO-d6): 0 8.01 (s, 1H, NH(C=O)NHAr), 7.83 (dd, J = 
7.8/1.6 Hz, 1 H, aryl 6-H), 6.91 (t, J = 5.4 Hz, 1 H, NH(C=O)NHAr), 6.85 
(d, J = 9.7 Hz, 2H, aryl-dioxy ring), 6.82 (d, J = 9.30 Hz, 2H, aryl-dioxy 
ring), 6.78 (dd, J = 7.8/1.7 Hz, 1 H, aryl 3-H), 6.73, (ddd, J = 7.7f7.3/1.2 
Hz, 1H, aryI4-H), 6.68, (ddd, J = 7.8f7.3/1.7 Hz, 1H, aryl 5-H), 6.09 (br 
s, 1 H, phenol), 3.80 - 4.00 (m, 6H CH20Ar, cPe CH, CH(OH), ArOCH2), 
3.61 (t, J = 4.8 Hz, 2H, cPeOCH2 ), 3.19 (dt, J = 5.8/5.8 Hz, 2H, 
NHCH2CH2), 2.75 (dd, J = 12.1/3.9 Hz, 1 H, CH(OH)CH2NH), 2.61 -
2.69 (m, 3H, NHCH2CH2, CH(OH)CH2NH), 1.40-1.72 (m, 8H, cPe CH2 ). 
13C NMR (DMSO-d6): 0 155.81 (C=O), 152.70, 152.52, 145.63, 128.43 
(aryl 4° C), 121.34 (aryl 4-C), 119.04 (aryl 5-C), 118.76 (aryl 6-C), 
115.34 (CH aryl-dioxy ring), 114.82 (aryl 3-C), 80.84 (CPe CH), 71.14 
(ArOCH2). 67.75 (CH(OH», 67.72 (CH20Ar), 66.72 (CPeOCH2), 51.95 
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(CH(OH)CH2NH), 49.18 (NHCH2CH2), 40.11(NHCH2CH2), 31.79 (2-C 
and 5-C cPe ring), 23.12 (3-C and 4-C cPe ring). 
mlz: HRMS (TOF ES+) C25H36N306 [MHr calcd 474.2599; found 
474.2600. 
HPLC Rt : 4.10 (System 1 b), 11.84 (System 3). 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(3-hydroxyphenyl)urea (71u) 
Q o ~ o o oI H H 
o O ~ N ~ N n N ~ O H H
OH H 0 V 
Epoxide opening of 2-«4-(2-(cyclopentyloxy)ethoxy)phenoxy) 
methyl)oxirane (62) with 1-(2-aminoethyl)-3-(3-hydroxyphenyl)urea 
hydrochloride (70b), was carried out as described in the procedure for 
1-(2-(3-( 4-(2-( cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(2-hydroxyphenyl)urea (71t). Purification 
was achieved via PLC (eluent 37% aq NH3I'MeOH/DCM 2:10:88) to give 
21 mg of beige semi-solid. 
Yield: 25 %. 
IR: 3350 (br, O-H, str), 2932, 2868 (alkyl, C-H, str), 1675 (urea C=O, 
str), 1559, 1507 (aryl, str), 1108 (C-O-C, str), 826 (aryl, C-H, bend, 
para-disubstituted ring), 765 (aryl, C-H, bend, meta-disubstituted ring). 
1H NMR (OMSO-ds): 6 9.18 (br s, 1H, phenol), 8.47 (s, 1H, 
NH(C=O)NHAr), 6.98 (s, 1 H, aryl 2-H), 6.96 (dd, J = 8.1 Hz, 1 H, aryl 5-
H), 6.77 - 6.90 (m, 4H, aryl-dioxy ring), 6.71 (d, J = 7.8 Hz, 1H, aryl 6-
H) , 6.28 (dd, J = 7.8/1.8 Hz, 1H, aryl 4-H), 6.16 (t, J = 5.2 Hz, 1H, 
NH(C=O)NHAr), 3.75 - 4.02 (m, 6H, CH20Ar, cPeCH, CH(OH), 
ArOCH2), 3.61 (t, J = 4.8 Hz, 2H, cPeOCH2), 3.15 (dt, J = 5.7/5.7 Hz, 
2H, NHCH2CH2), 2.70 (dd, J = 12.0/3.7 Hz, 1H, CH(OH)CH2NH), 2.54 
- 2.67 (m, 3H, CH(OH)CH2NH, NHCH2CH2),1.38 - 1.74 (m, 8H, cPe 
CH2). 
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13C NMR (DMSO-d&): ~ ~ 155.24 (C=O), 157.65, 152.73, 152.51, 141.66, 
(aryl 4° C), 129.20 (aryl 5-C), 115.34 (CH aryl-dioxy ring), 108.38 (aryl 
6-C), 108.10 (aryl 4-C), 104.68 (aryl 2-C), 80.84 (CPe CH), 71.22 
(ArOCH2), 68.01 (CH(OH», 67.72 (CH20Ar ), 66.72 (CPeOCH2), 52.14 
(CH(OH)CH2NH), 49.23 (NHCH2CH2), 38.99 (NHCH2CH2). 31.79 (2-C 
and 5-C cPe ring), 23.12 (3-C and 4-C cPe ring). 
mlz: HRMS (TOF ES+) C25H3eN30e [MHt calcd 474.2599; found 
474.2642. 
HPLC Rt : 3.90 (System 1 b), 11.02 (System 3). 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(4-hydroxyphenyl)urea (57) 
Q o ~ o u uI H H ~ ~ O ~ N ~ N I ( N ~ ~
OH H 0 ~ O H H
Refer to general procedure for synthesis of aromatically substituted 1-
(2 -(3-( 4-(2 -( cyclopentyloxy)ethoxy)phenoxy)-2-
hyd roxypropylamino )ethyl)-3-( aryl) ureas. 
Yield: 29%. 
Mp: 135 - 138°C. 
IR: 3311 (br. O-H, str). 2929. 2869 (alkyl C-H. str), 1636 (urea C=O. 
str). 1509, 1568 (aryl, str) , 1111 (C-O-C, str) , 820 (aryl C-H, bend, para-
disubstituted ring). 
1H NMR (DMSO-d&): ~ ~ 8.91 (br s, 1 H, phenol), 8.20 (s, 1 H, 
NH(C=O)NHAr), 7.13 (d, J = 8.8 Hz, 2H, aryl C-H ortho to urea), 6.84 
(5, 4H, aryl-dioxy ring), 6.62 (d, J = 8.8 Hz, 2H, aryl C-H ortho to 
phenol), 6.02 (t, J = 5.4 Hz, 1 H, NH(C=O)NHAr), 4.96 (br s. 1 H, NH), 
3.79 - 3.97 (m, 6H, CH20Ar. cPe CH, CH(OH), ArOCH2), 3.61 (t, J = 
4.8 Hz. 2H. cPeOCH2). 3.12 - 3.16 (m, 2H, NHCH2CH2). 2.56 - 2.71 (m. 
4H. CH(OH)CH2NH, NHCH2CH2). 1.54 - 1.69 (m, 6H, cPe CH2) , 1.42 -
1.51 (m. 2H. cPe CH2). 
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13C NMR (DMSO-d6): ~ ~ 152.74, 152.49, 151.85, 132.14 (aryl 4° C), 
155.65 (C=O), 119.72 (aryl C-H ortho to urea), 115.33 (CH aryl-dioxy 
ring), 115.04 (aryl C-H ortho to phenol), 80.84 (CPe CH), 71.23 
(ArOCH2), 68.08 (CH(OH», 67.71 (CH20Ar), 66.72 (CPeOCH2), 52.20 
(CH(OH)CH2NH), 49.38 (NHCH2CH2), 39.15 (NHCH2CH2), 31.78 (2-C 
and 5-C cPe ring), 23.12 (3-C and 4-C cPe ring). 
mlz: HRMS (TOF ES+) C2sH36N30S [MHt calcd 474.2599; found 
474.2578. 
HPLC Rt : 3.17 (System 1b), 10.30 (System 3). 
tert-Butyl 2-(3-(3,4-difluorophenyl)ureido)ethylcarbamate (72) 
Refer to general procedure for synthesis 
H H B o c ' N ~ N I ( N ~ F F of phenyl substituted tert-butyl 2-(3-
H 0 lAF phenylureido)ethylcarbamates. Product 
isolated as brown oil. 
Yield: 75%. 
IR: 3336 (carbamate N-H, str), 2980, 2942 (alkyl C-H, str), 1683 
(carbamate C=O, str), 1641 (urea C=O, str), 1514 (aryl, str), 1287 (C-F, 
str). 
1H NMR (DMSO-d6): ~ ~ 8.81 (s, 1 H, NH(C=O)NHAr), 7.62 (ddd, J = 
13.717.5/2.6 Hz, 1H, aryl 2-H), 7.26 (ddd, J = 10.6/9.5/9.2 Hz, 1H, aryl 
5-H), 6.98 - 7.05 (m, 1 H, aryl 6-H), 6.84 (t, J = 4.6 Hz, 1 H, 
NH(C=O)NHAr), 6.24 (t, J = 5.8 Hz, 1 H, O(C=O)NH), 3.11 (dt, J = 
6.2/5.8 Hz, 2H, CH2NH(C=O)NH), 2.99 (dt, J = 6.2/5.8 Hz, 2H, 
CH2NH(C=O)O), 1.37 (s, 9H, C(CH3)J). 
13C NMR (DMSO-d6): ~ ~ 155.71, 155.09 (C=O), 117.17 (JCF = 19.1 Hz, 
aryl 5-C), 113.53 (JCF = 8.1 Hz, aryl 6-C), 106.39 (JCF = 22.1 Hz, aryl 2-
C), 77.63 (Boc 4° C), 45.99 (CH2NH(C=O)NH), 40.28 (BocNHCH2), 
28.22 (Boc CH3). 
mlz: HRMS (TOF ES+) C14H20F2N303 [MHt calcd 316.1467; found 
316.1460. 
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1-(2-Aminoethyl)-3-(3,4-difluorophenyl)urea hydrochloride (73) 
H H tett-Butyl 2-(3-(3,4-difluorophenyl)ureido) 
H 3 N ~ ~ I( I ~ ~ ethylcarbamate (72) (1.966 g, 6.23 mmol) @ N N'CCF 
C G 0 ~ ~I F was dissolved in MeOH (10 mL) with 
vigorous stirring. To this was added 4 M HGl/dioxane (40 mL) and the 
solution stirred for 4 hours. After removal of all solvents in vacuo, the 
crude residue was triturated with toluene and dried to give a beige solid 
in quantitative yield. 
Yield: 100%. 
Mp: 191 - 193 °G. 
IR: 3311 (urea N-H, str) , 3011 (NH3+, str) , 1676 (urea C=O, str) , 1573 
(aryl, str), 1516 (NH3+, bend), 1242 (G-F, str). 
1H NMR (DMSO-d6): ~ ~ 9.51 (s, 1 H, NH(C=O)NHAr), 8.05 (br s, 3H, 
NH3+), 7.64 (ddd, J = 14.0n.8/2.6 Hz, 1H, aryl 2-H), 7.27 (ddd, J = 
10.4/9.2/9.2 Hz, 1H, aryI5-H), 7.02 -7.10 (m, 1H, aryI6-H), 6.78 (br s, 
1 H, NH(C=O)NHAr), 3.33 (t, J = 6.2/Hz, 2H, CH2NH(C=O)NH), 2.86 (tq, 
J = 5.8/5.8 Hz, 2H, CH2NH3 +). 
13C NMR (DMSO-d6): ~ ~ 155.61 (C=O), 137.73 (JCF = 11.3 Hz, aryI1-C), 
117.20 (JCF = 17.8 Hz, aryI5-C), 113.59 (JCF = 8.8 Hz, aryI6-C), 106.41 
(JCF = 22.1 Hz, aryI2-C), 46.00 (CH2NH(C=O)NH), 37.09 (CH2NH3+). 
m/z: HRMS (TOF ES+) C9H12F2N30 [MHt calcd 216.0943; found 
216.0937. 
4-Amino-2-fluorophenol (75) 
H2N'CCF 2-Fluoro-4-nitrophenol (74) (1.19g, 7.57mmol) was 
I ~ ~ dissolved in methanol (40mL) and hydrogenated over 
OH 
10% Pd/C (125 mg), at room temperature and 
atmospheric pressure. The suspension was filtered over celite and 
washed with excess MeOH. Removal of excess solvent in vacuo 
afforded 867 mg of light brown solid. 
Yield: 90 %. 
180 
Experimental 
Mp: 169 - 172°C. 
IR: 3354 (OH, str) , 3292 (NH, str) , 1608, 1525 (aryl, str), 1401 (O-H, 
bend), 1206 (C-F, str) , 1110 (C-OH, str), 728 (C-F, str). 
1H NMR (DMSO-ds): (58.57 (s, 1H, OH), 6.62 (dd, J = 10.1/8.5 Hz, 1H, 
6-H), 6.34 (dd, J = 10.7/2.8 Hz, 1H, 3-H), 6.20 (ddd, J = 8.3/2.8/1.1 Hz, 
1 H, 5-H), 4.68 (s, 2H, NH2). 
1lC NMR (DMSO-ds): (5 151.53 (JCF = 238.3 Hz, 2-C), 141.94 (JCF = 8.7 
Hz, 4-C), 134.68 (JCF= 13.1 Hz, 1-C), 118.43 (JCF = 4.8Hz, 6-C), 109.97 
(JCF = 2.4 Hz, 5-C), 102.19 (JCF = 21.4 Hz, 3-C). 
mlz: HRMS (TOF ES+) CSH7FNO [MHt calcd 128.0506; found 
128.0504. 
1-(3-Fluoro-4-hydroxyphenyl)-3-(2-phthalimidoethyl)urea (76) 
~ ~ ~ ~ F Isocyanate solution was prepared as 
P h t h N ~ ~ ]' '(X described for 1-(2-hydroxyphenyl)-3-(2-
OH phthalimidoethyl) urea (69a) via curtius 
reaction starting with 3-phthalimidopropanoic acid (28) (1.000 g, 4.56 
mmol). To this was added 4-amino-2-f1uorophenol (75) (830 mg, 6.53 
mmol, 1.4 eq) and stirred with heating under reflux overnight. After 
cooling, the formed precipitate was collected by filtration (suction) and 
washed with EtOAc, which on drying gave 866 mg of solid. 
Yield: 55 %. 
Mp: 226 - 227°C. 
IR: 3373 (OH, str) , 3227 (urea NH, str) , 1772, 1709 (phth C=O, str), 
1653 (urea C=O, str) , 1608 (aryl, str), 1404 (O-H, bend), 1227, 724 (C-
F, str). 
1H NMR (DMSO-ds): (5 9.26 (br s, 1H, OH), 8.21 (s, 1H, 
NH(C=O)NHAr), 7.77 -7.92 (m, 4H, phth C-H), 7.16 -7.25 (m, 1H, aryl 
C-H), 6.69 - 6.79 (m, 2H, aryl C-H), 6.20 (t, J = 5.97 Hz, 1 H, 
NH(C=O)NHAr), 3.67 (t, J = 5.3 Hz, 2H, NCH2), 3.30 - 3.35 (m, 2H, 
CH2NH). 
181 
Experimental 
13C NMR (DMSO-ds): 0 168.03 (phth C=O), 155.38 (urea C=O), 150.45 
(JCF = 238.7 Hz, 3-C phenylurea), 134.27, 122.96 (phth C-H), 132.56 
(JCF = 16.3 Hz, 4-C phenylurea), 131.82 (phth 40 C), 128.85 (1-C 
phenylurea), 117.44, 114.22 (JCF = 3.9 Hz, 5-C and 6-C phenylurea), 
106.85 (JCF = 21.8 Hz, 2-C phenylurea), 38.19 (NCH2), 37.58 (CH2NH). 
mlz: HRMS (TOF ES+) C17H1SFN304 [MHt calcd 344.1041; found 
344.1014. 
1-(2-Aminoethyl)-3-(3-fluoro-4-hydroxyphenyl)u rea hyd rochloride 
(77) 
H H Phthalimide deprotection of 1-(3-fluoro-
e E f ) ~ N ' y ' N ' ( J C F F
CI H3N II I 4-hydroxyphenyl)-3-(2-phthalimidoethyl) 
o ::::::..... OH 
urea (76) (800 mg, 2.33 mmol) was 
carried out as described in the synthesis of 1-(2-aminoethyl)-3-(2-
hydroxyphenyl)urea hydrochloride (70a) to give 487 mg of white solid 
requiring no further purification. 
Yield: 84 %. 
Mp: 190 - 195 °C. 
IR: 3372 (OH, str) , 3128 (br, urea NH, str) , 3042 (br, NH3+, str) , 1674 
(urea C=O, str) , 1612 (aryl, str), 1284 (O-H, bend), 1213 (C-F, str). 
1H NMR (DMSO-ds): 0 9.35 (br s, 1H, OH), 8.93 (s, 1H, 
NH(C=O)NHAr), 7.98 (br s, 3H, NH3+), 7.33 - 7.42 (m, 1H, aryl C-H), 
6.78 - 6.88 (m, 2H, aryl C-H), 6.55 (t, J = 5.1 Hz, 1 H, NH(C=O)NHAr), 
3.30 (dt, J = 6.1/5.6 Hz, 2H, CH2NH), 2.79 - 2.91 (m, 2H, NH3+CH2). 
13C NMR (DMSO-d&): 0155.86 (C=O), 150.49 (JCF = 232.0 Hz, aryl 3-
C), 139.01 (JCF = 11.0 Hz, aryl 4-C), 132.57 (JCF = 8.2 Hz, aryl 1-C), 
117.61,114.08 (JCF = 3.3 Hz, aryl5-C and 6-C), 106.70 (JCF = 22.5 Hz, 
aryl 2-C), 39.10 (CH2NH), 37.17 (NH3 +CH2). 
mlz: HRMS (TOF ES+) C9H13FN302 [MHt calcd 214.0986; found 
214.1002. 
182 
Experimental 
Benzyl 3-(benzyloxy)-4-fluorobenzoate (79a) 
o 
~ O B n nBnO I ~ ~h F 
NaH 60% suspension in mineral oil (546 mg, 
equivalent to 338 mg of NaH, 14 .09 mmol, 2.2 eq) 
was weighed into a flame-dried flask and 
suspended in dry DMF (30 mL), under a nitrogen 
atmosphere over an ice bath. To this was added 4-fluoro-3-
hydroxybenzoic acid (78a) (1.000 g, 6.41 mmol) and the mixture was 
stirred at room temperature for 30 minutes. Benzyl bromide (2.410 g, 
1.676 mL, 14.09 mmol, 2.2 eq) was added to the flask, and the mixture 
stirred for a further 48 hours at room temperature. After removal of 
solvent in vacuo, the crude slurry was dissolved in water (30 mL) before 
extraction with EhO (3 x 20 mL). The combined organic layers were 
washed with aqueous 2 M NaOH (1 x 30 mL). Removal of solvent 
afforded the desired compound as colourless translucent oil in 
quantitative yield with no further purification required. 
Yield: 100%. 
IR: 3066 (aryl C-H, str), 2933 (alkyl C-H, str), 1718 (ester C=O, str), 
1287 (C-F, str), 1202 (ester C-O, str), 1099 (C-O-C, str), 761 (C-F, 
bend), 697 (aryl C-H bend, phenyl ring). 
1H NMR: ~ ~ 7.82 (dd, J = 7.9/1.8 Hz, 1 H, aryl 2-H), 7.73 (ddd, J = 
8.4/4.4/2.1 Hz, 1 H, aryl 6-H), 7.34 - 7.53 (m, 10H, aromatic benzyl C-
H), 7.15 (dd, J = 10.5/8.2 Hz, 1H, aryl 5-H), 5.39 (s, 2H, benzyl ester 
CH2), 5.19 (s, 2H, benzyl ether CH2). 
13C NMR: ~ ~ 165.44 (C=O), 155.98 (JCF = 254.8 Hz, aryl 4-C), 146.69 
(JCF = 10.2 Hz, aryl 3-C), 136.00, 135.93 (benzyl 4° C), 128.66, 128.65, 
128.34, 128.28, 128.20, 127.59 (aromatic benzyl C-H), 126.54 (JCF =3.4 
Hz, aryl 1-C), 123.65 (JCF =8.5 Hz, aryl 6-C), 116.64 (JCF =2.8 Hz, aryl 
2-C), 116.17(JCF =19.2 Hz, aryl 5-C), 71.25 (benzyl ether CH2), 66.90 
(benzyl ester CH2). 
m/z: HRMS (TOF ES+) C21H1sF03 [MHt calcd 337.1234; found 
337.1208. 
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Benzyl 3,4-bis(benzyloxy)benzoate (79b) 
o Refer to the procedure for benzyl 3-(benzyloxy)-4-
B n o ~ o B n n fluorobenzoate (79a). 3,4-dihydroxybenzoic acid 
~ o B n n (78b) was benzyl-protected in a similar manner to 
4-fluoro-3-hydroxybenzoic acid (78a), using 3.3 eq of benzyl bromide to 
afford a waxy yellow solid in quantitative yield requiring no further 
purification. 
Yield: 100%. 
Mp: 69.5 - 71.5 °C (lit. 66 - 67°C) 178. 
IR: 3030 (aryl C-H, str), 2923 (alkyl C-H, str) , 1693 (ester C=O, str), 
1599, 1588, 1516 (aryl, str), 1275 (ester C-O, str) , 741, 696 (aryl C-H 
bend, phenyl ring). 
1H NMR: ~ ~ 7.65 - 7.72 (m, 2H, aryl 2-H and 6-H), 7.28 - 7.52 (m, 15H, 
aromatic benzyl C-H), 6.93 (d, J = 8.7 Hz, 1 H, aryl 5-H), 5.33 (s, 2H, 
benzyl ester CH2), 5.23, 5.20 (s, 2 x 2H, 2 x benzyl ether CH2). 
13C NMR: ~ ~ 166.17 (C=O), 153.10 (aryI4-C), 148.43 (aryI3-C), 136.94, 
136.64, 136.35 (benzyl 4° C), 128.70, 128.67, 128.63, 128.26, 128.18, 
128.10,128.03,12.51,127.23 (benzyl C-H), 124.26 (aryI1-C), 123.11 
(aryl 6-C), 115.75 (aryl 2-C), 113.35 (aryl 5-C), 71.34, 70.93 (benzyl 
ether CH2), 66.60 (benzyl ester CH2). 
m/z: HRMS (TOF ES+) C28H2S04 [MHt calcd 425.1747; found 
425.1706. 
3-(Benzyloxy)-4-fluorobenzoic acid (80a) 
o Benzyl 3-(benzyloxy)-4-fluorobenzoate (79a) 
H O ~ O B n n (2.067g, 6.15 mmol and lithium hydroxide (736 mg, 
V F 30.74 mmol, 5 eq) were dissolved in 
waterlTHF/MeOH 1:1:1 (45 mL) in a flask flushed with nitrogen. After 
overnight stirring, THF and MeOH were removed in vacuo and the 
remaining aqueous slurry diluted to 30 mL with more water. After 
washing with Et20 (2 x 30 mL), the aqueous layer was acidified with 
conc HCI to approximately pH 4. The acidified aqueous layer was 
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extracted with DCM (2 x 30 mL). Removal of organic solvent in vacuo, 
gave 1.299 g of the desired free acid as a white solid requiring no 
further purification. 
Yield: 86%. 
Mp: 207 - 209°C. 
IR: 3036 (aryl C-H, str), 2954, 2881, 2843, 2624 (C02H O-H, str), 1678 
(C02H C=O, str), 1610, 1520 (aryl, str), 1302 (C-F, str), 740 (C-F, 
bend), 765, 695 (aryl C-H bend, phenyl ring). 
1H NMR (DMSO-ds): 6 13.06 (br s, 1 H, C02H), 7.74 (dd, J = 8.3/2.7 Hz, 
1 H, aryl 2-H), 7.57 (ddd, J = 8.3/4.5/1.9 Hz, 1 H, aryl 6-H), 7.47 (d, J = 
8.3 Hz, 2H, benzyl2-H and 6-H), 7.40 (dd, J = 7.517.5 Hz, 2H, benzyl 3-
Hand 5-H), 7.28 - 7.37 (m, 2H, aryl 5-H, benzyl 4-H), 5.24 (s, 2H, 
benzyl CH2). 
13C NMR (DMSO-ds): 6 166.37 (C=O), 154.65 (JCF = 245.7 Hz, aryl 4-
C), 146.06 (JCF = 11.3 Hz, aryl 3-C), 139.16 (benzyl 4° C), 128.46, 
128.07, 127.74 (benzyl C-H), 127.60 (JCF = 3.0 Hz, aryl 1-C), 123.01 
(JCF= 7.9 Hz, aryI6-C), 116.09 (JCF= 19.7 Hz, aryI5-C), 115.9 (JCF = 
3.0 Hz, aryl 2-C), 70.24 (benzyl CH2). 
mlz: HRMS (TOF ES-) C14H10F03 [M-Hr calcd 245.0619; found 
245.0617. 
3,4-bis(Benzyloxy)benzoic acid (80b) 
o 
~ O B n nHO I ~ ~ OBn 
further purification. 
Yield: 85%. 
Benzyl 3,4-bis(benzyloxy)benzoate (79b) was 
hydrolysed as described in the procedure for 3-
(benzyloxy)-4-fluorobenzoic acid (80a). The desired 
free acid was collected as white solid requiring no 
Mp: 189 -191°C (lit. 187 -188 °C)178. 
IR: 3033 (aryl C-H, str), 2906, 2864, 2547 (C02H O-H, str), 1679 (C02H 
C=O, str), 1601, 1521 (aryl, str), 761,694 (aryl C-H bend, phenyl ring). 
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1H NMR (DMSO-d6): ~ ~ 12.56 (br s, 1H, C02H) , 7.52 - 7.59 (m, 2H, aryl 
2-H and 6-H), 7.41 - 7.49 (m, 4H, 2 x benzyl 2-H and 6-H), 7.26 - 7.41 
(m, 6H, 2 x benzyl 3-H, 4-H and 5-H), 7.11 (d, J = 8.2 Hz, 1 H, aryl 5-H), 
5.20, 5.15 (s, 2 x 2H, 2 x benzyl CH2). 
13C NMR (DMSO-d6): ~ ~ 166.88 (C=O), 152.01 (aryI4-C), 147.57 (aryl 3-
C), 136.86, 136.57 (benzyl 4° C), 128.25, 128.20, 127.71, 127.61, 
127.32, 127.27 (benzyl C-H), 123.44, 123.40 (aryl 1-C, aryl 6-C), 
114.70 (aryI2-C), 112.96 (aryl 5-C), 70.09, 69.88 (benzyl CH2). 
mlz: HRMS (TOF ES-) C21 H1704 [M-Hr calcd 333.1132; found 
333.1109. 
Benzyl 2-aminoethylcarbamate (82) 
C b Z ' N ~ N H 2 2 Ethylenediamine (54) (16.71 mL, 250 mmol, 5 eq) was 
H dissolved in dry OCM (50 mL) and cooled to 0 °C with 
vigorous stirring. A solution of benzylchloroformate (7.14 mL, 50 mmol) 
in dry OCM (250 mL) was dripped slowly into the solution of 
ethylenediamine over 10 minutes. The mixture was allowed to stir 
overnight at room temperature before washing with aqueous 2 M NaOH 
(1 x 100 mL) and water (2 x 100 mL). The organic layer was then 
extracted with aqueous 1 M HCI (3 x 100 mL). The combined acidic 
aqueous layers were basified with aqueous 2 M NaOH before finally 
extracting with OCM (3 x 80 mL). Concentration of the organic fractions 
gave poor yield, and the desired product was found to be trapped in the 
basified aqueous layer. This aqueous layer was concentrated in vacuo 
before re-extraction with OCM (3 x 50 mL). After concentration of the 
combined organic layers, eth crude product was purified by FCC (eluent 
37% aq N H ~ M e O H / O C M M 1 :5:94) to give 3.51 g of colourless semi-solid. 
Yield: 36%. 
IR: 3321 (NH2, str) , 3032 (aryl C-H, str) , 2948 (alkyl C-H, str), 1690 
(carbamate C=O, str) , 1541 (aryl, str), 746, 697 (aryl C-H bend, phenyl 
ring). 
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1H NMR: ~ ~ 7.19 - 7.42 (m, 5H, aromatic benzyl C-H), 5.53 (br s, 1H, 
carbamate NH), 5.06 (s, 2H, benzyl CH2), 3.19 (dt, J = 5.9/5.9 Hz, 2H, 
NHCH2), 2.76 (t, J = 5.9 Hz, 2H, CH2NH2), 1.32 (br s, 1 H, NH2). 
13C NMR: ~ ~ 156.79 (C=O), 136.60 (benzyl 4° C), 128.51, 128.08 
(aromatic benzyl C-H, 66.62 (benzyl CH2), 43.74 (NHCH2), 41.67 
(CH2NH2). 
mlz: HRMS (TOF ES+) C10H1SN202 [MHt calcd 195.1128; found 
195.1128. 
Benzyl 2-(3-(3-(benzyloxy)-4-fluorophenyl)ureido)ethylcarbamate 
(83a) 
H H A solution of 3-(benzyloxy)-4-
CbZ .... N ~ N ' ) . ( " N U O B n n
II I f1uorobenzoic acid (80a) (1.000 g, 4.06 
H 0 .0 
F mmol), DPPA (918 !-IL, 4.26 mmol, 1.05 
eq) and TEA (1.132 mL, 8.12 mmol, 2 eq) in dry toluene (20 mL) was 
stirred at room temperature, under a nitrogen atmosphere. After 
disappearance of starting materials by TLC (approximately 1 hour), the 
mixture was refluxed to promote conversion to the isocyanate. After 
evolution of nitrogen gas had ceased, benzyl 2-aminoethylcarbamate 
(82) (868 mg, 4.47 mmol, 1.1 eq) was added and the reaction cooled to 
room temperature. The formed precipitate was collected by filtration 
(suction) and washed with MeOH, before drying to afford 1.090 g of 
white solid. 
Yield: 61%. 
Mp: 209 - 211°C. 
IR: 3303 (N-H, str) , 2949 (alkyl C-H, str) , 1685 (carbamate C=O, str), 
1637 (urea C=O, str), 1615, 183, 1523 (aryl, str), 1282 (C-F, str), 746, 
695 (aryl C-H, bend, phenyl ring). 
1H NMR (DMSO-d6): ~ ~ 8.56 (s, 1 H, NH(C=O)NHAr), 7.23 - 7.52 (m, 
12H, aromatic benzyl C-H, aryl 6-H, carbamate NH), 7.06 (dd, J = 
11.1/9.0 Hz, 1 H, aryl 5-H), 6.81 - 6.89 (m, 1 H, aryl 2-H), 6.18 (t, J = 5.2 
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Hz, NH(C=O)NHAr), 5.14 (s, 2H, benzyl carbamate CH2), 5.02 (s, 2H, 
benzyl ether CH2), 3.14, 3.09 (t, J = 5.5 Hz, 2 x 2H, NHCH2CH2NH). 
13C NMR (DMSO-d6): 6 156.28,155.26 (C=O), 145.82 (JCF = 11.6 Hz, 
aryl 3-C), 137.28 (JCF = 3.5 Hz, aryI1-C), 137.15, 136.53 (benzyl 4° C), 
128.27, 128.36, 128.04, 127.78 (benzyl C-H), 115.68 (JCF = 16.5 Hz, 
aryl 5-C), 109.74 (JCF = 5.2 Hz, aryl 6-C), 105.28 (aryl 2-C), 70.07 
(benzyl ether CH2), 65.27 (benzyl carbamate CH2), 45.99, 40.75 
(NHCH2CH2NH). 
m/z: HRMS (TOF ES+) C24H2SFN304 [MHt calcd 438.1824; found 
438.1792. 
8enzyI2-(3-(3,4-bis(benzyloxy)phenyl)ureido)ethylcarbamate (83b) 
H H 3,4-bis(Benzyloxy)benzoic acid (80b) 
Cbz, ~ N " w " ' N y y O S n n "'1 & • ~ ~ II ~ ~ was reacted In a simi ar lashlon to 3-
o ..& OSn (benzyloxy)-4-f1uorobenzoic acid (80a) 
as described in the procedure for benzyl 2-(3-(3-(benzyloxy)-4-
fluorophenyl)ureido)ethylcarbamate (83a). In this case the precipitate 
formed was not the desired product and the remaining crude mixture 
was purified by FCC (eluent EtOAclPE 30:70 to 50:50 over 20 column 
volumes, then 50:50 to 100:0 over 10 column volumes), to give 479 mg 
of white solid. 
Yield: 15%. 
Mp: 171 -179°C. 
IR: 3424 (N-H, str), 3034 (aryl C-H, str) , 2934 (alkyl C-H, str) , 1684 
(carbamate C=O, str) , 1636 (urea C=O, str), 1601, 1576, 1513 (aryl, 
str), 750, 696 (aryl C-H bend, phenyl ring). 
1H NMR (DMSO-d6): 6 8.42 (s, 1H, NH(C=O)NHAr), 7.25 - 7.48 (m, 
12H, aromatic benzyl C-H, aryl 2-H), 7.21 (dd, J = 7.817.8 Hz, 2H, 
benzyl 3-H and 5-H), 7.14 (d, J = 7.8 Hz, benzyl 2-H and 6-H), 6.95 (t, J 
= 7.5Hz, 1H, carbamate NH), 6.90 (d, J = 8.9 Hz, 1H, aryl 5-H), 6.81 
(dd, J = 8.4/2.3 Hz, 1 H, aryl 6-H), 6.16 (t, J = 5.3 Hz, 1 H, 
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NH(C=O)NHAr), 5.05 (s, 2H, benzyl carbamate CH2), 5.03, 5.02 (s, 2 x 
2H, benzyl ether CH2), 3.12, 3.08 (t, J = 5.5 Hz, 2 x 2H, NHCH2CH2NH). 
13C NMR (DMSO-ds): 6 155.38, 148.51 (C=O), 142.65 (aryl 3-C), 
139.15 (aryl 4-C), 137.60, 137.22, 137.15 (benzyl 4° C), 128.79, 
128.33, 128.27, 127.73, 127.63, 127.55, 127.51 (benzyl C-H), 121.85 
(aryl 1-C), 119.89, 119.84 (aryl 5-C, aryl 6-C), 105.61 (aryl 2-C), 70.90, 
70.02 (benzyl ether CH2), 65.22 (benzyl carbamate CH2), 45.97, 40.84 
(NHCH2CH2NH). 
mlz: HRMS (TOF ES+) C31H32N305 [MHt calcd 526.2336; found 
526.2322. 
1-(2-Aminoethyl)-3-(4-fluoro-3-hydroxyphenyl)urea hydrochloride 
(84a) 
Benzyl 2-(3-(3-(benzyloxy)-4-f1uoro 
H H ~ ~ H 3 ~ ~ N I ( N ' C ( 0 H H phenyl)ureido)ethylcarbamate (83a) was 
o I ~ ~ hydrogenated as described in the 
F 
procedure for 4-(2-( cyclopentyloxy) 
ethoxy)phenol (61), with the addition of a few drops of conc HC!. The 
reaction mixture was filtered over celite with additional MeOH washings, 
before concentration of the filtrate. The hydrochloride salt was collected 
in quantitative yield. 
Yield: 100%. 
Mp: 186 - 188°C. 
IR: 3350 (O-H, str) , 3266 (urea N-H, str) , 3142 (NH3+, str) , 2948 (alkyl 
C-H, str) , 1670 (urea C=O, str) , 1619, 1563, 1516 (aryl, str), 1182 (C-F, 
str) , 1125 (C-O, str) , 779 (C-F, bend). 
1H NMR (DMSO-ds): 6 9.74 (br s, 1H, OH), 9.00 (s, 1H, 
NH(C=O)NHAr), 8.02 (br s, 3H, NH3+), 7.17 (dd, J = 6.0/2.4 Hz, 1H, aryl 
2-H), 6.94 (dd, J = 11.2/8.8 Hz, 1 H, aryl 5-C), 6.75 (ddd, J = 8.8/3.2/2.8 
Hz, 1 H, aryl 6-C), 6.57 - 6.66 (br m, 1 H, NH(C=O)NHAr), 3,25 - 3,35 
(br m, 2H, CH2NH3 +), 2,85 (dt, J = 6,0/5,6 Hz, 2H, CH2NH), 
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13C NMR (DMSO-d6): ~ ~ 155.73 (C=O), 146.05 (JCF = 235.2 Hz, aryl 4-
C), 144.56 (JCF = 11.9 Hz, aryl 3-C), 136.80 (JCF = 3.0 Hz, aryl 1-C), 
115.51 (JCF = 19.2 Hz, aryl 5-C), 108.30 (JCF = 5.6 Hz, aryl 6-C), 107.47 
(JCF = 1.6 Hz, aryI2-C), 46.01 (CH2NH), 37.10 (CH2NH3 +). 
mlz: HRMS (TOF ES+) CgH13FN302 [MHt calcd 214.0986; found 
214.0973. 
1-(2-(3-(4-(2-(CycJopentyJoxy)ethoxy)phenoxy)-2-
hydroxypropyJamino)ethyJ)-3-(3-f1uoro-4-hydroxyphenyJ)urea 
hydroformate (85a) 
Q o ~ o ' Q Q HC08 I 2 H H 
o O ~ N ~ N I ( N ' O F F
O H2 0 I H ® 0 OH 
2-«4-(2-(Cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane (62) (50 mg, 
0.18 mmol), TEA (50 tJL, 0.36 mmol, 2 eq) and 1-(2-aminoethyl)-3-(3-
fJuoro-4-hydroxyphenyl)urea hydrochloride (77) (67 mg, 0.27 mmol, 1.5 
eq) were dissolved in EtOH (2 mL) before exposing to MW conditions 
(140°C, 80W, 250 psi) for 8 minutes. Purification via PLC (eluent 37% 
aq NHJlMeOH/DCM 1:5:94) and preparative HPLC afforded 13 mg of 
white semi-solid. 
Yield: 13 %. 
IR: 3377 (br, OH, str) , 2912, 2868 (alkyl C-H, str), 1647 (urea C=O, str), 
1614, 1568, 1508 (aryl, str) , 1236 (C-F, str), 822 (aryl C-H, bend, para-
disubstituted ring). 
1H NMR (DMSO-d6): 6 9.30 (br s, 1H, phenolic OH), 8.60 (s, 1H, 
NH(C=O)NHAr), 7.32 - 7.42 (m, 1H, phenylurea C-H), 6.75 - 6.92 (m, 
6H, C-H aryl-dioxy ring, phenylurea C-H), 6.26 (t, J = 5.6 Hz, 1 H, 
NH(C=O)NHAr), 3.75 - 4.04 (m, 6H, CH20Ar, cPe CH, CH(OH), 
ArOCH2), 3.61 (t, J = 4.8 Hz, 2H, cPeOCH2), 3.20 - 3.27 (m, 2H, 
NHCH2CH2), 2.72 - 2.94 (m, 4H, CH(OH)CH2NH, NHCH2CH2), 1.52 -
1.75 (m, 6H, cPe CH2), 1.41 - 1.52 (m, 2H, cPe CH2). 
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13C NMR (DMSO-ds): ~ ~ 155.74 (C=O), 152.79, 152.54 (aryl-dioxy ring 
4 ° C), 148.93 (aryl 4-C), 102.53 (JCF = 20.6 Hz, aryl 2-C), 115.43, 
115.39 (aryl-dioxy ring C-H), 80.88 (CPe CH), 70.92 (ArOCH2), 69.04 
(CH(OH», 67.76 (CH20Ar), 66.73 (CPeOCH2), 50.89 (CH(OH)CH2NH), 
48.73 (NHCH2CH2), 37.43 (NHCH2CH2), 31.81 (2-C and 5-C cPe ring), 
23.14 (3-C and 4-C cPe ring). 
m/z: HRMS (TOF ES+) C25H35FN30S [MHt calcd 492.2504; found 
492.2503. 
HPLC Rt : 3.82 (System 1 b), 10.65 (System 3). 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(3,4-difluorophenyl)urea (85b) 
Q o ~ o ' O OI H H 
h O ~ N ~ N n N ~ F F
OH H 0 ~ F F
Epoxide opening of 2-({4-(2-(cyclopentyloxy)ethoxy)phenoxy) 
methyl)oxirane (62) with 1-(2-aminoethyl)-3-(3,4-difluorophenyl)urea 
hydrochloride (73), was carried out as described for 1-(2-(3-(4-(2-
(cyclopentyloxy)ethoxy)phenoxy)-2-hyd roxypropylamino )ethyl)-3-(2-
hydroxyphenyl)urea (71t). Purification was achieved via PLC (eluent 
37% aq NHyMeOH/DCM 2: 1 0:88) to give 50 mg of yellow solid. 
Yield: 28%. 
Mp: 113 -115 °c. 
IR: 3323 (br, OH, str) , 2929, 2871 (alkyl C-H, str), 1645 (urea C=O, str), 
1581 (N-H, bend), 1510 (aryl, str), 1234 (C-F, str), 759 (C-F, bend). 
1H NMR (DMSO-ds): ~ ~ 8.90 (s, 1H, NH(C=O)NHAr), 7.63 (ddd, J = 
13.8n.9/2.6 Hz, 1H, aryl 2-H), 7.26 (ddd, J = 10.4/9.2/9.2 Hz, 1H, aryl 
5-H), 6.96 - 7.06 (m, 1H, aryl 6-H), 6.84 (s, 4H, C-H aryl-dioxy ring), 
6.32 (t, J = 5.2 Hz, 1H, NH(C=O)NHAr), 5.11 (br s, 1H, OH), 3.76 - 4.03 
(m, 6H, CH20Ar, cPe CH, CH(OH), ArOCH2), 3.61 (t, J = 4.6 Hz, 2H, 
cPeOCH2). 3.14 - 3.24 (m, 2H. NHCH2CH2). 2.59 - 2.81 (m, 4H. 
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CH(OH)CH2NH, NHCH2CH2), 1.52 -1.75 (m, 6H, cPe CH2), 1.41 -1.52 
(m, 2H, cPe CH2). 
13C NMR (DMSO-d6): ~ ~ 155.19 (C=O), 153.83 (JCF = 233.5 Hz, aryl 3-
C), 151.24 (JCF = 257.3 Hz, aryl 4-C), 127.26 (aryl 1-C), 117.2 (JCF = 
16.1 Hz, aryl5-C) 115.32 (CH aryl-dioxy ring), 113.5 (JCF = 10.5 Hz, aryl 
6-C), 106.30, (JCF = 24.1 Hz, aryI2-C), 80.84 (CPe CH), 71.08 (ArOCH2), 
68.64 (CH(OH», 67.68 (CH20Ar) 66.71 (CPeOCH2), 51.82 
(CH(OH)CH2NH), 48.93 (NHCH2CH2), 38.67 (NHCH2CH2), 31.79 (2-C 
and 5-C cPe ring), 23.13 (3-C and 4-C cPe ring) 
mlz: HRMS (TOF ES-) C2sH32F2N30s [M-Hr calcd 492.2316; found 
492.2361. 
HPLC Rt : 4.65 (System 1b), 13.70 (System 3). 
Phenyl-2-(tert-butyloxycarbonyl)aminoethylcarbamate (86) 
H tert-Butyl 2-aminoethylcarbamate (64) (1.000 
B o c ' ~ ~ N I ( 0 ~ ~ g, 6.25 mmol) and TEA (759 mg, 1.045 mL, 
o V 7.5 mmol, 1.2 eq) were dissolved in dry OCM 
(20 mL) under a nitrogen atmosphere. Phenylchloroformate (1.076 g, 
862 ~ L , , 6.87 mmol, 1.1 eq) was added and the mixture stirred for 1 
hour. After confirmation of total amine consumption by TLC, the 
mixture was diluted to 50 mL with OCM before washing with aqueous 1 
M NaOH (1 x 50 mL), and water (1 x 50 mL). Removal of all volatiles 
gave 1.521 g of cream solid which was used without any further 
purification. 
Yield: 87%. 
IR: 3333 (carbamate N-H, str) , 2977 (alkyl, C-H, str), 1716, 1689 
(carbamate C=O, str) , 1526 (aryl, str) , 1366 (C(CH3h, str) , 769, 699 
(aryl C-H bend, phenyl ring). 
m/z: HRMS (TOF ES+) C14H21N204 [MHt calcd 281.1496; found 
281.1516. 
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Phenyl 2-aminoethylcarbamate hydrochloride (87) 
Phenyl-2-(terl-butyloxycarbonyl)aminoethyl 
H ~ ~ H 3 ~ ~ N I ( 0 ~ ~ carbamate (86) was dissolved in Et20 (15 
o ~ ~ mL) and 4 M HCII dioxane (15 mL). After 10 
minutes the formed precipitate was filtered (suction) and washed with 
Et20 to give a white solid in quantitative yield. 
Yield: 100 %. 
Mp: 166 - 168 °C. 
IR: 3336 (carbamate N-H, str), 2891 (NH3+, str), 1715 (carbamate C=O, 
str), 1536 (aryl, str), 761, 708 (aryl C-H bend, phenyl ring). 
1H NMR (DMSO-d6): ~ ~ 8.23 (br s, 3H, NH3 +), 7.97 (t, J = 5.3 Hz, 1 H, 
carbamate NH), 7.38 (dd, J = 7.717.7 Hz, 2H, aryl 3-H and 5-H), 7.20 
(dd, J = 7.717.1 Hz, 1H, aryI4-H), 7.13 (d, J = 7.7 Hz, 2H, aryl 2-H and 
6-H), 3.35 (dt, J = 6.1/6.1 Hz, 2H, CH2NH), 2.86 - 3.01 (m, 2H, 
CH2NH3+). 
13C NMR (DMSO-d6): ~ ~ 154.49 (C=O), 150.95 (aryI1-C), 129.21 (aryl 3-
C and 5-C), 125.03 (aryl 4-C), 121.77 (aryl 2-C and 6-C), 38.41, 38.20 
(CH2). 
mlz: HRMS (TOF ES+) C9H13N202 [MHt calcd 181.0972; found 
181.0965. 
tert-Butyl 2-(2-phenylacetamido)ethylcarbamate (88) 
H tett-Butyl 2-aminoethylcarbamate (64) (1 g, 
~ ~ I '-':: 6.25 mmol) and TEA (958 IJL, 6.88 mmol, 1.1 Boc, ~ N r o o
o .b eq) were dissolved in dry OCM (20 mL) and 
cooled to 0 °C under a nitrogen atmosphere. Phenyl acetyl chloride 
(826 IJL, 6.25 mmol, 1 eq) was added and the mixture stirred at room 
temperature for 2 hours. The TEA.HCI salt was filtered before 
concentration of the filtrate in vacuo. The crude residue was dissolved 
in EtOAc (50 mL) and washed with acidified water (25 mL, pH 4 
adjusted using aqueous 1 M KHS04), aqueous 2M NaOH (25 mL) and 
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water (25 mL). The organic layer was concentrated in vacuo to give 
1.460 g of white solid requiring no further purification. 
Yield: 84 %. 
Mp: 133 -135°C. 
IR: 3370 (amide N-H, str) , 3332 (carbamate N-H, str) , 2983, 2940 (alkyl 
C-H, str). 1687 (carbamate C=O, str) , 1649 (amide I, C=O str) , 1530 
(amide II, N-H bend), 1497 (aryl, str) , 1365 (C(CH3), str), 698 (aryl C-H 
bend, phenyl ring). 
1H NMR (CDCb): 0 7.25 - 7.39 (m, 5H, phenyl CH), 6.05 (br s, 1 H, 
amide NH), 4.87 (br s, 1 H, carbamate NH), 3.55 (s, 2H, CH2C=O), 3.29 
- 3.33 (m, 2H, CH2NH), 3.18 - 3.22 (m, 2H, CH2NH), 1.42 (s, 9H, 
(CH3h)· 
13C NMR (CDCb): 0 171.85 (amide C=O), 156.83 (carbamate C=O), 
134.94 (phenyl 1-C), 129.53, 129.12 (phenyl 2-C, 3-C, 5-C, 6-C), 
127.45 (phenyl 4-C), 79.76 (Boc 4°C), 43.92 (CH2C=O) , 40.80, 40.42 
(NHCH2CH2NH), 28.50 «CH3h). 
mlz: HRMS (TOF ES+) C15H23N203 [MHt calcd 279.1703; found 
279.1686. 
2-(2-Phenylacetamido)ethylammmonium trifluoroacetate (89) 
H tert-Butyl 2-(2-phenylacetamido)ethyl 
e H ~ ~ N ~ ~ carbamate (88) (1.310 g, 4.71 mmol) 
CF3C02 0 V 
was dissolved in TFAlDCM (20 mL 1:1) 
and stirred for 2 hours at room temperature. Removal of volatiles in 
vacuo gave 1.518 g of semi-solid requiring no further purification. 
Yield: 100%. 
IR: 3054 (br, NH3+, str) , 1653 (amide I, C=O str) , 1538 (amide II, N-H 
bend), 715 (aryl C-H bend, phenyl ring). 
1H NMR (DMSO-d6): 0 8.30 (t, J = 5.4 Hz, 1H, amide NH), 7.90 (br s, 
3H, NH3+), 7.20 - 7.31 (m, 5H, phenyl CH), 3.43 (s, 2H, CH2C=O). 3.28 
(dt, J = 6.0/6.4 Hz, 2H, CH2NH), 2.84 - 2.90 (m, 2H, CH2NH3+). 
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13C NMR (DMSO-d6): Z) 171.03 (amide C=O), 158.46 (JCF = 33.6, 
formate C=O), 136.05 (phenyI1-C), 129.16, 128.23 (phenyI2-C, 3-C, 5-
C, 6-C), 126.44 (phenyl 4-C), 42.29 (CH2C=O), 38.60 (CH2NH3+), 36.63 
(CH2CH2CH2). 
mlz: HRMS (TOF ES+) C1oH15N20 [MHt calcd 179.1179; found 
179.1196. 
tert-Butyl 2-(3-phenylthioureido)ethylcarbamate (90) 
H H tert-Butyl 2-aminoethylcarbamate (64) (593 
Soc" ~ ~N'y"'ND ~ ~ II I mg, 3.70 mmol) and phenylisothiocyanate 
S ~ ~
(442 IJL, 3.70 mmol, 1 eq) were reacted in a 
manner analogous to that described in the general procedure for 
synthesis of phenyl substituted 1-(2-aminoethyl)-3-(phenyl)urea 
hydrochlorides (65a - 65r) to give 920 mg of white solid. 
Yield: 84%. 
Mp: 138 - 140°C. 
IR: 3327 (br, carbamate N-H, str) , 1688 (carbamate C=O, str) , 1588 
(aryl, str) , 1277 (thiourea, str) , 1180 (C=S, str), 693 (aryl C-H bend 
phenyl ring). 
1H NMR (CDCb): Z) 7.85 (br s, 1H, NH(C=S)NHPh), 7.42 (dd, J = 
7.7n.7 Hz, 2H, 3-H and 5-H phenyl ring), 7.29 (dd, J = 7.3n.3 Hz, 1H, 
4-H phenyl ring), 7.22 (d, J = 7.7 Hz, 2H, 2-H and 6-H phenyl ring), 6.85 
(br s, 1H, O(C=O)NH), 4.90 (br s, 1H, NH(C=S)NHPh), 3.74 (dt, J = 
5.9/5.2 Hz, 2H, CHzNH(C=S)NH), 3.32 (dt, J = 6.3/5.6 Hz, 2H, 
CH2NH(C=O)O), 1.34 (s, 9H, C(CH3h). 
13C NMR (CDCb): Z) 181.17 (C=S), 157.02 (C=O), 136.05 (4° C), 
130.20 (phenyl 3-C and 5-C), 127.39 (phenyl 4-C), 125.46 (phenyl 2-C 
and 6-C), 79.99 (Boc 4° C), 47.00, 39.83 (CH2), 28.38 (CH3). 
mlz: HRMS (TOF ES+) C14H22N302S [MHt calcd 296.1427; found 
296.1409. 
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1-(2-Aminoethyl)-3-phenylthiourea hydrochloride (91) 
H H 
tert-Butyl 2-(3-phenylthioureido )ethyl 
~ I I H 3 ~ ~ N I ( N ~ ~ carbamate (90) (882 mg, 2.99 mmol) was 
S V stirred overnight in 4 M HCI in dioxane (20 
mL). Removal of all volatiles in vacuo gave 592 mg of cream crystalline 
solid requiring no further purification. 
Yield: 86%. 
Mp: 183 -185°C. 
IR: 3355, 3166 (thiourea N-H, str), 2949 (NH3 +, str), 2804, 2629 (alkyl 
C-H, str), 1595 (aryl, str), 1320 (thiourea, str), 1095 (C=S, str), 733, 693 
(aryl C-H bend phenyl ring). 
1H NMR (DMSO-d6): ~ ~ 10.10 (s, 1H, NH(C=S)NHPh), 8.22 (t, J = 5.5 
Hz, NH(C=S)NHPh), 8.08 (br s, 3H, NH3+), 7.46 (dd, J = 8.6/1.1Hz, 2H, 
2-H and 6-H phenyl ring), 7.32 (dd, J = 7.4n.4 Hz, 2H, 3-H and 5-H 
phenyl ring), 7.11 (dd, J = 7.4n.4 Hz, 1 H, 4-H phenyl ring), 3.74 (dt, J = 
6.4/5.9 Hz, 2H, CH2NH(C=O)NH), 2.95 - 3.06 (m, 2H, CH2NH3+). 
13C NMR (DMSO-d6): 0 180.99 (C=S), 139.08 (4° C), 128.08, 124.26, 
123.11 (Phenyl C-H), 41.23,37.92 (CH2). 
mlz: HRMS (TOF ES+) C9H14N3S [MHt calcd 196.0903; found 
196.0889. 
tert-Butyl 2-(benzylsulfonamido )ethylcarbamate (92) 
H 0 tert-Butyl 2-aminoethylcarbamate (64) (500 
SOC ~ N I I V V' ~ ~ ' ~ I I -...:::: mg, 3.12 mmol) and TEA (478 IJL, 3.43 
o d- mmol, 1.1 eq) were dissolved in dry OCM (10 
mL) under a nitrogen atmosphere. Phenylmethanesulfonyl chloride 
(595 mg, 3.12 mmol, 1 eq) in OCM (5 mL) was added dropwise whilst 
cooling the mixture over an ice bath. After stirring at room temperature 
overnight, the crude mixture was diluted to 30 mL with OCM before 
washing with aqueous 1 M KHS04 (20 mL), aqueous 1 M NaOH (20 
mL) and water (20 mL). Removal of all volatiles in vacuo gave 761 mg 
of white solid requiring no further purification. 
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Yield: 78 %. 
Mp: 110 - 114°C. 
IR: 3366 (carbamate N-H, str), 3293 (sulfonamide N-H, str) , 2983, 2939 
(alkyl C-H, str), 1691 (carbamate C=O, str) , 1532 (aryl, str) , 1367, 1171 
(sulfonamide, str), 698 (aryl C-H bend phenyl ring). 
1H NMR (COCh): ~ ~ 7.34 - 7.42 (m, 5H, phenyl C-H), 4.78 - 4.93 (m, 
2H, 2 x N-H), 4.25 (s, 2H, S02CH2), 3.11 - 3.23 (m, 2H, C=ONHCH2), 
2.96 - 3.08 (m, 2H, CH2NHS02), 1.43 (s, 9H, C(CH3h). 
13C NMR (CDCh): ~ ~ 156.52 (C=O), 130.76, 129.0, 128.92 (Phenyl C-
H), 129.39 (4° C), 80.00 (Boc 4° C), 59.07 (S02CH2), 44.05 
(CH2NHS02), 41.04 (C=ONHCH2), 28.48 (CH3). 
mlz: HRMS (TOF ES+) C14H23N204S [MHt calcd 315.1373; found 
315.1397. 
N-(Aminoethyl)benzylsulfonamide hydrochloride (93) 
H 0 Boc-deprotection of tert-butyI 2-
g( H 3 ~ ~ N N ... # ~ ~ (benzylsulfonamido)ethylcarbamate (92) 
o V (704 mg, 2.24 mmol) was achieved as 
described for tert-butyl 2-(3-phenylthioureido)ethylcarbamate (90), 
giving 552 mg of cream solid requiring no further purification. 
Yield: 98 %. 
Mp: 191.5 - 193.5 °C. 
IR: 3338 (sulfonamide N-H, str) , 2999 (NH3+, str), 1589, 1502 (aryl, str) , 
697 (aryl C-H bend phenyl ring). 
1H NMR (CDCh): ~ ~ 8.08 (br s, 3H, NH3+), 7.45 (t, J = 5.9 Hz, 1H, 
NHS02), 7.33 - 7.42 (m, 5H, phenyl C-H), 4.40 (s, 2H, S02CH2), 3.16 
(dt, J = 6.8/5.9 Hz, 2H, CH2NHS02), 2.77 - 2.90 (m, 2H, NH3+CH2). 
13C NMR (CDCb): ~ ~ 130.81, 128.37, 128.09 (Phenyl C-H), 130.05 (4° 
C), 57.22 (S02CH2), 39.17 (CH2). 
mlz: HRMS (TOF ES+) C9H 15N202S [MHt calcd 215.0849; found 
215.0845. 
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tett-Butyl 3-carboxypropylcarbamate (95) 
B o c ' N ~ O H H y-Aminobutyric acid (94) (3.946 g, 38.27 mmol) 
H 0 and NaHC03 (7.07 g, 84.19 mmol, 2.2 eq) were 
dissolved in waterfTHF (4:1, 100 mL). Boc20 (9.186 g, 42.09 mmol, 1.1 
eq) was added and the mixture stirred at room temperature for 48 
hours. THF was removed in vacuo before washing the remaining 
aqueous mixture with DCM (2 x 50 mL). The aqueous layer was then 
acidified using 2M aqueous HCI to pH 4 before extraction with DCM (4 x 
30 mL). The organic layers were combined and concentrated to give 
6.711 g of clear colourless oil requiring no further purification. 
Yield: 86%. 
IR: 2984 (O-H, str), 1717 (acid C=O, str) , 1700 (carbamate C=O, str) , 
1369 (C(CH3), str), 1264, 1165 (C-O, str). 
1H NMR (CDCb): 510.13 (br s, 1H, C02H), 5.05 - 5.15 (br m, 1H, NH), 
2.90 - 3.13 (br m, 2H, NHCH2), 2.24 (t, J = 7.3 Hz, 2H, CH2C02H), 1.68 
(tt, J= 7.017.0 Hz, 2H, CH2CH2CH2), 1.23-1.38 (m, 9H, (CH3h) 
1lC NMR (CDCb): 5 177.58 (C02H), 156.28 (carbamate C=O), 79.17 
(Boc 4° C), 39.65 (CH2NH), 30.65 (CH2C02H), 28.21 «CH3h», 24.94 
(CH2CH2CH2) 
mlz: HRMS (TOF ES+) C9H1SN04 [MHt calcd 204.1230; found 
204.1250. 
tett-Butyl 3-(phenylcarbamoyl)propylcarbamate (96) 
H terl-Butyl 3-carboxypropylcarbamate (95) 
~ ~ II I '-'::: (921 mg, 4.53 mmol) and OCC (1.028 g, 4.98 Boc, ~ N ' O O
o .b 
mmol, 1.1 eq) were dissolved in OCM (25 
mL) and stirred for 30 minutes. Aniline (454 IJL, 4.98 mmol, 1.1 eq) was 
added and the mixture stirred at room temperature for 48 hours. The 
reaction mixture was diluted to 50 ml with OCM before washing with 
acidified water (30 ml, pH 4 adjusted using aqueous 1M KHS04), 
saturated aqueous NaHC03 (30 mL) and brine (30 mL). The organic 
layer was concentrated in vacuo and the crude residue purified via FCC 
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(eluent EtOAclhexanes 10:90 to 80:20 over 10 column volumes). The 
product was recrystallised from MeCN to give 700 mg of crystalline 
white solid. 
Yield: 86 %. 
Mp: 141 -144°C. 
IR: 3336 (amide N-H, str), 3329 (carbamate N-H, str), 2932, 2851 (alkyl 
C-H, str), 1691 (carbamate C=O, str) , 1653 (amide I, C=O str), 1573 
(aryl, str) , 1531 (amide II, N-H bend), 1365 (C(CH3), str). 
1H NMR (CDCb): ~ ~ 8.71 (br s, 1H, amide NH), 7.60 (d, J = 7.8 Hz, 2H, 
2-H and 6-H phenyl ring), 7.31 (dd, J = 7.6n.6 Hz, 2H, 3-H and 5-H 
phenyl ring), 7.08 (dd, J = 7.4n.4 Hz, 1H, 4-H phenyl ring), 4.81 (br s, 
1 H, carbamate NH), 3.25 (dt, J = 6.0/6.0 Hz, 2H, NHCH2), 2.38 (t, J = 
6.5 Hz, 2H, CH2CONH), 1.88 (tt, J = 6.4 Hz, 2H (CH2CH2CH2), 1.46 (s, 
9H, (CH3h)· 
13C NMR (CDCh): ~ ~ 171.31 (amide C=O), 157.36 (carbamate C=O), 
138.57 (phenyI1-C), 129.01 (phenyl 3-C and 5-C), 124.05 (phenyI4-C), 
119.84 (phenyl 2-C and 6-C), 79.95 (Boc 4°C), 39.40 (CH2NH), 34.80 
(CH2CONH), 28.51 «CH3h), 27.48 (CH2CH2CH2). 
mlz: HRMS (TOF ES+) C1sH23N203 [MHt calcd 279.1703; found 
279.1695. 
3-(Phenylcarbamoyl)propylammonium trifluoroacetate (97) 
H fett-Butyl 3-(phenylcarbamoyl)propyl 
CF C ~ ~ H ~ ~ N ~ ~ carbamate (96) (653 mg, 2.35 mmol) 
3 2 0 V 
was dissolved in TFAlDCM (20 mL 1:1) 
and stirred for 2 hours at room temperature. Removal of volatiles in 
vacuo gave 773 mg of semi-solid requiring no further purification. 
Yield: 100%. 
IR: 3061 (br, NH3+, str) , 2937 (alkyl C-H, str) , 1673 (amide I, C=O str), 
1543 (amide II, N-H bend), 757, 700 (aryl C-H bend, phenyl ring). 
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1H NMR (DMSO-d&): ~ ~ 10.03 (s, 1H, NH), 7.87 (br s, 3H, NH3+), 7.59 (d, 
J = 7.6 Hz, 2H, phenyl 2-H and 6-H), 7.29 (dd, J = 7.617.6 Hz, 2H, 
phenyl 3-H and 5-H), 7.02 (dd, J = 7.417.4 Hz, 1 H, phenyl 4-H), 2.80 -
2.91 (m, 2H, CH2NH3+), 2.42 (t, J = 7.2 Hz, 2H, COCH2), 1.85 (tt, J = 
7.3 Hz, 2H, C H 2 C H ~ H 2 ) . .
13C NMR (DMSO-d6): ~ ~ 170.30 (amide C=O), 158.47 (JCF = 34.1 Hz, 
formate C=O), 155.03 (JCF = 341.0 Hz, CF3), 139.20 (phenyl 1-C), 
128.72 (phenyI3-C and 5-C), 123.14 (phenyI4-C), 119.14 (phenyl 2-C 
and 6-C), 38.55 (CH2 NH3 +), 32.95 (CH2C=O), 23.00 (CH2CH2CH2). 
mlz: HRMS (TOF ES+) C1OH1SN20 [MHt calcd 179.1179; found 
179.1191. 
tert-Butyl 3-(phenoxycarbonyl)propylcarbamate (98) 
B 0 fett-Butyl 3-carboxypropylcarbamate (95) o c ' N ~ ~ ~
H 0 V (2.000 g, 9.84 mmol) and DCC (2.232 g, 
10.82 mmol, 1.1 eq) were dissolved in DCM 
(30 mL) and stirred for 30 minutes. Phenol (1.018 g, 10.82 mmol, 1.1 
eq) was added and the mixture stirred for 48 hours. TLC monitoring 
indicated slow progression of the reaction, thus DMAP (122 mg, 1 
mmol, 0.1 eq) was added and the reaction left to stir for a further 24 
hours. The precipitated N,N'-dicyclohexylurea was filtered (suction) and 
the filtrate diluted to 50 mL with DCM before washing with acidified 
water (1 x 30 mL, water acidified to pH 4 with aqueous 1 M KHS04 
solution) and aqueous 0.5 M NaOH (1 x 30 mL). After concentrating 
the organic layer, FCC (eluent EtOAclhexanes 20:80) was required to 
afford 1.894 g of white crystalline solid. 
Yield: 69%. 
Mp: 62 - 65 °C. 
IR: 3389 (carbamate N-H, str), 2983, 2937, 2873 (alkyl C-H, str), 1756 
(ester C=O, str) , 1688 (carbamate C=O, str) , 1526 (aryl, str) , 1370 
(C(CH3h, str) , 1186, 1137 (ester C-O, str) , 755, 691 (aryl C-H bend, 
phenyl ring). 
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1H NMR: l) 7.38 (ddd, J = 7.617.612.0 Hz, 2H, aryl 3-H and 5-H), 7.23 
(ddd, J = 7.6rT.6/1.0 Hz, 1H, aryI4-H), 7.08 (dd, J = 8.5/1.4 Hz, 2H, aryl 
2-H and 6-H), 4.67 (br s, 1 H, NH), 3.26 (dt, J = 7.0/6.2 Hz, 2H, NHCH2), 
2.61 (t, J = 7.0 Hz, 2H, C H ~ = O ) , , 1.94 (tt, J = 7.0n.0 Hz, 2H, 
CH2CH2CH2), 1.45 (s, 9H, (CH3h). 
13C NMR: l) 172.01 (C=O, ester), 156.14 (C=O, carbamate), 150.76 
(aryI1-C), 129.56 (aryl 3-C and 5-C), 125.97 (aryI4-C), 121.68 (aryl 2-C 
and 6-C), 79.51 (Boc 4° C), 39.99 (NHCH2), 31.79 (CH2C=O), 28.55 
«CH3h) 
mlz: HRMS (TOF ES+) C1sH22N04 [MHt calcd 280.1543; found 
280.1515. 
Phenyl 4-aminobutanoate hydrochloride (99) 
e @ 0'0 tert-ButyI 3-(phenoxycarbonyl)propyl 
CI H 3 N ~ ~ I ~ ~
° .0 carbamate (98) was Boc-deprotected in a 
similar fashion to phenyl-2-(tert-
butyloxycarbonyl)aminoethylcarbamate (86) as described in the method 
for phenyl 2-aminoethylcarbamate hydrochloride (87), to give 1.289 g of 
the desired hydrochloride salt as a yellow semi-solid. 
Yield: 98%. 
IR: 2973 (br, NH3+, str) , 1751 (ester C=O, str) , 1197, 1167 (ester C-O, 
str), 755, 693 (aryl C-H bend, phenyl ring). 
1H NMR (DMSO-d6): l) 8.22 (br s, 3H, NH3+), 7.42 (ddd, J = 7.617.6/2.0 
Hz, 2H, aryl 3-H and 5-H), 7.26 (ddd, J = 7.617.6/1.0 Hz, 1H, aryl 4-H), 
7.14 (dd, J = 8.5/1.4 Hz, 2H, aryl 2-H and 6-H), 2.82 - 2.92 (m, 2H, 
CH2NH3+), 2.74 (t, J = 7.5 Hz, 2H, CH2C=O), 1.93 (tt, J = 7.617.6 Hz, 
2H, CH2CH2CH2). 
13C NMR (DMSO-d6): l) 171.13 (C=O, ester), 150.40 (aryl 1-C), 129.47 
(aryl 3-C and 5-C), 125.82 (aryl 4-C), 121.77 (aryl 2-C and 6-C), 37.91 
(CH2NH3+), 30.45 (CH2C=O), 22.25 (CH2CH2CH2). 
mlz: HRMS (TOF ES+) C1oH14N02 [MHt calcd 180.1019; found 
180.1011. 
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2-(2-Hydroxyethyl)phthalimide (101) 
Phthalic anhydride (12.125 g, 81.86 mmol) and 
PhthNL OH ethanolamine (100) (4.94 mL, 81.86 mmol, 1 eq) were 
heated to 175°C with stirring, under a water condenser for 2 hours. On 
cooling, the crude solid was crushed before collecting by filtration 
(suction) and washing with water to give 13.010 g of beige crystalline 
solid. 
Yield: 83 %. 
Mp: 134 - 137°C. 
IR: 3472 (br, OH, str), 2948, 2886 (alkyl C-H, str) , 1767, 1697 (phth 
C=O, str), 1606 (aryl, str) , 1393 (O-H, bend), 1056 (C-OH, str). 
1H NMR (CDCb): ~ ~ 7.79 - 7.87 (2H, m, phth C-H), 7.67 - 7.76 (2H, m, 
phth C-H), 3.81 - 3.94 (m, 4H, 2 x CH2), 2.40 (br s, 1 H, OH). 
13C NMR (CDCb): 6 168.98 (C=O), 134.25, 123.43 (phth C-H), 132.09 
(phth 4° C), 61.19 (CH20H), 40.97 (NCH2). 
mlz: HRMS (TOF ES+) C1oH10N03 [MHt calcd 192.0655; found 
192.0665. 
2-Phthalimidoethyl phenylcarbamate (102) 
2-(2-Hydroxyethyl)phthalimide (101) (2.000 g, 
H 10.46 mmol) was dissolved in dry OCM (30 P h t h N . - . . . . . . . . . . . . . O ' Y ' N ~ 1 1~ ~8 V mL) under a nitrogen atmosphere. Phenyl 
isocyanate (1.137 ml, 10.46 mmol, 1 eq) was 
added and the mixture stirred for 48 hours. Hexanes were added to the 
mixture until a precipitation of a solid was observed. After collection by 
filtration (suction), this crude solid was purified by FCC (eluent 
EtOAclhexanes 30:70 to 50:50 over 10 column volumes to give 400 mg 
of white solid. 
Yield: 12%. 
Mp: 109-111 °c (lit. 179 °C)179. 
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IR: 3286 (N-H, str), 1775 (phth C=O, str). 1711 (carbamate C=O, str). 
1600 (aryl. str), 769, 720 (aryl C-H. bend. phenyl ring). 
1H NMR (CDCI3): is 7.81 - 7.90 (2H. m. phth C-H). 7.68 - 7.77 (2H. m, 
phth C-H). 7.33 (d. J = 8.1 Hz. 2H. 2-H and 6-H phenyl ring). 7.27 (dd. J 
= 8.8/8.8 Hz. 2H. 3-H and 5-H phenyl ring). 7.04 (dd. J = 7.5n.5 Hz, 1H, 
4-H phenyl ring). 6.69 (br s. 1 H, NH). 4.42 (t. J = 5.2 Hz. 2H. CH20). 
4.02 (t, J = 5.5 Hz. 2H. NCH2). 
13C NMR (CDCb): 6 168.32 (phth C=O). 153.17 (carbamate C=O), 
137.72 (phenyl 1-C). 134.23, 123.55 (phth C-H). 132.12 (phth 4° C), 
129.14 (phenyl 3-C and 5-C). 123.71 (phenyl 4-C). 118.90 (phenyl 2-C 
and 6-C). 62.55 (CH20). 37.48 (NCH2). 
mlz: HRMS (TOF ES+) C17H1SN204 [MHt calcd 311.1026; found 
311.1014. 
2-Aminoethyl phenylcarbamate hydrochloride (103) 
H Phthalimide deprotection of 2-
e ® ~ o o NU) 
CI H3N I( I phthalimidoethyl phenylcarbamate (102) 
o .0-
(348 mg. 1.13 mmol) was carried out as 
described for 1-(2-hydroxyphenyl)-3-(2-phthalimidoethyl)urea (69a) to 
give 180 mg of white solid requiring no further purification. 
Yield: 74 %. 
Mp: 176 - 180°C. 
IR: 3361 (br. carbamate N-H. str). 3012 (br. NH3+. str). 1711 
(carbamate C=O. str). 1601 (aryl, str). 760, 688 (aryl C-H, bend. phenyl 
ring). 
1H NMR (DMSO-d,): 6 9.73 (s. 1H, C=ONH), 8.26 (br s. 3H, NH3+), 
7.48 (d. J = 7.5 Hz. 2H. 2-H and 6-H phenyl ring). 7.28 (dd, J = 7.2n.2 
Hz, 2H. 3-H and 5-H phenyl ring). 7.00 (dd. J = 7.2n.2 Hz. 1 H. 4-H, 
phenyl ring). 4.29 (t. J = 5.6 Hz. 2H, CH20), 3.09 (dt. J = 5.6/5.2 Hz, 2H, 
NH3+CH2). 
13C NMR (DMSO-d,): 6 153.10 (C=O). 138.89 (4° C). 128.75, 122.57, 
118.29 (phenyl C-H), 60.70 (CH20). 38.19 (NH3+CH2). 
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mlz: HRMS (TOF ES+) C9H13N202 [MHr calcd 181.0972; found 
181.0971. 
tert-Butyl 2-hydroxyethylcarbamate (104) 
Ethanolamine (100) (4.940 mL, 81.86 mmol) was 
Soc, ~ O H H~ ~ dissolved in water (75 mL) and THF (35 mL). To this 
was added Boc20 (19.650 g, 90.05 mmol, 1.1 eq) and the mixture 
stirred at room temperature overnight. After removal of THF in vacuo, 
the aqueous slurry was extracted with DCM (3 x 30 mL). The organic 
layer was concentrated to give 13.077 g of clear colourless oil. 
Yield: 99%. 
IR: 3360 (O-H, str) , 2978, 2934 (alkyl C-H, str), 1689 (carbamate C=O, 
str) , 1527 (carbamate-amide 11* N-H bend), 1393, 1367 (C(CH3h, str) , 
1252, 1173 (C-O. str). *nomenclature derived from hydrogen-bonded 
and non-hydrogen bonded bands shown with amides. 
1H NMR: 6 5.18 (br s, 1H. OH). 3.64 (dt, J = 5.5/4.9 Hz, 2H. CH20H). 
3.26 - 3.35 (br m, 1H. NH), 3.23 (dt, J = 5.1/5.1 Hz, 2H, NHCH2), 1.40 
(s. 9H. (CH3h). 
13C NMR: 0 156.91 (C=O). 79.67 (Boc 40 C), 62.31 (CH20H), 43.17 
(NHCH2). 28.46 «CH3h)· 
mlz: HRMS (TOF ES+) C7H1SN03 [MHt calcd 162.1125; found 
162.1129. 
tert-Butyl 2-(2-phenylacetoyloxy)ethylcarbamate (105) 
S o c ' N ~ O ~ ~ telt-Butyl 2-hydroxyethylcarbamate (104) was 
H 0 V reacted with phenyl acetyl chloride as 
described in the procedure for telt-butyl 2-(2-
phenylacetamido)ethylcarbamate (88). The desired ester was 
recovered as 4.895 g of a yellow crystalline solid. 
Yield: 94%. 
Mp: 53 - 55 °C. 
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IR: 3399 (carbamate N-H, str), 2980, 2934, 2902 (alkyl C-H, str) , 1730, 
(ester C=O, str) , 1716 (carbamate C=O, str) , 1522 (aryl, str) , 1366 
(C(CH3)J, str) , 1251, 1162 (ester C-O, str) , 762, 709 (aryl C-H bend, 
phenyl ring). 
1H NMR: () 7.24 - 7.37 (m, 5H, aromatic C-H), 4.72 (br s, 1 H, NH), 4.14 
(t, J = 5.3 Hz, 2H, CH20), 3.64 (s, 2H, (C=O)CH2), 3.32 - 3.40 (br m, 
2H, NHCH2), 1.44 (s, 9H, (CH3)J). 
13C NMR: () 171.61 (C=O, ester), 155.85 (C=O, carbamate), 133.93 
(aryl 4 0 C), 129.31 (aryl 2-C and 6-C), 128.74 (aryl 3-C and 5-C), 
127.30 (aryl 4-C), 79.66 (Soc 40 C), 64.08 (CH20), 41.34 «C=O)CH2), 
39.70 (NHCH2), 28.46 «CH3h). 
mlz: HRMS (TOF ES+) C1sH22N04 [MHt calcd 280.1543; found 
280.1537. 
2-Aminoethyl 2-phenylacetate hydrochloride (106) 
tert-Butyl 2-(2-phenylacetoyloxy)ethyl 
e c ± > ~ o r o oCI H3N I carbamate (105) was Boc-deprotected in a 
o ~ ~
similar fashion to phenyl-2-(tert-
butyloxycarbonyl)aminoethylcarbamate (86) as described in the method 
for phenyl 2-aminoethylcarbamate hydrochloride (87), to give 3.260 g of 
the desired hydrochloride salt as a beige crystalline solid. 
Yield: 91%. 
Mp: 81 - 83 DC. 
IR: 3059 (br, NH3+, str) , 1748 (ester C=O, str), 1216, 1145 (ester C-O, 
str), 754, 704 (aryl C-H bend, phenyl ring). 
1H NMR (DMSO-ds): () 8.30 (br s, 3H, NH3+), 7.19 - 7.42 (m, 5H, 
aromatic C-H), 4.25 (t, J = 4.9 Hz, 2H, CH20) , 3.74 (s, 2H, (C=O)CH2), 
3.07 (br s, 2H, C H ~ H 3 + ) . .
13C NMR (DMSO-ds): () 171.11 (C=O), 134.15 (aryl 4 0 C), 129.51(aryl 
2-C and 6-C), 128.30 (aryl 3-C and 5-C), 126.84 (aryl 4-C), 60.76 
(CH20), 46.00 «C=O)CH2), 37.72 (CH2NH3+). 
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mlz: HRMS (TOF ES+) C1OH14N02 [MHt calcd 180.1019; found 
180.1031. 
Pyridinium 3-phthalimidopropane-1-sulfonate (108) 
o 
/'0.. ./"'0... II e PhthN- '-./' -$-0 
II 
o 
(t) 3-Aminopropane sulfonic acid (107) (1.045 
H 
N g. 7.51 mmol) and phthalic anhydride (1.112 0= // g. 7.51 mmol. 1 eq) were dissolved in 
pyridine (20 mL) and refluxed at 120°C for 2 hours. Removal of 
pyridine in vacuo and subsequent trituration of the crude solid with 
Et20. gave 2.369 9 of white crystalline solid. 
Yield: 91%. 
Mp: 110-112 DC. 
IR: 3068 (pyridinium N-H. str). 2981. 2940, 2877 (alkyl C-H. str). 1718 
(phth C=O. str). 1613. 1544 (aryl, str) , 1395, 1032 (sulfonate C-O. str). 
756 (phth C-H bend), 770. 721 (pyridinium C-H, bend). 
1H NMR (DMSO-d6): l) 8.93 (d, J = 5.1 Hz, 2H, pyridinium 2-H and 6-H), 
8.57 (dddd, J = 7.8n.8/1.6/1.6 Hz, 1H, pyridinium 4-H), 8.05 (dd, J = 
7.8/6.6 Hz. 2H. pyridinium 3-H and 5-H), 7.78 - 7.89 (m, 4H, phth C-H), 
3.62 (t. J = 7.4 Hz, 2H. NCH2), 2.44 - 2.54 (m, 3H, C H ~ 0 3 - , , NH), 1.89 
(tt, J = .4n.4 Hz. 2H, CH2CH£H2). 
13C NMR (DMSO-d6): l) 167.90 (phth C=O), 145.72 (pyridinium 4-C), 
142.63 (pyridinium 2-C and 6-C), 134.30 (phth C-H). 131.59 (phth 4° C), 
127.03 (pyridinium 3-C and 5-C), 122.94 (phth C-H), 49.05 (CH2S03-), 
37.02 (NCH2), 24.50 (CH2CH2CH2). 
mlz: HRMS (TOF ES+) C11H12N05S [MHt calcd 270.0431; found 
270.0404. 
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1-(2-Phenoxyethylamino)-3-(4-(2-
(cyclopentyloxy)ethoxy)phenoxy)propan-2-o1 (11 Oa) 
Experimental 
2-«4-(2-(Cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane (62) (50 mg, 
0.18 mmol) and 2-phenoxyethylamine (47 ~ L , , 0.36 mmol, 2 eq) were 
dissolved in propan-2-o1 (3 mL) before heating under reflux overnight. 
After removal of all solvent in vacuo, the crude residue was purified via 
PLC (eluent 37% aq NH;VMeOH/DCM 2:5:93) to give 51 mg of white 
solid. 
Yield: 68 %. 
Mp: 155 - 157 DC. 
IR: 3406 (O-H, str), 2930, 2864 (alkyl C-H, str) , 1507 (aryl, str), 1109 
(C-O, str), 762, 695 (aryl C-H bend, phenyl ring). 
1H NMR: l) 7.29 (dd, J = 8.7n.5 Hz, 2H, phenoxy 3-H and 5-H), 6.96 
(dd, J = 7.4n.4 Hz, 1H, phenoxy 4-H), 6.91 (d, J = 7.7 Hz, 2H, phenoxy 
2-H and 6-H), 6.80 - 6.86 (m, 4H, aryl-dioxy ring), 3.91 - 4.11 (m, 8H, 
O C H 2 C H ~ A r , , N H C H 2 C H ~ A r , , A r O C H ~ H , , CH(OH), cPe CH), 3.72 (t, 
J = 5.2 Hz, 2H, cPeOCH2), 3.06 (t, J = 5.1 Hz, 2H, NHCH2CH20Ar), 
2.94 (dd, J = 12.1/3.9 Hz. 1H, CH(OH)CH2NH), 2.84 (dd, J = 12.2n.9 
Hz. 1 H. C H ( O H ) C H ~ H ) , , 1.44 - 1.84 (m, 8H, cPe CH2). 
1lC NMR: l) 158.87 (phenoxy 1-C), 153.49. 153.04 (aryl-dioxy 4D C), 
129.64 (phenoxy 3-C and 5-C), 121.07 (phenoxy 4-C), 115.83, 115.55 
(aryl-dioxy C-H), 114.63 (phenoxy 2-C and 6-C), 82.10 (CPe CH), 71.17 
(ArOCH2CH(OH», 68.57, 68.36 (NHCH2CH20Ar, CH(OH», 67.44 
(CPeOCH2). 67.32 (CPeOCH2CH2), 51.76 (CH(OH)CH2NH), 48.93 
(NHCH2CH2). 32.41 (2-C and 5-C cPe ring), 23.68 (3-C and 4-C cPe 
ring). 
mlz: HRMS (TOF ES+) C24H34NOs [MHt calcd 416.2431; found 
416.2456. 
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HPLC Rt : 4.47 (System 1b), 12.64 (System 3). 
1-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-phenylthiourea (11 Ob) 
Experimental 
2-«4-(2-(Cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane (62) (50 mg, 
0.18 mmol) was opened with 1-(2-aminoethyl)-3-phenylthiourea 
hydrochloride (91) according to the method described for 1-(2-(3-(4-(2-
(cyclopentyloxy)ethoxy)phenoxy)-2-hydroxypropylamino)ethyl)-3-(2-
hydroxyphenyl)urea (71t). Purification via PLC (eluent 37% aq 
NH:YMeOHIOCM 1 :5:94) afforded 31 mg of white semi-solid. 
Yield: 18 %. 
IR: 3283 (O-H, str), 2931, 2869 (alkyl C-H, str), 1508 (aryl, str), 1315 
(thiourea, str), 1110 (C=S, str), 810 (aryl C-H, bend, para-disubstituted 
ring), 765, 695 (aryl C-H bend, phenyl ring). 
1H NMR (DMSO-d.): 0 9.66 (br s, 1H, NH(C=S)NHAr), 7.73 (br s, 1H, 
NH(C=S)NHAr), 7.42 (d, J = 8.1 Hz, 2H, 2-H and 6-H phenyl ring), 7.29 
(dd, J = 7.417.4 Hz, 2H, 3-H and 5-H phenyl ring), 7.08 (dd, J = 7.417.4 
Hz, 1H, 4-H phenyl ring), 6.84 (s, 4H, aryl-dioxy ring), 4.99 (br s, 1H, 
OH), 3.75 - 4.03 (m, 6H, C H ~ A r , , CPe CH, CH(OH), ArOCH2), 3.62 (t, J 
= 4.9 Hz, 2H, CPeOCH2), 3.55 (br s, 2H, NHCH2CH2), 2.75 (t, J = 6.3 
Hz, 2H, N H C H ~ H 2 ) , , 2.67 - 2.73 (m, 1H, CH(OH)CH2NH), 2.61 (dd, J = 
11.8/5.9 Hz, 1H, CH(OH)CHzNH), 1.39 -1.76 (m, 8H, cPe CH2). 
13C NMR (DMSO-d.): 0 180.26 (C=S), 152.72, 152.50 (aryl-dioxy 4° C), 
141.37 (phenyl 1-C), 128.58 (phenyl 3-C and 5-C), 128.54 (phenyl 2-C 
and 6-C), 124.00 (phenyI4-C), 115.34 (aryl-dioxy C-H), 80.83 (CPe CH), 
71.18 (ArOCH2), 68.03 (CH(OH», 67.72 (CH20 Ar), 66.71 (CPeOCH2), 
52.00 (CH(OH)CH2NH), 51.10 (NHCH2CH2), 43.68 (NHCH2CH2), 31.78 
(2-C and 5-C cPe ring), 23.10 (3-C and 4-C cPe ring), 
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mlz: HRMS (TOF ES+) C25H36N304S [MHr calcd 474.2421; found 
474.2433. 
HPLC Rt : 4.25 (System 1b). 12.02 (System 3). 
N-(2-(3-(4-(2-(Cyelopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-benzylsulfonamide (11 Oe) 
2-«4-(2-(Cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane (62) (50 mg. 
0.18 mmol) was opened with N-(aminoethyl)benzylsulfonamide 
hydrochloride (93) according to the method described for 1-(2-(3-(4-(2-
(cyclopentyloxy)ethoxy)phenoxy)-2-hydroxypropylamino)ethyl)-3-(2-
hydroxyphenyl)urea (71t). Purification via PLC (eluent 37% aq 
NHYMeOHIDCM 1 :5:94) afforded 79 rng of white solid. 
Yield: 45 %. 
Mp: 104 - 106 °C. 
IR: 3296 (sulfonamide N-H. str) , 3239 (O-H, str) , 2958, 2929, 2868 
(alkyl C-H, str). 1510 (aryl. str). 1352, 1159 (sulfonamide. str) , 1119 (C-
O-C. str) , 827 (aryl C-H, bend, para-disubstituted ring), 764, 697 (aryl 
C-Hbend.phenylring) 
1H NMR (DMSO-d.): 6 7.29 - 7.43 (m, 5H, C-H, phenyl ring), 6.84 (s, 
4H, aryl-dioxy ring). 4.94 (br s, 1H, OH), 4.33 (s, 2H, S02CH2), 3.74 -
4.02 (m. 6H, CH;PAr, cPe CH, CH(OH), ArOCH2), 3.62 (t, J = 4.9 Hz, 
2H. cPeOCH2). 2.97 (t, J = 6.5 Hz, 2H, C H ~ H S 0 2 ) , , 2.52 - 2.69 (m, 4H, 
N H C H ~ H 2 , , C H ( O H ) C H ~ H ) , , 1.40-1.77 (m, 8H, cPe CH2). 
13C NMR (DMSO-d.): 6 152.75, 152.48 (aryl-dioxy 4° C), 130.78 
(phenyl 2-C and 6-C), 130.46 (phenyl 1-C), 128.25 (phenyl 3-C and 5-
C), 127.88 (phenyl 4-C). 115.33, 115.30 (aryl-dioxy C-H), 80.83 (CPe 
CH). 71.17 (ArOCH2), 68.20 (CH(OH», 67.71 (CH20Ar), 66.71 
(CPeOCH2), 57.20 (S02CH2), 52.07 (CH(OH)CH2NH), 49.35 
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(NHCH2CH2), 42.69 (NHCH2CH2), 31.77 (2-C and 5-C cPe ring), 23.10 
(3-C and 4-C cPe ring). 
mlz: HRMS (TOF ES+) C2sH37N20 6S [MHt calcd 493.2367; found 
493.2419. 
HPLC Rt : 4.39 (System 1b), 12.05 (System 3). 
2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl phenylcarbamate (110d) 
2-«4-(2-(Cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane (62) (50 mg, 
0.18 mmol) was opened with 2-aminoethyl phenylcarbamate 
hydrochloride (103) according to the method described for 1-(2-(3-(4-(2-
(cyclopentyloxy)ethoxy)phenoxy)-2-hydroxypropylamino)ethyl)-3-(2-
hydroxyphenyl)urea (71t). Purification via PLC (eluent 37% aq 
NHJlMeOH/DCM 1 :5:94) afforded 66 mg of white solid. 
Yield: 40 %. 
Mp: 94 - 96 ac. 
IR: 3315 (O-H/N-H, str) , 2957, 2926, 2871 (alkyl C-H, str) , 1705 
(carbamate C=O, str) , 1539 (carbamate-amide 11*, N-H bend), 1509 
(aryl, str) , 1092 (C-O, str) , 824 (aryl C-H, bend, para-disubstituted ring), 
765, 691 (aryl C-H bend, phenyl ring). *nomenclature derived from 
hydrogen-bonded and non-hydrogen bonded bands shown with amides. 
1H NMR (DMSO-ds): ~ ~ 9.64 (s, 1H, carbamate NH), 7.46 (d, J = 7.3 Hz, 
2H, 2-H and 6-H phenyl ring, 7.26 (dd, J = 7.317.3 Hz. 2H, 3-H and 5-H 
phenyl ring), 6.99 (dd, J = 7.317.3 Hz, 1 H, 4-H phenyl ring), 6.84 (5, 4H, 
aryl-dioxy CH), 4.99 (br s, 1 H, OH), 4.14 (t, J = 5.7 Hz, 2H, CH20C=O), 
3.76 - 4.00 (m, 6H, CH20Ar, cPe CH, CH(OH), ArOCH2), 3.61 (t. J = 
4.8 Hz, 2H, cPeOCH2), 2.82 (t, J = 5.7 Hz, 2H, NHCH2CH20), 2.71 {dd, 
210 
Experimental 
J = 11.9/3.8 Hz, 1 H, CH(OH)CH2), 2.61(dd, J = 11.5/6.1 Hz, 1H, 
CH(OH)CH2), 1.41 - 1.75 (m, 8H, cPe CH2). 
13C NMR (DMSO-d6): (5 153.56 (C=O), 152.72, 152.48 (aryl-dioxy 4° C), 
139.18 (phenyI1-C), 128.68 (phenyI3-C and 5-C), 122.25 (phenyI4-C), 
118.11 (phenyl 2-C and 6-C), 115.32 (aryl-dioxy C-H), 80.82 (CPe CH), 
71.16 (ArOCH2), 68.18 (CH(OH», 67.70 (CH20Ar), 66.70 (CPeOCH2), 
63.87 (NHCH2CH20), 52.30 (CH(OH)CH2NH), 48.20 (NHCH2CH2), 
31.77 (2-C and 5-C cPe ring), 23.10 (3-C and 4-C cPe ring). 
mlz: HRMS (TOF ES+) C2sH3SN20S [MHt calcd 459.2490; found 
459.2128. 
HPLC Rt : 4.47 (System 1b), 12.64 (System 3). 
4-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino)-N-phenylbutanamide hydroformate (11 Oe) 
Q o ~ o ~ ~ . HCo,H 
~ O ~ N ~ ~ ~ ~
OH H 0 V 
2-«4-(2-(Cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane (62) (50 mg, 
0.18 mmol) was opened with 3-(phenylcarbamoyl)propylammonium 
trifluoroacetate (97) according to the method described for 1-(2-(3-(4-(2-
(cyclopentyloxy)ethoxy)phenoxy)-2-hydroxypropylamino )ethyl)-3-(2-
hydroxyphenyl)urea (71t). Purification via PLC (eluent 37% aq 
NHJlMeOH/DCM 2:8:90) and preparative HPLC afforded 19 mg of white 
semi-solid. 
Yield: 23 %. 
IR: 3419 (amide N-H, str) , 2955, 2868 (alkyl C-H, str) , 1662 (amide I, 
C=O str), 1509 (aryl, str), 1560 (amide II, N-H bend), 1111 (C-O, str), 
757 (aryl C-H bend, phenyl ring). 
1H NMR (DMSO-d6): (5 9.83 (s, 1 H, amide NH), 8.28 (br s, 2H, NH2 +), 
7.58 (d, J = 7.6 Hz, 2H, phenyl 2-H and 6-H), 7.27 (dd, J = 7.817.8 Hz, 
2H, phenyl 3-H and 5-H), 7.01 (dd, J = 7.417.4 Hz, 1H, phenyI4-H), 6.84 
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(s, 4H, aryl-dioxy CH), 3.98 (t, J = 4.8 Hz, 2H, CH20Ar), 3.78 - 3.96 (m, 
4H, ArOCH2, CH(OH), cPe CH), 3.62 (t, J = 4.9 Hz, 2H, cPeOCH2), 2.76 
(dd, J = 11.9/4.1 Hz, 1 H, CH(OH)CH2), 2.61 - 2.69 (m, 3H, 
CH{OH)CH2, NHCH2), 2.36 (t, J = 7.4 Hz, 2H, CH2C=O), 1.72 - 1.82 
(m, 2H, CH2CH2CH2), 1.41 -1.72 (m, 8H, cPe CH2). 
13C NMR (OMSO-ds): 6 170.95 (C=O), 152.66, 152.57 (aryl-dioxy 4 0 C), 
139.30 (phenyl 1-C), 128.63 (phenyl 3-C and 5-C), 122.95 (phenyI4-C), 
119.04 (phenyl 2-C and 6-C), 115.36 (aryl-dioxy C-H), 80.85 (CPe CH), 
71.01 (ArOCH2), 67.73 (CH20Ar), 67.20 (CH{OH)), 66.72 (CPeOCH2), 
51.60 (CH(OH)CH2NH), 48.28 (NHCH2), 33.97 (CH2C=O), 31.79 (2-C 
and 5-C cPe ring), 24.26 (CH2CH2CH2), 23.12 (3-C and 4-C cPe ring). 
mlz: HRMS (TOF ES+) C26H37N20S [MHt calcd 457.2697; found 
457.2716. 
HPLC Rt : 4.30 (System 1b), 12.44 (System 3). 
N-(2-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino )ethyl)-2-phenylacetamide 
(110f) 
hydroformate 
2-({4-{2-(Cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane (62) (55 mg, 
0.20 mmol) was opened with 2-{2-phenylacetamido)ethylammonium 
trifluoroacetate (89) according to the method described for 1-(2-(3-(4-(2-
(cyclopentyloxy)ethoxy)phenoxy)-2-hydroxypropylamino)ethyl)-3-(2-
hydroxyphenyl)urea (71t). Purification via PLC (eluent 37% aq 
NHJlMeOH/DCM 2:8:90) and preparative HPLC afforded 15 mg of white 
semi-solid. 
Yield: 16 %. 
IR: 3441 (amide N-H, str), 2956, 2870 (alkyl C-H, str) , 1652 (amide I, 
C=O str), 1510 (aryl, str), 1539 (amide II, N-H bend), 1123 (C-O, str), 
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820 (aryl C-H, bend, para-disubstituted ring), 699 (aryl C-H bend, 
phenyl ring). 
1H NMR (DMSO-d6): ~ ~ 8.08 (br s, 1H, amide NH), 7.17 - 7.32 (m, 5H, 
phenyl CH), 6.85 (s, 4H, aryl-dioxy CH), 3.98 (t, J = 4.8 Hz, 2H, 
CH20Ar), 3.90 - 3.96 (m, 1H, cPe CH), 3.77 - 3.90 (m, 3H, ArOCH2, 
CH(OH», 3.62 (t, J = 4.9 Hz, 2H, cPeOCH2), 3.40 (s, 2H, C=OCH2), 
3.12 - 3.20 (m, 2H, CH2NHC=O), 2.56 - 2.77 (m, 4H, CH(OH)CH2NH, 
CH2NHCH2), 1.41 - 1.76 (m, 8H, cPe CH2). 
13C NMR (DMSO-d6): ~ ~ 170.17 (C=O), 152.71, 152.52 (aryl-dioxy 4° C), 
136.44 (phenyl 1-C), 128.95, 128.15 (phenyl 2-C, 3-C, 5-C, 6-C), 
126.25 (phenyl 4-C), 115.33 (aryl-dioxy C-H), 80.83 (CPe CH), 71.10 
(ArOCH2), 67.72 (CH20Ar, CH(OH», 66.71 (CPeOCH2), 51.85 
(CH(OH)CH2NH), 48.46 (CH2NHCH2), 42.36 (C=OCH2), 38.45 
(CH2NHC=O), 31.77 (2-C and 5-C cPe ring), 23.10 (3-C and 4-C cPe 
ring). 
mlz: HRMS (TOF ES+) C2SH37N20S [MHt calcd 457.2697; found 
457.2688. 
HPLC Rt : 4.20 (System 1b), 12.14 (System 3). 
1-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropyl)pyrrolidin-2-one hydroformate (113a) 
Q o ~ o ~ ~
~ o ~ ~ , \ \
OH f-I 
o 
2 -( (4-(2-( Cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane (62) was 
reacted with phenyl 4-aminobutanoate hydrochloride (99) under 
microwave conditions as described in the method for 1-(2-(3-(4-(2-
(cyclopentyloxy)ethoxy)phenoxy)-2-hydroxypropylamino)ethyl)-3-(3-
f1uor0-4-hydroxyphenyl)urea hydroformate (85a). Isolation of the major 
peak by preparative HPLC gave 10 mg of the title compound as white 
semi-solid. The desired phenyl 4-(3-(4-(2-
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(cyclopentyloxy)ethoxy)phenoxy)-2-hydroxypropylamino )butanoate 
(112a) was not isolated. 
Yield: 7%. 
IR: 3329 (O-H, str), 2933, 2870 (alkyl C-H, str), 1658 (Iactam C=O, str), 
1513 (aryl, str), 1025 (C-O-C, str), 828 (aryl C-H, bend, para-
disubstituted ring). 
1H NMR (DMSO-ds): ~ ~ 6.82 - 6.87 (m, 4H, aryl-dioxy C-H), 5.16 (d, J = 
5.4 Hz, 1H, OH), 3.98 (t, J = 4.7 Hz, 2H, CH20Ar) 3.90 - 3.96 (m, 2H, 
cPe CH, CH(OH», 3.74 - 3.83 (m, 2H, ArOCH2), 3.62 (t, J = 4.7 Hz, 2H, 
cPeOCH2), 3.37 - 3.49 (m, 2H, CH(OH)CH2NCH2), 3.28 - 3.36 (m, 1 H, 
CH(OH)CH2N), 3.23 (dd, J = 13.117.3 Hz, 1H, CH(OH)CH2N), 2.20 (t, J 
= 8.0Hz, 2H, (C=O)CH2), 1.90 (tt, J = 7.617.6 Hz, 2H, 
NCH2CH2CH2(C=O», 1.41 - 1.76 (m, 8H, cPe CH2). 
13C NMR (DMSO-ds): 6 174.26 (C=O), 152.61 (aryl-dioxy 4° C), 115.39, 
115.36 (aryl-dioxy C-H), 80.83 (CPe CH), 71.02 (ArOCH2), 67.71 
(CH20Ar), 67.10 (CH(OH», 66.70 (CPeOCH2), 47.92 
(CH(OH)CH2NCH2), 45.75 (CH(OH)CH2N), 31.77 (2-C and 5-C cPe 
ring), 30.34 (CHiC=O», 23.10 (3-C and 4-C cPe ring), 17.72 
(NCH2CH2CH2(C=O». 
mlz: HRMS (TOF ES+) C20H30N05 [MHt calcd 364.2118; found 
364.2124. 
1-(3-(4-(2-(Cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropyl)imidazolidin-2-one 
hydroformate (113b) 
2-«4-(2-(Cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane (62) was 
reacted with phenyl 2-aminoethylcarbamate hydrochloride (87) under 
microwave conditions as described in the method for 1-(2-(3-(4-(2-
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(cyclopentyloxy)ethoxy)phenoxy)-2-hyd roxypropylamino )ethyl)-3-( 3-
fluoro-4-hydroxyphenyl)urea hydroformate (85a). Isolation of the major 
peak by preparative HPLC gave 9 mg of the title compound as white 
semi-solid. The desired phenyl 2-(3-(4-(2-(cyclopentyloxy)ethoxy) 
phenoxy)-2-hydroxypropylamino)ethylcarbamate (112b) was not 
isolated. 
Yield: 6%. 
IR: 3390 (O-H, str), 2956, 2871 (alkyl C-H, str), 1667 (imidazolidinone 
C=O, str), 1509 (aryl, str) , 1040 (C-O-C, str), 821 (aryl C-H, bend, para-
disubstituted ring). 
1H NMR (DMSO-ds): ~ ~ 6.83 - 6.87 (m, 4H, aryl-dioxy C-H), 6.30 (br s, 
1 H, NH), 5.15 (d, J = 5.0 Hz, 1 H, OH), 3.98 (t. J = 4.6 Hz, 2H, CH20Ar) 
3.85 - 3.96 (m, 2H, cPe CH, CH(OH», 3.73 - 3.85 (m, 2H, ArOCH2), 
3.62 (t, J = 4.6 Hz, 2H, cPeOCH2), 3.35 - 3.49 (m, 2H, 
CH(OH)CH2NCH2), 3.16 - 3.26 (m, 3H, CH(OH)CH2N, CH2NH(C=O», 
3.07 (dd, J = 13.6/6.8 Hz, 1H, CH(OH)CH2N), 1.41 - 1.76 (m, 8H, cPe 
CH2). 
13C NMR (DMSO-de): ~ ~ 162.53 (C=O), 152.66, 152.56 (aryl-dioxy 4° C), 
115.37,115.33 (aryl-dioxy C-H), 80.83 (CPe CH), 70.94 (ArOCH2), 67.88 
(CH(OH», 67.68 (CH20Ar), 66.71 (CPeOCH2), 46.93 (CH(OH)CH2N), 
46.13 (CH(OH)CH2NCH2), 37.58 (CH2NH(C=O», 31.77 (2-C and 5-C 
cPe ring), 23.12 (3-C and 4-C cPe ring). 
m/z: HRMS (TOF ES+) C19H29N205 IMHt calcd 365.2071; found 
365.2090. 
2-(4-Fluorophenethyloxy)acetlc acid (115) 
F NaH 60% suspension in mineral oil (2.400 g, ~ O - ' l r 0 H H equivalent to 1.440 9 of NaH, 60 mmol, 2 eq) 
o was weighed into a flame-dried flask and 
suspended in dry DMF (60 mL) with stirring, under a nitrogen 
atmosphere. To this was added 4-fluorophenethyl alcohol (114) (4.205 
g, 3.751 mL, 30 mL) and the temperature was raised to 60°C with 
stirring for 15 minutes. Chloroacetic acid (2.835 g, 30 mmol, 1 eq) was 
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added to the flask and the mixture allowed to stir at 60°C for a further 
2.5 hours. After cooling and removal of solvent, the residue was 
suspended in Et20 (30 mL) and extracted with water (2 x 30 mL). The 
combined aqueous layers were acidified with aqueous 2 M HCI (to 
around pH 3) before extraction with EtOAc (3 x 30 mL). After removal 
of solvent, the crude solid was recrystallised from cyclohexane to yield 
3.000 g of pink crystals. 
Yield: 50%. 
Mp: 84 - 86°C (lit. 82 - 85 °C)98. 
IR: 2964, 2893 (alkyl C-H, str), 2772, 2677, 2571 (O-H, str, carboxylic 
acid), 1733 (carboxylic acid), 1510 (aryl, str), 1137 (C-F, str) , 1103 (C-
O-C, str), 840 (aryl C-H, bend, para-disubstituted ring), 770 (C-F, 
weak). 
1H NMR: is 8.5 - 10.4 (br s, 1H, C02H), 7.19 (dd, J = 8.6/5.7 Hz, 2H, 
aryl 3-H and 5-H), 6.99 (dd, J = 8.6/8.6 Hz, 2H, aryl 2-H and 6-H), 4.12 
(s, 2H, CH2C02H), 3.76 (t, J = 6.8 Hz, 2H, CH20), 2.92 (t. J = 6.8 Hz, 
2H, ArCH2). 
m/z: HRMS (TOF ES-) C10H10F03 [M-Hr calcd 197.0619; found 
197.0629. 
2-(4-Fluorophenethyloxy)ethanol (116) 
F Lithium aluminium hydride (472 mg, 12.45 ~ ~ ~ O H H mmol, 1 eq) was suspended in anhydrous 
o THF (15 mL) over ice with stirring. 2-(4-
fluorophenethyloxy)acetic acid (115) (2.467 g, 12.45 mmol) in 
anhydrous THF (15 mL) was slowly dripped in the suspension over 10 
minutes and the resulting mixture stirred overnight at room temperature 
under a nitrogen atmosphere. After quenching carefully with water, the 
suspension was filtered (gravity) and the filtrate concentrated to an oil. 
Purification was achieved by FCC (eluent EtOAc/hexanes 60:40), 
yielding 1.52 g of clear, colourless oil. 
Yield: 67%. 
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IR: 3417 (br, O-H, str) , 2922, 2870 (alkyl C-H, str), 1510 (aryl, str), 1117 
(C-O-C, str), 830 (aryl C-H, para-disubstituted ring). 
1H NMR: ~ ~ 7.15 (dd, J = 8.6/5.5 Hz, 2H, aryl 3-H and 5-H), 6.95 (dd, J = 
8.8/8.8 Hz, 2H, aryl 2-H and 6-H), 3.65 - 3.72 (m, 2H, CH20H), 3.65 (t, 
J = 7.0 Hz, 2H, ArCH2CH2), 3.53 (t, J = 4.8 Hz, 2H, OCH2CH20H), 2.85 
(t, J = 7.0 Hz, 2H, ArCH2), 2.38 (br s, 1H, OH). 
mlz: HRMS (TOF ES-) C11H14F04 [M+HC02r calcd 229.0882; found 
229.0883. 
2-(2-(Cyclopropylmethoxy)ethoxy)-tetrahydro-2H-pyran (118) 
o 0 NaH 60% suspension in mineral oil (6.659 g, 
V o ~ ~D equivalent to 3.995 g of NaH, 0.166 mol, 1.2 
eq) was weighed into a flame-dried flask and 
washed with hexanes (2 x 50 mL) under nitrogen atmosphere. 
Residual hexanes were allowed to evaporate under nitrogen flow before 
suspending the NaH in dry THF and cooling to 0 DC. 
Cyclopropylmethanol (117) (10.000 g, 0.139 mol) was dissolved in dry 
THF (20 mL) and dry DMF (30 mL) before adding dropwise over 30 
minutes to the suspended NaH with stirring. The mixture was brought 
to room temperature before dropwise addition of 2-
chloroethoxytetrahydro-2H-pyran (30.71 mL 0.208 mol 1.5 eq) in dry 
THF (20 mL) over 30 minutes. The mixture was stirred at room 
temperature overnight before quenching with MeOH (20 mL). All 
solvents were removed before dissolving the residue in EbO (200 mL) 
and washing with water (2 x 150 mL) and brine (150 mL). After removal 
of solvent, the resulting crude oil was purified by FCC (eluent OCM) to 
give 5.878 g of colourless oil. 
Yield: 21%. 
IR: 2941, 2869 (alkyl C-H, str) , 1124 (C-O-C, str). 
1H NMR: (54.65 (t, J = 3.6 Hz, 1 H, CH THP group), 3.85 - 3.90 (m, 2H, 
OCH2 THP group, THPOCH2), 3.59 - 3.67 (m, 3H, THPOCH2, 
CH20CH2CPr), 3.48 - 3.53 (OCH2 THP group), 3.34 (dd, J = 24.2/6.9 
Hz, 1H, OCH2CPr), 3.34 (dd, J = 6.9/3.5 Hz, 1H, OCH2CPr), 1.49 - 1.86 
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(m, 6H, 3 x CH2 THP group), 1.02 - 1.12 (m, 1 H, cPr CH), 0.51 - 0.55 
(m, 2H, cPr CH2), 0.19 - 0.26 (m, 2H, cPr CH2)*. *Refers to cis-protons 
of cPr ring. 
13C NMR: 0 98.88 (CH THP group), 75.92 (OCH2CPr), 69.65 
(CH20CH2CPr), 66.66 (THPOCH2), 62.16 (OCH2 THP group), 30.53 
(OCHCH2 THP group), 25.41 (OCH2CH2 THP group), 19.46 (OCH 
CH2CH2 THP group), 10.54 (CPr CH), 3.00, 2.91 (CPr CH2). 
m/z: HRMS (TOF ES+) C11H21 03 [MHt calcd 201.1485; found 
201.1488. 
2-(Cyclopropylmethoxy)ethanol (119) 
~ O ~ O H H 2-(2-(Cyclopropylmethoxy)ethoxy)-tetrahydro-2H-
V pyran (118) (1.800 g, 8.99 mmol) was diluted in 
EtOH (60 mL). PPTS (226 mg, 0.90 mmol, 0.1 eq) in EtOH (15 mL) 
was added and the solution stirred at 55°C for 4 hours. Excess solvent 
was removed and on dilution of the residue with PE/Et20 (15:85), PPTS 
precipitated out. Following filtration of PPTS the remaining crude 
product was purified by FCC (eluent pet ether 40o-60°C/Et20 15:85) to 
afford 670 mg of colourless oil. 
Yield: 79%. 
IR: 3409 (br, O-H, str) , 3081 (CPr C-H, str) , 2865 (alkyl C-H, str), 1430 
(C-H, deformation (def», 1117 (C-O-C, str), 1070 (C-OH, str). 
1H NMR: 6 3.73 - 3.77 (m, 2H, CH20H), 3.58 (t, J = 4.9 Hz, 2H, 
CH2CH20H), 3.33 (d, J = 7.2 Hz, 2H, cPrCH20), 2.06 (t, J = 6.6 Hz, 1 H, 
OH), 1.08 (m, 1H, CH), 0.53 - 0.58 (m, 2H, cPr CH2)*, 0.20 - 0.24 (m, 
2H, cPr CH2)*. *Refers to cis-protons of cPr ring. 
13C NMR: 6 75.98 (CPrCH20), 71.48 (OCH2CH20H), 61.87 (CH20H), 
10.53 (CH CPr), 2.95 (CPr CH2). 
m/z: HRMS (TOF ES+) CeH12Na02 [MNar calcd 139.0730; found 
139.0745. 
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1-(2-( 4-Fluorophenethyloxy)ethyloxy)-4-(benzyloxy)benzene (1228) 
F ~ ~ 2-(4-Fluorophenethyloxy)ethanol 
~ o ~ O U U (116) was reacted with 4-
~ ~ I (benzyloxy)phenol as described in 
OSn 
the method for 1-(2-
(cyclopentyloxy)ethoxy)-4-(benzyloxy)benzene (60). After work-up, the 
organic layer was concentrated and purified by FCC (eluent 
EtOAc/hexanes 15:85) to give 999 mg of white crystalline solid. 
Yield: 35%. 
Mp: 59 - 61 °c. 
IR: 2864, 2929 (alkyl C-H, str) , 1509 (aryl, str), 1119 (C-O-C, str). 827 
(aryl C-H, bend, para-disubstituted ring), 739, 698 (aryl C-H, bend, 
phenyl ring). 
1H NMR: ~ ~ 7.30 - 7.45 (m, 5H, aromatic benzyl CH), 7.19 (dd, J = 
8.6/5.5 Hz, 2H, 3-H and 5-H of f1uorophenyl ring), 6.97 (dd, J = 8.8/8.8 
Hz, 2H, 2-H and 6-H of f1urophenyl ring), 6.91, 6.85 (d, J = 9.2 Hz, 2 x 
2H, para-disubstituted aryl-dioxy ring), 5.02 (s, 2H, PhCH20), 4.06 (t, J 
= 4.7 Hz, 2H, CH20ArOBn), 3.78 (t, J = 4.7 Hz, 2H, CH2CH20ArOBn), 
3.72 (t, J = 7.1 Hz, 2H, FCsH4CH2CH20), (t, J = 7.1 Hz, 2H, FCeH .. CH2) 
13C NMR: 0 161.64 (JCF = 244.1 Hz, CF), 153.26 (2 x 4 0 C, aryl-dioxy 
ring), 137.38 (4 0 benzyl C), 134.69 (JCF = 3.0 Hz, 4-C f1uorophenyl ring), 
130.44 (JCF = 7.7 Hz, 3-C and 5-C f1uorophenyl ring), 128.68, 128.02, 
127.61 (benzyl CH), 115.77, 115.90 (CH aryl-dioxy ring), 115.22 (JCF = 
20.8 Hz, 2-C and 6-C f1uorophenyl ring), 72.48 (FCsH4CH2CH20), 70.78 
(benzyl CH2), 69.63 (CH2CH20ArOBn), 68.19 (CH20ArOBn), 35.55 
(FCsH4CH2). 
m/z: HRMS (TOF ES+) C23H24F03 [MHr calcd 367.1704; found 
367.1698. 
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1-( (4-(2-Ethoxyethoxy)phenoxy)methyl)benzene (122b) 
2-Ethoxyethanol (120) was reacted with 4-
. / ' - o ~ o U U (benzyloxy)phenol as described in the 
OBn method for 1-(2-(cyclopentyloxy)ethoxy)-4-
(benzyloxy)benzene (60). DEAD was used instead of DBAD as the 
azodicarboxylate. After work-up, the organic layer was concentrated 
and purified by FCC (eluent EtOAc/hexanes 20:80) to give 2.314 g of 
white crystalline solid. 
Yield: 85%. 
Mp: 32.5 - 34.5 °C (lit: 35 - 37 °C)180. 
IR: 2975, 2925, 2864 (alkyl C-H, str), 1509 (aryl, str) , 1126 (C-O-C, 
str) , 826 (aryl C-H, bend, para-disubstituted ring), 732, 693 (aryl C-H, 
bend, phenyl ring). 
1H NMR: ~ ~ 7.25 - 7.32 (m, 5H, aromatic benzyl CH), 6.90, 6.86 (d, J = 
9.2 Hz, 2 x 2H, para-disubstituted aryl ring), 5.01 (s, 2H, PhCH20), 4.07 
(t, J = 4.9 Hz, 2H, CH20ArOBn), 3.77 (t, J = 4.9 Hz, 2H, 
CH2CH20ArOBn), 3.60 (q, J = 7.0 Hz, 2H, CH3CH20), 1.24 (1. J = 7.0 
Hz, 3H CH3)' 
13C NMR: ~ ~ 153.32, 153.21 (4° aryl C), 137.40 (4° benzyl C), 128.67, 
128.01, 127.62 (benzyl CH), 115.86, 115.75 (aryl CH), 70.77 (benzyl 
CH2), 69.20, 68.21, 66.96 (CH20), 15.31 (CH3). 
m/z: HRMS (TOF ES+) C17H2103 [MHr calcd 273.1485; found 
273.1506. 
1-(2-(Cyclopropylmethoxy)ethoxy)-4-(benzyloxy)benzene (122c) 
~ o o Method A V O ~ ~~ O B n n 2-(Cyclopropylmethoxy)ethanol (119) was 
reacted with 4-(benzyloxy)phenol as described in the method for 1-(2-
(cyclopentyloxy)ethoxy)-4-(benzyloxy)benzene (60). DEAD was used 
instead of DBAD as the azodicarboxylate. After work-up, the organic 
layer was concentrated and purified by FCC (eluent EtOAclhexanes 
15:85) to give 843 mg of white waxy solid. 
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Yield: 82%. 
MethodS 
1-«4-(2-(Allyloxy)ethoxy)phenoxy)methyl)benzene (122d) (2.000 g, 
7.03 mmol) underwent Simmons-Smith cyclopropanation as described 
for 5-(2-(allyloxy)ethoxy)-2-(4-methoxybenzyloxy)benzonitrile (SO) in the 
synthesis of 5-(2-( cyclopropylmethoxy)ethoxy)-2 -( 4-methoxybenzyloxy) 
benzonitrile (51). After overnight stirring, the reaction was quenched 
with aqueous saturated ammonium chloride solution (100 mL), before 
extraction with OCM (3 x 50 mL). The combined organic extracts were 
washed with aqueous saturated NaHC03 solution (1 x 30 mL) and 
water (1 x 30 mL). After removal of solvent in vacuo, the residue was 
passed through a silica plug (eluent EtOAc) to remove inorganic 
impurities. Concentration of these washings gave 2.044 g of yellow 
crystalline solid. 
Yield: 97%. 
Mp: 30.5 - 32.5 °c 
IR: 2920, 2862 (alkyl C-H, str) , 1509 (aryl, str), 1137, 1114 (C-O-C, str), 
827 (aryl C-H, bend, para-disubstituted ring), 732, 693 (aryl C-H, bend, 
phenyl ring). 
1H NMR: 67.33 - 7.45 (m, 5H, aromatic benzyl CH), 6.95, 6.91 (d, J = 
9.2 Hz, 2 x 2H, para-disubstituted aryl ring), 5.01 (s, 2H, PhCH20), 4.10 
(t, J = 5.0 Hz, 2H, CH20ArOBn), 3.82 (t, J = 5.0 Hz, 2H, 
CH2CH20ArOBn) 3.42 (d, J = 6.8 Hz, 2H, cPrCH20) 1.10 - 1.20 (m, 1 H, 
CH), 0.54 - 0.66 (m, 2H, cPr CH2)*, 0.23 - 0.34 (m, 2H, cPr CH2)*. 
*Refers to cis-protons of cPr ring. 
13C NMR: 6 153.30,153.19 (4° aryl C), 137.39 (4° benzyl C), 128.67, 
128.47, 128.00 (benzyl CH), 115.85, 115.73 (aryl CH), 76.36 
(CPrCH20), 70.76 (benzyl CH2), 69.09 (CH2CH20ArOBn), 68.20 
(CH2CH20Ar), 10.69 (CPr CH), 3.18 (CPr CH2). 
m/z: HRMS (TOF ES+) C19H2303 [MHt calcd 299.1642; found 
299.1636. 
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1-((4-(2-(Allyloxy)ethoxy)phenoxy)methyl)benzene (122d) 
HA 2-Allyloxyethanol (121) was reacted 
H B Y O ~ 0 Y ' l l l with 4-(benzyloxy)phenol in similar 
He ~ O B n n conditions as described for 1-(2-
(cyclopentyloxy)ethoxy)-4-(benzyloxy)benzene (60). DIAD was used in 
the place of DBAD. The desired product was obtained as 4.021 g of 
white crystalline solid, after purification by FCC (eluent Et20/PE 25:75). 
Yield: 71%. 
Mp: 35 - 38°C. 
IR: 3064 (alkene C-H, str), 2928, 2863 (alkyl C-H, str), 1510 (aryl, str), 
1115 (C-O-C, str) , 919 (alkene C-H, deformation), 826 (aryl C-H, bend, 
para-disubstituted ring), 735, 694 (aryl C-H, bend, phenyl ring). 
1H NMR: 6 7.31 - 7.51 (m, 5H, aromatic benzyl C-H), 6.95, 6.91 (d, J = 
9.1/1.9 Hz, 2 x 2H, para-disubstituted aryl ring), 5.93 - 6.06 (m, 1 H, Hc), 
5.37 (d, J = 17.2 Hz, 1H, HA), 5.26 (d, J = 10.2 Hz, 1H. He). 5.04 (s. 2H, 
benzyl CH2), 4.07 - 4.17 (m, 4H, CH20Ar, CH2=CHCH2), 3.81 (t. J = 4.3 
Hz, 2H, allyl-OCH2). 
13C NMR: 6 153.19, 153.13 (aryl-dioxy 4° C), 137.31 (benzyl 4° C). 
134.66 (CH2=CH). 128.52 (aromatic benzyl 3-C and 5-C). 127.84 
(aromatic benzyl 4-C), 127.45 (aromatic 2-C and 6-C), 117.19 
(CHrCH), 115.77, 115.62 (aryl-dioxy C-H), 72.30 (CH2=CHCH2). 70.59 
(benzyl CH2), 68.63, 68.06 (OCH2CH20). 
m/z: HRMS (TOF ES+) C1sH2103 [MHr calcd 285.1485; found 
285.1490. 
4-(2-(4-Fluorophenethyloxy)ethyloxy)phenol (1238) 
F 1-(2-(4-~ ~ 0 Fluorophenethyloxy)ethyloxy)-4-~ o ~ Y ' I l l~ ~ (benzyloxy)benzene (1228) was 
OH hydrogenated according to the 
procedure for synthesis of 4-(2-(cyclopentyloxy)ethoxy}phenol (61). 
After filtration over celite and evaporation of volatiles, no further workup 
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was required and the desired compound was isolated in quantitative 
yield as clear oil. 
Yield: 100%. 
IR: 3366 (br, O-H, str), 2925, 2871 (alkyl C-H, str), 1510 (aryl, str), 1222 
(C-F), 1121 (C-O-C, str) , 828 (aryl C-H, bend, para-disubstituted ring), 
738 (C-F) 
1H NMR: (S 7.18 (dd, J = 8.6/5.5 Hz, 2H, 3-H and 5-H of f1uorophenyl 
ring), 6.96 (dd, J = 8.8/8.8 Hz, 2H, 2-H and 6-H of f1urophenyl ring), 
6.74, 6.76 (d, J = 9.2 Hz, 2 x 2H, para-disubstituted phenol), 6.00 (br s, 
1H, OH), 4.05 (t, J = 4.7 Hz, 2H, CH20Ar), 3.80 (t, J = 4.9 Hz, 2H, 
CH2CH20Ar), 3.75 (t, J = 7.2 Hz, 2H, FCsH4CH2CH20), 2.90 (t, J = 7.1 
Hz, 2H, FCsH4CH2). 
13C NMR: (S 161.59 (JCF = 245.0 Hz, CF), 152.64, 150.08 (4° C, aryl-
dioxy ring), 134.43 (JCF = 3.1 Hz, 4-C f1uorophenyl ring), 130.40 (JCF = 
8.0 Hz, 3-C and 5-C f1uorophenyl ring), 116.19, 115.92 (CH phenolic 
ring), 115.19 (JCF = 21.1 Hz, 2-C and 6-C f1uorophenyl ring), 72.48 
(FCsH4CH2CH20), 69.58 (CH2CH20Ar), 68.13 (CH20Ar), 35.34 
(FCsH4CH2). 
m/z: HRMS (TOF ES-) C1sH1SF03 [M-Hr calcd 275.1089; found 
275.1090. 
4-(2-Ethoxyethoxy)phenol (123b) 
o 1-( (4-(2-Ethoxyethoxy)phenoxy)methyl) / ' O ~ ~ ~~ ~ benzene (122b) (904 mg, 3.32 mmol) was 
OH dissolved in EtOH (60 mL) before 
hydrogenating over 10% Pd/C (168 mg) at room temperature and 
atmospheric pressure for 48 hours. The suspension was filtered over 
celite and washed with excess EtOH. Removal of excess solvent gave 
viscous amber oil. The crude oil was dissolved in OCM (20 mL) and 
washed with aqueous 2 M NaOH solution (3 x 20 mL). The combined 
aqueous extracts were acidified with concentrated HCI (until the pH was 
below 7) to effect an emulsion, before extracting with OCM (3 x 30 mL). 
The combined organic layers were washed with water (1 x 30 mL) and 
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brine (1 x 30 mL). Solvent removal afforded 413 mg of clear, colourless 
oil. 
Yield: 68%. 
IR: 3365 (br, O-H, str), 2976, 2873 (alkyl C-H, str), 1602, 1511 (aryl, 
str), 1105 (C-O-C, str), 826 (aryl C-H, bend, para-disubstituted ring). 
1H NMR: ~ ~ 6.81, 6.74 (d, J = 9.0 Hz, 2H, aryl-H), 4.57 (br s, 1 H OH); 
4.06 (t, J = 4.9 Hz, 2H, CH20Ar), 3.77 (t, J = 4.9 Hz, 2H, CH2CH20Ar), 
3.60 (q, J = 7.0 Hz, 2H, CH3CH20), 1.24 (t, J = 7.0 Hz, 3H eH3).'32 
13e NMR: ~ ~ 152.54, 150.05 (4° aryl e), 116.12, 115.80 (aryl CH). 
69.11, 68.03, 66.99 (CH20). 15.06 (eH3). 
m/z: HRMS (TOF ES-) e10H'303 [M-Hr calcd 181.0870; found 
181.0890. 
4-(2-(eyclopropylmethoxy)ethoxy)phenol (123c) 
~ o ~ O ~ ~ 1-(2-(Cyclopropylmethoxy)ethoxy)-4-
V ~ ~ (benzyloxy)benzene (122c) (840 mg. 2.82 
OH 
mmol) was hydrogenated according to the 
method for 4-(2-(cyclopentyloxy)ethoxy)phenol (61). After 4 hours of 
stirring, the suspension was filtered over celite and washed with excess 
EtOH. Excess solvent was removed to give amber oil. The crude oil 
was purified by FCC (eluent EtOAclhexanes 30170) to give 508 mg of 
colourless oil. 
Yield: 100%. 
IR: 3367 (br. O-H, str), 2873 (alkyl C-H. str), 1510 (aryl. str), 1448 (C-H, 
def), 1101 (C-O-C, str). 826 (aryl C-H, bend, para-disubstituted ring). 
1H NMR: ~ ~ 6.72 - 6.77 (m. 4H. aryl-H). 5.70 - 5.50 (br s, 1H, OH). 4.06 
(t, J = 5.0 Hz. 2H CH20Ar). 3.81 (t. J = 5.0 Hz. 2H. C H ~ H 2 0 A r ) . . 3.40 
(d, J = 6.8 Hz, 2H, cPrCH20), 1.07 - 1.11 (m, 1 H, cPr CH), 0.48 - 0.60 
(m, 2H, cPr CH2)*, 0.17 - 0.28 (m. 2H, cPr CH2)*. *Refers to cis-protons 
of cPr ring. 
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13C NMR: 6 152.69, 149.90 (4° aryl C), 116.07, 115.76 (aryl CH), 76.38 
(CPrCH20), 69.02 (CH2CH20Ar), 68.05 (CH20Ar), 10.50 (CPr CH), 3.14 
(CPr CH2). 
m/z: HRMS (TOF ES") C12H1 503 [M-Hr calcd 207.1027; found 
207.1026. 
2-«4-(2-(4-Fluorophenethyloxy)ethyloxy)phenoxy)methyl)oxlrane 
(124a) 
NaH 60% suspension in 
mineral oil (13 mg, equivalent 
to 7.8 mg of NaH. 0.33 mmol, 
1.1 eq) was suspended in dry 
DMF (2 mL) with stirring, under a nitrogen atmosphere. To this was 
added 4-(2-(4-fluorophenethyloxy)ethyloxy)phenol (123a) (82 mg, 0.30 
mmol) in dry OMF (4 mL) and stirred until no further hydrogen gas 
evolution was visible. rac-Epichlorohydrin (800 ~ L . . 10.22 mmol, 34 eq) 
was added and the reaction stirred overnight at room temperature. The 
reaction mixture was diluted with water (30 mL) before extraction with 
Et20 (3 x 30 mL). The combined organic extracts were concentrated 
before purification over a silica plug (initial wash with hexanes, followed 
by EtOH/OCM 5:95) to give 70 mg of clear yellow oil. 
Yield: 71%. 
IR: 3051 (epoxide C-H, str, weak), 2871, 2923 (alkyl C-H, str), 1508 
(aryl, str) , 1229 (C-F), 1124 (C-O-C, str), 827 (aryl C-H, bend, para-
disubstituted ring). 
1H NMR: 6 7.19 (dd, J = 8.6/5.6 Hz, 2H, 3-H and 5-H of f1uorophenyl 
ring), 6.96 (dd, J = 8.8/8.8 Hz, 2H, 2-H and 6-H of flurophenyl ring), 6.85 
(s, 4H, aryl-dioxy ring), 4.17 (dd, J= 11.1/3.2 Hz, 1H, ArOCH2CH), 4.06 
(t, J = 4.7 Hz, 2H, CH20Ar) , 3.90 (dd, J = 11.0/5.7 Hz, 1 H, ArOCH2CH), 
3.78 (t, J = 4.9 Hz, 2H, CH2CH20Ar), 3.72 (t, J = 7.1 Hz, 2H, 
FC6H4CH2CH20), 3.32 - 3.35 (m, 1 H, epoxide CH), 2.89 (t, J = 7.1 Hz, 
2H, FC6H4CH2), 2.87 - 2.91 (m, 1H, epoxide CH2), 2.74 (dd, J = 4.912.7 
Hz, 1 H, epoxide CH2). 
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13C NMR: ~ ~ 162.58 (JCF = 243.7 Hz, CF), 153.43, 152.92 (4° C, aryl-
dioxy ring), 134.66 (JCF = 3.4 Hz, 4-C fluorophenyl ring), 130.40 (JCF = 
7.9 Hz, 3-C and 5-C fluorophenyl ring), 115.71 (CH aryl-dioxy ring), 
115.39 (JCF = 21.1 Hz, 2-C and 6-C fluorophenyl ring), 72.40 
(FCeH4CH2CH20), 69.54, 69.56 (CH2CH20Ar, ArOCH2CH), 68.11 
(CH20Ar), 50.34 (epoxide CH), 44.77 (epoxide CH2), 35.49 
(FCsH4CH2). 
m/z: HRMS (lOF ES+) C19H22F04 [MHt calcd 355.1316; found 
355.1315. 
2-( (4-(2-Ethoxyethoxy)phenoxy)methyl)oxlrane (124b) 
~ o ~ o ~ ~ 4-(2-Ethoxyethoxy)phenol (123b) (413 
~ ~ mg, 2.27 mmol) was dissolved in 
°v aqueous 2 M NaOH solution (4.0 mL) 
and stirred for 10 minutes. rac-Epichlorohydrin (533 ~ L , , 6.81 mmol, 3 
eq) was added and the mixture stirred at 60°C for 24 hours. The 
cooled mixture was extracted with OCM (3 x 20 mL) and the organic 
layers combined. After solvent removal, the product purified by FCC 
(eluent Et20) to give 417 mg of colourless oil. 
Yield: 84%. 
IR: 2975, 2927, 2872 (alkyl C-H, str) , 1508 (aryl, str), 1231 (epoxide C-
C, str) , 1122 (C-O-C, str), 826 (aryl C-H, bend, para-disubstituted ring). 
1H NMR: ~ ~ 6.83 - 6.88 (m, 4H, para-disubstituted aryl ring), 4.17 (dd, J 
= 11.2/3.2 Hz, 1 H, ArOCH2CH), 4.07 (t, J = 4.9 Hz, 2H, CH20Ar), 3.91 
(dd, J = 10.08/5.6 Hz, 1H, ArOCH2CH), 3.77 (t, J = 4.9 Hz, 2H, 
CH2CH20Ar), 3.60 (q, J = 7.0 Hz, 2H, CH3CH20), 3.34 (m, 1 H, epoxide 
CH), 2.89 (dd, J = 5.0/4.0 Hz, 1H, epoxide CH2), 2.74 (dd, J = 5.012.6 
Hz, 1H, epoxide CH2), 1.25 (t, J = 7.0 Hz, 3H, CH3). 
13C NMR: ~ ~ 153.41,152.79 (4° aryl C), 115.63, 115.60 (aryl CH), 69.45 
(ArOCH2CH), 69.05 (C2H50CH2), 68.06 (CH20Ar), 66.84 (CH3CH20), 
50.27 (epoxide CH), 44.74 (epoxide CH2), 15.18 (CH3). 
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m/z: HRMS (TOF ES+) C13H1904 [MHt calcd 239.1278; found 
239.1262. 
2-((4-(2-(Cyclopropylmethoxy)ethoxy)phenoxy)methyl)oxlrane 
(124c) 
4-(2-(Cyclopropylmethoxy)ethoxy) V o ~ ° Y ' ) ) phenol (123c) (450 mg, 2.16 mmol) ~ o ~ o o
V was dissolved in aqueous 2 M NaOH 
solution (1.5 mL) and stirred for 10 minutes. rsc-Epichlorohydrin (507 
IJL, 6.481 mmol, 3 eq) was added and the mixture stirred at 60°C for 24 
hours. The cooled mixture was extracted with OCM (3 x 25 mL) and the 
organic layers combined. After solvent removal, the product purified by 
FCC (eluent EtOAc/hexanes 30:70) to give 356 mg of colourless oil. 
Yield: 62%. 
IR: 3080 (epoxide C-H, str) , 2926, 2872 (alkyl C-H, str), 1508 (aryl, str), 
1230 (epoxide C-C, str), 1113 (C-O-C, str) , 826 (aryl C-H, bend, psrs-
disubstituted ring). 
1H NMR: ~ ~ 6.83 (s, 4H, aryl CH), 4.15 (dd, J = 11.0/3.2 Hz, 1 H, 
ArOCHzCH), 4.06 (t, 4.9 Hz, 2H, CH20Ar) , 3.88 (dd, J = 11.0/5.7 Hz, 
1 H, ArOCH2CH), 3.78 (t, J = 5.0 Hz, 2H, CH2CH20Ar), 3.36 (d, J = 6.8 
Hz, 2H, cPrCH20), 3.29 - 3.33 (m, 1 H, epoxide CH), 2.87 (dd, J = 
4.8/4.3 Hz, 1H, epoxide CH2), 2.72 (dd, J = 4.9/2.7 Hz, 1H, epoxide 
CH2), 1.05 -1.10 (m, 1H, cPr CH), 0.51 - 0.55 (m, 2H, cPr CH2)*, 0.19-
0.22 (m, 2H, cPr CH2)*. *Refers to cis-protons of cPr ring. 
13C NMR: ~ ~ 153.48, 152.86 (4 0 aryl C), 115.68 (aryl CH), 76.32 
(CPrCH20), 69.53 (ArOCH2CH), 69.05 (CH2CH20Ar), 68.14 (CH20Ar), 
50.35 (epoxide CH), 44.80 (epoxide CH2), 10.66 (CPr CH), 3.16 (CPr 
CH2). 
m/z: HRMS (TOF ES+) C1sH21 04 [MHt calcd 265.1434; found 
265.1407. 
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1-(2-(3-(4-(2-(4-Fluorophenethyloxy)ethyloxy)phenoxy)-2-
hydroxypropylamino )ethyl)-3-(4-hydroxyphenyl)urea (125a) 
2-( (4-(2 -( 4-Fluorophenethyloxy)ethyloxy)phenoxy)methyl)oxirane (124a) 
was opened with 1-(2-aminoethyl)-3-(4-hydroxyphenyl)urea (56) as 
described in the general procedure for synthesis of aromatically 
su bstituted 1-(2 -(3-( 4-(2 -( cyclopentyloxy)ethoxy)phenoxy)-2 -hyd roxy 
propylamino)ethyl)-3-(aryl)ureas. 
Yield: 25%. 
Mp: 113 - 115°C. 
IR: 3308 (br, O-H, str), 2926, 2868 (alkyl C-H, str), 1636 (urea C=O, 
str), 1510, 1572 (aryl, str), 1229 (C-F), 1120 (C-O-C, str), 831 (aryl C-H, 
bend, para-disubstituted ring). 
1H NMR (DMSO-ds): ~ ~ 8.92 (br s, 1H, phenol), 8.22 (s, 1H, 
NH(C=O)NHAr), 7.28 (dd, J = 8.3/5.8 Hz, 2H, 3-H and 5-H of 
fluorophenyl ring), 7.14 (d, J = 8.8 Hz, 2H, aryl C-H ortho to urea), 7.08 
(dd, J = 8.9/8.9 Hz, 2H, 2-H and 6-H of f1urophenyl ring), 6.82, 6.85 (d. J 
= 9.3 Hz, 2 x 2H, aryl-dioxy ring), 6.62 (d, J = 8.8 Hz, 2H, aryl C-H ortho 
to phenol), 6.03 (t, J = 5.2 Hz, 1 H, NH(C=O)NHAr), 5.01 (br s, 1 H, NH), 
3.99 (t, J = 4.3 Hz, 2H, CH20Ar), 3.78 - 3.93 (m, 3H, CH(OH), 
ArOCH2), 3.69 (t, J = 4.3 Hz, 2H, CH2CH20Ar), 3.64 (t, J = 6.9 Hz, 2H, 
FCsH4CH2CH20), 3.11 - 3.19 (m, 2H, NHCH2CH2), 2.81 (t. J = 6.8 Hz, 
2H, FCsH4CH2), 2.58 - 2.76 (m, 4H, CH(OH)CH2NH, NHCH2CH2). 
13C NMR (DMSO-ds): ~ ~ 160.80 (JCF = 241.3 Hz, CF), 155.70 (C=O), 
152.76, 152.47,151.88,132.12, (aryl 4° C), 135.18 (JCF = 3.2 Hz, 4-C 
fluorophenyl ring). 130.59 (JCF = 7.8 Hz, 3-C and 5-C fluorophenyl ring). 
119.28 (aryl C-H ortho to urea), 115.33, 115.36 (CH aryl-dioxy ring), 
115.06 (aryl C-H ortho to phenol), 114.84 (JCF = 21.0 Hz, 2-C and 6-C 
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f1uorophenyl ring), 71.21 (FC6H4CH2CH20, ArOCH2), 68.71 
(CH2CH20Ar), 67.99 (CH(OH», 67.49 (CH20Ar), 51.13 
(CH(OH)CH2NH), 49.35 (NHCH2CH2), 39.05 (NHCH2CH2), 34.56 
(FC6H4CH2). 
m/z: HRMS (TOF ES+) C2sH3sFN30e [MHt calcd 528.2510; found 
528.2514. 
HPLC Rt: 3.47 (System 1b), 11.50 (System 3). 
1-(2-(3-(4-(2-Ethoxyethoxy)phenoxy)-2-hydroxypropylamlno)ethyl)-
3-(4-hydroxyphenyl)urea (125b) 
/'-o/'-..../°Y') ~ o - " Y ' ~ ~ ~ ' ( ~ ~ ~
OH ° ~ O H H
2-«4-(2-Ethoxyethoxy)phenoxy)methyl)oxirane (124b) was opened with 
1-(2-aminoethyl)-3-(4-hydroxyphenyl)urea (56) as described in the 
general procedure for synthesis of aromatically substituted 1-(2-(3-(4-
(2-(cyclopentyloxy)ethoxy)phenoxy)-2-hydroxypropylamin0)ethyl)-3-
(aryl)ureas. 
Yield: 21%. 
Mp: 96 - 98°C. 
IR: 3336 (br, O-H, str) , 2926, 2866 (alkyl C-H, str), 1636 (urea C=O, 
str), 1513, 1574 (aryl, str), 1123 (C-O-C, str) , 819, 835 (aryl C-H, bend, 
para-disubstituted ring). 
1H NMR (MeOD-d4): l) 7.12 (d, J = 8.9 Hz, 2H, aryl C-H ortho to urea), 
6.87 (d, J = 9.0 Hz, 2H, aryl-dioxy ring), 6.84 (d, J = 9.0 Hz, 2H, aryl-
dioxy ring), 6.70 (d, J = 8.9 Hz, 2H, aryl C-H ortho to phenol), 4.01 -
4.08 (m, 1 H, CH(OH», 4.03 (t, J = 4.6 Hz, 2H, CH20ArO), 3.87 - 3.95 
(m, 2H, ArOCH2CH(OH», 3.75 (t, J = 4.7 Hz, 2H, OCH2CH20ArO), 3.59 
(q, J = 7.0 Hz, 2H, CH3CH2), 3.34 (t, J = 6.1 Hz, 2H, CH2CH2NH), 2.74 
- 2.90 (m, 4H, CH(OH)CH2NH, NHCH2CH2), 1.21 (t. J = 7.0 Hz, 3H, 
CH3). 
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1lC NMR (MeOD-d4): l) 159.22, 154.63, 154.60, 132.32 (aryl 4° C), 
123.56 (aryl C-H ortho to urea), 116.59, 116.55 (CH aryl-dioxy ring), 
116.34 (aryl C-H ortho to phenol), 72.38 (ArOCH2), 70.29 
(CH2CH20Ar), 69.65 (CH(OH», 69.14 (CH20Ar), 67.72 (CHlCH2) 
52.94 (CH(OH)CH2NH), 50.55 (NHCH2CH2), 40.26 (NHCH2CH2), 14.40 
(CH3). 
m/z: HRMS (TOF ES+) C22H32NlOS [MHt calcd 434.2286; found 
434.2291; (TOF ES") C22HlONlOS [M-Hr calcd 432.2140; found 
432.2134. 
HPLC Rt : 2.29 (System 1b), 8.72 (System 2). 
1-(2-(3-(4-(2-(Cyclopropylmethoxy)ethoxy)phenoxy)-2-
hydroxypropylamino)ethyl)-3-(4-hydroxyphenyl)urea 
(12Sc) 
formate 
2-( (4-(2-(Cyclopropylmethoxy)ethoxy)phenoxy)methyl)oxirane (124c) 
was opened with 1-(2-aminoethyl)-3-(4-hydroxyphenyl)urea (56) as 
described in the general procedure for synthesis of aromatically 
su bstituted 1-(2-(3-(4-(2 -( cyclopentyloxy)ethoxy)phenoxy)-2-hydroxy 
propylamino )ethyl)-3-( aryl)ureas. 
Yield: 21%. 
Mp: semi-solid. 
IR: 3307 (br, O-H, str) , 2929, 2870 (alkyl C-H, str) , 1634 (urea C=O, 
str), 1509, 1570 (aryl, str), 1111 (C-O-C, str), 830 (aryl C-H, bend, para-
disubstituted ring). 
1H NMR (MeOD-d4): l) 7.09 - 7.16 (m, 2H, aryl C-H ortho to urea), 6.90 
(d, J = 9.0 Hz, 2H, aryl-dioxy ring), 6.86 (d, J = 9.4 Hz, 2H, aryl-dioxy 
ring), 6.70 (d, J = 9.3 Hz, 2H, aryl C-H ortho to phenol), 4.18 - 4.27 (m, 
1 H, CH(OH», 4.05 (t, J = 4.6 Hz, 2H, CH20ArO) , 4.00 (dd, J = 9.8/4.9, 
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1H, ArOCH2CH(OH)), 3.95 (dd, J = 9.8/5.3, 1H, ArOCH2CH(OH», 3.79 
(t, J = 4.7 Hz, 2H, OCH2CH20ArO), 3.51 (t, J = 5.3 Hz, 2H, 
CH2CH2NH), 3.37 (d, J = 6.9 Hz, 2H, cPrCH20), 3.28 - 3.35, 3.15 -
3.24 (m, 4H, CH(OH)CH2NH, NHCH2CH2), 1.01 -1.13 (m, 1H, cPr CH), 
0.50 - 0.57 (m, 2H, cPr CH2)*, 0.19 - 0.26 (CPr CH2)*. *Refers to cis-
protons of cPr ring. 
13C NMR (MeOD-d4): 6 159.81,154.90,154.20,132.28,131.90 (aryl 4° 
C), 123.71 (aryl C-H ortho to urea), 116.65, 116.64 (CH aryl-dioxy ring), 
116.38 (aryl C-H orthoto phenol), 77.11 (CPrCH20), 71.78 (ArOCH2), 
70.18 (CH2CH20Ar), 69.17 (CH20Ar), 66.81 (CH(OH», 51.54, 50.69 
(CH(OH)CH2NH, NHCH2CH2), 38.02 (NHCH2CH2), 11.36 (CPr CH), 3.47 
(CPr CH2). 
m/z: HRMS (TOF ES+) C24H34N306 [MHt calcd 460.2442; found 
460.2429. 
HPLC Rt : 2.88 (System 1 a), 9.84 (System 2). 
2-((Oxiran-2-yl)methoxy)benzonitrile (127a) 
o ~ o o 2-Hydroxybenzonitrile (126a) was alkylated with rae-
N C ~ ~ epichlorohydrin in a similar manner to 4-(2-
U (cyclopentyloxy)ethoxy)phenol (61) as described in the 
preparation of 2-« 4-(2-( cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane 
(62). Purification by FCC (eluent EtOAclhexanes 50:50) gave 623 mg 
of a pale yellow waxy solid. 
Yield: 21%. 
Mp: 62 - 64 °c (lit. 65 °C)143. 
IR: 3080 (epoxide C-H, str) , 2957,2931 (alkyl C-H, str), 2228 (CN, str), 
1599,1581,1494 (aryl, str), 1258 (epoxide C-O, str), 1112 (C-O-C), 752 
(aryl 1 ,2-disubstituted ring C-H, bend). 
1H NMR: 6 7.45 - 7.54 (m, 2H, aryl 4-H and 6-H), 6.93 - 7.03 (m, 2H, 
aryl 3-H and 5-H), 4.36 (dd, J = 11.4/2.6 Hz, 1 H, ArOCH2CH), 4.04 (dd, 
J = 11.4/5.3 Hz, 1H, ArOCH2CH), 3.33 - 3.89 (m, 1H, epoxide CH), 
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2.88 (dd, J = 4.7/4.4 Hz, 1 H, epoxide CH2), 2.81 (dd, J = 4.7/2.6 Hz, 1H, 
epoxide CH2). 
13C NMR: 5 160.01 (aryl 2-C), 134.45 (aryl 4-C), 133.69 (aryl 6-C), 
121.33 (aryl 5-C), 116.21 (CN), 112.63 (aryl 3-C), 101.97 (aryl 1-C), 
69.31 (ArOCH2), 49.82 (epoxide CH), 44.37 (epoxide CH2). 
mlz: HRMS (TOF ES+) C1oH10N02 [MHt calcd 176.0706; found 
176.0709. 
2-«2-chloro-5-methylphenoxy)methyl)oxirane (127b) 
~ I I 2-Chloro-5-methylphenol (126b) was alkylated with 
° \;0 C I ~ ~ rac-epichlorohydrin in a similar manner to 4-(2-
~ ~ (cyclopentyloxy)ethoxy)phenol (61) as described in the 
preparation of 2-« 4-(2-( cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane 
(62). Purification by FCC (eluent EtOAc/hexanes 20:80) gave 1.406 9 
of a pale yellow crystalline solid. 
Yield: 50%. 
Mp: 43 - 45°C. 
IR: 3064 (epoxide C-H, str) , 3017 (aryl C-H, str), 2929 (alkyl C-H, str), 
1585, 1493 (aryl, str), 1065 (C-O, str), 796 (C-CI, bend). 
1H NMR: 5 7.17 (d, J = 7.9 Hz, 1 H, aryl 3-H), 6.71 - 6.75 (m, 1 H, aryl 6-
H), 6.65 - 6.71 (m, 1H, aryl 4-H), 4.23 (dd, J = 11.2/2.9 Hz, 1H, 
ArOCH2CH) , 3.95 (dd, J = 11.3/5.5 Hz, 1 H, ArOCH2CH), 3.30 - 3.36 
(m, 1H, epoxide CH), 2.77 (dd, J = 4.7/4.4 Hz, 1H, epoxide CH2), 2.81 
(dd, J = 4.8/2.5 Hz, 1 H, epoxide CH2), 2.27 (s, 3H, CH3). 
13C NMR: 5 153.62 (aryl 1-C), 137.88 (aryl 5-C), 129.71 (aryl 3-C), 
122.58 (aryl 4-C), 119.83 (aryl 2-C), 114.85 (aryl 6-C), 69.57 (ArOCH2), 
49.96 (epoxide CH), 44.36 (epoxide CH2), 21.12 (CH3). 
m/z: HRMS (TOF ES+) C10H12CI02 [MHt calcd 199.0520; found 
199.0507. 
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1-(2-(2-Hydroxy-3-((2-cyano)phenoxy)propylamino)ethyl)-3-(3-
chlorophenyl)urea hydroformate (128a) 
H H 
O ~ N ~ N I ( N y y C I IN C ~ ~ OH H 0 V .HC02H 
V 
2-«Oxiran-2-yl)methoxy)benzonitrile (127a) was opened with 1-(2-
aminoethyl)-3-(3-chlorophenyl)urea hydrochloride (66k) according to 
the method described for 1-(2-(3-(4-(2-( cyclopentyloxy)ethoxy) 
phenoxy)-2 -hyd roxypropylamino )ethyl)-3-(2-hydroxyphenyl)urea (71 t). 
Purification via PLC (eluent 37% aq NHJlMeOH/DCM 1 :10:89) and 
preparative HPLC afforded 14 mg of white solid. 
Yield: 11%. 
Mp: 51 - 53°C. 
IR: 3394 (br, OH, str), 2228 (CN, str) , 1683 (urea C=O, str) , 1596, 1549 
(aryl, str) , 1111 (C-O-C, str) , 755 (C-CI, bend). 
1H NMR (DMSO-d&): ~ ~ 9.11 (s, 1 H, NH(C=O)NHAr), 8.26 (br s, 1 H, 
formate HC02-), 7.71 (dd, J = 7.5/1.6 Hz, 1H, cyanophenyl ring 3-H), 
7.67 (dd, J = 1.8/1.8 Hz, 1H, chlorophenyl ring 2-H), 7.64 (ddd, J = 
7.9n.9/1.5 Hz, 1H, cyanophenyl ring 5-H), 7.26 (d, J = 8.6 Hz, 1H, 
cyanophenyl ring 6-H), 7.21 (dd, J = 8.3/8.3 Hz, 1 H, chlorophenyl 5-H), 
7.18 (ddd, J = 8.3/1.8/1.8 Hz, 1H, chlorophenyl ring 6-H), 7.08 (ddd, J = 
7.5n.5/1.0 Hz, 1H, cyanophenyl ring 4-H), 6.91 (ddd, J = 7.5/2.0/2.0 Hz, 
1 H, chlorophenyl ring 4-H),6.63 (t, J = 5.2 Hz, 1 H, NH(C=O)NHAr), 4.07 
- 4.18 (m, 2H, ArOCH2), 3.97 - 4.06 (m, 1H, CH(OH», 3.23 (dt, J = 
5.8/5.8 Hz, 2H, NHCH2CH2), 2.87 (dd, J = 12.3/4.6 Hz, 1H, 
CH(OH)CH2NH), 2.72 - 2.81 (m, 3H, CH(OH)CH2NH, NHCH2CH2). 
13C NMR (DMSO-d6): ~ ~ 164.39 (formate C=O)160.20 (cyanophenyl ring 
1-C), 155.22 (C=O), 142.21 (chlorophenyl ring 1-C), 135.02 
(cyanophenyl ring 5-C), 133.66 (cyanophenyl ring 3-C), 133.04 
(chlorophenyl ring 3-C), 130.17 (chlorophenyl ring 5-C), 121.08 
(cyanophenyl ring 4-C), 120.45 (chlorophenyl ring 4-C), 116.89 
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(chlorophenyl ring 2-C), 116.41 (CN), 115.91 (chlorophenyl ring 6-C), 
113.17 (cyanophenyl ring 6-C), 100.64 (cyanophenyl ring 2-C), 71.30 
(ArOCH2), 66.96 (CH(OH)), 51.21 (CH(OH)CH2NH), 48.69 (NHCH2CH2), 
38.24 (NHCH2CH2). 
mlz: HRMS (TOF ES+) C19H22CIN403 [MHt calcd 389.1375; found 
389.1410. 
HPLC Rt : 3.65 (System 1b), 10.62 (System 3). 
1-(2-(3-(2-Chloro-5-methylphenoxy)-2-hydroxypropylamin0 )ethyl)-
3-(3-chlorophenyl)urea hydroformate (128b) 
2-«2-chloro-5-methylphenoxy)methyl)oxirane (127b) was opened with 
1-(2-aminoethyl)-3-(3-chlorophenyl)urea hydrochloride (66k) according 
to the method described for 1-(2-(3-(4-(2-(cyclopentyloxy)ethoxy) 
phenoxy)-2-hyd roxypropylamino )ethyl)-3-(2 -hyd roxyphenyl) urea (71 t). 
Purification via PLC (eluent 37% aq NH3I'MeOH/DCM 1: 1 0:89) and 
preparative HPLC afforded 16 mg of white solid. 
Yield: 14%. 
Mp: 43 - 45°C. 
IR: 3370 (br, OH, str) , 3070 (aryl C-H, str) , 1675 (urea C=O, str) , 1594, 
1550 (aryl, str), 1065 (C-O, str), 774 (C-CI, bend). 
1H NMR (DMSO-ds): 6 9.15 (s, 1H, NH(C=O)NHAr), 8.27 (br s, 1H, 
formate HCO£), 7.67 (dd, J = 2.111.1 Hz, 1H, chlorophenyl ring 2-H), 
7.26 (d, J = 8.0 Hz, 1 H, p-chlorotolyl ring 3-H), 7.22 (dd, J = 8.0/8.0 Hz, 
1H, chlorophenyl 5-H), 7.19 (ddd, J = 8.3/1.8/1.8 Hz, 1H, chlorophenyl 
ring 6-H), 6.98 (d, J = 1.4 Hz, 1 H, p-chlorotolyl ring 6-H), 6.91 (ddd, J = 
6.6/2.3/2.3 Hz, 1 H, chlorophenyl ring 4-H), 6.76 (ddd, J = 8.0/1.7/0.6 
Hz, 1H, p-chlorotolyl ring 4-H), 6.70 (t, J = 5.4 Hz, 1H, NH(C=O)NHAr), 
4.00 (br s, 3H, ArOCH2, CH(OH», 3.23 (dt, J = 5.9/5.7 Hz, 2H, 
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NHCH2CH2), 2.87 (dd, J = 11.9/3.7 Hz, 1H, CH(OH)CH2NH), 2.72 -
2.82 (m, 3H, CH(OH)CH2NH, NHCH2CH2), 2.28 (s, 3H, CH3). 
13C NMR (DMSO-d6): 6 164.52 (formate C=O), 155.24 (C=O), 153.56 
(p-chlorotolyl ring 1-C), 142.24 (chlorophenyl ring 1-C), 138.06 (p-
chlorotolyl ring 5-C), 133.03 (chlorophenyl ring 3-C), 130.16 
(chlorophenyl ring 5-C), 129.40 (p-chlorotolyl ring 3-C), 122.06 (p-
chlorotolyl ring 4-C), 120.42 (chlorophenyl ring 4-C), 118.31 (p-
chlorotolyl ring 2-C), 116.88 (chlorophenyl ring 2-C), 115.90 
(chlorophenyl ring 6-C), 114.71 (p-chlorotolyl ring 6-C), 71.19 (ArOCH2), 
67.03 (CH(OH», 51.44 (CH(OH)CH2NH), 48.67 (NHCH2CH2), 38.22 
(NHCH2CH2), 20.83 (CH3). 
mlz: HRMS (TOF ES+) C19H24CI2N303 [MHt calcd 412.1189; found 
412.1157. 
HPLC Rt : 4.20 (System 1b), 12.78 (System 3). 
1-(2-(2-Hyd roxy -3-phenoxypropylam ina )ethyl)-3-(3-
chlorophenyl)urea hydroformate (128c) 
H H 
O ~ N ~ N n N ~ C I I
6 OH H 0 V .HC02H ~ I I
Glycidyl phenyl ether (127c) was opened with 1-(2-aminoethyl)-3-(3-
chlorophenyl)urea hydrochloride (66k) according to the method 
described for 1-(2-(3-(4-(2-( cyclopentyloxy)ethoxy)phenoxy)-2-
hydroxypropylamino )ethyl)-3-(2-hydroxyphenyl)urea (71 t). Purification 
via PLC (eluent 37% aq NH3/MeOH/DCM 1:10:89) and preparative 
HPLC afforded 16 mg of white solid. 
Yield: 12%. 
Mp: 142 - 144 °C. 
IR: 3278 (br, OH, str), 3066 (aryl C-H, str), 1690 (urea C=O, str), 1594, 
1496 (aryl, str), 1073 (C-O, str) , 775 (C-CI, bend), 755, 689 (aryl C-H, 
bend, phenyl ring). 
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1H NMR (DMSO-d6): 6 9.14 (s, 1H, NH(C=O)NHAr), 8.27 (br s, 1H, 
formate HCO£), 7.67 (d, J = 1.7 Hz, 1 H, chlorophenyl ring 2-H), 7.27 
(ddd, J = 6.9/6.9/2.0 Hz, 2H, phenyl ring 3-H and 5-H), 7.22 (dd, J = 
8.0/8.0 Hz, 1H, chlorophenyl 5-H), 7.19 (ddd, J = 8.3/1.8/1.8 Hz, 1H, 
chlorophenyl ring 6-H), 6.88 - 6.96 (m, 4H, phenyl ring 2-H, 4-H and 6-
H, chlorophenyl ring 4-H), 6.66 (t, J = 5.2 Hz, 1 H, NH(C=O)NHAr), 3.86 
- 4.00 (m, 3H, ArOCH2, CH(OH», 3.22 (dt, J = 6.1/5.8 Hz, 2H, 
NHCH2CH2), 2.83 (dd, J = 12.1/4.0 Hz, 1H, CH(OH)CH2NH), 2.66 -
2.78 (m, 3H, CH(OH)CH2NH, NHCH2CH2). 
13C NMR (DMSO-d6): 0 164.49 (formate C=O), 158.55 (phenyl 1-C), 
155.23 (C=O), 142.25 (chlorophenyl ring 1-C), 133.04 (chlorophenyl 
ring 3-C), 130.17 (chlorophenyl ring 5-C), 129.44 (phenyl 3-C and 5-C), 
120.52 (phenyl 4-C), 120.43 (chlorophenyl ring 4-C), 116.88 
(chlorophenyl ring 2-C), 115.90 (chlorophenyl ring 6-C), 114.46 (phenyl 
2-C and 6-C), 70.38 (ArOCH2), 67.32 (CH(OH», 51.59 
(CH(OH)CH2NH), 48.76 (NHCH2CH2), 38.36 (NHCH2CH2). 
mlz: HRMS (TOF ES") C1sH21CIN303 [M-Hr calcd 362.1277; found 
362.1258. 
HPLC Rt : 3.65 (System 1b), 11.10 (System 3). 
2-«Naphthalen-1-yloxy)methyl)oxirane (130) 
o ~ o o 1-Naphthol (129) was alkylated with rae-
c c ~ ~ epichlorohydrin in a similar manner to 4-(2-I -& -& (cyclopentyloxy)ethoxy) phenol (61) as described in 
the preparation of 2-«4-(2-
(cyclopentyloxy)ethoxy)phenoxy)methyl)oxirane (62). Purification by 
FCC (eluent EtOAc/PE 10:90) gave clear, colourless oil in quantitative 
yield. 
Yield: 100%. 
IR: 3054 (epoxide C-H, str), 3005 (aryl C-H, str), 2926, 2874 (alkyl C-H, 
str), 1595, 1580, 1509 (aryl, str), 1241 (epoxide C-O, str), 1101 (C-O-
C), 793, 772 (aryl C-H bend) 
236 
Experimental 
1H NMR: ~ ~ 8.35 - 8.42 (m, 1 H, naphthyl 8-H), 7.82 - 7.88 (m, 1 H, 
naphthyl 5-H), 7.51 - 7.58 (m, 2H, naphthyl 6-H and 7-H), 7.50 (d, J = 
8.3 Hz, 1H, naphthyI4-H), 7.40 (dd, J = 8.1/8.1 Hz, 1H, naphthyl 3-H), 
6.80 (d, J = 7.5 Hz, 1H, naphthyl 2-H), 4.37 (dd, J = 11.1/3.2 Hz, 1H, 
ArOCH2), 4.09 (dd, J = 11.1/5.5 Hz, 1 H, ArOCH2), 3.44 - 3.50 (m, 1 H, 
epoxide CH), 2.94 (dd, J = 4.7/4.7 Hz, 1H, epoxide CH2), 2.83 (dd, J = 
4.8/2.8 Hz, 1 H, epoxide CH2). 
13C NMR: ~ ~ 154.20 (naphthyl 1-C), 134.51 (naphthyl 4a-C), 127.44 
(naphthyl 5-C), 126.49 (naphthyl 6-C), 125.74 (naphthyl 7-C), 125.58 
(naphthyl 8a-C), 125.29 (naphthyl 3-C), 122.02 (naphthyl 8-C), 120.78 
(naphthyl 4-C), 105.00 (naphthyl 2-C), 68.89 (ArOCH2), 50.15 (epoxide 
CH), 44.55 (epoxide CH2). 
m/z: HRMS (TOF ES+) C13H 1302 [MHt calcd 201.0910; found 
201.0924. 
1-(2-(2-Hydroxy-3-(naphthalen-1-yloxy)propylamino)ethy1)-3-(3-
chlorophenyl)urea hydroformate (131) 
2-«Naphthalen-1-yloxy)methyl)oxirane (130) was opened with 1-(2-
aminoethyl)-3-(3-chlorophenyl)urea hydrochloride (66k) according to 
the method described for 1-(2-(3-(4-(2-(cyclopentyloxy)ethoxy) 
phenoxy)-2 -hyd roxypropylamino )ethyl)-3-(2-hyd roxyphenyl)urea (71 t). 
Purification via PLC (eluent 37% aq NHJlMeOH/DCM 1:10:89) and 
preparative HPLC afforded 18 mg of white solid. 
Yield: 16%. 
Mp: 64 - 66 ac. 
IR: 3369 (br, O-H, str) , 3057 (aryl C-H, str) , 1669 (urea C=O, str), 1598, 
1549 (aryl, str), 1103 (C-O-C, str) , 794 (aryl1,3-disubstituted ring C-H, 
bend), 772 (C-CI, bend). 
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1H NMR (DMSO-d6): ~ ~ 9.13 (s, 1H, NH(C=O)NHAr), 8.65 (br s, 2H, 
NH2 +), 8.29 (dd, J = 8.3/1.9 Hz, 1 H, naphthyl 8-H), 7.87 (dd, J = 7.5/1.9 
Hz, 1H, naphthyI5-H), 7.69 (d, J= 1.7 Hz, 1H, chlorophenyl ring 2-H), 
7.47 - 7.57 (m, 3H, naphthyl 4-H, 6-H and 7-H), 7.42 (dd, J = 7.917.9 
Hz, 1 H, naphthyl 3-H), 7.20 - 7.29 (m, 2H, chlorophenyl ring 6-H, 
naphthyl 2-H), 6.92 - 7.03 (m, 2H, chlorophenyl ring 4-H and 5-H), 6.57 
(t, J = 5.9 Hz, 1 H, NH(C=O)NHAr), 4.30 - 4.40 (m, 1 H, CH(OH)), 4.11 -
4.20 (m, 2H, ArOCH2), 3.42 - 3.49 (m, 2H, NHCH2CH2), 3.10- 3.32 (m, 
4H, CH(OH)CH2NH, NHCH2CH2). 
13C NMR (DMSO-d6): 0 155.54 (C=O), 153.70 (naphthyl 1-C), 141.81 
(chlorophenyl ring 1-C), 134.01 (naphthyl 4a-C), 133.06 (chlorophenyl 
ring 3-C), 130.26 (chlorophenyl ring 5-C), 127.41 (naphthyl 5-C), 126.52 
(naphthyl 6-C), 126.14 (naphthyl 7-C), 125.24 (naphthyl 8a-C), 124.85 
(naphthyl 3-C), 121.83 (naphthyl 8-C), 120.90 (naphthyl 4-C), 120.27 
(chlorophenyl ring (4-C), 117.18 (chlorophenyl ring 2-C), 116.17 
(chlorophenyl ring 6-C), 105.23 (naphthyl 2-C), 69.92 (ArOCH2), 64.99 
(CH(OH», 49.64 (CH(OH)CH2NH), 47.64 (NHCH2CH2), 37.40 
(NHCH2CH2)' 
mlz: HRMS (TOF ES+) C22H25CIN303 [MHt calcd 414.1579; found 
414.1568. 
HPLC Rt : 4.49 (System 1 b), 13.44 (System 3). 
1-(2-(3-(4-(2-Ethoxyethoxy)phenoxy)-2-hydroxypropylamino)ethyl)-
3-(3-chlorophenyl)urea hydroformate (132a) 
2-«4-(2-Ethoxyethoxy)phenoxy)methyl)oxirane (124b) was opened with 
1-(2-aminoethyl)-3-(3-chlorophenyl)urea hydrochloride (66k) according 
to the method described for 1-(2-(3-(4-(2-(cyclopentyloxy)ethoxy) 
phenoxy)-2 -hyd roxypropylamino )ethyl)-3-(2-hyd roxyphenyl)urea (71 t). 
Purification via PLC (eluent 37% aq NHJlMeOH/DCM 1: 1 0:89) and 
preparative HPLC afforded 11 mg of beige semi-solid. 
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Yield: 11%. 
IR: 3339 (br, OH, str) , 2975, 2928, 2868 (alkyl C-H, str) , 1632 (urea 
C=O, str), 1592, 1508 (aryl, str), 1121 (C-O-C, str), 823 (aryl C-H, bend, 
para-disubstituted ring), 774 (C-CI, bend). 
1H NMR (DMSO-d6): l) 9.02 (5, 1H, NH(C=O)NHAr), 8.27 (br 5, 1H, 
formate HCO£), 7.67 (dd, J = 2.012.0 Hz, 1H, aryl 2-H), 7.22 (dd, J = 
7.7n.7 Hz, 1H, aryl 5-H), 7.18 (ddd, J = 8.3/1.8/1.8 Hz, 1H, aryl 6-H), 
6.91 (ddd, J = 7.4/1.8/1.8 Hz, 1 H, aryl 4-H), 6.86, 6.83 (d, J = 9.2 Hz, 2 
x 2H, aryl-dioxy C-H), 6.51 (t, J = 5.3 Hz, 1 H, NH(C=O)NHAr), 3.99 (t, J 
= 4.7 Hz, 2H, CH20Ar), 3.78 - 3.92 (m, 3H, CH(OH), ArOCH2) , 3.66 (t, 
J = 4.7 Hz, 2H, CH2CH20Ar), 3.48 (q, J = 7.0 Hz, 2H, CH3CH2), 3.19 
(dt, J = 6.2/5.8 Hz, 2H, NHCH2CH2), 2.74 (dd, J = 12.1/4.3 Hz, 1H, 
CH(OH)CH2NH), 2.68 (t, J = 6.2 Hz, 2H, NHCH2CH2), 2.63 (dd, J = 
12.1/6.6 Hz, 1 H, CH(OH)CH2NH), 1.20 (t, J = 6.6 Hz, 3H, CH3). 
13C NMR (DMSO-de): l) 155.14 (C=O), 152.70, 152.49 (aryl-dioxy 4° C), 
142.24 (aryl 1-C), 133.05 (aryl 3-C), 130.18 (aryl 5-C), 120.41 (aryl 4-
C), 116.84 (aryl 2-C), 115.87 (aryl 6-C), 115.34, 115.25 (aryl-dioxy C-
H), 71.14. (ArOCH2), 68.42 (CH2CH20Ar), 67.79 (CH(OH», 67.51 
(CH20Ar), 65.64 (CH3CH2), 51.94 (CH(OH)CH2NH), 48.96 
(NHCH2CH2), 38.90 (NHCH2CH2), 15.09 (CH3). 
m/z: HRMS (TOF ES-) C22H29CIN305 [M-Hr calcd 450.1801; found 
450.1801. 
HPLC Rt : 3.93 (System 1 b), 11.69 (System 3). 
1-(2-(3-(4-(2-( eye lopropylmethoxy)ethoxy )phenoxy )-2-
hydroxypropylamino)ethyl)-3-(3-ehlorophenyl}urea hydroformate 
(132b) 
~ O ~ O U U\I I H H ~ ~ O ~ N ~ N I ( N ~ C I I
OH H 0 V 
2-«4-(2-(Cyclopropylmethoxy)ethoxy)phenoxy)methyl)oxirane (124e) 
was opened with 1-(2-aminoethyl)-3-(3-chlorophenyl)urea hydrochloride 
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(66k) according to the method described for 1-(2-(3-(4-(2-
(cyclopentyloxy)ethoxy)phenoxy)-2 -hyd roxypropylami no )ethyl)-3-(2-
hydroxyphenyl)urea (71t). Purification via PLC (eluent 37% aq 
NH:vMeOH/DCM 1: 1 0:89) and preparative HPLC afforded 9 mg of 
beige semi- solid. 
Yield: 9%. 
IR: 3403 (br, OH, str) , 3078 (CPr C-H, str), 2927, 2867 (alkyl C-H, str), 
1632 (urea C=O, str) , 1592, 1508 (aryl, str), 1117 (C-O-C, str), 822 (aryl 
C-H, bend, para-disubstituted ring), 768 (C-CI, bend). 
1H NMR (DMSO-d6): l) 8.95 (s, 1H, NH(C=O)NHAr), 8.26 (br s, 1H, 
formate HCO£), 7.67 (dd, J = 2.0/2.0 Hz, 1 H, aryl 2-H), 7.22 (dd, J = 
7.7n.7 Hz, 1H, aryl 5-H), 7.18 (ddd, J = 8.3/1.8/1.8 Hz, 1H, aryl 6-H), 
6.91 (ddd, J = 7.4/1.8/1.8 Hz, 1 H, aryl 4-H), 6.80 - 6.88 (m, 4H, aryl-
dioxy C-H), 6.43 (t, J = 5.1 Hz, 1H, NH(C=O)NHAr), 3.99 (t, J = 4.7 Hz, 
2H, CH-zQAr) , 3.78 - 3.92 (m, 3H, CH(OH), ArOCH2), 3.66 (t, J = 4.7 
Hz, 2H, CH2CH20Ar), 3.28 (d, J = 7.1 Hz, 2H, cPrCH20), 3.18 (dt, J = 
5.9/5.6 Hz, 2H, NHCH2CH2), 2.72 (dd, J = 11.9/4.0 Hz, 1H, 
CH(OH)CH2NH), 2.66 (t, J = 6.2 Hz, 2H, NHCH2CH2), 2.61 (dd, J = 
12.1/6.8 Hz, 1H, CH(OH)CH2NH), 1.06 - 0.94 (m, 1H, cPr CH), 0.42-
0.49 (m, 2H, cPr CH2)*, 0.13 - 0.19 (CPr CH2)*. *Refers to cis-protons of 
cPr ring. 
13C NMR (DMSO-d6): l) 155.10 (C=O), 152.72, 152.49 (aryl-dioxy 4° C), 
142.22 (aryl 1-C), 133.05 (aryl 3-C), 130.18 (aryl 5-C), 120.42 (aryl 4-
C), 116.84 (aryl 2-C), 115.87 (aryl 6-C), 115.34, 115.28 (aryl-dioxy C-
H), 74.75 (CPrCH20), 71.17. (ArOCH2), 68.33 (CH2CH20Ar), 67.91 
(CH(OH», 67.58 (CH20Ar), 52.04 (CH(OH)CH2NH), 49.02 
(NHCH2CH2), 38.90 (NHCH2CH2), 10.48 (CPr CH), 2.86 (CPr CH2). 
mlz: HRMS (lOF ES-) C24H31CIN30s [M-Hr calcd 476.1958; found 
476.1991. 
HPLC Rt : 3.95 (System 1b), 11.73 (System 3). 
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